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Abstract 
 
 
 
 
There are considerable differences in the timing, type and extent of age-related decline 
between individuals who share the same chronological age, which may be driven by a 
combination of genetic, stochastic and environmental factors. Biomarkers of ageing 
(BoA) that can discriminate between individuals who differ in their biological age will 
therefore be useful to understand biological mechanisms, develop and test interventions 
and allow the prediction of age-related events so interventions can be implemented. In 
recent years, a variety of mechanistic candidate BoA have been discovered on the basis 
of a greatly improved understanding of the cellular and molecular biology of ageing. 
These include various measures of oxidative stress, which is thought to contribute 
causally to the ageing of organisms via its acceleration of cellular senescence. However, 
their reliability and validity as BoA, especially within population based cohorts are 
scarce. This study therefore focused on various oxidative stress-related measures as 
candidate BoA including: reactive oxygen species (ROS) production from dysfunctional 
mitochondria, by measuring superoxide levels, mitochondrial mass and mitochondrial  
membrane potential in blood mononuclear cells by flow cytometry; and also markers of 
lipid peroxidation, F2-isoprostanes, by measuring 8-iso Prostaglandin F2 by Automated 
Dissociation Enhanced Lanthanide Fluorescence Immunoassay (AutoDELFIA). Despite 
providing evidence of experimental reliability for all measures and also some evidence 
of construct validity for ROS production from dysfunctional mitochondria in terms of: 
associations with chronological age, associations with some markers of oxidative stress-
induced cellular senescence, validation in a dietary restricted animal model of ageing 
and a role in an immunosenescent phenotype; there was no evidence of predictive 
validity in terms of longevity or age-related health outcomes in a population based 
cohort of the very old, the Newcastle 85+ study. This questions the predictive validity 
of these parameters as candidate BoA in the very old population. 
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Chapter 1.  Introduction 
 
1.1.   Concerns of increasing life expectancy         
     
1.1.1. Population ageing 
 
It is well acknowledged that the human population worldwide is increasing. For 
example, in England alone for males and females respectively there was an estimated 
population of 23.21 and 24.49 million in 1990, which rose to 24.03 and 25.20 million in 
2000, and 25.76 and 26.48 million in 2010 (Figure 1.1. A.) (Office for National 
Statistics (ONS), 2011a). The major reason for the increase in population is increasing 
life expectancy. For example, the average life expectancy at birth in England for males 
and females respectively was 72.85 and 78.43 years in 1990, which rose to 75.29 and 
80.12 years in 2000, and 78.31 and 82.33 years in 2010 (Figure 1.1. B.) (ONS, 2011b). 
The age structure of the population worldwide is therefore changing where older 
individuals are becoming a proportionally larger share of the total population known as 
population ageing. For example, the proportion of the very old population in England 
(those aged 85 years and older) are currently the lowest however they are the fastest 
growing sector of the population (Figure 1.2.) (ONS, 2011c; ONS, 2011d; ONS, 
2011e). Although population ageing is experienced more in developed countries, it is 
becoming more apparent in the developing world however at varying levels and in 
different time frames (Stefansson, 2005). It is predicted that by 2050 the proportion of 
the older population (those aged 60 years or older) in the world will exceed the younger 
population (those aged 15 years or under) for the first time in history (United Nations 
(UN), 2002). 
 
1.1.2. Scenarios of increasing life expectancy 
  
Since the older population are more vulnerable to longstanding illnesses and disabilities 
and report the worst self-reported health (Figures 1.3. A. and 1.3. B.), a major concern 
is an increase in the number of morbid years towards the end of life (ONS, 2010). There 
are however three possible scenarios of increasing life expectancy (Figure 1.4.) (Fries, 
1996).  
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Figure 1.1. A. Mid-year population estimates and B. life expectancy at birth in 
England by gender between 1990-2010. (ONS, 2011a; ONS, 2011b). (Chart was 
created from data tables provided) 
 
 
 
 
 
 
 
Figure 1.2. Mid-year population estimates and population growth in England by 
age group between 1990, 2000 and 2010. (ONS, 2011c; ONS, 2011d; ONS, 2011e). 
(Chart was created from data tables provided) 
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Figure 1.3. A. The percentage of people with a disability (including those with a 
limiting longstanding illness/es) in England by age group in 2008-09 and B. the 
percentage of people with self-reported ‘very good health’ in England by age 
group in 2006-08. (ONS, 2010). (Chart was created from data tables provided) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Future scenarios of increasing life expectancy. (Adapted from (Fries, 
1996)).  
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Scenario I suggests the age of morbidity has not changed or is increasing slower than 
life expectancy so there is an expansion in the number of morbid years. Scenario II 
suggests the age of morbidity is increasing at the same rate as life expectancy and so the 
number of years of morbidity does not change. Scenario III suggests that the age of 
morbidity is increasing faster than life expectancy and so there is compression in the 
number of morbid years.  
 
1.1.3. Current scenario  within the United Kingdom (UK) 
 
Demographic data shows that scenario III (compression of morbidity) has taken place in 
the United Kingdom (UK) between 2005-07 to 2008-10 (Figure 1.5. A.) however shows 
different scenarios for each constituent country of the UK (ONS, 2012). England and 
Wales showed scenario III (compression of morbidity) (Figures 1.5. B. and 1.5. C. 
respectively) where as Scotland (males only) and Northern Ireland showed scenario I 
(expansion of morbidity) (Figures 1.5. D. and 1.5. E. respectively) (ONS, 2012). 
Different scenarios for other countries are also shown. For example, scenario III 
(compression of morbidity) took place in Austria between 1978 and 1998 (Doblhammer 
and Kytir, 2001) where as scenario I (expansion of morbidity) took place in Australia 
between 1980 and 2003 and in the United States (US) between 1998 and 2008 (Lynch et 
al., 2007; Crimmins and Beltran-Sanchez, 2011). The global outcome of increasing life 
expectancy is therefore uncertain and differs between population groups.  
 
1.1.4. Implications in the expansion of morbidity 
 
An expansion in the number of morbid years as shown for some countries will have 
great impacts on many economic, social and political factors.  The retirement window 
will become larger putting higher financial demands on the working-age population. 
This is because larger contributions will be needed for taxes, pensions and investments 
to secure their future and support the current elderly population. This will also include 
contributions to increased medical costs and demands on health care services. It will 
impact socially on younger generations where longer care of elderly family members 
will be needed.  There will be the need for improved information and analysis of the 
impact of an ageing population for potential policy changes which could involve  
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Figure 1.5. Life expectancy (LE) and healthy life expectancy (HLE) at  birth in the 
UK and constituent countries in 2005-07 and 2008-10. (ONS, 2012). (Chart was 
created from data tables provided)  
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finances, transportation, housing, health services and infrastructure. This is “to ensure 
that people everywhere will be enabled to age with security and dignity and continue to 
participate in their societies as citizens with full rights” (UN, 2002). There is therefore a 
great importance in understanding the complex biology of ageing and its association 
with frailty and disease (Kirkwood, 2008). The aim is to acquire scientific insights that 
can help ensure the extra years of life we are gaining are as healthy, productive and 
enjoyable as possible. 
 
1.2.   Current understanding of the biology of ageing 
 
The biological process of ageing is considered complex involving numerous genetic and 
non-genetic factors and to date, no overall definition exists. It is however generally 
accepted that biological ageing is characterised by the gradual decline of functional 
capacity over time increasing vulnerability to age-related frailty, disability, disease and 
eventually death (Kirkwood, 2008). This is the result of the lifelong accumulation of 
damage at the cellular and molecular level, which gradually overwhelms defence, repair 
and maintenance systems (Zglinicki, 2004). Recent advances in ageing research has 
identified potential mechanisms and products of this damage, such as those discussed in 
Section 1.4., which could potentially be used to measure ageing.   
 
1.3.   Biomarkers of ageing (BoA) 
 
1.3.1. Definition of BoA 
 
There are considerable differences between individuals with respect to the timing, type 
and extent of age-related decline driven by a combination of genetic, stochastic and 
environmental factors (Kirkwood, 2008). There is therefore the need to find biological 
measurements that can discriminate between individuals who share the same 
“chronological age” but differ in their “biological age”. These so-called biomarkers of 
ageing (BoA) were first defined by Baker and Sprott  in 1988 (Baker and Sprott, 1988) 
as “biological parameters of an organism that either alone or in some multivariate 
composition will, in the absence of disease, allow better prediction of functional 
capability at some late age than will chronological age”. Understanding why individuals 
differ in their biological age through measuring BoA will be useful to understand 
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biological mechanisms, develop and test interventions, and allow the prediction of age-
related events so that interventions can be implemented (Figure 1.6.). Overall, BoA will 
have the potential to help make sure the extra years of life we are gaining are spent in 
good health.  
 
1.3.2. Investigating the reliability and validity of BoA 
 
There are various steps to consider when investigating candidate BoA (Figure 1.6.). 
Firstly, the degree of measurement reliability needs to be established. This is greatly 
important in population studies to ensure the variability of candidate BoA reflects 
genuine inter-individual differences and not measurement error, especially when only  
 one measurement may be obtained.  Evidence of experimental and intra-individual 
stability should therefore be shown. Experimental stability concerns various handling 
factors during preparation and measurement, where significant effects can be controlled 
during experimentation. Intra-individual stability concerns the day-day behaviours or 
environmental conditions of an individual that may change or fluctuate candidate BoA 
and therefore impact on their day-day repeatability (Hershberger and Moskowitz, 2001; 
Nesselroade and Ram, 2004). These factors could be identified and controlled before 
experimentation or by using statistical approaches during data analysis (Hershberger 
and Moskowitz, 2001; Nesselroade and Ram, 2004). Examples of factors that could 
affect the intra-individual variability of candidate BoA include changes in diet, 
smoking, alcohol consumption, medication, sleep quality, physical activity, use of aids 
and appliances, social events and seasonal/environmental exposures. Secondly, 
evidence of construct validity should be shown which is defined here as the ability of a 
measurement to reflect the construct being investigated, in this case biological ageing. 
This is important to understand biological mechanisms and to develop and test 
interventions. BoA should therefore correlate but change independently of 
chronological age, reflect known mechanisms of ageing and be associated with age-
related outcomes (Sprott, 2010). Analysis here could be confounded by inter-individual 
variation defined as individual differences among different people (Hershberger and 
Moskowitz, 2001). This could be fixed variables including age, gender, ethnicity, 
genetic differences such as mitochondrial haplogroup or genetic disease(s) or 
disorder(s), age of natural mother/fathers death, having offspring, having siblings,  
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Figure 1.6. The identification and value of biomarkers of ageing (BoA). 
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education, employment history and/or life history events or could be changeable 
variables (as mentioned for inter-individual stability) such as diet, smoking, alcohol 
consumption, medication, sleep quality, physical activity, use of aids and appliances, 
social events and  seasonal/environmental exposures. Again these factors could be 
identified and controlled before experimentation or by using statistical approaches 
during analysis (Hershberger and Moskowitz, 2001). The third and most important step 
when investigating candidate BoA is that they should be able to predict the years of 
remaining good health and the trajectory towards a wide range of age-related outcomes 
and mortality better than chronological age (Sprott, 2010). This is important to 
determine when the implementation of an intervention may be useful. Another criterion 
of BoA is that they should cause no harm when tested repeatedly. For example, analysis 
of blood sample or an image. They should also be technically simple enough to measure 
so most clinical laboratories can perform the test accurately and reproducibly without 
the need for specialized equipment or techniques. 
 
1.3.3. Current status of efforts in BoA development 
 
Research into the development of BoA began in the late 1960’s where Alex Comfort 
first described the necessity and possibility of developing a technique to measure 
biological ageing rate in humans. This would then allow the identification and 
development of interventions that will increase health-span (Comfort, 1969). Since then 
the field of BoA development has exponentially increased (Figure 1.7.). Many 
candidate BoA have been proposed including various anthropometric (St-Onge, 2005), 
physical (Guralnik et al., 1989), physiological (Masoro, 1988),  haematological 
(particularly in relation to immunology) (DelaRosa et al., 2006) and biochemical 
measurements (Stadtman, 1988) which will be termed here as “classical” BoA and also 
various cellular and molecular measures discovered by the advancing mechanistic 
aspects of biological ageing (Cristofalo, 1988) termed here as “newer” BoA. The 
proposal for many of these candidate BoA comes from evidence of construct validity 
including changes with chronological age, reflecting known mechanisms of ageing 
and/or be associated with age-related outcomes. However although the gold standard 
criteria of BoA, the predictive validity, has also been investigated for many of the 
proposed BoA in longitudinal population studies (Figure 1.8.) there are many 
inconsistencies in their findings. Therefore to date, no measure meeting the full criteria  
10 
 
 
 
 
 
 
Figure 1.7. The exponential growth in the field of BoA development. The electronic 
database MEDLINE via the database provider OvidSP was searched up to 2012 for 
studies on the topic of BoA using the following search terms: [ageing adj marker$] OR 
[ageing adj biomarker$] OR [ageing adj measur$] OR [marker$ adj of adj ageing 
[biomarker$ adj of adj ageing [measur$ adj of adj ageing] OR [aging adj marker$] OR 
[aging adj biomarker$] OR [aging adj measur$] OR [marker$ adj of adj aging] OR 
[biomarker$ adj of adj aging] OR [measur$ adj of adj aging] OR [marker$ adj of adj 
biological adj ageing]  [biomarker$ adj of adj biological adj ageing] OR [measur$ adj of 
adj biological adj ageing] OR [marker$ adj of adj biological adj aging] OR 
[biomarker$ adj of adj biological adj aging] OR [measur$ of adj biological adj aging] 
OR [marker$ adj of adj biological adj age] OR [biomarker$ adj of adj biological adj 
age] OR [measur$ adj of adj biological adj age] restricted to abstracts, studies in 
humans and from 1946 onwards. (adj: adjacent, $: truncation) 
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Figure 1.8. The number of studies investigating the predictive validity of various 
candidate BoA. The electronic database MEDLINE via OvidSP was searched up to 
November 2012 using specific search terms: [Candidate BoA* (*total of 71 using a 
combination of appropriate words/truncations)] AND [predict$] AND [survival OR 
death OR mortality OR $morbid$ OR disabil$ OR cognit$] restricted to abstracts, 
studies in humans and from 1946 onwards. Full details of the search terms are shown in 
Appendix A. 
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of BoA has been identified (Sprott, 2010). For example, this is shown for the most 
frequently investigated candidate BoA in the six main groups which include body mass 
index, physical activity, systolic blood pressure, platelet count, C reactive protein and 
interleukin-6 (Table 1.1.). Some studies find statistically significant predictions of age-
related outcomes with these candidate BoA but others do not and some even find 
opposing directions of associations. The ideal BoA is one that can be applied to all 
members of the population at any given age however this data suggests that this is 
unlikely and the predictive power of a BoA changes between different populations. 
Identifying and providing explanations for these discrepancies will be important in BoA 
research. On one hand it could be differences in the quality of the studies such as 
sample size, the use of appropriate statistical techniques, adjustment of appropriate  
confounders, the reliability of the experimental technique that was used to measure the 
candidate BoA or it could be differences between population groups included such as 
age, gender, lifestyle habits, environmental influences and presence of disease(s) etc. 
For example, body mass index was positively associated and predictive of age-related 
outcomes in participants of the Melbourne Collaborative Cohort Study (Wong et al., 
2012), was negatively associated and predictive of age-related outcomes in participants 
of the PROTEGER study (Zhang et al., 2012), however was not associated or predictive 
of age-related outcomes in another population-based cohort (Thrift et al., 2012). This 
was also the case for other candidate BoA.  Differences between these studies that could 
reflect their inconsistencies include age of the participants, ratio of males to females, 
follow up length, age-related outcome investigated, statistical analysis used, types of 
confounders adjusted for or health/disease status of the participants. Further studies are 
needed to determine which variables are the reasons for the inconsistencies between 
studies. For example, a particular variable such as age could be investigated by dividing 
studies into different age groups and determining the predictive value of the candidate 
BoA in each age group. The value of the candidate BoA investigated may change 
throughout the lifespan and thus although may be predictive of age-related events early 
in life it may not be predictive later on in life and vice versa (McClearn, 1992; Sprott, 
2010). The reasons for this are not well understood but could be due to different intra- 
and extra-organismic environmental influences on the candidate BoA that confound its 
association with age-related outcomes within different age groups (McClearn, 1992). It 
may therefore be necessary to define BoA that are valid early in life and others that are  
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Candidate 
BoA 
Age (years) Gender n 
Follow 
up 
(years) 
Age-related 
outcome 
predicted 
Association 
Statistical 
analysis 
Adjustments Study Reference 
Body mass 
index 
Mean 64.0 
SD 3.3 
38% male 7,142 14 Disability ▲ AUROC Age, education and smoking status 
Community-based cohort 
(Melbourne Collaborative 
Cohort Study) 
(Wong et 
al., 2012) 
 
Mean 86.8 
SD 6.9 
26% male 331 1 
All cause 
mortality ▼
♀
 
Cox 
proportional 
hazard models 
Age, smoking status, total-to-high density 
lipoprotein cholesterol ratio and plasma glucose 
Hospital-based cohort of 
patients with 
cardiovascular disease 
(PROTEGER study) 
(Zhang et 
al., 2012) 
 18-79 89% male 783 6.4 
All cause 
mortality 
X 
Cox 
proportional 
hazard models 
Age, gender, pre-treatment tumour stage, 
treatment and presence of comorbidities 
Population-based cohort of 
participants with  
esophageal 
 adenocarcinoma or 
gastroesophageal junction 
adenocarcinoma 
(Thrift et 
al., 2012) 
Physical 
activity 
≥20 49% male 67,740 16 
Cardiovascular 
mortality 
▲
♂ 
(obese only) 
Cox 
proportional 
hazard models 
Age, smoking status, ever use of blood pressure 
medication, use of alcohol, marital status, 
and education 
Community-based cohort 
(The HUNT study) 
(Vatten et 
al., 2006) 
 
Mean 78.9 
SD 2.2 
38% male 1,021 8.34 
All cause 
mortality ▼
♀
 
Cox 
proportional 
hazard models 
Age, baseline vulnerability and  
grade of disability 
Community-based cohort 
(Brønshøj-Husum Study) 
(Schultz-
Larsen et 
al., 2012) 
 35-79 
100% 
male 
9,824 u/k 
Prostate cancer 
mortality 
X 
Multivariate 
logistic 
regression 
Age, education, urban-rural residence, smoking 
status and body mass index 
Population-based cohort 
(The Puerto Rico Heart 
Health Program) 
(Crespo et 
al., 2008) 
Systolic 
blood 
pressure 
≥25 45% male 8,534 3 
All cause 
mortality ▲
♂
 
Cox 
proportional 
hazard models 
Age Population-based cohort 
(Stevenson 
et al., 2012) 
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Mean 67 
SD 13 
70% male 500 2 
All cause 
mortality 
▼ 
Cox 
proportional 
hazard models 
Age, gender, B-blocker therapy, hyponatremia, 
uric acid, electrocardiographic readings 
 and six-minute walking distance 
Outpatient-based cohort of 
patients with heart failure 
(Zafrir et 
al., 2012) 
 ≥80 u/k 287 u/k 
All cause 
mortality 
X 
Cox 
proportional 
hazard models 
Age, gender, weight,  mobility at entry, smoking 
status, bacteriuria,  electrocardiographic  
readings, serum cholesterol levels, haematocrit 
levels  and socioeconomic status (two u/k) 
Population-based cohort of 
elderly entering a 
residential home 
(Dontas et 
al., 1996) 
Platelet 
count 
16-99 54% male 40,797 6 
All cause 
mortality 
▲ 
Cox 
proportional 
hazard models 
Age, gender, ten pre-existing comorbid states, 
categories of dialysis, primary insurance, marital 
status, standardized mortality ratio of the dialysis 
clinic during entry quarter, dialysis dose, 
presence or absence of a dialysis catheter and 
residual renal function during the entry quarter 
Population-based cohort of 
patients with end-stage 
renal disease with a history 
of  hemodialysis  
(Molnar et 
al., 2011) 
 14-92 63% male 793 2.8 
All cause 
mortality 
▼ 
Cox 
proportional 
hazard models 
Dynamic International Prognostic Scoring 
System risk, unfavourable karyotype and  
red cell transfusion dependent 
Population-based cohort of 
patients with  primary 
myelofibrosis 
(Gangat et 
al., 2011) 
 21-68 u/k 111 5 
All cause 
mortality 
X 
Cox 
proportional 
hazard models 
u/k 
Hospital-based cohort of 
chemotherapy treated 
patients 
(Wang et 
al., 2012) 
C reactive 
protein 
u/k u/k 281 7.25 
All cause 
mortality 
▲ 
Cox 
proportional 
hazard models 
None 
Population-based cohort of 
patients on haemodialysis 
(Suzuki et 
al., 2012) 
 41-85 64% male  296 5.75 
All cause 
mortality 
X 
Cox 
proportional 
hazard models 
Age and gender 
Population-based cohort of 
patients with suspected 
myocaridal infarction 
(Lyngbaek 
et al., 2012) 
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Table 1.1. Inconsistencies between studies investigating the most popular studied candidate BoA as predictors of age-related outcomes. (SD: 
standard deviation, ▲: positive association, ▼: negative association, X: no association, 
♂
: males only, 
♀
: females only, AUROC: area under the receiver 
operating curve, u/k: unknown, n/a: not available/no data identified)
 
 
Interleukin 
6 
Mean 73.0  
SD 3.0 
58% male 972 9.4 
All cause 
mortality 
▲ 
Cox 
proportional 
hazard models 
Age, gender, race, clinic site, body mass index, 
smoking status and pack-years smoked, 
adiponectin, plasminogen activator inhibitor 1, 
visceral fat area and hypertension 
Community-based  
cohort of older adults  
(Health ABC Study) 
(van den 
Borst et al., 
2012) 
65-94 45% male 638 3 
All cause 
mortality 
X 
Multivariate 
logistic 
regression 
Age, gender, education, high waist 
circumference, high blood pressure, low high-
density lipoprotein cholesterol, high low-density 
lipoprotein cholesterol, high triglycerides, C-
reactive protein, hospital stay in previous years, 
alcohol intake, smoking in pack-years, low 
physical activity, liver disease, coronary heart 
disease, diabetes mellitus, depression, and cancer 
Community -based 
study of older adults  
(InCHIANTI Study) 
(Alley et 
al., 2007) 
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valid throughout different stages of the lifespan and treat each measurement occasion as 
a spearate predictive event.  
 
Longitudinal regional birth cohort studies are advantageous for BoA investigation since 
this will reduce the effects of intra- and extra-organismic environmental influences and 
thus confounding in the association between candidate BoA and age-related outcomes 
and thus their prediction. This is because there is the elimination of a chronological age 
effect and participants will be expected to have a similar timings of life history events, 
lifestyle factors and seasonal/environmental exposures. The variation in these factors 
within the study group could be investigated first to determine if this is the case. Valid 
BoA specific to different age groups could be defined.  Since there is a wide variability  
in age-related outcomes amongst the elderly and some individuals preserve high levels 
of health and functional ability (Collerton et al., 2009), a longitudinal birth cohort of the 
elderly is likely to be informative in the validation of candidate BoA. Another 
advantage is that it will allow the prediction of morbidity and mortality factors in a 
shorter time scale than in a younger population group. Disadvantages to birth cohorts 
however is that they will only identify BoA of a narrow age group and more studies will 
be needed to cover all age ranges.  
 
Although some classical BoA may have been validated as predictors of age-related 
outcomes in specific population groups they still don’t provide a meaningful insight into 
the mechanistic aspects of biological ageing. This limits the development of potential 
interventions that will increase health-span. However, their identification is still 
important since they can be informative by their association and thus construct 
validation of “newer” mechanistic cellular and molecular BoA. This is especially so 
when longitudinal studies are now identifying newer candidate BoA where 
measurement may have taken place sometime after the start of the study and only one 
measurement may be available. Validating them with informative BoA will allow the 
decision of whether further measurements of cellular and molecular BoA should take 
place or not which has timing, material use and financial implications.  
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1.4.   The role of reactive oxygen species (ROS) in ageing  
 
1.4.1. Free radicals and ROS 
 
A free radical is an independent molecular species that contains one or more unpaired 
valence electrons not contributing to intermolecular bonding. Most free radicals are 
highly reactive because their unpaired electron/s will either accept or donate an electron 
from other appropriate molecular species which could be another radical or a non-
radical. If the other molecule is a non-radical then a chain reaction is initiated until two 
free radicals react to form a two-electron bond in which the chain reaction is then 
stopped. Oxygen free radicals take an electron away from the target molecule to pair 
with their single free electron, which is known as oxidation. Highly reactive oxygen free 
radicals are a major cause of structural changes and thus damage to molecules.  There 
are other related oxygen molecules that do not fit the definition of a free radical but 
contribute to their production or are able to oxidise molecules such as singlet oxygen 
and hydrogen peroxide. The term “reactive oxygen species” (ROS) is therefore used to 
refer to both these oxidants and the oxygen free radical. 
 
1.4.2. ROS generation 
 
ROS are generated by sources endogenous and exogenous to cells. Endogenous 
production includes on-going metabolism, especially from the respiratory chain during 
oxidative phosphorylation in the mitochondria which is thought to be the major source 
of ROS production (Turrens and Boveris, 1980; Turrens, 2003). The enzyme complexes 
I and III are thought to be the major sites of ROS production in the mitochondria 
(Figure 1.9.). Other various enzymatic reactions leading to the production of ROS 
include xanthine oxidase (McCord, 1985), cytochrome P450, (Ekstrom and Ingelman-
Sundberg, 1989), nitric oxide synthase (Giulivi et al., 1998), lipoxygenase (Kukreja et 
al., 1986), cyclooxygenase (Swindle et al., 2007) and quinine reductase (Cadenas et al., 
1992). Endogenous ROS are also produced from the auto-oxidation of 
neurotransmitters, norepinephrine and dopamine, and the auto-oxidation of catecholes 
to quinines (Seacat et al., 1997; Manini et al., 2007). Exogenous factors can also 
influence and enhance endogenous ROS production such as infection and chronic  
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Figure 1.9. The generation of ROS in the mitochondrial respiratory chain. The 
main function of the mitochondria is the production of metabolic energy in the form of 
adenosine triphosphate (ATP) from adenonine diphosphate (ADP). Oxygen (O2) 
consumed by a cell drives the translocation of electrons through a series of enzyme 
complexes (complex I to V) and shuttle proteins, coenzyme Q (CoQ) and cytochrome c 
(Cyt c).  From glycolysis within the cell, pyruvate enters the mitochondrion which is 
converted to acetyl-CoA initiating the citric acid cycle. Nicotine adenine dinucleotide 
(NADH), which is generated from the citric acid cycle, is oxidised and releases its 
electron pairs as hydrogen atoms in the first proton pump of the electron transport 
system in complex I. From here to the end of the chain enough energy is generated to 
synthesize ATP. Nicotinamide adenine dinucleotide (NAD) is regenerated to allow the 
cycle to continue. Although most of the oxygen consumed by a cell is reduced to water 
(H2O), a small proportion (0.2-2%) is converted to ROS in the form of superoxide, 
mainly documented in complex I and III (Chance and Williams, 1956; Boveris and 
Chance, 1973; Balaban et al., 2005; Li et al., 2013).  
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inflammation involving various cytokines and growth factors (Lo and Cruz, 1995; 
Floyd et al., 1999; Kohchi et al., 2009), ultraviolet light (Masaki et al., 1995), ionizing 
radiation (Leach et al., 2001), various chemotherapeutic agents  (Gille and Nohl, 1997) 
and hyperthermia (Salo et al., 1991).  Examples of ROS include the superoxide radical, 
hydrogen peroxide, hydroxyl radical, nitric oxide and peroxynitrite. 
 
1.4.3. ROS damage 
 
ROS are unstable and have the tendency to capture electrons from neighbouring 
molecules to attempt to restore their stable resting state. Extracting an electron from a  
nearby molecule causes a series of chain reactions as molecules obtain electrons from 
one another. ROS are important in many biological processes such as the regulation of 
vascular tone, sensing of oxygen tension and regulation of functions that are controlled 
by oxygen concentration, enhancement of signal transduction from various membrane 
receptors including the antigen receptor of lymphocytes, activation of oxidative stress 
responses that ensure the maintenance of redox homeostasis (Droge, 2002) and also 
fighting off invading bacteria and viruses in immune cells during infection (Kohchi et 
al., 2009). However when overwhelmed by high ROS levels, membranes are damaged 
by lipid peroxidation (Niki et al., 2005), cytosolic enzymes and proteins are functionally 
compromised (Stadtman and Levine, 2000), and DNA is directly or indirectly damaged 
(Richter et al., 1988; Cooke et al., 2003). ROS induce damage to lipids by oxidising 
polyunsaturated fatty acids residues which leads to alterations in cellular membrane 
fluidity/macroviscosity and consequently the function of receptors, ion pumps and 
transport of metabolites. This can have detrimental effects in vivo including 
mitochondrial dysfunction (Lucas and Szweda, 1998) and thus decreased respiratory 
control (Rafique et al., 2001) and has been implicated in cardiovascular and 
neurological damage  (Semchenko et al., 1983; Meerson et al., 1987). ROS may also 
induce modification to the amino acids of proteins through oxidation of the protein 
backbone, formation of protein cross linking, oxidation of amino acid side chains and 
protein fragmentation which results in loss of function or enzymatic activity due to the 
loss of secondary or tertiary structure of the protein. Protein oxidation has been 
associated with alterations of ion pumps and changes in membrane potential and has 
been implicated in various cardiac, metabolic and neurological disorders (Wolff and 
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Dean, 1987; Richards et al., 1988; Smith et al., 1991; Ylaherttuala et al., 1995). ROS 
induce damage to DNA of the nucleus and the mitochondria by creating a wide range of 
different structural lesions which affects either the base or the sugar residue of DNA 
including oxidised purines, oxidised pyrimidines, abasic sites, single strand breaks and 
double strand breaks leading to instability and mutations affecting its function. For 
example,  mutations in mitochondrial DNA results in the decline of  functional 
respiratory chain proteins. This leads to the reduction in the bioenergetics capacity of 
the tissue ultimately resulting in age-related pathology, senescence  and possibly more 
mitochondrial DNA mutations (Wallace, 1999). An increase in oxidative DNA lesions 
have been found in many tumours (Matsui et al., 2000) indicating a role in the etiology 
of cancer and also other age-related pathological conditions such as neurodegenerative 
disease (Alam et al., 1997), inflammatory disease (Frenkel et al., 1993) and 
cardiovascular disease (Collins et al., 1998). The damage to lipids, proteins and DNA  
depends on which ROS is involved, its reactivity, its localization, the oxidisable  
molecules present, the ratio of ROS/oxidant, the antioxidant defences available and 
available repair. Lipid peroxidation may also initiate other molecules to lipoxidation-
derived damage since chain reactions create hydroperoxides and endoperoxides which 
are involved in producing reactive intermediates including alkanals, alkenals, 
hydroalkenals, glyoxal, and malondialdehyde which induce DNA and protein damage 
(Ueda et al., 1985; Park et al., 2002). 
 
1.4.4. Antioxidant defences 
 
Cells have antioxidant defence systems that help protect from the destructive effect of 
ROS by either inhibiting its generation or directly removing it. They are therefore 
involved in the maintenance of cellular homeostasis. Effective antioxidant defences may 
be achieved through the upregulation of genes that encode antioxidants and systems 
involved. Antioxidants may be enzymatic or non-enzymatic. The importance and 
efficacy of various antioxidants defences depends on which ROS is involved, how it is 
generated, where it is generated and which target of damage is selected. However in 
some situations, antioxidants may protect against ROS in one system but fail to protect 
in another system (Burton and Ingold, 1984; Palozza et al., 1995; Edge et al., 1997). For 
example, antioxidants have been shown to become pro-oxidants when iron and copper 
are not in their normal non-catalytic state (Bagnati et al., 1999) as shown in some 
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disease states such as hemochromatosis (Britton and Brown, 1995). Important 
enzymatic antioxidants are superoxide dismutase, catalase and glutathione peroxidases 
and non-enzymatic defence systems include glutathiones and vitamins such as vitamin 
A, C and E. 
   
1.4.5. Repair/elimination of ROS damage 
 
Antioxidants are unable to completely remove ROS and therefore mechanisms have 
evolved that can monitor and repair the damage to lipids, proteins and DNA, or if 
damage is too extensive remove the cell or prevent it from dividing. This serves to 
maintain intracellular homeostasis and thus genomic stability for healthy functioning 
and survival. Different cellular responses are triggered depending on the type and extent  
of oxidative damage. Repair of oxidative modification to double bonds in phospholipid  
acyl chains is made by deacylation followed by rapid and selective reacylation of lyso- 
phospholipids (Kuypers, 2007). This is accomplished by an adenosine triphosphate 
(ATP)-dependent process in which fatty acids are taken up from plasma, activated to 
acyl Coenzyme A and used to generate phospholipid. Long-chain acyl Coenzyme A 
synthetases have been shown play a crucial role in plasma membrane phospholipid 
turnover (Kuypers, 2007). Little is known about the repair of protein modification by 
oxidative damage however it is classified as either direct or indirect. Direct repair 
involves specific enzymatic systems which catalyse the reduction of oxidative products 
of sulphur-containing amino acids including: the glutaredoxin/glutathione/glutathione 
reductase and the thioredoxin/thioredoxin reductase systems which reverse the 
oxidation of disulfide bridges and cysteine sulfenic acids; and the methionine sulfoxide 
reductases which reduce methionine sulfoxide back to methionine within proteins 
(Petropoulos and Friguet, 2006). Indirect repair involves the recognition, removal, 
degradation and replacement of the damage protein by triggering de novo protein 
synthesis.  Various DNA repair systems are involved in the removal of damaged DNA 
by ROS depending on the type of lesion induced including: base excision repair which 
removes oxidised purines, pyrimidines and basic sites; repair of single and double 
strand breaks; repair of mitochondrial DNA damage; and the repair of bulky DNA 
lesions by nucleotide excision repair (Lu et al., 2001). 
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1.4.6. The oxidative stress theory of ageing 
 
The oxidative stress theory of ageing is one of the most studied mechanistic insights  
into the biological ageing process. Denham Harman in 1956 first postulated that free 
radicals play a role in biological ageing when he recognised that ionizing radiation of 
living organisms, which induces the formation of free radicals, induces mutations, 
cancer and physiological changes seen with in age-related outcomes giving rise to the 
“free radical theory of ageing”  (Harman, 1956). This theory suggests that ROS are 
involved in the progressive loss of homeostatic regulation of biological function over 
time due to damage caused by them at the cellular and molecular level increasing 
vulnerability to detrimental health outcomes and thus mortality. Further evidence that 
free radicals are produced endogenously was made by the discovery of the highly  
specialized enzyme superoxide dismutase which is able to convert superoxide into water 
and hydrogen (McCord and Fridovich, 1969). This suggested that ageing could be 
accelerated by the failure in the antioxidant defence system or by pro-oxidant 
generation. Harman in 1972 then modified the “free radical theory of ageing” to the 
“mitochondrial free radical theory of ageing” when he suggested that mitochondria are 
the major sources of ROS production and are also a major target of ROS resulting in 
their damage (Harman, 1972). This is because mitochondria lack nucleotide excision 
repair mechanisms and are therefore inefficient in repairing DNA damage caused by 
ROS. The mitochondrial nuclear genome also lacks histone protection and is therefore 
at an increased risk of damage by ROS. The “mitochondrial free radical theory of 
ageing” was then modified to the “oxidative stress theory of ageing” to include other 
related oxygen molecules that do not fit the definition of a free radical but contribute to 
their production or are able to oxidise molecules such as singlet oxygen and hydrogen 
peroxide (Yu and Yang, 1996). 
 
1.4.7. Cellular senescence 
 
In 1961, Hayflick and Moorhead proved that somatic cells have a limited lifespan when 
they discovered that embryo-derived fibroblasts can only divide for  a limited number of 
times in culture known as the Hayflick limit (Hayflick and Moorhead, 1961). When  
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cells reach the Hayflick limit they become irreversibly arrested in the cell cycle and are 
therefore unable to continue cell proliferation known as cellular senescence. Cellular 
senescence is not limited to fibroblasts but is also observed in other cell types such a  
keratinocytes (Rheinwald and Green, 1975), endothelial cells (Mueller et al., 1980),  
lymphocytes (Tice et al., 1979), adrenocortical cells (Hornsby and Gill, 1978) and 
chondrocytes (Evans and Georgescu, 1983). Since cell lines from tumours never reach 
replicative senescence and are therefore immortal it is thought that cellular senescence 
evolved as a mechanism to supress tumour progression and therefore prevent the 
development of cancer. However there is increasing evidence that cellular senescence 
contributes to biological ageing where an increasing number of studies have shown that 
senescent cells can be found in vivo and are associated with the detrimental outcomes 
associated with ageing (Martin et al., 1970; Dimri et al., 1995; Paradis et al., 2001; 
Going et al., 2002; Minamino et al., 2003). It is therefore thought that an accumulation 
of senescent cells will disrupt normal tissue function thus leading to age-related 
pathology.  
 
1.4.8. The role of ROS production from dysfunctional mitochondria in cellular 
senescence and other cellular senescence phenotypes 
 
In addition to growth arrest, senescent cells show other phenotypic changes distinct 
from their replicative counterparts which provide mechanistic insights into the causes 
and/or consequences of cellular senescence. These phenotypes may therefore serve as 
potential BoA. In 1990, Harley et al. demonstrated using fibroblasts that during each 
round of cellular division the DNA-protein structures that cap the ends of linear 
chromosomes, known as telomeres which prevent DNA repair machineries recognizing 
them as DNA damage, get shorter and are therefore a possible mechanistic cause of 
cellular senescence (Harley et al., 1990). In 1995, von Zglinicki discovered that ROS 
accelerated the onset of replicative senescence by increasing the rate of telomere 
shortening (von Zglinicki et al., 1995; von Zglinicki, 2002). In 1998, Bodnar et al. 
supported this mechanism when they found that the expression of the catalytic subunit 
of telomerase (hTERT), an enzyme able to elongate telomeres, leads to  life-span 
extension of human cells (Bodnar et al., 1998). It was suggested that telomeres act as a 
biological clock and once they reach a critical length then cellular senescence will be 
triggered. Telomere length has therefore been extensively studied as a potential BoA 
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however there are many conflicting studies which, as like other “classical” BoA, may be 
because of the diminishing association between telomere length and mortality with age 
(Martin-Ruiz et al., 2005). In fact, other characteristics of telomere dysfunction 
independent of telomere length may also be important initiators of cellular senescence 
(Hewitt et al., 2012). This could include the disruption of telomeric repeat-binding 
factors (TRF1, TRF2, POT1 etc.) which are essential in the formation of t-loops that cap 
and protect telomeres (de Lange, 2005). In 2003, di Fagagna et al. demonstrated that the 
main initiator of cellular senescence is a DNA damage response when telomeres 
become uncapped which includes induction of DNA damage foci and induction of DNA 
repair and damage checkpoint factors (di Fagagna et al., 2003). There is also evidence 
for a telomere-independent DNA damage response that drives cellular senescence 
(Nakamura et al., 2008). Cellular senescence however is much more complex than 
solely a DNA damage response and other key players are required to maintain the 
cellular senescence state. Studies found that senescent cells express many genes 
differentially than non-senescent cells (Shelton et al., 1999). The most prominent genes  
involved in senescence are those involved in inflammatory signalling known as the 
senescence associated secretary phenotype (SASP) (Coppe et al., 2008) and those 
involved in mitochondrial dysfunction (Passos et al., 2007a). ROS production from 
dysfunctional mitochondria is thought to be the driving force of cellular senescence 
which links these key players by increasing the rate of telomere shortening (von 
Zglinicki et al., 1995; von Zglinicki, 2002), as well as feeding into a continuous DNA 
damage response that sustains the SASP; indicated by the accumulation of 
inflammatory mediators, and mitochondrial dysfunction; indicated by the enhanced 
production of superoxide together with (frequently) increased mitochondrial mass and 
decreased mitochondrial membrane potential. This maintains an irreversible state of 
persistent damage in senescent cells and may even induce senescence in neighbouring 
cells (Acosta et al., 2008; Kuilman et al., 2008; Passos et al., 2010; Nelson et al., 2012). 
The subsequent dysregulation of physiological function contributes to age-related 
pathology and/or carcinogenesis (Tchkonia et al., 2010; Baker et al., 2011). It is 
therefore hypothesized that the main players, ROS production from dysfunctional 
mitochondria, are potential BoA (Figure 1.10.). However their reliability and validity 
have not been investigated in large population studies, especially within the very old 
population. 
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Figure 1.10. ROS production from dysfunctional mitochondria is hypothesized to 
be the driving force of cellular ageing and is therefore a potential BoA.  
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1.5. Potential oxidative stress-related BoA 
 
1.5.1. Superoxide production, mitochondrial mass and mitochondrial membrane 
potential as markers of mitochondrial ROS production and dysfunction and their 
measurement by flow cytometry 
 
Mitochondria are semi-autonomous organelles that contain their own genome. Although 
most mitochondrial proteins are encoded by genes in the nucleus, some components of 
the electrol transport chain are encoded by the mitochondrial DNA (mtDNA). The main 
function of the mitochondria is the production of ATP by oxidative phosphorylation (as 
mentioned previously) however they are also involved in a variety of other important  
functions including various signalling events, apoptosis and ROS production.  The 
function of mitochondria is reflected in their dynamic nature. They are able to 
continuously fuse and divide when adapting to changes in physiological conditions 
which serves to maintain their function (Seo et al., 2010). 
 
Fusion and fission is thought to conserve healthy mitochondria by sustaining the 
integrity of mtDNA. A single cell can contain both mutant and wild-type mtDNA, 
known as mtDNA heteroplasmy however when a threshold of 70-90% mutant mtDNA 
is reached then cellular dysfunction occurs (Wallace and Fan, 2009; Seo et al., 2010). 
One hypothesis is that efficient fusion of mitochondria enables the complementation of 
mutant mtDNA  since this will be diluted by the introduction of wild-type mtDNA, 
preventing the threshold being reached (Chan, 2006; Seo et al., 2010). A balance of 
fusion and fission will therefore allow the distribution of healthy mitochondria. If the 
protein machinery involved in fusion and fission were to become damaged, which may 
occur directly or indirectly by oxidative stress, then this will cause substantial changes 
in mitochondrial dynamics, notably in mitochondrial mass and membrane potential. 
Changes in these parameters therefore reflects mitochondrial dysfunction. This would 
then results in further ROS production, resulting in a vicious cycle of self-amplifying 
damage. Since ageing is thought be the result of increasing mtDNA mutations and the 
duplication and turnover of mitochondria is an ongoing process, measuring 
mitochondrial ROS production, mass and membrane potential may serve as potential 
BoA.  
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It has previously been shown that in human fibroblasts and other tissues that high 
mitochondrial ROS production, high mitochondrial mass and low mitochondrial 
membrane potential are associated with cellular senescence (Passos et al., 2007a; Passos 
et al., 2007b; Passos et al., 2010; Wang et al., 2010). While the association of increased 
mitochondrial mass in cellular senescence has been contested (Sahin et al., 2011), 
increases in ROS and decreases in mitochondrial functionality, typically associated with 
low mitochondrial membrane potential, have commonly been found in ageing and 
senescence (Hagen et al., 1997; Hagen et al., 1999; Kokoszka et al., 2001; Moiseeva et 
al., 2009). It is therefore hypothesized that these measurements reflecting mitochondrial 
dysfunction are potential oxidative stress-related BoA (Figure 1.11.). 
 
The use of fluorescent probes that bind to the mitochondria independent or dependent of 
mitochondrial membrane potential have been widely used to measure mitochondrial 
ROS production, mass and membrane potential. These can can be detected using 
fluorescence microscopy or flow cytometry however the latter is a preferred technique 
due to its rapid measurement on individual cells, especially when large number of 
samples are to be measured. Flow cytometers are laser based and measure cellular 
parameters within a fluid stream based on light scatter and fluorescence. The light 
scatter from the laser can be measured as forward scatter (FSC) which is an 
approximation of cell size  or as side scatter (SSC) which is an approximation of 
granularity or shape. FSC and SSC parameters are first used to identify the cell 
population of interest. When cells are labeled with a flurochrome the emitted light can 
be detected by florescent detectors for which many cellular properties can be measured. 
These may include specific cellular components or cellular functions depending on the 
type of probe used. There are various probes available that permit the measurement of 
ROS production, mitochondrial mass and mitochondrial membrane potential. 
Dihydroethodium (DHE) is a widely used probe for detecting intracellular superoxide 
levels. Within the cytosol it exhibits a blue fluorescence but when it becomes oxidized 
by superoxide it forms ethidium which intercalates with DNA and emits a red 
fluorescence. The specificity of DHE to superoxide has been demonstrated by various 
studies and it has been reported as the “gold standard” for superoxide detection (Rothe 
and Valet, 1990; Bindokas et al., 1996). Probes that measure mitochondrial mass need  
 
 
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. Proposed model and potential markers of mitochondrial dysfunction. 
(Adapted from (Seo et al., 2010)). 
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to be independent of membrane potential. MitoTracker probes including MitoTracker 
Green FM  are cell-permeant mitochondrion-selective probes that contain a mildly thiol- 
reactive chloromethyl moiety. The chloromethyl group appears to be responsible for 
keeping the probe associated with the mitochondria (Presley et al., 2003). To measure 
the mitochondrial membrane potential fluorescent probes with dual fluorescent signal 
emissions were developed that are sensitive to a switch in membrane potential. One of 
these probes is 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine 
iodide (JC-1). It exhibits potential-dependent accumulation in mitochondria that is 
detectable by a fluorescent shift from green to orange. Membrane potential is measured 
by the orange to green fluorescent intensity ratio. JC-1 is one of the most stable of the 
mitochondrial membrane probes. 
 
 
1.5.2. F2-isoprostanes as markers of lipid peroxidation and their measurement by 
automated dissociation enhanced fluorescence immunoassay (AutoDELFIA) 
 
Since ROS are often present at low concentrations or are short lived in biological 
systems an alternative oxidative stress-related BoA is to measure the damage caused or 
products of the damage. Isoprostanes are prostaglandin-like molecules formed from 
non-cyclooxygenase oxidative modifications of arachidonic acid from the free radical 
attack of cellular membrane phospholipids or circulating low density lipoproteins. The 
first class of isoprostanes identified were the F2-isoprostanes (Figure 1.12). They are 
derived from the precursor arachidonic acid which undergoes hydrogen and oxygen 
insertion. Four different peroxyl radicals are formed depending on the site of insertion. 
Endocylization of the radicals takes place and further oxidation yields endoperoxide 
regioisomers. These are then reduced to form F2-isoprostanes. These can be designated 
5, 12, 8  or 15 series depending on the carbon to which the side chain hydroxyl is 
attached. Although some compounds are favoured evidence that all four are produced 
has been shown (Liu et al., 1999). Isoprostanes are released by cellular activation and 
circulate in the plasma either as free form or esters in phospholipids and are excreted in 
the urine. The F2-isoprostanes are the most studied and have been shown to be accurate 
markers of oxidative stress in vivo, including measurements in plasma and urine  
(Morrow et al., 1990a; Morrow et al., 1990b; Morrow and Roberts, 1997; Morrow and 
Roberts, 2002; Cracowski and Durand, 2006; Morrow, 2006; Montuschi et al., 2007).  
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Several methods have been developed to analyse F2-isoprostanes including gas 
chromatography mass spectroscopy (GCMS) (Liu et al., 2009), liquid chromatography 
with tandem mass spectroscopy (LCMS/MS) (Liang et al., 2003; Sircar and Subbaiah, 
2007), radio immunoassay (RIA) (Basu, 1998) and enzyme immunoassay (EIA) (Sasaki 
et al., 2002). Although GCMS is the preferred the adaptation of this method, 
LCMS/MS, is also widely used. The advantage of this technique is that it has a high 
resolution of separation, high specificity and sensitivity and determines multiple F2- 
-isoprostane isomers at a time. However it is not the method of choice when analysing a 
large number of samples since it is laboriously intensive, requires expensive equipment, 
skilled operators and is time consuming. Alternatively EIA have also been developed to 
quantify F2-isoprostanes using antibodies generated against some selected isomers such 
as 8-isoprostanes. EIA are low cost and easy to use. A disadvantage to the EIA method 
is that questions remain on the specificity of the antibody to specific isomers. Time-
resolved fluorescence immunoassays (TR-FIAs) including automated dissociation 
enhanced lanthanide fluorescence immunoassay (AutoDELFIA) offers greater 
sensitivity, specificity and wide linear range than conventional EIA. TR-FIAs utilize 
lanthanide chelates which have unique fluorescence properties, a large stoke shift, high 
florescent intensity and long decay times giving this method high sensitivity and 
specificity (PerkinElmer, 2006). TR-FIA can be performed manually or high throughput 
on a full automated walkway which performs all sample and reagent handling and all 
assay stages including measurements automatically. This therefore brings cost and time 
saving. Some studies comparing the GCMS method with EIA have reported good 
agreement however not identical results (Soffler et al., 2010) where as others have not 
shown any agreement (Il'yasova et al., 2004). The adaptations of these methods, 
LCMS/MS and DELFIA, therefore need to be investigated for their agreement. 
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Figure 1.12.  Formation of the F2-isoprostane series. (Milne et al., 2005). 
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1.5.3. Peripheral blood as a surrogate tissue for measuring potential oxidative stress-
related BoA in population studies 
 
A criteria of a BoA is that it should cause no harm when tested repeatedly within 
individuals and it should also be technically simple enough to measure so most clinical 
laboratories can perform the test accurately and reproducibly, without the need for 
specialized equipment or techniques. This therefore must be taken into consideration  
when deciding which are the most suitable markers and methods for measuring 
potential oxidative stress-related BoA within a large population studies. There are 
various surrogate tissues available that can easily be obtained which are assumed to be 
informative of other inaccessible tissues. Surrogate tissues that would enable the direct 
measurement of mitochondrial ROS production and dysfunction within cells include 
blood cells, buccal cells, hair follicle, and skin. Oxidative stress could also be measured 
indirectly by measuring products of oxidative damage, such as F2-isoprostanes, which  
may be present in blood plasma, urine, stool, saliva, sputem, nasal lavage, cerumen, hair 
shaft, or nail (Rockett et al., 2004). Despite all of these being easy assessable, blood is 
the most appropriate surrogate tissue since it can be obtained in large quantities 
enabling greater sensitivity and specificity and also it can be used to compare and  
validate potential oxidative stress related BoA measured directly in blood cells and 
those measured indirectly in plasma.  Limitations however to using peripheral blood are 
that this would only be a reflection of one type of tissue. Tissues may age at different 
rates, as reflected by different timings and types of age-related diseases, and thus 
oxidative stress-related BoA may be tissue dependant. However  many studies, although 
found in different levels, have shown agreements between various cellular senescence 
and oxidative stress-related markers in peripheral blood and other tissues suggesting 
they may be tissue independent (Table 1.2). Peripheral blood therefore offers a 
significant promise for the measurement of potential BoA as a substitute for tissues that 
are not easily assessable due to practical and ethical barriers.  
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     Reference Tissue Mean (p value) R2 (p value) n 
     Telomere length     
(Friedrich et al., 2000) Leukocytes
a
 6546±519SD bp  9 
 Skin tissue
b
 7792±596SD bp (<0.01
a+b
) 0.79 (0.017)
a+b
 9 
 Synovial tissue
c
 7910±420SD bp (<0.001
a+c
) 0.54 (0.038)
a+c
 9 
     DNA damage adducts     
(Godschalk et al., 1998) Monocytes
a
 2.9(0.7-0.1 range) x10
8
n/t   10 
 Skin tissue
b
 0.28(0.25-0.81 range) x10
8
n/t  0.74 (0.006
 
)
a+b
 10 
     DNA repair     
(Herrera et al., 2009) Lymphocytes
a
 0.60±0.29SD  23 
 Colon tissue
b
 3.78±5.53SD (0.001
a+b
) 0.53 (0.034)
a+b
 23 
     
Table 1.2. Agreement between various cellular senescence and oxidative stress 
related biomarkers in peripheral blood and other tissues of humans. (bp: base pairs, 
n/t: not tested, SD: Standard deviation). 
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1.6.   Overall aims  
 
The overall aim of this study is to assess the reliability and validity of potential 
oxidative stress-related BoA in the very old population specifically ROS production and 
mitochondrial dysfunction in PBMCs by flow cytometry and plasma F2-isoprostanes by 
AutoDELFIA 
 
The specific questions asked are: 
 
 Does the predictive value of various classical BoA change in different age groups 
and if so which are predictive in the very old population? This is so they can be 
used to validate potential oxidative stress-related BoA in this age group. 
 
 Are potential oxidative stress-related BoA experimentally reliable? 
 
 Are potential oxidative stress-related BoA valid in the very old population? 
 
 Are potential oxidative stress-related BoA valid in a mouse model of ageing? 
 
 Are potential oxidative stress-related BoA associated with age-related outcomes 
in the very old population? 
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Chapter 2.  Materials and Methods 
                                                                                     
2.1.   The Newcastle 85+ study             
                                                                          
2.1.1. Study design 
 
A full description of the Newcastle 85+ study design, a community-based cohort study 
of health and ageing in the very old, has previously been published (Collerton et al., 
2007; Collerton et al., 2009; Davies et al., 2010). Briefly the study invited all surviving 
adults born in 1921 who turned 85 in 2006 when the study commenced and were 
permanently registered with a participating general practice in Newcastle upon Tyne 
and North Tyneside (North-East England). All eligible individuals were invited to 
participate including those in institutions and those with cognitive impairment. The 
study excluded only those with end stage terminal illness and those who might pose a 
safety risk to a nurse visiting alone. Participants were visited by a research nurse at their 
place of residence (i.e. their own home, care home: nursing or residential) at baseline 
(phase 1: 2006-7, n=854), 18 months (phase 2: 2007-9, n=631) and 36 months (phase 3: 
2009-10, n=484).  Attrition between phases 1 and 3 was mainly due to deaths (62.7%, 
232/370) with the remainder due to drop out. At each phase a multi-dimensional health 
assessment was undertaken including questionnaires, physical measurements, function 
tests and a blood sample. Bloods were drawn between 7:00am and 10:30am with great 
attention to getting the blood samples to the laboratory as quickly as possible. 95% of 
samples were received for processing within 1 hour of venepuncture. Blood processing 
was carried out at the Biomarkers Laboratory, Edwardson Building, Institute for Ageing 
and Health (IAH), Newcastle University, Newcastle upon Tyne, UK by Carmen Martin-
Ruiz, Claire Kolenda, Craig Parker, Paul Collier, Sam Jameson, Hanna Curtis and Anna 
Tang. A review of general practice records was also undertaken during phase 1 and 
phase 3 assessments by trained research nurses. Ethical approval was obtained from the 
Newcastle and North Tyneside Research Ethics Committee (reference number 
06/Q0905/2). Written informed consent was obtained from either participants or from a 
consultee, usually a relative or carer, when participants lacked capacity to consent. The 
study population at baseline was sociodemographically representative of the local 
(Newcastle upon Tyne and North Tyneside) and wider (England and Wales) population 
(Collerton et al., 2009). A summary of the study recruitment is shown in Figure 2.1. 
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Figure 2.1. Recruitment of the Newcastle 85+ study. (Figure was adapted from data 
kindly supplied by Karen Davies, Senior Clinical Research Nurse Manager of the 
Newcastle 85+ Study) 
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All data reported in this study are from the phase 3 assessments (participants aged 88-89 
years) unless otherwise stated within the result sections. 
 
2.1.2. Characteristics 
 
Gender, ethnicity, age of natural mother and/or fathers death, place of birth, has/had 
sibling(s), any full-time higher education, number of years in main job/role, has 
offspring, marital status, living alone, housing type,  alcohol consumption,  smoking 
status, non-prescribed supplementation use, prescribed supplementation use, aids and 
appliance use, social participation, important key events and blood fasting status were 
assessed using questionnaires at participants place of residence by trained research 
nurses.  
 
2.1.3. Mitochondrial haplogroups 
 
Mitochondrial haplogroups were determined using a stepwise algorithm (Torroni et al., 
1996) by primer extension of multiplex polymerase chain reaction (PCR) products with 
the detection of the allele specific extension products by matrix-associated laser 
desorption/ionization time of flight (Sequenom MassARRAY, San Diego, California, 
US) at the Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic 
Medicine, Newcastle University, Newcastle upon Tyne, UK by Deepthi Ashok as 
described in (Collerton et al., 2013).  
 
2.1.4. Anthropometry 
 
Anthropometry was measured at participant’s place of residence by trained research 
nurses. Weight, body fat %, body fat mass, fat free mass and total body water were 
measured using an electronic body composition analyser (Tanita Europe B.V., 
Middlesex, UK). Height was calculated using the average of two right arm demi-span 
measures (1.35 multiplied by demi-span plus 60.1 for females and 1.40 multiplied by 
demi-span plus 57.8 for males) due to difficulties measuring height in the elderly. 
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2.1.5. Haematology 
 
Full blood counts (red blood cells, white blood cells, neutrophils, lymphocytes, 
monocytes, eosinophils and basophils) were measured by analysts at the Freeman 
Hospital, Newcastle upon Tyne, UK. 
 
2.1.6. Biochemistry 
 
Electrolytes, urate, urea, creatinine, liver panel (total protein, bilirubin and alanine 
transaminase), bone panel (albumin, calcium, albumin-adjusted calcium, phosphate and 
alkaline phosphatase), glucose, glycosylated haemoglobin (HbA1c); lipid profile 
(cholesterol, triglycerides, high and low density lipoproteins, apolipoproteins (A1 and 
B)), serum cortisol, thyroid function (free triiodothyronine (T3), free thyroxine (T4), 
thyroid stimulating hormone and thyroid peroxidase antibody), high-sensitivity C-
reactive protein (CRP), rheumatoid factor (RhF) and N-terminal pro b-type natriuretic 
peptide (NT-pro BNP) were measured by analysts at the Royal Victoria Infirmary, 
Newcastle upon Tyne, UK as described in (Collerton et al., 2013). 
 
2.1.7. Nutrition 
 
Plasma total homocysteine, plasma vitamin B2, and plasma vitamin B6 were measured 
by the Nutritional Biomarker Analysis team from the Elsie Widdowson Laboratory at 
the MRC Human Nutrition Research Unit, Cambridge, UK and serum ferritin, red cell 
folate, vitamin B12 and serum vitamin D were measured at the Royal Victoria 
Infirmary, Newcastle upon Tyne, UK as described in (Martin-Ruiz et al., 2011a). 
 
2.1.8. Inflammatory response  
 
Inflammatory response was measured at the Biomarkers Laboratory, Edwardson 
Building, IAH, Newcastle University, Newcastle upon Tyne, UK by Claire Kolenda and 
Craig Parker. Lithium heparin (LiHep) blood samples were stimulated with ultrapure 
lipopolysaccharide (Autogenbioclear, Nottingham, UK) and serum supernatants were 
incubated for 24 hours at 37˚C. Il-6 and TNF-α were measured by 
electrochemiluminescence on a 96-well Multi-SPOT Meso Scale Discovery assay using 
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the SECTOR Imager 6000 (Meso Scale Diagnostics, LLC. Gaithersburg, Maryland, 
US) as decribed in (Martin-Ruiz et al., 2011a).  
 
2.1.9. Lymphocyte subpopulations  
 
Lymphocyte subpopulations were measured at the Biomarkers Laboratory, Edwardson 
Building, IAH, Newcastle University, Newcastle upon Tyne, UK by Anna Tang and 
Sam Jameson. Blood samples stained with fluorescently-labelled antibodies (BD 
Biosciences Oxford, UK) to determine the % of B lymphocytes  (all (CD19 positive 
(+)), Memory (CD27+) and Naive (CD27 negative (-))), Cytotoxic T lymphocytes (all 
(CD3+/CD8+), Memory (CD45RO+/CD27-) and Naive (CD45RO-/CD27+)) and 
Helper T lymphocytes (all (CD4+), Memory (CD45RO+/CD27-) and Naive (CD45RO-
/CD27+)) were measured by 4-colour flow-cytometry (Becton Dickinson FACScan 
Flow Cytometery system, BD Biosciences, California, US) as described in (Martin-Ruiz 
et al., 2011a). 
 
2.1.10. Telomere length 
 
Telomere length was measured at the Biomarkers Laboratory, Edwardson Building, 
IAH, Newcastle University, Newcastle upon Tyne, UK by Carmen Martin-Ruiz and 
Craig Parker. The abundance of telomeric template versus a single gene (glyceraldehyde 
3-phosphate dehydrogenase) was measured by quantitative real-time polymerase chain 
reaction (PCR) (7900HT Fast Real Time PCR system, Applied Biosystems, California, 
US) as described in (Martin-Ruiz et al., 2011a). 
 
2.1.11. DNA damage and repair 
 
DNA damage and repair were measured at the Biomarkers Laboratory, Edwardson 
Building, IAH, Newcastle University, Newcastle upon Tyne, UK by Craig Parker. DNA 
damage (gamma ray-induced DNA strand breakage) and DNA repair capacity of 
peripheral blood mononuclear cells (PBMCs) were measured by automated 
Fluorometric analysis of DNA unwinding (FADU) analysis. PBMCs from LiHep blood 
were isolated by density gradient centrifugation using Leucosep® tubes (Greiner, North 
Carolina, US) and kept in culture with RPMI 1640 medium (R0883, Sigma, Poole, UK) 
plus 10% foetal bovine serum, 1% penicillin/streptomycin and 2% glutamine at 37˚C 
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with 5% carbon dioxide overnight. Three 50 microliter (μl) aliquots of 5x105 cells were 
prepared per participant: control cells (C), damaged cells (D) which were treated with 5 
grays (Gy) of gamma-irradiation (a dose estimated to halve the integrity of the DNA 
through single strand breaks), and repaired cells (R) which after 5Gy of gamma-
irradiation were kept for 1 hour at 37˚C to allow for the damage to be repaired. Cell 
suspensions were kept on ice at all times. Samples were then treated with 10mM of 
sodium phosphate, 0.25M of meso-inositol, 1mM of magnesium chloride  and pH7.2 
then applied onto 96-well black microplates with six repeats for each of the conditions 
described above. By means of an epMotion liquid handling robot with thermal modules 
(Eppendorf UK Ltd, Histon, UK), cells were sequentially treated as follows: 12 minutes 
at 4˚C with lysis buffer (9M urea, 10mM of sodium hydroxide, 25mM of trans-1,2-
diaminocylohexan-N,N,N′N′-tetraacetic acid; 0.1% sodium dodecyl sulfate), 15 minutes 
at 4˚C plus 90 minutes incubation at 30˚C with alkaline buffer (40% lysis buffer in 0.M 
sodium hydroxide), 10 minutes at room temperature with neutralising buffer (1M 
glucose, 15mM beta-mercaptoethanol) and 7 minutes at room temperature in the dark 
with 1xSYBR Green (diluted in 48mM sodium hydroxide). The plates were then 
measured for fluorescence (excitation 485nm, emission 535nm) using the TECAN 
SPECTRAFluor Plus fluorimeter (TECAN UK, Reading, UK). Each plate included an 
internal control of sheared salmon sperm DNA, 60 ng/μl. Gamma ray-induced DNA 
damage (D) was estimated as the percentage of fluorescence per signal intensity in 
samples (C) that is lost in samples (D): D = 100 x (1 – (average signal for samples 
D)/(average signal for samples C)), the breakage remaining after 1 hour repair (B) was 
estimated as the percentage of fluorescence signal intensity in samples (C) that is lost in 
samples (R): B = 100 x (1 – (average signal for samples R)/(average signal for samples 
C)), while DNA repair was estimated as % damage that has been recovered after 1 hour 
of repair: 100 x (D – B)/D. (This was described in (Martin-Ruiz et al., 2011a). 
 
2.1.12. F2-isoprostanes by liquid chromatography-tandem mass spectrometry 
(LCMS/MS)  
 
F2-isoprostanes by LCMS/MS were measured at Institute of Cellular Medicine, 
Framlington Place, Newcastle University, Newcastle upon Tyne, UK by Michael Dunn. 
Isoprostanes iPF2α-III (8-iso Prostaglandin F2α) and iPF2a-I (5-iPF2α-VI) were extracted 
from ehtylenediaminetetraacetic acid (EDTA) plasma samples (300μl).  Internal 
standard, isoprostanes iPF2α-III, iPF2α-I and the deuterated analogue iPF2α-III–D4 
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(Cayman Chemical Ann Arbor, Michigan, US), were diluted in LC/MS/MS grade 
methanol. Calibration curve standards and EDTA plasma samples (300μl) were spiked 
with 2ng of iPF2α-III–D4, treated with 500μl of aqueous 1M potassium hydroxide and  
incubated at 37˚C for 14 hours. After incubation, the pH of the samples was adjusted to 
pH3 with 2% orthophosphoric acid and centrifuged at 13000 revolutions per minute 
(rpm). Samples were then applied for purification onto 96 well Bond Elute Plexa solid 
phase extraction cartridges (100mg), Varian, Harbor City, California, US) 
preconditioned with water and methanol. After washing with 5% methanol, the 
isoprostanes were eluted with methanol. Eluates were evaporated to dryness under a 
stream of nitrogen and reconstituted in 100μl of 90:10 water:methanol. A seven point 
linear calibration curve was established over a range of 0.1-10ng/ml for both iPF2α-III 
and iPF2α-I. The seven calibration standards were run both before and after the 
participants' samples. Every 20 samples, an internal control sample (10% methanol 
spike with iPF2α-III and iPF2α-I) was run to monitor intra-assay and inter-assay 
variability. Quantitation of plasma iPF2α-III  and iPF2α-I was performed using a 
Quantum Ultra triple quadrupole mass spectrometer coupled to a Surveyor LC system 
operating with Xcalibur software, version 2.0 (Thermo Fisher Scientific, Hemel 
Hempstead, UK). A Rheodyne 10 port switching valve was used for on-line solid phase 
extraction (2mm) x 20mm Strata C18-E 20 µm cartridge, Phenomenex, Macclesfield, 
UK). Samples were loaded onto the on-line extraction cartridge with 80:20 
water:methanol at a flow of 1ml/minute. Liquid chromatographic separation was carried 
out on a 2.1mm x 50mm x 2.5μm XBridge C18 column (Waters, Manchester, UK), with 
gradient elution comprising solvent A of 20mM ammonium bicarbonate/ammonium 
carbonate in water and solvent B of 20mM ammonium bicarbonate/ammonium 
carbonate in 95:5 methanol: water, at pH9.2 and a flow rate of 200μl/minute. A solvent 
gradient of 90% A, 10% B to 40% A and 60% B over 20 minutes, followed by 100% B 
for a further 5 minutes was employed. The analytical runs were performed at 40
o
C. The 
mass spectrometer was operated using multiple reaction monitoring in negative ion 
mode, with a heated electrospray ionisation source with argon as collision gas. 
Precursor, product ions and collision energy were determined after optimising of 
MS/MS conditions by infusion of 100μg)/ml solutions of iPF2α-III, iPF2α-I and iPF2α-
III–D4 in methanol. Both iPF2α-III and iPF2α-I had a parent ion mass-to-charge ratio 
(m/z) of 353.2, with iPF2α-III giving a diagnostic product ion m/z of 193.1, while iPF2α-I 
gave a diagnostic product ion m/z of 115.1. The internal standard, iPF2α-III–D4, had a 
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parent ion m/z of 357.2, giving a diagnostic product ion m/z of 197.1. (This was 
described in (Martin-Ruiz et al., 2011a). 
 
2.1.13. Health assessments and function tests 
 
Health assessments and function tests were measured at participant’s place of residence 
(except general practice record reviews) by trained research nurses. Disability score 
(calculated from 17 self-reported activities of daily living (ADL) with participants 
scoring 1 for each activity in which they required help or were only independent with 
difficulty), cognitive impairment (using the Standardised Mini-Mental State 
Examination (SMMSE) with scores ranging from 0 to 30 (26-30 normal, 22-25 mildly 
impaired, 18-21 moderately impaired and 0-17 severely impaired), self-reported 
physical activity and sleep quality were assessed by questionnaires.  A simple disease 
count score (0-18) was derived from selected chronic diseases (hypertension, ischemic 
heart disease, cardiovascular disease, peripheral vascular disease, heart failure, arterial 
fibrillation, arthritis, osteoporosis, chronic obstructive pulmonary disease, other 
respiratory disease, diabetes, hypothyroidism or hyperthyroidism, cancer in past five 
years, eye disease, dementia, parkinsonism and renal impairment) reviewed within 
general practice records. Hand grip strength was measured using a digital handgrip 
dynamometer (Takei A5401, Chasmors Ltd., London, UK). Four  measurements were 
obtained alternating the first with the participants right hand then the left hand, then 
again with the right hand and finally again with the left hand.  A mean value using the 
highest value from each hand was then calculated and recorded. Timed up and go 
(TUG) test was measured using a stop watch recording the time it took the participant to 
walk three meters from a seated position and back using a standardised chair (46cm to 
seat 64 cm to arm). Time commenced from the point where the participant started to 
move until the participant sat back down.  The use of a walking aid or not was also 
recorded.  Spirometry measures including forced expiratory volume in 1 second (FEV1) 
were measured using a spirometer (Microlab spirometer, CareFusion, Basingstoke, UK) 
connected to a tablet computer for which data was recorded using the Spida 5 software 
program.  
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2.2. Younger control participants 
 
2.2.1. Study design 
 
Blood samples were taken from 19 volunteers in total and were used for experimental 
investigations, to examine age-related changes and to compare with the very old from 
the Newcastle 85+ study. The date of birth was known for 12 of the volunteers with an 
age range of 22-55 years.  
 
2.3. Animal model of ageing study 
 
2.3.1. Study design 
 
Since dietary restriction is known to delay ageing rate, extend survival, delay the 
appearance of most age-related diseases and is becoming increasing recognised to slow 
the rate of accrual of age-related oxidative stress (Merry, 2004), this was used as a 
validated model of ageing.  C57Bl/6 mice were fed an ad libitum (AL) diet since birth  
or 60% of an ad lib diet since 3 months of age (dietary restricted (DR)). Peripheral 
blood samples were taken at 25 month of age (AL (n=10) and DR (n=11)) and bone 
marrow samples were taken at 2 month of age (AL (n=6)), 25 months of age (AL 
(n=12) and DR (n=11)) and 32 month of age (AL (n=10) and DR (n=10)). Mice were  
housed in cages in groups of up to 6 which did not change from weaning (56 x 38 x 18 
cm, North Kent Plastics, Kent, UK). Each mouse was identified with an ear notch. Mice 
were provided with sawdust and paper bedding and had free  access to water. Mice were 
housed at 20 ± 2
o
C under a 12 hour light/dark photoperiod with lights on at 7am.  
 
2.4. Quantification of ROS production and mitochondrial function by flow 
cytometry  
  
2.4.1. Human peripheral blood mononuclear cells (PBMC) isolation 
 
PBMCs from LiHep blood collected at phase 3 (n=362) of the Newcastle 85+ study and 
from control participants (n=20) were isolated by density gradient centrifugation using 
Leucosep® tubes and suspended in culture with RPMI 1640 medium (R0883) plus 10% 
foetal bovine serum, 1% penicillin/streptomycin and 2% glutamine at 37˚C with 5% 
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carbon dioxide at the Biomarkers Laboratory, Edwardson Building, Newcastle 
University by the Biomarkers team. Flow cytometry of human PBMCs was performed 
at the Biogerontology Biomarkers Laboratory, Edwardson Building, IAH, Newcastle 
University by myself and also partially by Deepthi Ashok who introduced me to the 
technique at the beginning of phase 3 of the Newcastle 85+ study.  
 
2.4.2. Mouse PBMC isolation 
 
PBMCs from EDTA blood was centrifuged at 300rpm for 15 minutes at 4
o
C. Plasma 
was transferred to a new tube and the remaining blood was diluted in cold 1x PBS in a 
1:1 ratio. Diluted blood was pipetted slowly on top of half its volume of lymphoprep
TM
 
(1114544, Axis-Shield, Oslo, Norway) making sure they did not mix. Blood was 
centrifuged at 800rpm for 15 minutes at room temperature with no brake applied. 
PBMC layer was brought to a new tube and the volume was adjusted  to 1-2ml with 
cold PBS. PBMCs were centrifuged at 800rpm for 15 minutes at 4
o
C.  Supernatant was 
removed and the pellet was re-suspended in 1ml of RPMI 1640 medium (R7509, Sigma, 
Poole, UK). Since the volume of blood collected for some mice was too little for 
analysis individually, some mice blood had to be combined which were grouped by 
gender, age, dietary group and to the best ability pathology. Mouse PBMCs were 
isolated and analysed by flow cytometry at the Biogerontology laboratory, Edwardson 
Building, IAH, Newcastle University by myself. 
 
2.4.3. Mouse bone marrow isolation 
 
The hind limbs were collected from mice and kept in cold PBS until analysis. All hair 
and skin was removed from the tibia and femur using sharp small scissors and pointed 
curve forceps and the foot was cut off. The muscles of the tibia were moved down to the 
knee with scissors whilst tightly holding the leg from the knee and the tibia was 
dislocated with blunt forceps and put into cold PBS. The muscles from the femur were 
removed upto the hip bone whilst tightly holding the femur and cut with scissors from 
the hip joint and put into cold PBS. The ends of the bones were cut and, using a 1ml 
syringe and needle, were flushed with PBS to make a cell suspension. The clumps were 
broken by pipetting up and down with a syringe and needle in a petri dish. The cells 
were transferred to a 15ml falcon tube. Cells were centrifuged at 1300rmp for 5 minutes 
at 4
o
C. The supernatant was removed and the pellet was re-suspended in 1ml red blood 
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cell lysis buffer for 5 minutes, stopping the reaction with 10ml of PBS. Cells were 
centrifuged at 1300rpm for 5 minutes at 4
o
C. Supernatant was removed and the pellet 
was re-suspended in 1ml of RPMI 1640 medium (R7509). Mouse bone marrow was 
isolated and analysed by flow cytometry at the Biogerontology laboratory, Edwardson 
Building, IAH, Newcastle University by myself. 
 
2.4.4. Human PBMC subpopulation isolation 
 
Populations of Helper T Lymphocytes (CD4+), Cytotoxic T Lymphocytes 
(CD3+/CD8+), Natural Killer T lymphocytes (CD8+CD56+), Naïve and Non-
Senescent Memory T cells (CD8+CD56-CD27+) and Senescent Memory T Cells 
(CD8+CD56-CD27-) were isolated by immunomagnetic sorting (MACS,  Miltenyi 
Biotec, Bergisch Gladbach, Germany) out of 20ml blood samples from four volunteers 
(age range 30-50 years). This was decribed in (Spyridopoulos et al., 2009). 
 
2.4.5. Quantification of superoxide levels, mitochondrial mass and mitochondrial 
membrane potential 
 
The appropriate volume of cell suspension containing 1x10
5
 cells was centrifuged at 
800rpm for 5 minutes. Supernatant was removed and cells were incubated with  10μM 
DHE (D-23107, Life Technologies, Invitrogen, Paisly, UK) to measure superoxide 
levels, 100nM MitoTracker Green FM (M-7514, Life Technologies, Invitrogen, Paisly, 
UK) to measure mitochondrial mass or 7.7μM 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidaz olylcarbocyanine iodide (JC-1) (T-3168, Life Technologies, 
Invitrogen, Paisly, UK) to measure mitochondrial membrane potential in 1ml of RPMI-
1640 medium (R7509) at 37
o
C for 30 minutes, shortly vortexing for 10 seconds before 
incubation.  RPMI-1640 medium (R7509) alone was used as an unstained control.  
After incubation 3ml of RPMI-1640 (R7509) was added and cells were centrifuged for 
5 minutes at 800rmp. Supernatant was removed and 2ml of RPMI-1640 medium 
(R7509) was added.  Samples were analysed immediately. Flow cytometry data 
acquisition and analysis were performed using the Partec PAS particle analysing system 
(Partec, Munster, Germany). A small amount of Fluoresbrite calibration grade 3.0 
micron YG microspheres (18861-1, Polysciences, Eppelheim, Germany) was used to 
check fluorescence was maintained at 487nm in all fluorescent channels (FL). 1x10
4 
events (cells) were analysed per sample. DHE and MitoTracker Green FM were 
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analysed in the SSC vs. the red fluorescent channel (FL3) and JC-1 in the green 
fluorescent channel (FL1) vs. FL3 channel (Figure 2.2. A. i., B. i and C. i. respectively).  
Cells of interest were first identified based on their size (FSC) and density (SSC) in the 
unstained control using a polygon to gate cells. Cells were then identified in the 
appropriate channel cytogram, as described above, in the unstained control by applying 
the polygon and a quadrant was used to gate all unstained cells. The mean fluorescence 
of unstained cells was recorded. The unstained polygon and quadrant was then applied 
to the stained cells in which the mean fluorescence was recorded. Normalized mean 
fluorescence was then quantified, which was used to represent either mean PBMC 
superoxide levels, mitochondrial mass or mitochondrial membrane potential in arbitrary 
units (AU). Since the density gradient centrifugation  method  used  isolates PBMC 
subpopulations lymphocytes and monocytes only, we were also able to quantify 
measures in these two subpopulations based on their SSC, since lymphocytes have a 
lower granularity than monocytes (Fleisher and Marti, 2001). To confirm that the  
cell population remaining unstained in all the stained samples were red blood cells, the 
analysis was repeated however lysing the red blood cells before staining (Figure 2.2. A. 
ii., B. ii and C. ii). This was also confirmed by staining unlysed and lysed red blood cell 
samples with with 2μl PerCP Mouse Anti-Human CD45 to identify PBMCs 
(lymphocytes sand monocytes) (557513, BD Pharmingen™, San Jose, California, US) 
in 1ml RPMI medium (R7509)  (Figure 2.2. D. i. and ii respectively).  This unstained  
population was removed in all lysed red blood cell samples, confirming that some red 
blood cells remain after the density gradient method using Leucosep® tubes. Since red 
blood cell lysis affects the stability of the parameters, as investigated in Chapter 4, it is 
not appropriate to remove red blood cells from the samples by this method, since this 
will cause experimental variability within the sample. Gating the red blood cells out is 
therefore more appropriate. 
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                                   Unstained                                                            Unstained  
 
 
 
 
 
 
 
                               DHE stained                                                        DHE stained 
 
 
          
A.    
 
           i. Unlysed         ii. Lysed 
                                                      
                                   Unstained                                                            Unstained 
 
 
 
 
 
 
 
MitoTracker Green FM stained                           MitoTracker Green FM stained         
B.   
          
           i. Unlysed                                                           ii. Lysed                                                              
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D.   
 
i. Unlysed                                                           ii. Lysed 
 
                                                             
                                         Unstained                                                            Unstained 
 
 
 
 
 
 
 
PerCP Mouse Anti-Human CD45 stained          PerCP Mouse Anti-Human CD45 stained          
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.  
   
           i. Unlysed                                                           ii. Lysed                                                               
                                   Unstained                                                            Unstained 
 
 
 
 
 
 
 
                                JC-1 stained                                                        JC-1 stained              
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Figure 2.2. Quantification of superoxide levels, mitochondrial mass and 
mitochondrial membrane potential in PBMCs and cell subpopulations by flow 
cytometry. A. Superoxide levels: unstained cells and DHE stained cells in i. unlysed and ii. 
lysed samples, B. Mitochondrial mass: unstained cells and MitoTracker Green FM stained 
cells in i. unlysed and ii. lysed samples,  C. Mitochondrial membrane potential: unstained 
and JC-1 stained cells in i. unlysed and ii. lysed samples, D. CD45 expression: unstained 
cells and PerCP Mouse Anti-Human CD45 stained cells in i. unlysed and ii. lysed samples 
E. Confirmation of PBMC subpopulations: unstained cells and PerCP Mouse Anti-Human 
CD45 and  FITC Mouse Anti-Human CD14 stained cells. (●: Red blood cells (CD45-
CD14-), ●: PBMCs (CD45+), ●: Lymphocytes (CD45+CD14-), ●: Monocytes 
(CD45+CD14+)) 
 
 
 
 
 
 
 
 
 
E.  
 
                                                         
                                                                                                                                                                   Unstained 
 
 
 
 
 
 
 
PerCP Mouse Anti-Human CD45 and  FITC Mouse Anti-Human CD14 stained          
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2.4.6. Confirmation of PBMC subpopulations 
 
Correct distinction between lymphocytes and monocytes by size/granularity was 
confirmed with a parallel experiment performed in a subset of control samples where 
1x10
5
 cells were incubated with 2μl PerCP Mouse Anti-Human CD45 in 1ml RPMI 
medium (R7509) to identify both lymphocytes and monocytes and 6μl FITC Mouse 
Anti-Human CD14 (555397, BD Pharmingen™, San Jose, CA, USA) in 1ml RPMI 
medium (R7509) to identify monocytes only (Figure 2.2. E.) 
 
 
2.5. Quantification of F2-isoprostanes by AutoDELFIA 
 
2.5.1. Plasma sample collection 
 
Plasma samples from LiHep blood collected at phase 1 (n=654), phase 2 (n=500) (of  
which n=438 participated in both phase 1 and phase 2) and phase 3 (n=379) (of which 
n=320 participated in both phase 1 and phase 3, n=323 participated in phase 2 and phase 
3 and  n=287 participated in phase 1, phase 2 and phase 3) of the Newcastle 85+ study 
and from younger control participants (n=19), were prepared at the Biomarkers 
Laboratory, Edwardson Building, IAH, Newcastle University by the Biomarker team 
and stored at –70oC. AutoDELFIA 1235 (Perkin Elmer Massachusetts, US) isoprostane 
analysis was performed at Unilever Discover, Colworth Science Park, Sharnbrook, 
Bedford by myself and Duncan Talbot. 
 
2.5.2. Reagent preparation 
 
A 1/2706 dilution of an 8.2 mg/ml anti-8-iso Prostaglandin F2 antibody (Prepared by 
Colworth monoclonal group, clone 6514:14) was prepared in DELFIA assay buffer 
(1244-111, Perkin Elmer, Massachusetts, US) and 0.2 micrometre (m) filtered (expiry 
date 2 weeks hence). A 1/160 dilution of a europium labelled ovalbumin-8-iso 
Prostaglandin F2 (Labelled by Dave Tolley, Unipath, Batch DT5) was prepared in 
tracer stability buffer containing 50mM Tris, 0.9% sodium chloride, 0.1% sodium azide, 
pH7.8 and purified 0.1% bovine serum albumin (CR84-100, Perkin Elmer, 
Massachusetts, US) which was free from heavy metals and 0.2m filtered (expiry date 2 
weeks hence). (Assay utilised in (Hall et al., 2008; Carter et al., 2013). 
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2.5.3. Preparation of F2-isoprostane standards and quality control 
 
1mg of 8-iso Prostaglandin F2 (1635, Cayman Chemical, Michigan, US) was weighed 
into a glass vial in an enclosed Mettler AE160 four figure balance and dissolved in 1ml 
dimethylformamide. The standard and quality control (QC) solutions (Figure 2.3.) were 
then prepared in clean graduated round-bottomed flasks by weighing on a Mettler PE 
1600 two-figure balance. Solutions were mixed and stored at 4
0
C overnight prior to 
testing. The following day the standards and QC samples were allowed to warm to room 
temperature, mixed and assayed. They were then aliquotted into labelled 2.5ml and 3ml 
standard vials respectively. Standards and QC samples were then stored at -20
0
C. (This 
was described in (Talbot and Butlin)). 
 
2.5.4. Quantification of 8-iso Prostaglandin F2 
 
50l standard, QC or plasma sample (phase 1 and 2 matched on same plate, phase 3 on 
independent day) were dispensed, in replicate, into dry solid yellow low fluorescence 
anti-mouse plates (AAAND-003, Perkin Elmer, Massachusetts, US). The AutoDELFIA 
further diluted the anti-8-iso Prostaglandin F2 antibody 1/100 in assay buffer (i.e. a 
final antibody dilution of 1/270,600: 0.03 g/ml). 100l antibody in assay buffer was 
then added to each well of the plate. The AutoDELFIA 1235 automatic immunoassay 
system diluted the europium (Eu
3+
) labelled ovalbumin-8-iso Prostaglandin F2 tracer a 
further 1/100 in assay buffer (i.e. a final tracer dilution of 1/16,000). 50l diluted tracer  
was then added to each well of the plate. The plate was incubated with shaking for 60 
minutes. The plate was washed 6 times with 400l diluted (250ml in 6 litres pure H2O) 
wash buffer (1244-114, Perkin Elmer, Massachusetts, US) 200µl of enhancement 
solution (1244-105, Perkin Elmer, Massachusetts, US) was added to each well.  The 
plate was shaken for 5 minutes and the fluorescent counts read by the AutoDELFIA. 
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Figure 2.3. F2-isoprostane standards and QC samples. (Taken from (Talbot and 
Butlin)). 
 
 
 
 
 
 
 
 
 
Intermediate 1 (1000 ng/ml) 
- 0.5g 1mg/ml 8-iso Prostaglandin F2 to 500g with phosphate buffered saline (PBS) 
+ 0.5% ovalbumin 
Intermediate 1 (1000 ng/ml) 
- 0.5g 1mg/ml 8-iso Prostaglandin F2 to 500g with PBS + 0.5% ovalbumin 
Standard F (100 ng/ml) 
- 50g intermediate 1 to 500g with buffer 
Standard E (25 ng/ml) 
- 12.5g intermediate 1 to 500g with buffer 
Standard D (5 ng/ml) 
- 125g intermediate 2 to 500g with buffer 
Standard C (1 ng/ml) 
- 25g intermediate 2 to 500g with buffer 
Standard B (0.25 ng/ml) 
- 6.25g intermediate 2 to 500g with buffer 
Standard A (0 ng/ml) 
- 500g buffer 
QC - High  (50 ng/ml) 
- 25 g intermediate 1 to 500g with buffer 
QC - Medium (2 ng/ml) 
- 50g intermediate 2 to 500g with buffer 
QC - Low (0.5 ng/ml) 
- 12.5g intermediate 2 to 500g with buffer 
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The concentration values were calculated from the standard curve in the AutoDELFIA 
Multicalc programme. Figure 2.4. shows the AutoDELFIA 8-iso Prostaglandin F2 
assay format. Figure 2.5. shows the 8-iso prostaglandin F2 AutoDELFIA assay 
schedule. To ensure there was no carry-over during sample pipetting, alternate solutions 
of high standard, buffer, low standard and buffer were dispensed across a 96 well plate 
and assayed. This formed part of the routine AutoDELFIA maintenance. The 
expectation was that sample position and carry-over during pipetting was insignificant 
and would have no effect on assay precision. (This was described in (Talbot and 
Butlin)). 
 
2.6. Experimental reliability assessments 
 
2.6.1. Experimental handling variables 
 
To investigate the effects of experimental handling on PBMC superoxide levels, 
mitochondrial mass and mitochondrial membrane potential and plasma 8-iso 
prostaglandin F2 directly, control samples were subjected to various experimental 
handling variables specific to the method used as shown in Figure 2.6. and as described 
in Table 2.1. and Table 2.2. respectively. For red blood cell lysis, after cells were 
centrifuged at 800rmp for 5 minutes in the first step of Section 2.4.5, the supernatant 
was removed and the pellet was re-suspended in 1ml red blood cell lysis buffer for 5 
minutes, stopping the reaction with 10ml of PBS. Cells were centrifuged at 800rpm for 
5 minutes at 4
o
C. Supernatant was removed and the pellet was re-suspended in 1ml of 
RPMI 1640 medium (R7509). The method described in Section 2.4.5 was then 
followed. 
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Figure 2.4. AutoDELFIA 8-iso Prostaglandin F2 assay format. (Adapted from 
(Talbot and Butlin)). 
 
 
 
 
 
# PGF.ASS 
# *********************************** 
# Cassette types and volumes (ul) in reag. bottles 
# in 1 plate and 4 plate kits. 
# variables: cassType,Buff1Vol,TracerVol,AntibodyVol,Buff2Vol 
#call DspDefs1 1  50000 1400 750 0 
#call DspDefs4 3 180000 1400 750 0 
DATA DSPDATA 
# *********************************** 
BEFORENEXT LOAD SAMPDIL 
LOAD SAMPLER 
BEFORENEXT DISP DILPGFA 
#inc dilBtl 
BEFORENEXT DISP DILPGFT 
#dec dilbtl 
#define wellVol 100 
DISP PIPDIL 
#inc dilBtl 
#define wellVol 50 
DISP PIPDIL 
#inc dilBtl 
SHAKE 3600 600 
WASH WSH6 
ENHDISP ESD1 
SHAKE 300 300 
#define plateType 2 
COUNT CNT1 
MOVETO SHAKE 
/ 
 
Figure 2.5. AutoDELFIA 8-iso prostaglandin F2 assay schedule. (Taken from 
(Talbot and Butlin)). 
 
Anti- 
mouse 
plate 
50l 
Isoprostane- 
ovalbumin- 
Eu
3+ 
tracer 
200l  
Enhancement 
solution 
   5 minutes 
 
100l  
anti- 
isoprostane 
monoclonal 
antibody 
Wash  
x 6 
50l 
Standard 
or  
plasma  
sample 
60 minutes 
Read 
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Figure 2.6. Workflow of flow cytometry analysis to measure ROS production and 
mitochondrial dysfunction, AutoDELFIA analysis to measure F2-isoprostanes and  
handling factors that may affect the stability of the measurements.  
Storage time 
 
LiHep blood sample collected 
Centrifuged with density gradient 
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o
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1x10
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Table 2.1.  Description of experimental handling variables investigated specific to 
the measurement of ROS production and mitochondrial function by flow 
cytometry. 
 
 
 
Table 2.2.  Description of experimental handling variables investigated specific to 
the measurement of F2-isoprostanes by AutoDELFIA. 
 
 
 
Experimental variable Method description 
Short-term storage time 
Isolated PBMCs were stored in RPMI at 37
o
C for 2 hours before 
analysis preparation and compared to 0 hour controls 
Long-term storage time 
Isolated PBMCs were stored in RPMI at 37
o
C for 24 hours before 
analysis preparation and compared to 0 hour controls 
Frozen storage 
Isolated PBMCs were stored in 90% FBS and 10% DMSO at         
-70
o
C before analysis preparation and compared to fresh controls 
 Cryogenic storage 
Isolated PBMCs were stored in 90% FBS and 10% DMSO at          
-196
o
C before analysis preparation and compared to fresh controls 
Red blood cell lysis 
Red blood cells in isolated PBMC samples were lysed and 
compared to unlysed controls 
Probe freeze-thaw cycles 
PBMCs were stained with DHE, MitoTracker Green FM and JC-1 
probes that had been frozen at -70
o
C and thawed for 5 or 10 cycles 
and compared to freshly prepared controls
 
Mechanical stress 
Stained PBMCs before incubation were subjected to a 2000rpm or 
3000rmp vortex compared to 1000rpm controls
 
 Light exposure 
Stained PBMCs that were unprotected from light were compared 
to light-protected (by foil) controls 
Probe incubation temperature  
Stained PBMCs were incubated for 30 minutes at 20
o
C or 4
o
C and 
compared to 37
o
C controls
 
Experimental variable Method description 
Storage time 
Plasma samples were thawed at room temperature and stored at 
4
o
C for 24, 48 or 72 hours and compared to 0 hour controls 
Plasma freeze-thaw cycles 
Plasma sample were thawed at room temperature and                  
refrozen at -80
o
C or 2, 3 or 4 cycles and  compared to 1 freeze-
thaw cycle controls 
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2.6.2. Intra- and inter-assay precision analysis 
 
After considering the above experimental variables the reliability of flow cytometry to 
measure PBMC superoxide levels, mitochondrial mass and mitochondrial membrane 
potential and AutoDELFIA to measure plasma 8-iso Prostaglandin F2 was assessed by 
investigating the average intra- and inter-assay coefficient of variation (C) of three 
individual control samples. The individual intra- and inter-assay CV of the flow 
cytometry method was calculated from three repeats of the same sample tube and three 
individually prepared tubes respectively. The individual intra- and inter-assay CV of the 
AutoDELFIA method was calculated from ten repeats on the same assay plate and 
twenty repeats on separate assay plates respectively. A CV≤15% is considered 
acceptable for the above defined intra-assay and  inter-assay precision (Litwin, 2001). 
 
2.6.3. Day-day assay precision and intra-individual reproducibility analysis 
 
To further assess the reliability of flow cytometry to measure PBMC superoxide levels, 
mitochondrial mass and mitochondrial membrane potential and AutoDELFIA to  
measure plasma 8-iso prostaglandin F2 the day-day reproducibility was assessed, which 
also permitted the assessment of intra-individual stability. For the flow cytometry 
analysis six individual PBMC control samples were taken on two separate occasions 
with an interval of one week and measured independently. The average day-day CV was 
calculated to assess the short-term day-day reproducibility and the correlation between 
day one and day seven repeats was calculated to assess the short-term intra-individual 
stability of PBMC superoxide levels, mitochondrial mass and mitochondrial membrane 
potential.  For the AutoDELFIA analysis twelve individual control samples were taken 
on two separate occasions with an interval of one week but were measured on the same 
occasion on the same plate. The short-term day-day reproducibility could therefore not 
be assessed by this method however the short-term intra-individual stability of plasma 
8-iso prostaglandin F2 was assessed by calculating the correlation between day one and 
day seven repeats. The long-term day-day reproducibility and thus long-term intra-
individual stability was assessed by calculating the average day-day CV and correlation 
between the Newcastle 85+ samples at phase 1 and phase 2 (both measured on the same 
occasion) with phase 3 (measured independently of phase 1 and phase 2). A CV ≤20% 
is considered acceptable for day-day precision (Litwin, 2001). 
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2.6.4. Investigating the specificity of AutoDELFIA to the 8-iso Prostaglandin F2 
isomer 
 
Four control plasma samples were spiked with 0, 5, 10, 20 and 40ng/ml of 8-iso 
Prostaglandin F2 (16350, Cayman Chemical Ann Arbor, Michigan, US), 5-iPF2 -V1 
(16350, Cayman Chemical Ann Arbor, Michigan, US) or 8-iso Prostaglandin F2 plus  
5-iPF2 -V1. The recovery of 8-iso Prostaglandin F2 by AutoDELFIA was determined. 
 
 
2.7. Structured literature reviews 
 
2.7.1.  Classical BoA and their ability to predictor age-related outcomes;           
specifically mortality, co-morbidity, disability and/or cognitive                    
impairment 
 
The literature search aimed to identify studies investigating various classical BoA as  
predictors of age-related outcomes, specifically mortality, co-morbidity, disability 
and/or cognitive impairment. The electronic database MEDLINE was searched via the 
database provider OvidSP up to November 2012 using specific search terms: [classical 
BoA* (*total of 62 using a combination of appropriate words/truncations)] AND 
[predict$] AND [survival OR death OR mortality OR $morbid$ OR disabil$ OR 
cognit$] restricted to abstracts, studies in humans and from 1946 onwards. Full details 
of the search terms are shown in Appendix A. The specific classical BoA (1-62 as 
described in Appendix A) were selected since these were available measures in the 
Newcastle 85+ study.  Studies returned for each classical BoA were ordered by earliest 
date of publication and screened to find the first study that met a specific criterion I) 
participants were from a healthy population (i.e. not a disease study), II) participants 
were not institutionalised (i.e. to increase representativeness of the population groups), 
III) the study was not a review and IV) the study was a longitudinal follow up. Studies 
were divided into four age groups: I) young (<45 years), II) middle (>45 and <70 years), 
III) old (> 70 years) and VI) combined (combination of young, middle and/or old age 
groups). The age range of participants, number of participants, follow-up length, 
outcome predicted, association found, dataset used and study reference was recorded if 
available. Data from a previous publication of the Newcastle 85+ study cohort (Martin-
Ruiz et al., 2011b), which investigated the association between the classical BoA and 
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the four age-related outcomes investigated above, was compared to the structured 
review data to determine which classical BoA are valid within the very old population. 
This study used data collected at baseline (phase 1) of the Newcastle 85+ study (See 
Section 2.1.).  
 
2.7.2. The  effects of dietary restriction on potential oxidative stress and                        
cellular senescence-related BoA in leukocytes 
 
The literature search aimed to identify studies investigating the effect of dietary  
restriction on potential oxidative stress and cellular senescence-related BoA in 
leukocytes, specifically ROS production and mitochondrial dysfunction, telomere 
length, DNA damage, DNA repair, IL-6, TNF-α  and lymphoid / myeloid ratio.  The 
electronic database MEDLINE was searched via the database provider OvidSP and also 
PubMed during July 2012 using specific search terms: [calorie restriction OR dietary 
restriction] AND [peripheral blood OR white blood cells OR lymphocytes OR 
monocytes OR bone marrow OR lymphoid OR myeloid OR  plasma* OR serum* 
(*cytokines only)] AND [Potential oxidative stress and cellular senescence-related 
BoA* (*total of 7 using a combination of appropriate words/truncations] restricted to 
abstracts and from 1946 onwards. Full details of the search terms including the stages of 
identifying the included articles are shown in Appendix B.  ROS production and 
mitochondrial  dysfunction was a combined search, however within the articles ROS 
production, mitochondrial mass and mitochondrial membrane potential were searched 
for. There was therefore a total of 9 potential oxidative stress and cellular senescence-
related BoA searched. These specific potential oxidative stress and cellular senescence-
related BoA were selected since these were available measures in the Newcastle 85+ 
study.  Studies returned for each potential oxidative stress and cellular senescence-
related BoA were screened to find all studies that met the search criteria. The diet 
group, species, gender, age at start of diet, age at end of diet, diet duration, number of 
participants, cell/tissue type, marker used where relevant, levels obtained, units, 
significance levels and conclusion were recorded if available.  
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2.8. Statistical analysis 
 
For experimental data, the Student’s t-Test was used to test differences between two  
samples, the coefficient of variation (CV, %) was used to assess assay precision and 
Pearson’s correlation was used to test the strength of association between two continuous 
variables. All potential oxidative stress-related BoA had a non-normal distribution in the 
study population, assessed using the Kolmogorov-Smirnov test for normality (p<0.05) and 
also by viewing Q-Q plots (See Appendix C., Supplementary Table 7. and Supplementary 
Figure 1.). Attempts to normalise the data using logarithmic transformations (Lg10, Ln, 
Lngamma, Sqrt and Exp) were unsuccessful. Non-parametric statistical test were therefore 
employed including Spearman’s correlation to test for the relationship between two 
continuous variables; Mann-Whitney U to test differences between two groups and Kruskal-
Wallis to test differences between three or more groups of independent samples; and 
Wilcoxon Signed-Rank Test to test the differences between two groups and Friedman’s 
Test to test differences between three or more groups of related samples. Chi-square test 
was used to compare the distribution of grouped variables between two population groups. 
To test associations with survival, participants were divided into quartiles of superoxide 
levels, mitochondrial mass and mitochondrial membrane potential with the middle two 
quartiles grouped together to form the reference category to represent medium levels (See 
Appendix C, Supplementary Table. 15. for cut-off values). Cox regression was used to test 
for the differences between grouped variables and survival. p-values <0.05 were considered 
statistically significant. Since many of the markers are expected to have strong correlations 
with each other, reflecting common biological mechanisms, formal statistical correction for 
multiple comparisons was not applied since this would have been over-conservative. 
Sensitivity analysis was carried out by removing extreme outliers which were values more 
than 3 times the interquartile range (IQR) below the 25th or above the 75th percentiles, which 
were identified by default in SPSS boxplots. Potential confounders investigated were 
gender, ethnicity, mitochondrial haplogroup, age of natural parents death,  place of birth, 
has/had a sibling, had full-time higher education, number of years in main job/role, has 
offspring, marital status, living alone, housing type, alcohol status, smoking status, taking 
non-prescribed medicines, supplements and/or herbal remedies, taking prescribed 
medication, self-reported physical activity, use of aid(s)/appliance(s), social isolation, key 
event impact, sleep quality, body mass index, fasted blood sample and season of blood 
sample. Data analysis was performed using SPSS version 19.0. 
 
61 
 
Chapter 3. Structured literature review of classical BoA 
and their validation in the very old population 
 
3.1. Abstract 
 
Introduction To date, no biological parameter has been proven to meet the full criteria 
of a useful BoA. Although many studies investigating classical BoA have shown 
evidence for their ability to predict age-related outcomes there are many inconsistencies 
between studies. Aims This study aimed to investigate whether different age groups 
included in studies that investigate various classical BoA could be the reason for their 
conflicting conclusions. It then aimed to identify which classical BoA are valid in the 
very old population by comparing the literature and data from the very old population of 
the Newcastle 85+ study. Methods The literature was searched to identify studies that 
have investigated various classical BoA as predictors of age-related outcomes, 
specifically mortality, co-morbidity, disability and/or cognitive impairment, using 
specific search terms and criteria. Identified studies were divided into 4 age groups 
(young, middle, old and combined) and the type of association found, along with other 
study details, were recorded. Data from a previous study of the very old population in 
the Newcastle 85+ study was then compared to the literature review data. Results For 
10 of the 62 classical BoA investigated the predictive value was found to change 
between age groups which were; body mass index, waist to hip ratio, fat free mass, 
diastolic blood pressure, systolic blood pressure, creatinine, glucose, triglycerides, 
cholesterol and low density lipoproteins (LDL). There were even disagreements 
between the 10 informative classical BoA identified in the very old population of the 
Newcastle 85+ study compared to the old population investigated in the literature which 
were; hand grip strength, timed up and go (TUG), systolic blood pressure, forced 
expiratory volume in 1 second (FEV1), red blood cell count, haematocrit, haemoglobin, 
free triiodothyronine (Free T3), vitamin D and N-terminal pro b-type natriuretic peptide 
(NT-pro BNP). Changes in the predictive value for the remaining 52 classical BoA 
could not be concluded due to gaps in the literature. Conclusion The predictive value of 
many proposed classical BoA is different in different age groups, even in the old 
compared to the very old. This could be a reason why there are many inconsistencies 
between studies. Validating BoA should therefore be carried out in different age groups.  
There are 10 (and possibly 11) classical BoA that can be used to validate newer 
candidate cellular and molecular BoA in the very old population. 
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3.2. Introduction 
 
Many candidates have been proposed as valid BoA including various anthropometric, 
physical, physiological, haematological and biochemical measurements, termed here as 
classical BoA, however there are many inconsistencies between studies (Chapter 1, 
Table 1.1.). None of these markers therefore meet the full criteria of a useful BoA which 
is being able to predict detrimental outcomes associated with ageing in the absence of 
disease better than chronological age and be applicable to all members of the population 
at any given age (Baker and Sprott, 1988; Sprott, 2010). Although classical BoA may 
not provide a mechanistic insight into biological ageing they can be informative by their 
association and thus construct validation of “newer” mechanistic cellular and molecular 
BoA. It is therefore important to understand why classical BoA may be valid in one 
population group however not in another. It is also important for this study to determine 
which classical BoA are valid within the very old population of the Newcastle 85+ 
study. This is so they can be used to validate the potential oxidative stress-related BoA 
investigated in the proceeding chapters. This will be useful since some of the potential 
oxidative stress-related BoA were only measured in phase 3 of the Newcastle 85+ 
study. Although it can be determined if the potential oxidative stress-related BoA are 
associated with various age-related outcomes at phase 3 and survival, validating them 
with classical BoA is important since we will be unable to determine if these markers 
are predictors of various age-related outcomes and thus healthy life expectancy, since 
these data beyond phase 3 are not available at the current time.   
 
One reason for the conflicting conclusions between studies could be the differences in 
the age groups they have included since the predictive value of the marker investigated 
may vary by age group. For example, although there is an increased risk of mortality 
from high blood pressure in a younger population (Miura et al., 2001) there is an 
increased risk of mortality due to low blood pressure in the very old population (Mattila 
et al., 1988). Another example is cholesterol where again although there is an increased  
risk of mortality from high cholesterol in a younger population (Stamler et al., 2000), 
there is an increased risk of mortality due to low cholesterol in the very old population 
(Forette et al., 1989). This could be the case for other candidate BoA.  
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Differences in the prevalence of intra- and inter-individual factors that may alter the  
levels of candidate BoA could explain why their predictive value may be absent or 
reversed within different age groups. For example, the older population are more likely 
to be on antihypertensive medication than a younger population (Health and Social Care 
Information Centre (HSCIC, 2011) which could impact on the predictive value of blood 
pressure within this age group. Another reason could be because of different histories of 
specific diseases or disorders and thus different causes of mortality between a younger 
and older population. This can be explained by the various types of associations that 
may occur between a predictive variable and an age-related disease or disorder that 
increase the risk of mortality (Figure 3.1.). Many classical BoA follow a non-monotonic 
relationship in terms of their association with age-related outcomes.  For example, high 
blood pressure (hypertension) is associated with certain cardiovascular diseases 
including stroke (Yu et al., 2011), myocardial infarction (Pedrinelli et al., 2012), 
aneurysms  (Altay et al., 2012) and also chronic kidney disease determined by a 
reduction in glomerular filtration or presence of albuminuria (Chia and Ching, 2012). 
However, low blood pressure (hypotension) is also associated with other cardiovascular 
diseases including atherosclerosis (Rose et al., 2000) and neurological diseases (Qiu et 
al., 2003). Another example is cholesterol where high levels of LDL cholesterol 
(hypercholesterolemia) is associated with various cardiovascular diseases including 
stroke (Imamura et al., 2009), atherosclerosis (Kruth, 2001), coronary heart disease 
(Grundy, 1997) and myocardial infarction (Glazer et al., 2005), and endocrine diseases 
including diabetes (von Eckardstein and Sibler, 2011).  However, also low levels of 
LDL cholesterol  (hypocholesterolemia) is associated with depression (Tedders et al., 
2011), cancer (Strohmaier et al., 2013), haemorrhagic stroke (Wang et al., 2013) and 
various respiratory diseases  (Iribarren et al., 1997). The prevalence of specific diseases 
or disorders and causes of mortality vary between age group hence the reason why the 
predictive value of a candidate BoA may also vary. For example, using data from the 
UK population, the prevalence of various age-related diseases varies between age group 
(Figure 3.2.) (Eastern Region Public Health Observatory (ERPHO), 2010). For both 
men and women below 55-59 years the most prevalent age-related disease is the 
endocrine disease diabetes mellitus (ERPHO, 2010). However in those above this age 
group the most prevalent age-related disease is coronary heart disease in men and 
chronic kidney disease in women (ERPHO, 2010). There is also a decline in the 
prevalence of coronary heart disease in men at 80-84 years where chronic kidney 
disease now becomes the most prevalent (ERPHO, 2010).  
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Figure 3.1. Types of associations that may occur between a predictive variable and 
an age-related disease or disorder. 
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Figure 3.2. Chronic disease prevalence by age and gender in the UK in 1998. 
(ERPHO, 2010). A) Males, B) Females. (Chart was created from data tables provided) 
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There is also a decline in the prevalence of diabetes mellitus in men and women at 75-
79 years and also in chronic obstructive pulmonary disease (COPD) at 80-84 years 
(ERPHO, 2010).  Using data from the English and Welsh population demonstrates the 
causes of mortality also vary between age groups (Figure 3.3.) (ONS, 2006). In men 
aged between 50-54 and 70-74 years the leading cause of death is cancer however at 
ages above this the leading cause of death is cardiovascular disease (ONS, 2006). A 
similar pattern is shown for women however cancer is the leading cause of death 
between 1-4 and 70-74 years (ONS, 2006).  
 
The inconsistencies in the validation of candidate BoA could be because studies do not 
employ appropriate statistical method to control for intra- and inter- individual factors 
such as medication use and history and/or presence of a disease or disorder within their 
population group. Also the type of age-related outcome or cause of mortality may vary 
or not be specific enough. However a study by Langer in 1991 ruled out the most 
obvious causes for the improved survival of the very old with higher blood pressure  
including the use of hypertensive medication, pulse pressure, history of hypertension, 
history of coronary heart disease, isolated systolic hypertension, interval change in 
diastolic pressure, cholesterol, triglycerides, fasting plasma glucose, smoking and body 
mass index (Langer et al., 1991).  They concluded that the paradoxical relation of 
improved all-cause and cardiovascular survival in men aged 80 years or older with 
higher diastolic pressure is not explained by a wide range of biological and historical 
factors (Langer et al., 1991).  It therefore needs to be determined whether the value of 
various classical BoA varies by age group and if so which are valid within the very old 
population.  
 
This study therefore aimed to 1) carry out a structured literature review to determine 
whether different age groups included in studies investigating the predictive validity of 
various classical BoA is the reason for their opposing conclusions and 2) identify which 
classical BoA are valid within the very old population and determine the direction of 
association, which may be different to that of a younger age group, by investigating the 
predictive validity of various classical BoA in the very old population from the 
Newcastle 85+ study and comparing these results to the results of the literature review. 
It is hypothesised that the reason why there is disagreements between studies in the 
ability of classical BoA to predict age-related outcomes is because of the  
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Figure 3.3. Causes of death by age and gender in England and Wales in 2005. 
(ONS, 2006). A) Males, B) Females. (Chart was created from data tables provided) 
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different age groups within studies and that most classical BoA have different predictive 
values in an older population compared to a younger population. 
 
3.3. Results 
 
3.3.1. The value  of classical BoA as predictors of age-related outcomes in different 
age groups 
 
The first part of this study was to determine whether the predictive value of various 
classical BoA changes in different age groups and is therefore the reason why there are 
many inconsistencies between studies who investigate the validity of these measures as 
BoA. The literature was searched to identify longitudinal studies that have investigated 
the predictive ability of various classical BoA in a young (<45 years), middle (>45 and 
<70 years), old (> 70 years) and combined (combination of young, middle and/or old 
age groups) age group. The idea of the combined age group is to determine whether 
including a combination of young, middle and/or old age participants is the reason why 
no association is found, especially if different associations are found between the 
young, middle and old age groups.  
 
The literature search revealed that 55 out of the 62 selected classical BoA including 
various anthropometric, physical, physiological, haematological and biochemical 
measures, according to the search terms, had been investigated as a predictor of age-
related outcomes; specifically mortality, co-morbidity, disability and/or cognitive 
impairment (See Chapter 1, Figure 1.8.). After critically reviewing the literature using 
the specific criteria in Chapter 2. Section 2.7.1. data for 31 of the classical BoA was 
available for 1 or more of the age groups (Table 3.1.). A summary of these results is 
shown in Table 3.2.  
 
For 4 of the 31 classical BoA there was data available for each of the young, middle and 
old age groups. The predictive value for all 4 of these classical BoA changed in 
different age groups. These were body mass index, systolic blood pressure, triglycerides 
and cholesterol. For 19 of the 31 classical BoA there was data available for 2 or 3 of the 
young, middle, old and combined age groups. For 6 out of these 19 classical BoA the 
predictive value changed in different age groups. These were waist to hip ratio, fat free 
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Classical BoA Age group Age (years) n Follow up (years) Outcome predicted Association Study Reference 
Anthropometry        
 
Body mass index Young 20-44 26977 6 Mortality ▲
♀
 
The Italian RIFLE pooling project, 
Italy 
(Seccareccia et al., 1998) 
 Middle 40-64 3452 
♂
 18 Mortality X 
The Whitehall Study, 
England 
(Strachan, 1992) 
 Old 72 (Mean) 551 2.8 Mortality ▼ 
Elderly Program pilot project, 
USA 
(Siegel et al., 1987) 
 Combined 25-79 17159 
♀
 12 Mortality ~ 
Population-based based cohort 
study, Finland 
(Rissanen et al., 1991) 
Waist to hip ratio Young n/a n/a n/a n/a n/a n/a n/a 
 Middle 55-69 31702 
♀
 11-12 Mortality ▲ 
Iowa Woman’s Health Study, 
USA 
(Folsom et al., 2000) 
 Old 70+ 2032 3 Mortality X 
Population-based cohort study, 
Hong Kong 
(Woo et al., 2001) 
 Combined 55-102 6296 5.4 Mortality X 
The Rotterdam study, 
England 
(Visscher et al., 2001) 
Fat % Young n/a n/a n/a n/a n/a n/a n/a 
 Middle 45-59 15609 5.7 Mortality ▲
♀
 
Malmo Diet and Cancer Study, 
Sweden 
(Lahmann et al., 2002) 
 Old n/a n/a n/a n/a n/a n/a n/a 
 Combined 65-100 4809 3 Disability ▲ 
Cardiovascular Health Study, 
USA 
(Visser et al., 1998) 
Fat free mass Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old 69-80 1413 4 Mortality ▼ 
Community-based cohort study, 
Chile 
(Bunout et al., 2011) 
 Combined 65-100 4809 3 Disability X 
Cardiovascular Health Study, 
USA 
(Visser et al., 1998) 
 
 
 
Physical function 
 
       
70 
 
Physical function         
Physical activity Young n/a n/a n/a n/a n/a n/a n/a 
 Middle 40-49 15000 
♂
 4 Mortality ▼ 
The Oslo study, 
Sweden 
(Holme et al., 1981) 
 Old 75+ 545 
♀
 7 Disability ▼ 
The EPIDOS study, 
France 
(Carriere et al., 2005) 
 Combined 45-74 6109 7-13 Mortality ▼ 
NHANES I Epidemiologic follow-
up study, USA 
(Davis et al., 1994) 
Hand grip strength Young n/a n/a n/a n/a n/a n/a n/a 
 Middle 45-68 6089 
♂
 25 Disability ▼ 
The Honolulu Heart Program, 
USA 
(Rantanen et al., 1999) 
 Old 71-91 140 
♂
 4 Disability ▼ 
FINE study, 
Italy 
(Giampaoli et al., 1999) 
 Combined n/a n/a n/a n/a n/a n/a n/a 
Timed up and go  
(TUG) 
Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old 70+ 144 1.5 Morbidity X 
Community-based cohort study, 
Italy 
(Nikolaus et al., 1996) 
 Combined n/a n/a n/a n/a n/a n/a n/a 
Physiological function         
Diastolic blood pressure Young n/a n/a n/a n/a n/a n/a n/a 
 Middle 45-68 7610 
♂
 10 Mortality ▲ 
The Hoonolulu Heart Program, 
Hawaii 
(Yano et al., 1983) 
 Old 78-92 331 2 Mortality ▼ 
PROTEGER study, 
France 
(Vischer et al., 2009) 
 Combined n/a n/a n/a n/a n/a n/a n/a 
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Systolic blood pressure Young 30-49 159 15 Mortality ▲ 
Community-based cohort study, 
England 
(Bulpitt et al., 1986) 
 Middle 50-69 205 15 Mortality ▲ 
Community-based cohort study, 
England 
(Bulpitt et al., 1986) 
 Old 70+ 897 3-4 Mortality ▼
♀
 
Community-based cohort study, 
Australia 
(Korten et al., 1999) 
 Combined 50-79 1727 9 Mortality ▲ 
Community-based cohort study, 
USA 
(Barrett-Connor and Khaw, 1985) 
FEV1 Young n/a n/a n/a n/a n/a n/a n/a 
 Middle 40-59 1712 
♂
 25 Mortality ▼ 
Community-based cohort study, 
Italy 
(Menotti et al., 1987) 
 Old n/a n/a n/a n/a n/a n/a n/a 
 Combined 65+ 1909 6 Mortality ▼ 
Community-based cohort study, 
Poland 
(Jedrychowski et al., 1994) 
Forced vital capacity  
(FVC) 
Young n/a n/a n/a n/a n/a n/a n/a 
 Middle 40-59 1711 
♂
 25 Mortality ▼ 
The East-West study, 
Finland 
(Lammi et al., 1990) 
 Old n/a n/a n/a n/a n/a n/a n/a 
 
 
 
Combined 20-93 2710 8-10 Mortality ▼ 
The Copenhagen City Heart Study, 
Denmark 
(Lange et al., 1990) 
Peak expiratory flow rate 
(PEFR)    
Young n/a n/a n/a n/a 
n/a n/a 
n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old 70+ 754 5 Disability and mortality ▼ 
Community-based cohort study, 
USA 
(Fragoso et al., 2008) 
 Combined 60+ 2805 8 Disability ▼ 
Community-based cohort study, 
Australia 
(Simons et al., 2000b) 
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Haematology 
 
 
       
White blood cell count Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old n/a n/a n/a n/a n/a n/a n/a 
 Combined 47.5 (Mean) 2011 
♂
 13.6 Mortality ▲ 
Normative aging study, 
England 
(de Labry et al., 1990) 
Haematocrit Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old n/a n/a n/a n/a n/a n/a n/a 
 
 
Combined 25-64 1238 13 Mortality ▲ 
MONICA survey, 
Scotland 
(Woodward et al., 2003) 
Haemoglobin Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old n/a n/a n/a n/a n/a n/a n/a 
 Combined 20-49 6541 
♂
 20 Mortality ~ 
The tromso study, 
Norway 
(Skjelbakken et al., 2006) 
Biochemistry         
Creatinine Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old 75 (Mean) 4637 8 Mortality ~ 
Cardiovascular Health Study, 
USA 
(Shlipak et al., 2005) 
 Combined 40-79 96664 5.2 Mortality ▲
♀
 
Community-based cohort study, 
Japan 
(Irie et al., 2001) 
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Alanine transaminase Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old 73-94 686 11 Mortality X 
Longitudinal Study of Aging Danish 
Twins, England 
(Fraser et al., 2009) 
 Combined 50-75 1439 10 Mortality X 
The Hoorn study, 
Netherlands 
(Schindhelm et al., 2007) 
Albumin Young n/a n/a n/a n/a n/a n/a  
 Middle n/a n/a n/a n/a n/a n/a  
 Old 71+ 4116 3.7 Mortality ▼ 
Community-based cohort study, 
USA 
(Corti et al., 1994) 
 Combined 50-89 2342 3 Mortality ▼ 
Community-based cohort study, 
USA 
(Klonoff-Cohen et al., 1992) 
Alkaline phosphatase Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old n/a n/a n/a n/a n/a n/a n/a 
 Combined 38-65 1905644 12 Mortality ▲ 
Population-based study, 
USA 
(Fulks et al., 2008) 
Glucose Young n/a n/a n/a n/a n/a n/a n/a 
 Middle 45-64 10410 11.6 Mortality ▲ 
Community based Cohort study, 
Scotland 
(Janghorbani et al., 1993) 
 Old 85+ 558 5 Mortality ▼ 
Community-based cohort study, 
Finland 
(Kaltiala et al., 1987) 
 Combined 60+ 2419 9.4 Mortality ▲
♀
 
The Dubbo study, 
Australia 
(Simons et al., 2000a) 
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Glycosylated haemoglobin 
(HbA1c) 
 
Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old 70-89 314 
♂
 8.1 Mortality ▲ 
The seven countries study, 
Finland 
(Qiao et al., 2004) 
 Combined 49-77 1097 
♂
 8.8 Mortality ▲ 
The hoorn study, 
Netherlands 
(Qiao et al., 2004) 
Triglycerides Young 38-46 803 24 Mortality X 
Population-based study, 
Sweden 
(Lindquist et al., 2002) 
 Middle 50-60 659 24 Mortality ▲ 
Population-based study, 
Sweden 
(Lindquist et al., 2002) 
 Old 70 u/k 10 Mortality X 
Community-based cohort study, 
Sweden 
(Agner and Hansen, 1983) 
 Combined 45-78 1729 
♂
 5.7 Mortality X 
Population-based study, 
USA 
(Rhoads and Feinleib, 1983) 
Cholesterol Young 40 u/k u/k Mortality ▲ 
Framington Heart Study, 
USA 
(Kronmal et al., 1993) 
 Middle 50-70 u/k u/k Mortality X 
Framington Heart Study, 
USA 
(Kronmal et al., 1993) 
 Old 80 u/k u/k Mortality ▼ 
Framington Heart Study, 
USA 
(Kronmal et al., 1993) 
 Combined n/a n/a n/a n/a n/a n/a n/a 
 
High density lipoproteins  
(HDL) 
Young n/a n/a n/a n/a n/a n/a n/a 
Middle n/a n/a n/a n/a n/a n/a n/a 
Old 71-91 140 
♂
 4 Disability ▼ 
FINE study, 
Italy 
(Giampaoli et al., 1999) 
 Combined 40+ 10059 
♂
 15 Mortality ▼ 
Population-based cohort study, 
Israel 
(Goldbourt et al., 1985) 
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Low density lipoproteins  
(LDL) 
Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old 80 u/k u/k Mortality ▼ 
Framington Heart Study, 
USA 
(Kronmal et al., 1993) 
 Combined 40-69 2541 
♂
 10.1 Mortality ▲ 
Lipid Research Clinics Program 
Prevalence Study, USA 
(Pekkanen et al., 1990) 
Cortisol Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old n/a n/a n/a n/a n/a n/a n/a 
 Combined 60-80 19 4 Cognition ▲ 
Community-based cohort study, 
Canada 
(Lupien et al., 1994) 
Thyroid stimulating hormone Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old n/a n/a n/a n/a n/a n/a n/a 
 Combined 65+ 660 4 Cognition X  
Population-based cohort study, 
Italy 
(Forti et al., 2012) 
Rheumatoid factor 
(RhF) 
Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old n/a n/a n/a n/a n/a n/a n/a 
 Combined 25+ 2979 24 Mortality ▲ 
Community-based cohort study, 
USA 
(Jacobsson et al., 1993) 
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Table 3.1. Structured literature search results identifying studies that have investigated various classical BoA as predictors of age-related 
outcomes within various age groups. (Young: <45 years, Middle: ≥45-<70 years, Old: ≥70 years, Combined: Combination of young, middle and/or 
old groups, n: number of participants, ▲: positive association,▼: negative association, ~: non-linear association, X: no association, ♂: males only, ♀: 
females only, u/k: unknown, n/a: not available/no data identified)
Vitamin D Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old 77-100 998 3 Disability ▼ 
Cardiovascular Health Study All 
Stars, USA 
(Houston et al., 2011) 
 Combined 43 -73 10899 5.8 Mortality ▼ 
Community-based cohort study, 
USA 
(Vacek et al., 2012) 
Homocysteine Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old u/k 32 5 Cognitive impairment ▲ 
Community-based cohort study, 
Wales 
(McCaddon et al., 2001) 
 Combined 50-85 321 
♂ 
3 Cognitive impairment ▲ 
Veterans Affairs Normative Aging 
Study, USA 
(Tucker et al., 2005) 
NT-pro BNP Young n/a n/a n/a n/a n/a n/a n/a 
 Middle n/a n/a n/a n/a n/a n/a n/a 
 Old 75+ 499 7.9 Mortality ▲ 
Kuopio 75+ health study, 
Finland 
(Kerola et al., 2011) 
 Combined 52-74 13466 2.9 Mortality ▲
♂
 
Iwate-KENCO study, 
Japan 
(Nakamura et al., 2010) 
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Table 3.2. Summary of the structured literature search results identifying studies 
that have investigated various classical BoA as predictors of age-related outcomes 
within various age groups. Only those classical BoA that were identified as being 
investigated in 1 or more of the 4 age groups are shown. (Young: <45 years, Middle: 
≥45-<70 years, Old: ≥70 years, Combined: Combination of young, middle and/or old 
groups).
Classical BoA 
Age group 
Young Middle Old Combined 
Anthropometric     
Body mass index     
Waist to hip ratio     
Fat % 
 
    
Fat free mass     
Physical     
Physical activity     
Hand grip strength     
TUG     
Physiological     
Diastolic blood pressure     
Systolic blood pressure     
FEV1     
FVC     
PEFR        
Haematological     
White blood cell count     
Haematocrit     
Haemoglobin     
Biochemical     
Creatinine     
Alanine transaminase     
Albumin     
Alkaline phosphatase     
Glucose     
HbA1c     
Triglyceride     
Cholesterol     
HDL     
LDL     
Cortisol     
Thyroid stimulating 
hormone 
    
RhF     
Vitamin D     
Homocysteine     
NT-pro BNP     
  Positive association 
  Negative association 
  Non-linear association 
  No association 
  No data available 
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mass, diastolic blood pressure, creatinine, glucose and LDL. For 12 of these 19 classical 
BoA the predictive value is the same in at least 2 of the different age groups. These 
were fat %, physical activity, hand grip strength, FEV1, forced vital capacity (FVC) , 
peak expiratory flow rate (PEFR), albumin, glycosylated haemoglobin (HbA1c), HDL, 
vitamin D, homocysteine and B-type naturiuretic peptide. However it can not be ruled 
out whether the predictive value of these 12 classical BoA changes or not in different 
age groups at this stage since data for each age group was not available. The 1 
remaining classical BoA of these 19, alanine transaminase, was not found to be 
predictive of age-related outcomes. Again it can not be ruled out whether the predictive 
value of this classical BoA changes or not in different age groups at this stage since data 
for each age group was not available. For 8 of 31 classical BoA data for only 1 of the 
age groups was available. Therefore it can not be ruled out whether the predictive value 
of these classical BoA changes or not in different age group. 6 out of these 8 classical 
BoA were predictive of age-related outcomes. These were white blood cell count, 
haematocrit, haemoglobin, alkaline phosphatase, cortisol and rheumatoid factor (RhF). 
The remaining 2 of these 8 classical BoA were not predictive of age-related outcomes. 
These were TUG and thyroid stimulating hormone. Out of all 31 of the classical BoA 
within the literature search, 17 were valid predictors of age-related outcomes within the 
old population. These were body mass index, fat free mass, physical activity, hand grip 
strength, diastolic blood pressure, systolic blood pressure, PEFR, creatinine, albumin, 
glucose, HbA1c, cholesterol, HDL, LDL, vitamin D, homocysteine and NT-pro BNP. 4 
classical BoA were not predictors of age-related outcomes within the old population. 
These were waist to hip ratio, TUG, alanine transaminase and triglycerides. The 
remaining 10 were not identified as being investigated as predictors of age-related 
outcomes in the old population. These were fat mass, FEV1, FVC, white blood cell 
count, haematocrit, haemoglobin, alkaline phosphatase, cortisol, thyroid stimulating 
hormone and RhF. 31 of the 62 classical BoA searched in the literature were not 
identified as being investigated as predictors of age-related outcomes in any age group. 
Therefore in total there are 41 classical BoA that have not been investigated in the old 
population according to the literature search.  
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3.3.2. Validated classical BoA in the very old population 
 
Next the results from the literature search were compared to data from a previous 
publication of the Newcastle 85+ study cohort (Martin-Ruiz et al., 2011b) which 
investigated all but 2 (physical activity and oxygen saturation) of the classical BoA 
above and their association with the 4 age-related outcomes: mortality, co-morbidity, 
disability and/or cognitive impairment in the very old population. This study used 
ordinal polytomous regression to test for these associations. For each classical BoA 
gender-specific deciles were calculated and participants were allocated to 1 of 3 
categories: <10th percentile, 10–90th percentile, >90th percentile. The age-related 
outcome measures were short-term (18 month) survival; disease count categorised as 1–
2/3–6/7–18, disability score categorised as 0/1–6/7–12/13–17 and SMMSE categorised 
as 0–17/18–21/22–25/26–30. For associations between the classical BoA and short-term 
(18 month) survival, cox proportional hazards regression modelling was used for with 
proportional hazards verified via scaled Schoenfeld residuals. For associations between 
classical BoA and co-morbidity, disability and/or cognitive impairment, each classical 
BoA was first entered singly in regression models and then multivariable models were 
constructed using backwards elimination in both cases with adjustment for gender. The 
results for the classical BoA of the structured literature review were compared to 
classical BoA that were classified as informative BoA in the Newcastle 85+ study, 
which were those associating coherently with more than 1 age-related outcome in a 
multivariable analysis fitted with the 10/90th percentile (Figure 3.3.). The idea here was 
to determine if the results are comparable to the literature to support their use in the 
validation of potential oxidative stress-related BoA investigated in the proceeding 
chapters and also to fill in any gaps of the literature search if certain classical BoA were 
not identified as being investigated in the old population.   
 
39 of the 41 classical BoA that were not identified as being investigated in the old 
population by the literature review were investigated in the very old of the Newcastle 
85+ study. 5 of these were found to be informative BoA in the very old population. 
These were FEV1, red blood cell count, haematocrit, haemoglobin and Free T3. Only 4 
out of the 17 classical BoA that were found to be predictors of age-related outcomes of 
the old population were found as informative BoA  
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Classical BoA 
Structured  literature review 
Very old of  
Newcastle 85+ 
study 
Agreement  
with 
literature? 
Informative 
BoA in 
very old? 
Age group 
Young Middle Old Combined 
Anthropometric            
Body mass index            
Waist to hip ratio             
Fat %          ▬  
Fat free mass             
Total body water          ▬  
Physical function            
Physical activity          ▬  
Hand grip strength             
TUG            
Physiological            
Diastolic blood pressure             
Systolic blood pressure             
FEV1          ▬  
FVC          ▬  
PEFR            
Oxygen saturation           ▬ ▬ 
Haematological            
Red blood cell count          ▬  
White blood cell count          ▬  
Lymphocyte count           ▬  
Monocyte count          ▬  
Neutrophil count          ▬  
Basophil count           ▬  
Eosinophil  count          ▬  
Haematocrit           ▬  
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Haemoglobin           ▬  
Mean cell haemoglobin           ▬  
Mean corpuscular volume           ▬  
Platelet count          ▬  
Biochemical            
Sodium          ▬  
Potassium          ▬  
Urea           ▬  
Urate          ▬  
Creatinine            
Total protein          ▬  
Bilirubin           ▬  
Alanine transaminase             
Albumin            
Calcium           ▬  
Adjusted calcium           ▬  
Phosphate           ▬  
Alkaline phosphatase          ▬  
Glucose             
HbA1c            
Triglyceride             
Cholesterol            
HDL             
LDL             
Apolipoprotein A1           ▬  
Apolipoprotein B          ▬  
Cortisol           ▬  
Free Thyroxine (T4)           ▬  
Free T3          ▬  
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Table 3.3. Comparing the classical BoA in the structured literature search and Newcastle 85+ study. (Young: <45 years, Middle: ≥45-<70 years, 
Old: ≥70 years, Combined: Combination of young, middle and/or old groups).
Thyroid stimulating hormone           ▬  
Thyroid peroxidase          ▬  
C reactive protein (CRP)           ▬  
RhF          ▬  
Vitamin B2           ▬  
Vitamin B6           ▬  
Vitamin B12           ▬  
Vitamin D            
Ferritin           ▬  
Red cell folate           ▬  
Homocysteine             
  NT-pro BNP            
  Positive association   
  Negative association   
  Non-linear association   
  No association   
  No data available   
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in the very old population. These were hand grip strength, systolic blood pressure,  
vitamin D and NT-pro BNP. 3 out of the 4 classical BoA that were not found to be 
predictors of age related outcomes in the old population were also not found to be 
informative BoA in the very old population. 1 of these classical BoA that were not 
found to be predictors of age-related outcomes in the old population was found to be 
informative in the very old population. This was TUG. 1 of the classical BoA not 
investigated in the very old of the 85+ study but in the old population of literature 
review was predictive of age-related outcomes, this was physical activity. Since this is 
also predictive of age-related outcomes in the middle and combined age groups and in 
the same direction of association this is also likely to have predictive value in the very 
old population.  10 (and possibly 11) classical BoA can therefore be used to validate the 
potential oxidative-stress related BoA in the very old age group of the Newcastle 85+ 
study. These are:  hand grip strength, TUG, systolic blood pressure, FEV1, red blood 
cell count, haematocrit, haemoglobin, Free T3, vitamin D and NT-pro BNP and 
possibly physical activity. 
 
3.4. Discussion 
 
The first aim of this chapter was to determine whether different age groups included in 
studies that investigate various classical BoA could be the reason for their conflicting 
conclusions. Where data was available for more than 1 age group, which included 10 of 
the 31 classical BoA identified, the predictive value changed in different age groups.  
This supports the hypothesis that the reason why there are many inconsistencies 
between studies, who either claim the predictive validity of a classical BoA or not or 
even claim different directions of associations, is because classical BoA have different 
predictive values in different age groups. To further support this, although there are 
some gaps in the literature for specific age groups, it is clear that all the classical BoA 
identified as having a different predictive value in different age groups follow a positive 
association with age-related outcomes in the younger and/or middle age group but a 
negative association in the old age group. Where data was available for the young 
and/or middle age group and the old age group from the literature search this is true for: 
body mass index, which was predictive of mortality in a positive direction in the young 
(Seccareccia et al., 1998) but in a negative direction in the old (Siegel et al., 1987);  
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diastolic blood pressure, which was predictive of mortality in a positive direction in 
middle age (Yano et al., 1983) but in a negative direction in the old (Vischer et al., 
2009); systolic blood pressure, which was predictive of mortality in a positive direction 
in the young and middle age (Bulpitt et al., 1986)  but in a negative direction in the old 
(Korten et al., 1999); glucose, which was predictive if mortality in a positive direction 
in middle age (Janghorbani et al., 1993) and in a combined age group (Simons et al., 
2000a) but in a negative direction in the old  (Kaltiala et al., 1987); and cholesterol, 
which was predictive of mortality in a positive direction in the young, not predictive in 
middle age, but predictive in a negative direction in the old (Kronmal et al., 1993). To 
add to this; LDL, which was predictive of mortality in a positive direction in a 
combined age group aged 40-69 years, which thus can be classified in the young and 
middle age group (Pekkanen et al., 1990), but in a negative direction in the old 
(Kronmal et al., 1993). These markers could therefore potentially still be used as 
predictors of age-related outcomes in specific age groups they are identified as being 
valid, providing the direction of association is taken into consideration, however the 
difficulty would be where the cut-offs to define different age groups would be.  
 
The second aim of this chapter was to identify which classical BoA are valid in the very 
old population by comparing the literature and data from the very old population of the  
Newcastle 85+ study. It was shown that are even different predictive values within the 
defined age groups when comparing the old population in the literature review to the 
very old population of the Newcastle 85+ study. For example, body mass index (Siegel 
et al., 1987), fat free mass (Bunout et al., 2011), diastolic blood pressure (Vischer et al., 
2009), PEFR (Fragoso et al., 2008), creatinine (Irie et al., 2001), albumin (Corti et al., 
1994), glucose (Kaltiala et al., 1987), HbA1c (Qiao et al., 2004), cholesterol (Kronmal 
et al., 1993),  HDL (Giampaoli et al., 1999), LDL (Kronmal et al., 1993) and 
homocysteine (McCaddon et al., 2001) are predictors of age related outcomes in the old 
population but are not predictive in the very old population (Martin-Ruiz et al., 2011a). 
There are also situations where some studies find that a classical BoA is valid in one 
age group but another study finds it is not valid in another age group. For example, 
waist to hip ratio, which was predictive of mortality in a positive direction in middle 
age (Folsom et al., 2000) but was not predictive in the old (Woo et al., 2001) or a 
combined age group aged 55-102 years (Visscher et al., 2001); fat free mass, which 
was predictive of mortality in a negative direction in the old (Bunout et al., 2011) but  
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not predictive of disability in a combined age group aged 65-100 years (Visser et al., 
1998) and triglycerides which was predictive of mortality in a positive direction in 
middle age (Lindquist et al., 2002) but not in the young (Lindquist et al., 2002) or old 
(Agner and Hansen, 1983).   Could this therefore be due to overlapping age groups? 
Most studies don’t look at the non-linear relationship a BoA may have with an age-
related outcome; could this be useful? If so would this allow those validated classical 
BoA to be used across all age groups? There are two examples of classical BoA where 
a non-linear prediction is shown. The first is haemoglobin, which was predictive of 
mortality in a non-linear direction in the old population (Skjelbakken et al., 2006), and 
creatinine which was predictive of mortality in a non-linear direction in the old (Shlipak 
et al., 2005) but in a positive direction in a mixed age group aged 40-79 years (Irie et 
al., 2001). If looking at non-linear predictions is not suitable however, the above 
classical BoA do not conform to the full criteria of useful BoA since they can not be 
applied to all members of the population at any given age. 
 
The only classical BoAs that were not found not have different predictive values in 
different age groups (young, middle age  and old) were 2 markers of physical function, 
physical activity and hand grip strength, which were shown to be predictive of age-
related outcomes in a negative direction in middle and both old and very old age groups 
(physical activity not investigated in the very old)  (Holme et al., 1981; Davis et al., 
1994; Giampaoli et al., 1999; Rantanen et al., 1999; Carriere et al., 2005; Martin-Ruiz 
et al., 2011a). (Of course this could be the case for other classical BoA but these could 
not be identified in this study due to the gaps in the literature). One other marker of 
physical function, TUG, although was found to be predictive in the very old (Martin-
Ruiz et al., 2011a) was not found to be predictive in the old population of the literature 
search (Nikolaus et al., 1996). The young age group however was not investigated 
according to the literature search. This information needs to be filled to determine if 
these potential BoA meet the full criteria of a BoA and be applicable to all the 
population.  
 
For some classical BoA, inconsistencies between studies however could be explained 
by other differences between the two studies rather than difference between age groups  
included. One weakness of this study is that only one study per marker and age group 
were investigated. Comparisons of more than one study for the same marker and age 
group would allow the study to determine if differences in the predictive value between 
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studies were in fact due to age if similar studies show agreements. However, if they do 
not agree, then other factors could be the cause of inconsistences such as inter-cohort 
differences, numbers included, controlling of confounders and statistical analyses.  
Another weakness of this study is that the studies included were those that were older 
which may reduce the power of concluding that studies show true predictions since 
using newer studies may be more informative where they may employ more appropriate 
analysis due to advances over the years. It was assumed that it was more logical/fairer to 
describe the first study meeting the search criteria. It was not thought that this would 
effect the outcome of the study since the overall aim was to compare different age 
groups to see if there are different predictions in opposing directions, not to compare the 
quality of the studies. In fact, if the quality of the study was investigated, looking at 
older studies may be more informative of explaining that the disagreement between 
studies is due to differences in the quality of the studies and not because of different age 
groups investigated. To support this, it maybe useful to repeat the literature search 
looking at the more recent studies to see if there are agreements between older and 
newer studies to see if their associations and or analysis techniques are the same or 
different to further conclude that there are true differences in the predictive value of 
BoA between age groups.  
 
3.5. Conclusion 
 
The predictive value of many proposed classical BoA value is different in different age 
groups, even in the old compared to the very old. This could therefore be a reason why 
there are many inconsistencies between studies. Validating newer cellular and 
molecular BoA with classical BoA should therefore be carried out in different age 
groups.  There are 10 (and possibly 11) classical BoA that can be used to validate newer 
candidate cellular and molecular BoA in the very old population. 
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Chapter 4. The experimental and intra-individual  
reliability of potential oxidative stress-related BoA 
 
 
4.1. Abstract 
 
Background It is critically important that the reliability of the methods used to measure 
candidate BoA are investigated before they are measured in large population studies in 
order to continue their validation as predictors of age-related outcomes. Aims This 
study therefore aimed to investigate the experimental and intra-individual reliability of 
measuring ROS production and mitochondrial function by flow cytometry and F2-
isoprostanes by AutoDELFIA. Materials and Methods PBMC superoxide levels, 
mitochondrial mass and mitochondrial membrane potential, and also plasma 8-iso 
Prostaglandin F2 were measured in human controls to investigate various experimental 
handling, assay precision, intra-individual stability and method specificity. The 
Newcastle 85+ data was also used to investigate the longitudinal stability of 8-iso 
Prostaglandin F2. Results Variables found to affect the stability of ROS production and 
mitochondrial function in PBMCs during preparation before flow cytometry analysis 
were: sample storage at 37
o
C for 24 hours; frozen storage at -70
o
C and -196
o
C; 
removing red blood cells by lysis; and the staining temperature of cells. Storing plasma 
samples at 4
o
C for more than 48 hours after thawing affected the stability of 8-iso 
Prostaglandin F2. Intra- and inter-assay precision was acceptable for all parameters. 
There was good day-day repeatability of the flow cytometry analysis for superoxide and 
mitochondrial mass but not for mitochondrial membrane potential. Superoxide levels, 
mitochondrial mass and mitochondrial membrane potential were stable within the short-
term in the PBMC and lymphocyte populations but not in the monocyte population. 
There was also good day-day repeatability of the AutoDELFIA analysis. F2-
isoprostanes were stable in the short-term and also in the long-term in the very old 
population. Good specificity of the flow cytometry quantification method was shown 
and also good specificity of the AutoDELFIA method to detect the 8-iso Prostaglandin 
F2 isomer only. Conclusion This study identified variables that affect the stability of 
PBMC ROS production and mitochondrial function and plasma F2-isoprostanes during 
experimental analysis which can therefore be controlled. It also provided evidence of 
their experimental reliability and intra-individual stability.  
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4.2. Introduction 
 
The first step when investigating candidate BoA in large population studies should be to 
establish their degree of reliability. Reliability concerns measuring how much of the 
variability in a parameter can be attributed to genuine individual differences and not to 
measurement error (McClearn, 1992; McClearn, 1997). Although it is often thought that 
measurement error will be eliminated by repeating the measurement on two or more 
occasions this practice has its disadvantages. On one hand if there is no knowledge that 
certain handling factors can affect the stability of a candidate BoA then random 
systematic errors may occur during one of the multiple measurements thus making the 
combined measurements invalid. This would decrease the sensitivity and specificity of 
the method used and the power of obtaining statistical significance if this was the case 
when errors are not introduced. On the other hand it may only be appropriate to obtain 
one measurement due to cost, material and time constraints. Also when a new candidate 
BoA is investigated its measurement may be of value sometime after the start of a 
study, for example, in a life history cohort. One time measurements of newer more 
mechanistic cellular and molecular BoA can be validated with existing less mechanistic 
classical BoA, therefore one time measurements are not impractical. Determining 
factors that affect the reliability of BoA measurements is also valuable information 
when they are measured on different occasions by different investigators or in different 
laboratories which will prevent non-random systematic errors and thus experimental 
bias.  
 
An important factor that may affect the reliability of candidate BoA is its experimental 
stability which could be eliminated or controlled if identified to prevent unwanted 
measurement error. It concerns various handling factors during preparation and analysis 
of the sample. Experimental stability could be tested directly by comparing altered 
handling factors to a control or indirectly by determining the intra- and inter-assay 
repeatability, agreements with similar parameters and agreements with alternative 
methods. The handling factors investigated will vary depending on the sample and 
method being used. For this study it will be necessary to identify and investigate 
specific handling factors before and during flow cytometry and AutoDELFIA analysis 
that could potentially have an effect on the potential oxidative stress-related BoA being 
investigated (See Chapter 2. Figure 2.6.). Once factors that have an effect are identified 
then a standardised procedure can be implemented for all measurements. The handling 
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of the PBMC and plasma samples and the effect it may have on the potential oxidative 
stress-related BoA is very different and therefore needs to be investigated 
independently. 
 
Analysing ROS production and mitochondrial dysfunction in PBMCs is a direct way of 
measuring oxidative stress in cells and thus is still subject to variation if put under 
certain conditions ex vivo. Therefore conditions during sample preparation and analysis 
that might increase (or decrease) free radical reactions taking place within the cells 
needs to be investigated to prevent the measurement of artificial oxidative stress. This is 
particularly so when a large number of samples are to be compared and are measured on 
different occasions in large population studies.  
 
One issue is sample storage time since the cells are not in their normal environment and 
thus the time spent in altered temperatures, movements and culture medium could have 
an effect on the induction of an oxidative stress response. It has previously been shown 
that storage time decreases PBMC mitochondrial membrane potential (Cassart et al., 
2007). This suggests that mitochondrial function may be affected by storage conditions 
which may also influence ROS production. Using fresh PBMCs in large population 
studies can be problematic since only a few participant samples are available per day 
and thus variations in handling factors that affect the stability of the measurements 
could occur. Also logistics might require cryopreservation in order to obtain large 
numbers of patient materials that can be analysed at a later time point (Jeurink et al., 
2008). One way around this is to freeze the PBMC samples on the day of collection and 
separation so a larger number of samples can be measured per day. Although this may 
not be feasible at present due to the time needed to analyse a large number of samples 
this would be useful if there was ever an automatic system for the described flow 
cytometry protocol (See Chapter 2. Section 2.4.1.).  
 
A second issue is the separation of PBMCs (lymphocytes and monocytes) from other 
cells by density gradient centrifugation since this is not always perfect and sometimes 
red blood cells remain within the sample in different proportions which is dependant on 
the donor samples, the density gradient medium used and technical skills (Chan et al., 
2013). It would be ideal if red blood cells were eliminated from the PBMC samples 
since this will have an effect on the number of PBMCs counted by flow cytometry per 
individual if their red blood cell counts vary. Red blood cell presence may even have an 
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effect on PBMC ROS production and mitochondrial function in cells. It has been shown 
that lymphocytes in whole blood produce more cytokines when their production is 
stimulated than lymphocytes that have been separated by density gradient centrifugation 
(Suni et al., 1998; Song et al., 2002). This indicates that the presence of red blood cells 
in PBMC samples could have an effect on ROS production however this has not been 
investigated. Alternately red blood cell lysis buffer itself or factors released from lysed 
red blood cells could have an effect.  
 
A third issue to consider is the handling of the fluorescent probes. It is often reported 
that fluorescent probes loose their effectiveness when repeatedly freeze-thawed, 
possibly due to altered solubilisation and thus uneven loading in different samples or 
due to increased light exposure (Dinnen et al., 2013). A way around this is to store the 
probe in aliquots of the required volume. However the aliquots will need to be a larger 
volume than what is actually needed to stain the cells due to loss by pipetting which will 
lead to unnecessary probe wastage. It would therefore be more efficient to use larger 
aliquots thus the freeze-thaw stability of the probes should be investigated. Light 
exposure to the probe and to the stained cells is also an important factor to control since 
this may reduce the probes fluorescence known as photo-bleaching caused by the 
irreversible destruction of fluorophores due to prolonged exposure to light 
(Thermoscientific, 2013).  
 
Since measuring ROS production directly can be difficult due to its high reactivity and 
short half-life an alternative indirect method of investigating oxidative stress is to 
measure the products of ROS reactions or damage. Since these are end-products of 
oxidative damage it is considered a better way of measuring oxidative stress in vivo due 
to its stability since they are less likely to be altered during the analysis process. The 
products of lipid peroxidation, F2-isoprostanes, are thought to be the more accurate 
markers of oxidative stress in vivo (Milne et al., 2005).  Since samples used to measure 
F2-isoprostanes including plasma require little preparation and can be frozen once 
collected they can be measured in large batches for which automation is possible, 
reducing the effects of day-day handling variations. Analysis of F2-isoprostanes by EIA 
and TR-FIAs including AutoDELFIA also require less preparation steps than the 
alternative GCMS or LCMS/MS methods, again reducing the effects of handling. 
Storage time and the number of freeze-thaw cycles of plasma should be considered as 
factors that may influence F2-isoprostane concentration. 
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The second factor that may affect the reliability of candidate BoA is their intra-
individual variability which could also be eliminated or controlled if identified to 
prevent unwanted measurement error. Intra-individual variability concerns the day-day 
behaviours or environmental conditions of an individual that may change or fluctuate a 
candidate BoA and impact on its day-day repeatability, which could be eliminated or 
controlled before experimentation or by using statistical approaches during analysis 
(Hershberger and Moskowitz, 2001; Nesselroade and Ram, 2004). Intra-individual 
variability could be tested directly by comparing altered behaviour/environmental 
variables to a control or indirectly by determining short- and long-term stability. The 
elimination or control of intra-individual variables before experimentation would 
require the participants to refrain from a certain behaviour/environment known to affect 
the candidate BoA for a period of time before the sample collection. For example, 
variations in eating patterns are known to affect some blood measurements and 
therefore a 24 hour fasted blood sample is normally required. This however may not be 
feasible for many behaviours such as the taking of medication or environmental 
conditions such a seasonal changes. Therefore alternatively, information on 
participant’s behaviours could be gathered by questionnaires and be controlled for 
through statistical analysis. Examples of intra-individual factors that may affect 
candidate BoA measurements include changes in diet, smoking, alcohol consumption, 
medication, sleep quality, physical activity, use of aids and appliances, social events and 
seasonal/environmental exposures. This chapter will investigate intra-individual 
variability indirectly by determining the day-day intra-individual reproducibility of 
potential oxidative stress-related BoA. The direct investigation of intra-individual 
variability by comparing altered behaviour or environmental variables to a control was 
not tested before this study.  These variables, if any, were therefore not controlled by 
participants refraining from certain behaviours. This will therefore be investigated in 
chapter 5 through the examination of participant characteristics at the period the blood 
sample was taken. Variables found to have a significant impact on the parameters could 
then be controlled for in future analysis.  
 
Since using fluorescent probes to measure ROS production and mitochondrial function 
by flow cytometry and F2-isoprostanes by AutoDELFIA are rarely (if ever) measured in 
large population studies this information is therefore invaluable to continue their 
validation as potential BoA.  This study therefore aimed to investigate the experimental 
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and intra-individual reliability of measuring ROS production and mitochondrial 
function by flow cytometry and F2-isoprostanes by TR-FIA by AutoDELFIA. 
 
4.3. Results 
 
4.3.1. The effects of various experimental handling  
 
To ensure that PBMC superoxide levels, mitochondrial mass and mitochondrial 
membrane potential by flow cytometry remained stable between sample handling and 
analysis, various handling factors that may affect their stability were investigated in 
human control samples (Table 4.1). There was no significant effect after 2 hours storage 
of samples at 37
o
C prior to staining for any of the parameters but after 24 hours a 
significant increase in superoxide levels could be observed (p<0.01), independent of 
mitochondrial mass and mitochondrial membrane potential. All parameters were 
affected by frozen storage of cells in 90% FBS and 10% DMSO. At -70
o
C superoxide 
levels increased (p<0.01) and mitochondrial membrane potential decreased (p=0.02), 
however there was no significant change in mitochondrial mass. At -196
o
C superoxide 
levels and mitochondrial mass increased while mitochondrial membrane potential 
decreased (p<0.01). There was no significant effect of vortex-mediated mechanical 
stress for any of the parameters. Removing red blood cells by lysing them significantly 
stressed the remaining PBMCs as evidenced by increased superoxide levels and 
decreased mitochondrial membrane potential (p=0.01). There was no significant effect 
on repeatedly freeze-thawing DHE, MitoTracker Green FM or JC-1 stain solutions 
before cell staining on all parameters for up to 10 cycles. There was no effect of light 
exposure on stained cells but there was a significant effect of staining temperature on all 
parameters. 
 
To ensure that plasma 8-iso Prostaglandin F2 remained stable between sample handling 
and analysis by AutoDELFIA, various handling factors that may affect their stability 
were investigated in human control samples (Table 4.2). There was no significant effect 
of storing thawed plasma for 24 hours at 4
o
C on 8-iso Prostaglandin F2  concentration 
however it significantly deteriorated after 48
 
hours (p=0.03) and 72 hours (p=0.01). 
There was however no effect of three plasma freeze-thaw cycles. 
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Experimental variable Superoxide levels  (AU) Mitochondrial mass  (AU) Mitochondrial membrane potential (AU) 
 Mean ± SD Mean ± SD Mean ± SD 
Short-term storage time 
 0h (Control) 39.16 ± 5.53 28.53 ± 3.78 4.71 ± 0.58 
2h 32.42 ± 7.42 26.06 ± 2.45 4.52 ± 0.90 
p 0.28 0.40 0.77 
Long-term storage time 
0h (Control) 28.01 ± 2.54 50.83 ± 0.46 2.17 ± 0.17 
24h 80.91 ± 2.02 44.04 ± 4.50 2.26 ± 0.15 
p <0.01 0.06 0.54 
Frozen storage 
 Fresh (Control) 41.03 ± 14.45 42.62 ± 4.77 5.52 ± 0.98 
-70
o
C 85.9 ± 13.82 46.00 ± 7.99 3.28 ± 0.50 
p <0.01 0.56 0.02 
Cryogenic storage 
Fresh (Control) 53.85 ± 4.56 41.47 ± 8.04 4.83 ± 0.30 
-196
o
C 85.9 ± 13.82 101.63 ± 8.21 2.94 ± 0.27 
p <0.01 <0.01 <0.01 
 Mechanical stress 
1000rpm (Control) 50.69 ± 12.84
1 
39.72 ± 2.55
1 
3.13 ± 1.59
1 
2000rpm 49.63 ± 17.31
2 
41.92 ± 2.73
2 
3.49 ± 1.23
2 
3000rpm 53.83 ± 19.79
3 
37.69 ± 0.89
3 
2.97 ± 1.16
3 
p 0.94
1v2 
0.37
1v2 
0.77
1v2 
 0.83
1v3 
0.26
1v3 
0.90
1v3 
Red blood cell lysis 
No lysis (Control) 31.57 ± 1.68 40.05 ± 8.17 2.75 ± 0.40 
Lysis 126.31 ± 21.33 48.90 ± 5.48 1.56 ± 0.06 
p 0.01 0.19 0.01 
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Table 4.1. Stability of superoxide levels, mitochondrial mass and mitochondrial membrane potential in PBMCs during various experimental 
handling prior and during flow cytometry analysis.  Student's t-Test was used to test for the difference between the experimental variable and 
control (n=3). Where more than one variable was tested the single experimental variable (
2 
or 
3
)
 
was compared to the control (
1
).  
 
 
 
 
 
 
 
 
 
 
Probe freeze-thaw cycles 
0 cycles (Control) 194.98 ± 15.21
1 
46.00 ± 7.99
1 
3.28 ± 0.50
1 
5 cycles 195.65 ± 38.37
2 
48.22 ± 4.47
2 
3.31 ± 0.54
2 
10 cycles 211.94 ± 44.08
3 
44.95 ± 6.45
3 
3.36 ± 0.60
3 
p 0.98
1v2 
0.71
1v2 
0.94
1v2 
 0.56
1v3 
0.82
1v3 
0.86
1v3 
 Light exposure 
Unexposed (Control) 25.70 ± 5.05 60.12 ± 14.22 8.59 ± 0.62 
Exposed 25.40 ± 4.34 52.26 ± 3.59 6.41 ± 1.65 
p 0.94 0.41 0.10 
Probe incubation temperature 
 37
o
C (Control) 55.27 ± 11.18
1 
37.81 ± 12.25
1 
2.32 ± 0.20
1 
20
o
c 34.82 ± 5.54
2 
21.37 ± 6.11
2 
5.82 ± 0.85
2 
4
o
C 25.82 ± 6.33
3 
12.23 ± 1.57
3 3.47 ± 1.02
3 
p 0.05
1v2 
0.11
1v2 
<0.01
1v2 
 0.02
1v3 
0.02
1v3 0.13
1v3 
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Experimental variable 8-iso Prostaglandin F2α (ng/ml) 
 Mean ± SD 
Storage time 0h (Control) 39.66 ± 0.22
1 
24h 39.14 ± 0.37
2 
48h 38.66 ± 0.32
3 
72h 37.68 ± 0.42
4 
p 0.11
1v2 
 0.03
1v3 
 0.01
1v2 
Plasma freeze-thaw cycles 1 (Control) 40.27 ± 0.26
1
 
2 39.33 ± 0.92
2
 
3 39.74 ± 1.90
3
 
4 39.49 ± 1.22
4
 
p 0.15
1v2
 
 0.42
1v3
 
 0.23
1v2
 
 
Table 4.2. Stability of 8-iso Prostaglandin F2α in plasma during various 
experimental handling prior to AutoDELFIA analysis.  Student's t-Test was used to 
test for the difference between the experimental variable and control (n=2). Where more 
than one variable was tested the single experimental variable (
2 
or 
3 
or
 4
)
 
was compared 
to the control (
1
).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
4.3.2. Intra- and inter-assay precision  
 
After considering the above experimental variables the reliability of the flow cytometry 
method to evaluate ROS production and mitochondrial function in PBMCs and 
subpopulations was assessed by calculating the average intra- and inter-assay CV of 
three individual control samples (Figures 4.1 and 4.2. respectively). The average intra- 
and inter-assay precision of all parameters in all cell subpopulations was acceptable  
(CV≤15%) (with the exception inter-assay precision of mitochondrial membrane 
potential in PBMCs and monocytes which was borderline acceptable (22.45% and 
17.02% respectively)) (Litwin, 2001): superoxide levels measured by DHE showed an 
intra-assay CV of 4.77-6.84% and inter-assay CV of 5.22-6.81%, mitochondrial mass 
measured by MitoTracker Green FM showed intra-assay CV of 3.21-9.81% and inter-
assay CV of 10.79-13.36% and mitochondrial membrane potential measured by JC-1 
showed intra-assay CV of 6.43-12.23% and inter-assay CV (lymphocytes only) of 
10.83%. 
 
The reliability of the AutoDELFIA method to measure plasma 8-iso Prostaglandin F2 
concentration was also assessed by calculating the average intra- and inter-assay CV of 
ten and twenty repeats respectively of three individual control samples (Figure 4.3. and 
4.4. respectively). The average intra- and inter-assay CV was 25.28% and 23.64% 
respectively which was above the acceptable CV≤15%. Considering the individual 
samples separately there was acceptable intra- and inter-assay precision for plasma 8-iso 
Prostaglandin F2 concentrations above ≈6ng/ml with CVs of 2.51-6.00% and                     
8.20-4.99% respectively however at concentrations below ≈1ng/ml the intra- and inter-
assay precision was unacceptable with CVs of 67.34% and 57.73% respectively. It is 
likely that the low 8-iso Prostaglandin F2 concentration sample is below the limit of 
detection (LOD) for the AutoDELFIA assay which is 0.25ng/ml. The sensitivity or the 
LOD of the isoprostane AutoDELFIA assay is defined as the value which is 3 standard 
deviations below the mean of the zero standard measurement value (mean value–3SD) 
(n=26). Assay sensitivity was taken as the mean of the 3 values obtained from the 3 
separate runs. A standardised adjustment to 0.25ng/ml are made for samples which are 
below the LOD.  
 
 
 
97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Intra-assay precision of A. superoxide levels, B. mitochondrial mass 
and C. mitochondrial membrane potential in PBMCs and cell subpopulations, 
lymphocytes and monocytes, by flow cytometry analysis. (See Appendix C, 
Supplementary Table 1. for raw data).
■ Intra-assay repeat      Individual CV    ▬ Average CV     ▬ Target CV (≤ 15%) 
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Figure 4.2. Inter-assay precision of A. superoxide levels, B. mitochondrial mass 
and C. mitochondrial membrane potential in PBMCs and cell subpopulations, 
lymphocytes and monocytes, by flow cytometry analysis. (See Appendix C, 
Supplementary Table 2. for raw data). 
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Figure 4.3. Intra-assay precision of 8-iso Prostaglandin F2α in plasma by 
AutoDELFIA analysis. (See Appendix C, Supplementary Table 3. for raw data). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Inter-assay precision of 8-iso Prostaglandin F2α in plasma by 
AutoDELFIA analysis. (See Appendix C, Supplementary Table 4. for raw data). 
 
 
 
 
 
 
0.00
20.00
40.00
60.00
80.00
%
 C
V
 
0.00
3.00
6.00
9.00
12.00
1 2 3
n
g
/m
l 
Control sample 
 
■ Intra-assay repeat      
 Individual CV    
 ▬ Average CV     
 ▬ Target CV (≤15%) 
0.00
25.00
50.00
75.00
%
 C
V
 
0.00
5.00
10.00
15.00
1 2 3
n
g
/m
l 
Control sample 
 
■ Inter-assay repeat      
 Individual CV    
 ▬ Average CV     
 ▬ Target CV (≤15%) 
100 
 
4.3.3. Day-day assay precision and intra-individual reproducibility 
 
To evaluate the short-term day-day repeatability of the preparation and measurement by 
flow cytometry and also the short-term intra-individual stability of superoxide 
production, mitochondrial mass and mitochondrial membrane potential, six individual 
control blood samples were taken on two occasions with an interval of one week and 
samples were measured independently (On day 1 and day 7). Day-day assay precision 
of CV≤20% is considered acceptable. Measurements of superoxide levels and 
mitochondrial mass in total PBMCs and lymphocytes showed acceptable CVs (4.17%–
8.31%) (Figure 4.5. A. and B.) and were strongly correlated at both time points               
(r≥0.66) (Figure 4.6. A. and B.), however measurements in monocytes, despite showing 
acceptable CVs (12.42% and 13.19%) (Figure 4.5. A. and B.), showed little correlation 
(r≤0.19) (Figure 4.6. A. and B.). Measurements of mitochondrial membrane potential in 
total PBMCs and lymphocytes showed large CVs between time points (39.02% and 
23.92%) (Figure 4.5. C.) however strongly correlated (r≥0.64) (Figure 4.6. C.) while 
measurement in monocytes also had a large CV (56.97%) (Figure 4.5. C.) and little 
correlation between time points (r=0.25) (Figure 4.6 C).  
 
To evaluate the short-term day-day repeatability of the preparation and storage 
(however not measurement by AutoDELFIA since all samples were measured on the 
same occasion on the same plate) and also the short-term intra-individual stability of 
plasma 8-iso Prostaglandin F2, 16 individual control blood samples were taken on two 
occasions with an interval of one week and then samples were measured on the same 
occasion on the same plate. The average CV between time points was large (48.62%) 
(Figure 4.7.), however strongly correlated (r=0.94) (Figure 4.8.). Since CV varies 
between controls (10 had CV values below the 20% target and the remaining 6 were 
above 20%), the variation is more likely to be short-term intra-individual variation 
rather than preparation and storage variation. Also again the individual samples with 
CVs above 20% were of low 8-iso Prostaglandin F2 concentration and thus it is likely 
that their concentration is below or close to the (LOD of 0.25ng/ml for the 
AutoDELFIA assay.  
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Figure 4.5. Short-term day-day precision of A. superoxide levels, B. mitochondrial 
mass and C. mitochondrial membrane potential in PBMCs and cell 
subpopulations, lymphocytes and  monocytes, by flow cytometry analysis. Day 1 
and day 7 were measured independently. (See Appendix C, Supplementary Table 5. for 
raw data). 
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Figure 4.6. Short-term intra-individual stability of A. superoxide levels, B. 
mitochondrial mass and C. mitochondrial membrane potential in PBMCs and cell 
subpopulations, lymphocytes and  monocytes. Pearson’s correlation coefficient was 
used to test the strength of association between day 1 and day 7 intervals and thus in 
vivo stability (n=6). Error bars represent SD of two repeats. 
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Figure 4.7. Short-term day-day precision of 8-iso Prostaglandin F2α in plasma by 
AutoDELFIA analysis. Day 1 and day 7 were measured on the same occasion. (See 
Appendix C, Supplementary Table 6. for raw data). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Short-term intra-individual stability of 8-iso Prostaglandin F2α in 
plasma. Pearson’s correlation coefficient was used to test the strength of association 
between day 1 and day 7 intervals and thus in vivo stability (n=16). Error bars represent 
SD of two repeats. 
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Since the short-term day-day reproducibility of the AutoDELFIA method to measure 
plasma 8-iso Prostaglandin F2 could not be assessed by the previous method the long-
term day-day reproducibility and thus long-term intra-individual stability was assessed 
by calculating the average day-day CV and correlation between the Newcastle 85+ 
samples at phase 1 and phase 2 (both measured on the same occasion) with phase 3 
(measured independently of phase 1 and phase 2). The average CV between phase 1 and 
phase 3 was 29.11% and phase 2 and phase 3 was 30.22%, slightly above the target of 
20% (Figure 4.9.).  There is however a wide variation in individual CVs between phases 
with many above and below 20%. Thus the higher than target long-term day-day CV is 
more likely to be long-term intra-individual variation for some individuals rather than 
AutoDELFIA day-day variation. There are also many individuals with low 8-iso 
Prostaglandin F2 concentration and thus it is likely that their concentration is below or 
close to the LOD of 0.25ng/ml for the AutoDELFIA assay contributing to high CV. 
There was however a high correlation between phase 1 vs. phase 2, phase 1 vs. phase 3 
and phase 2 vs. phase 3 (r=0.86, r=0.75 and r=0.78 respectively, p<0.01 for all) 
demonstrating overall good long-term intra-individual stability (Figure 4.10.).   
 
4.3.4. The comparison and agreement of superoxide levels, mitochondrial mass and 
mitochondrial membrane potential in PBMC subpopulations, lymphocytes and 
monocytes 
 
Since the density gradient centrifugation method used isolates PBMC subpopulations 
lymphocytes and monocytes only we identified these subpopulations within the PBMC 
sample by flow cytometry which was confirmed by CD45 and CD14 antibody staining (See 
Chapter 2. Section 2.4. Figure 2.2.). In the very old population, superoxide levels and 
mitochondrial mass in monocytes were significantly higher than in lymphocytes whereas 
membrane potential was significantly lower (p<0.01) (Figure 4.11. A.). There was however 
a high positive correlation between superoxide levels and mitochondria mass and in both 
subpopulations of PBMCs (r=0.78 and r=0.84 respectively, p<0.01 for both) demonstrating 
high specificity of the flow cytometry quantification method and also cell type 
independency of these parameters (Figure 4.11. B.). The correlation between mitochondrial 
membrane potential in both subpopulations of PBMCs was also positive however of lower 
magnitude (r=0.40, p<0.01), which could be because of less specificity of the quantification 
method or cell type independency of this parameter (Figure 4.11. B.).  
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Figure 4.9. Long-term day-day precision of 8-iso Prostaglandin F2α in plasma by 
AutoDELFIA analysis. Average CV for phase 1 vs. phase 2 was 20.70 %, phase 1 vs. 
phase 3 was 29.11% and phase 2 vs. phase 3 was 30.22%. Phase 1 and phase 2 were 
measured on the same occasion, phase 3 was measured independently. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Long-term intra-individual stability of 8-iso Prostaglandin F2α in 
plasma of the very old population. Spearman’s correlation coefficient was used to test 
the strength of association between  phase 1, phase 2 and phase 3 intervals and thus in 
vivo stability. 
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Figure 4.11. Comparing ROS production and mitochondrial function in PBMC 
subpopulations, lymphocytes and monocytes, of the very old population. A. 
Comparison of medians and B. correlations of superoxide levels (n=248), mitochondrial 
mass (n=341) and mitochondrial membrane potential (n=347). Wilcoxon Signed-Rank 
Test was used to test differences between medians and Spearman’s correlation 
coefficient was used to test the strength of associations.  
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4.3.5. The agreement between the AutoDELFIA and the LCMS/MS method to measure 
plasma F2-isoprostanes 
 
Since there are many different isomers of F2-isoprostanes generated from the action of 
ROS on arachidonic acid in vivo the effectiveness of AutoDELFIA is based on the 
specificity of the antibody to the 8-iso Prostaglandin F2 isomer. Individual isoforms 
may be a result of different oxidative stress pathways and may have different biological 
roles. Using an alternative LCMS/MS method to measure F2-isoprostane isomers has 
advantages over AutoDELFIA including a high resolution of isomer separation, high 
specificity and sensitivity and determines multiple F2-isoprostane isomers at a time. 
However it is not the method of choice when analysing a large number of samples since 
it is laboriously intensive, requires expensive equipment, skilled operators and is time 
consuming. To further investigate the reliability of the AutoDELFIA method and its 
specificity to the 8-iso Prostaglandin F2 isomer it was compared to the 8-iso 
Prostaglandin F2 and 5-iPF2-V1 isomers measured by LCMS/MS in phase 1 samples 
of the Newcastle 85+ study. Concentrations of 8-iso Prostaglandin F2 measured by 
AutoDELFIA were not significantly different compared with the 8-iso Prostaglandin 
F2 isomer by LCMS/MS (p=0.14) however was significantly lower compared with 5-
IPF2α V1 isomer by LCMS/MS (p<0.01) (Figure 4.12. A.). There was however no 
correlation between 8-iso Prostaglandin F2 measured by AutoDELFIA with the 8-iso 
Prostaglandin F2 isomer or 5-IPF2α V1 isomer measured by LCMS/MS in the same 
participants (r=-0.04, p=0.26 and r=-0.01, p=0.81 respectively) but there was an 
agreement between both F2-isoprostane isomers measured by LCMS/MS (r=0.75, 
p<0.01) (Figure 4.12. B.). Since samples for the LCMS/MS assay were measured in 
batches and the batch-batch precision is unknown, this may have introduced 
experimental variability within the samples due to different experimental conditions. 
This could explain the disagreement between the AutoDELFIA and LCMS/MS 
methods. There were significant differences between 8-iso Prostaglandin F2 by 
AutoDELFIA for both 8-iso Prostaglandin F2 and 5-IPF2α V1 isomers for most 
LCMS/MS assay runs and there was no correlation between 8-iso Prostaglandin F2 by 
AutoDELFIA with either of the F2-isoprostane isomers measured by LCMS/MS (Figure 
4.12. C.) confirming no agreement between AutoDELFIA and LCMS/MS. 
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Figure 4.12. Agreement between 8-iso Prostaglandin F2  by AutoDELFIA with 8-
iso Prostaglandin F2  and 5-IPF2α V1  isomers by LCMS/MS A. Comparison of 
medians B. correlations and C. comparison of medians and correlation by LCMS/MS 
assay number (AutoDELFIA 8-iso Prostaglandin F2  vs. LCMS/MS 8-iso Prostaglandin 
F2  or 5-IPF2α V1:  n=645; LCMS/MS 8-iso Prostaglandin F2  vs. LCMS/MS 5-IPF2α 
V1: n=762). Wilcoxon Signed-Rank Test was used to test differences between medians 
and Spearman’s correlation coefficient was used to test the strength of associations.  
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4.3.6. The specificity of AutoDELFIA to the 8-iso Prostaglandin F2 isomer 
 
The reason for the disagreement between the AutoDELFIA and LCMS/MS methods to 
measure 8-iso Prostaglandin F2 is uncertain. It could be due to difference in the 
specificity of the methods to detect the 8-iso Prostaglandin F2 isomer. To further 
explore the ability of AutoDELFIA do detect the 8-iso Prostaglandin F2  isomer, 
control plasma samples were spiked with varying concentrations of 8-iso Prostaglandin 
F2  and 5-IPF2α V1 isomers,  alone or in combination, and the recovery of 8-iso 
Prostaglandin F2 was determined (Table 4.3.). AutoDELFIA detected increasing 
concentration of the 8-iso Prostaglandin F2 isomer however not for the 5-iPF2-V1 
demonstrating its specificity for the 8-iso Prostaglandin F2 isomer only. 
 
4.4. Discussion 
 
Assessing the reliability of potential BoA is critically important in population studies to 
ensure that variability reflects genuine inter-individual differences and not 
methodological error. This should be carried out before further validation analyses of 
potential BoA since controlling for these factors will increase the power of obtaining 
true results in future analysis. This is increasingly important when samples are handled 
on a daily basis where day-day experimental variables may vary. Since there is limited 
information in the literature on the reliability of measuring PBMC superoxide levels, 
mitochondrial mass and mitochondrial membrane potential by flow cytometry or 
plasma 8-iso Prostaglandin F2α by AutoDELFIA it was important that this was 
investigated for the future analysis of these parameters within this study. The overall 
aim of this chapter was to evaluate measurement error by investigating variables that 
may affect the experimental stability of these potential oxidative  stress-related BoA . 
 
The first step was to identify experimental handing variables that may introduce error 
during the measurement of the potential oxidative stress-related BoA in question. A 
significant experimental handling variable that had an effect on both ROS production 
and mitochondrial function in PBMCs and plasma 8-iso Prostaglandin F2α was the 
storage conditions. It was shown that the superoxide production in PBMCs was 
increased by sample storage at 37
o
C between 2 and 24 hours however there was no 
change in mitochondrial mass or membrane potential. This indicates that the increase in 
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Table 4.3.  The recovery of 8-iso Prostaglandin F2 by AutoDELFIA  in plasma samples spiked with 8-iso Prostaglandin F2α and/or  5-iPF2α–
V1.
Control 
plasma 
F2-isoprostane 
spike 
Plasma +                                             
8-iso Prostaglandin F2α spike 
Plasma +                                            
5-iPF2α-V1 spike 
Plasma + 8-iso Prostaglandin F2α                                   
+ 5-iPF2α–V1 spikes 
 (ng/ml) 
Raw 
(ng/ml) 
Recovered 
(ng/ml) 
% 
Recovery 
Raw 
(ng/ml) 
Recovered 
(ng/ml) 
%  
 Recovery 
Raw 
(ng/ml) 
Recovered 
(ng/ml) 
%  
 Recovery 
1 0 13.78 0.00 
_ 
13.78 0.00 
_
 13.78 0.00 
_
 
 5 17.15 3.37 67.37 13.05 -0.73 -14.67 15.88 2.10 42.02 
 10 21.09 7.31 73.09 14.04 0.26 2.62 20.32 6.54 65.40 
 20 30.08 16.30 81.49 13.14 -0.64 -3.21 30.65 16.86 84.32 
 40 51.57 37.79 94.47 14.30 0.52 1.30 47.61 33.83 84.58 
2 0 6.14 0.00 
_
 6.14 0.00 
_
 6.14 0.00 
_
 
 5 10.31 4.17 83.42 4.64 -1.50 -29.95 8.19 2.05 41.09 
 10 14.85 8.71 87.08 5.09 -1.05 -10.50 12.77 6.63 66.33 
 20 19.66 13.52 67.58 4.57 -1.57 -7.84 22.73 16.59 82.96 
 40 42.63 36.49 91.22 4.59 -1.55 -3.86 45.43 39.29 98.22 
1 0 1.14 0.00 
_
 1.14 0.00 
_
 1.14 0.00 
_
 
 5 4.11 2.97 59.31 0.80 -0.34 -6.88 2.89 1.75 34.92 
 10 5.17 4.03 40.26 0.25 -0.89 -8.92 5.93 4.78 47.85 
 20 12.36 11.22 56.08 2.22 1.08 5.38 13.14 12.00 59.98 
 40 25.06 23.91 59.79 0.85 -0.29 -0.72 25.90 24.76 61.89 
4 0 6.45 0.00 
_
 6.45 0.00 
_
 6.45 0.00 
_
 
 5 10.14 3.69 73.76 6.07 -0.39 -7.75 10.35 3.89 77.84 
 10 14.69 8.24 82.41 6.72 0.26 2.63 14.62 8.16 81.61 
 20 23.20 16.75 83.74 6.24 -0.21 -1.05 24.26 17.80 89.01 
 40 40.45 34.00 84.99 6.54 0.09 0.22 39.44 32.98 82.45 
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superoxide levels was independent of mitochondrial function.  It is therefore unclear by 
what mechanism superoxide production is increased since DHE is thought to reflect 
mitochondrial superoxide production. However these results suggest that this may not 
be the case and independent mechanisms of superoxide production may be involved. 
This study contradicts an earlier study that found storage time decreases PBMC 
mitochondrial membrane potential between 5 and 24 hours (Cassart et al., 2007). 
However differences between this study was that they investigated the storage time of 
the whole blood sample and not the isolated PBMCs and also their storage was at room 
temperature and not 37
o
C. Their cells, although stored in the natural medium unlike the 
samples of this study, were therefore not at their normal in vivo temperature which 
could explain the decrease in mitochondrial membrane potential. Interestingly, from the 
experiment of this study investigating the incubation temperature of cells stained with 
the JC-1 probe, mitochondrial membrane potential was significantly increased at room 
temperature (20
o
C) compared to 37
o
C, contradicting the study by Cassart et al, 2007. It 
seems however that PBMC mitochondrial function may be affected by temperature. If 
temperature is affecting mitochondrial function it would be interesting to know if it is 
also affected by temperature changes in vivo, which could be due to an illness, a 
medication or from the seasonal environment. It would not be so surprising if 
mitochondria are affected by temperature changes in vivo due to their dynamic nature in 
response to changes in physiological conditions, which serves to maintain their function 
(Seo et al., 2010). This could have implication in the second part of this chapter that 
investigated intra-individual reproducibility. Could differences in mitochondrial 
membrane potential between or within individuals reflect varying body temperatures? 
Unfortunately body temperature was not assessed within participants of the Newcastle 
85+ study; however, an indirect way of investigating this could be to look at seasonal 
variations which will be investigated in Chapter 5. The overall conclusion of this 
experiment for this chapter however is that PBMC samples that are to be used to 
measure ROS production and mitochondrial function should be analysed within 2 hours 
of storage. This can be problematic if there are a large number of samples to process 
and analyse. This study therefore investigated whether PBMC sample could be frozen 
so a larger number of samples could be measured per day. This could also be useful for 
future automatic measurement by flow cytometry. However, it was found that freezing 
(-70
o
C) and cryopreservation (-196
o
C) increased PBMC superoxide production and 
mitochondrial dysfunction and therefore frozen storage will not be possible.  
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Plasma 8-iso Prostaglandin F2α was also affected by storage conditions. Once plasma is 
thawed for experimental analysis, sample are stored at 4
o
C whilst material is being 
prepared for analysis by AutoDELFIA. This could also be done overnight so samples 
are ready for analysis the next day to save time. Also, sometimes the plasma sample are 
re-analysed, especially when their first measurement CV value was above 10%,  and are 
therefore stored at 4
o
C until the next analysis.  This study found that there was a 
significant deterioration in 8-iso Prostaglandin F2 between 24 and 48
 
hours storage at 
4
o
C. An explanation for this could be the presence of a metabolic enzyme in plasma that 
works efficiently at this temperature to metabolise 8-iso prostaglandin F2. Thawed 
plasma samples should therefore not be stored above -70
o
C for longer than 24 hours. 
Although storing plasma in several vials will minimise the need for multiple freezing 
and thawing, it is sometimes necessary to use plasma that has undergone more than one 
freeze-thaw cycle. There was however no effect of three repeated freeze-thaw cycles 
compared to the control. Plasma samples are therefore reliable up to a maximum of 
three freeze/thaw cycles.  
 
The remaining experimental handling variables investigated were specific to the 
analysis ROS production, mitochondrial mass and mitochondrial membrane potential by 
flow cytometry. This was because there are many more sample handling steps that were 
unknown to influence these parameters and also the fact that this was a direct way of 
measuring oxidative stress in cells, which are much more susceptible to changes from 
the in vivo environment than the indirect method of measuring endpoints of oxidative 
stress in the plasma, potentially generating artificial oxidative stress.   
 
Since it was originally thought that it would be more ideal that red blood cells were 
removed from the PBMC samples before analysing superoxide levels, mitochondrial 
mass and mitochondrial membrane potential for the reasons discussed previously in 
Section 4.1., red blood cells in PBMC samples were lysed and compared to unlysed 
controls. The idea was that if this method of removing red blood cells did not influence 
ROS production or mitochondrial function, then the sensitivity of the analysis may be 
improved allowing a more accurate counting of PBMC cells only, which may increase 
the power of obtaining true results in future analysis. However lysing red blood cells 
from the PBMC samples significantly stressed the remaining cells evidenced by 
increased superoxide levels which was dependent on mitochondrial dysfunction, 
evidenced by a significant decrease in mitochondrial membrane potential. Many studies 
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employ this method of removing red blood cells when PBMCs are being investigated. It 
could be argued that as long as the same conditions of red blood cell lysis are used for 
all the samples (i.e. the same concentration and length of time in lysis buffer) then this 
may not be a problem. However, different individuals may have difference sensitivities 
to the toxic effect of the lysis buffer, if this was involved in the induction of oxidative 
stress, and therefore this routine would not be ideal. Alternatively this study could 
support the findings of two earlier studies who found that PBMCs in the presence of red 
blood cells produce more cytokines than when red blood cells are removed by density 
gradient centrifugation (Suni et al., 1998; Song et al., 2002). If this was the case then 
red blood cell lysis buffer itself may not be the inducer of oxidative stress but the 
removal of red blood cells themselves. Could factors released by red blood cells reduce 
oxidative stress in PBMCs? Interestingly this is addressed in a study by Fonseca et al, in 
2001 who show that the presence of red blood cells in cultures of stimulated human 
peripheral blood lymphocytes strengthens their  proliferation and survival by inhibiting 
apoptosis through the reduction of ROS (Fonseca et al., 2001). This suggests that red 
blood cells play a role in maintaining PBMC homeostasis. This study supports this and 
also suggests that mitochondrial function is involved in the maintenance of PBMCs by 
red blood cells.  
 
The remaining experimental handling factor to influence superoxide levels, 
mitochondrial mass and mitochondrial membrane potential was the staining temperature 
of PBMCs. This is not so much surprising since it is expected that the probes are more 
likely to penetrate the cells at higher temperatures because of higher membrane 
permeability and thus increasing the effectiveness of the staining, evident by higher 
superoxide levels, mitochondrial mass and lower mitochondrial membrane potential at 
37
o
C compared to 20
o
C and 40
o
C. The overall message of this experiment is the 
importance of maintaining a strict staining time at the same temperature for each 
sample. It could be more interesting to investigate the storage temperature of the cells 
before staining which would indicate whether oxidative stress is induced due to changes 
from the normal physiological temperature of the cells at 37
o
C. This could be more 
informative on the effects experimental handling, since preparation of the cells is 
carried out at room temperature and thus the length of time in this temperature could 
vary for samples, especially when there are numerous samples to measure. Although it 
is suggested that experiments are carried out when cells are on ice, this also could 
introduce experimental error since individuals could have difference susceptibilities to 
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cellular stress at this temperature. The measurement would therefore reflect a cellular 
stress response rather than basal oxidative stress.  
 
One other factor investigated that was unknown to induce a stress response in PBMCs 
was putting the cells under a brief mechanical stress. The force of mechanical stress 
investigated was reflected in the force that the cells might be put under during the 
preparation of samples for flow cytometry analysis. This is when the cells are briefly 
vortex after staining.  The strength of the vortex could vary between samples or between 
investigators therefore it is interesting to know if this does induce a stress response and 
at what force.  There was however no effect of vortex mechanical stress at 1000, 2000 
and 3000rpm compared to the control concluding that this factor doe not need to be 
controlled for at this level of mechanical stress.  
 
Issues relating to the handling of the fluorescent probes were also investigated including 
the effects of freeze thawing probe aliquots since it is thought that this may reduce their 
effectiveness as discussed in Section 4.1. The reason why this is important to know is 
because this could not only have experimental implications but also financial. Storing 
aliquots in smaller volumes for one time use is more costly due to probe wastage by 
pipetting losses than being able to re-freeze the probes in larger aliquots and thawed for 
further experiments. It also requires more material for storing the probes. This study 
however found that freeze-thawing the DHE, MitoTracker Green and JC-1 probes for 
up to 10 cycles does not significantly reduce their effectiveness, supporting the use of 
larger probe aliquots and being able to freeze-thaw them without introducing error to 
the measurements. This study also found that the effectiveness DHE, MitoTracker 
Green and JC-1 probes are not reduced by unprotecting stained PBMCs from light.  
 
After considering the above handling variables, it was important to provide evidence of 
the assay precision of both the quantification of PBMCs superoxide levels, 
mitochondrial mass and mitochondrial membrane potential and also plasma 8-iso 
Prostaglandin F2 by AutoDELFIA. This was to determine whether handling variables, 
other than the ones investigated above, could be influencing and thus introducing errors 
within the measurements. There were three types of assay precision analyses 
investigated: 1)  intra-assay precision, by repeating the same sample preparation (i.e.  
within the same tube or on the same assay plate) which would determine whether errors 
are introduced during the instrumental measurement itself (i.e. by the flow cytometer or 
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AutoDELFIA equipment); 2) inter-assay precision, by repeating the same sample 
however from a different preparation (i.e. between different tubes or different assay 
plates) which would determine whether errors are introduced prior to the instrumental 
measurement during sample handling, which mainly reflects pipetting accuracy since 
other variables were kept the constant (See Chapter 2. Figure 2.6.); and 3) day-day 
assay precision, by repeating samples from the same individual at a seven day interval 
and thus the repeatability of all the experimental variables. This also permitted the 
analysis of intra-individual reproducibility.  
 
Concerning the measurement of ROS production and mitochondrial dysfunction by 
flow cytometry, there was good within and between-assay precision for PBMC and cell 
subpopulation superoxide levels, mitochondrial mass and membrane potential. This 
confirms that individual samples measured on the same day are comparable. However, 
although all markers were stable within individuals during a seven day interval in the 
PBMC and lymphocyte populations, this was not the case in the monocyte population. It 
is therefore unlikely that intra-individual factors will contribute to measurement error in 
the short term within the two former cell populations however this could be the case 
within the monocyte population. This could either reflect method precision or intra-
individual variability within the monocyte subpopulation. In support of the latter, 
monocyte populations have been shown to have a weaker diurnal rhythm than 
lymphocytes and other PBMC subpopulations, which demonstrates that they may be 
more sensitive to intra-individual factors (Ackermann et al., 2012), which could thus 
affect ROS production and mitochondrial function. One potential intra-individual factor 
is sleep quality since different PBMC subpopulation levels have different sensitivities to 
sleep deprivation (Ackermann et al., 2012). Other potential causes of intra-individual 
variation that could be explored in future analysis include diet, smoking, alcohol 
consumption, medications, illnesses and other key events. The seven day interval 
experiment also demonstrated good day-day repeatability of the flow cytometry analysis 
for superoxide and mitochondrial mass but not for mitochondrial membrane potential. A 
potential problem with the JC-1 dye for measuring mitochondrial membrane potential is 
that it is poorly soluble in aqueous solutions (Schwartz, 2001) and thus variation in the 
preparation of the stain on different occasions could be the reason for its day-day 
variability.  
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Concerning the measurement of F2-isoprostanes by AutoDELFIA, there was good 
precision for plasma 8-iso Prostaglandin F2 concentrations above ≈6ng/ml within and 
between assays and also day-day, however poor precision in samples at lower 
concentration. We can therefore be confident in the repeatability of plasma 8-iso 
Prostaglandin F2 measurements above 6ng/ml however we are less confident on the 
repeatability of samples under ≈1 ng/ml.  It is likely that the lowest 8-iso Prostaglandin 
F2 concentration sample is below the LOD for the AutoDELFIA assay which is 
0.25ng/ml. Adjustments will be made for samples which are below LOD in future 
analysis (i.e. to 0.25ng/ml). Further analysis could be to calculate the CV for a range of 
samples between 0.25ng/ml to 6ng/ml to determine which concentrations produce an 
acceptable CV, and thus further adjustments can be made accordingly. Although plasma 
8-iso Prostaglandin F2 in most individual (younger control and the very old population) 
was stable in the short (days) and long term (years), this was not the case for all 
individuals, demonstrated by a high CV between the two different occasions of blood 
sample withdrawals. It would therefore be worth investigating potential confounders as 
discussed above.   
 
Since PBMCs are used in this study as surrogate tissues to investigate potential 
oxidative stress-related BoA, specifically ROS production and mitochondrial function, 
the next part of this study was to determine if these parameters can be specifically 
measured and compared in different PBMC subpopulations. Measurement of these 
parameters specifically within lymphocyte and monocyte subpopulations was confirmed 
using antibodies that are specifically associated with these subpopulations (See Chapter 
2, Section 2.4.6.). Although the levels of superoxide and mitochondrial parameters 
varied between subpopulations, there was a correlation between them, providing 
evidence of good specificity of the flow cytometry quantification method and also 
suggesting that ROS production and mitochondrial function is independent, at least, of 
white blood cell type. This could be indicative that ROS production and mitochondrial 
function are also independent of tissue type. Since the overall goal of using a surrogate 
tissue for the measurement of a BoA is that they should be reflective of ageing in other 
tissues, further experiments investigating these parameters in different tissues would be 
invaluable to their future validation as candidate BoA. This however has impracticality 
issues for most tissues, however could, for example, be investigated in buccal cells, hair 
follicles and skin. To support this, various studies have also found different levels but  
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agreements between various markers implicated in the oxidative stress-driven pathway 
to cellular senescence in peripheral blood and other tissues, suggesting they are tissue 
independent (Godschalk et al., 1998; Friedrich et al., 2000; Herrera et al., 2009). 
However, the effects of the different levels of oxidative stress on driving cellular 
senescence and thus ageing in each cell type/tissue could vary.  
 
Alternatively, an overall measure of oxidative stress that is reflective of a combination 
of tissues, including F2-isoprostanes in plasma, would be more practical. Although this 
may not permit the prediction of a specific age-related outcome, it could be indicative of 
an overall age-related decline. The last part of the study was to provide further evidence 
of the reliability of plasma 8-iso Prostaglandin F2 by AutoDELFIA. This was to 
determine its agreement with an alternative method of measuring plasma 8-iso 
Prostaglandin F2 and also to determine whether there are agreements with an 
alternative F2-isoprostane isomer, 5-IPF2α V1.  There are many different F2-isoprostane 
isomers present in plasma that could reflect different tissues, extent of oxidative damage 
or even different biological roles, therefore it was interesting to determine if there are 
agreements between different isomers. The comparison with LCMS/MS permitted both 
these investigations, since it determines multiple F2-isoprostanes isomers at a time. 
There was agreement in the overall concentration of the 8-iso Prostaglandin F2 isomer, 
but the concentration of the 5-IPF2α V1 isomer was higher, concluding that different F2-
isoprostanes isomers are present in plasma in different concentrations. However, the 
disagreement between AutoDELFIA and LCMS/MS was confirmed when no 
correlation between the 8-iso Prostaglandin F2  isomer measured by both methods was 
shown.  There was however an agreement between F2-isoprostane isomers, indicated by 
a correlation between the 8-iso Prostaglandin F2  and 5-IPF2α V1 isomers measured by 
LCMS/MS. One issue in the disagreement between methods could be the specificity of 
the AutoDELFIA to the 8-iso Prostaglandin F2  isomer. This was further tested in a 
spiking experiment which provided evidence that AutoDELFIA was specific to 8-iso 
Prostaglandin F2 and did not detect the 5-IPF2α V1 isomer. However, cross-reactivity 
with other isomers could also occur. The unavailability of many isomers and pure 
material to fully characterise antibodies against specific isomers makes the assessment 
of cross-reactivity difficult. However, there are also disadvantages to LCMS/MS that 
could be the reason for the disagreement between methods including the fact that there 
are potential losses due to the required purification and derivatisation steps, where as 
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AutoDELFIA is performed directly on the sample. Further investigation as to why there 
are disagreements between methods is therefore required.    
 
4.5. Conclusion 
 
This study identified experimental variables that may affect the reliability of various 
potential oxidative stress-related BoA. These therefore should be controlled for in future 
analysis. When controlled there was evidence of experimental reliability and intra-
individual stability permitting their further validation as potential BoA. 
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Chapter 5. The construct validity of potential oxidative 
stress-related BoA in the very old population 
 
5.1. Abstract 
 
Background An important step when validating candidate BoA is to confirm that they 
reflect known phenomena of biological ageing. Aims This study therefore aimed to 
provide evidence of construct validity for potential oxidative stress-related BoA. 
Materials and Methods These were measured in the very old participants from the 
Newcastle 85+ study and also in younger controls to investigate associations with 
chronological age and other known biomarkers that reflect biological ageing including 
associations between the potential oxidative stress-related BoA themselves, biomarkers 
of known biological mechanisms of ageing, biomarkers of immune function and 
validated classical BoA in the very old population. Results It was surprising that 
superoxide levels were lower in the very old compared to the younger controls (p<0.01), 
however mitochondrial mass was higher (p=0.04) and mitochondrial membrane 
potential was lower (p<0.01). 8-iso Prostaglandin F2α was also lower in the very old 
population however did not reach significance (p=0.69). The correlations with 
chronological age was in the same direction as in the comparison between the young 
and very old, however only reached significance for mitochondrial membrane potential 
(r=-0.72, p<0.01) and nearly mitochondrial mass (r=0.51, p=0.08). There was 
significant longitudinal change in 8-iso Prostaglandin F2α at age 85, 86.5 and 88 years 
however these changes were not linear with age. There was an association between 
superoxide levels and mitochondrial mass (positive in lymphocytes and monocytes, 
p≤0.01) and superoxide levels and mitochondrial membrane potential (negative in 
PBMCs, p=0.01; positive in lymphocytes and monocytes, p=0.05 and p=<0.01 
respectively). There were no associations between ROS production and mitochondrial 
parameters with 8-iso Prostaglandin F2α. There were some significant associations 
between potential oxidative stress-related BoA and other biomarkers implicated in 
biological ageing, however not all were in the same direction as expected. An 
interesting further finding was that all potential oxidative stress-related BoA were 
associated with seasonal variation. Conclusion Some evidence of construct validity was 
shown for potential oxidative stress-related BoA and thus should be investigated for 
their predictive potential. Seasonal variation is a potential confounder and should be 
controlled for in future predictive validation analyses. 
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5.2. Introduction 
 
After establishing the methodological reliability of a candidate BoA the second step 
should be to provide evidence of its validity.  There are various methods of  evaluating 
the validity of a biomarker which can be complex depending on what type of biomarker 
is being investigated (Mayeux, 2004). However evaluating the validity of candidate 
BoA can be split into two major groups: construct validity and predictive validity 
(Ingram et al., 2001). Construct validity is defined here as the ability of the candidate 
BoA to reflect known phenomena of biological ageing (as the construct) which will be 
investigated in this chapter and also chapter 6.  Predictive validity is defined as the 
ability of a candidate BoA to correlate with and predict various age-related outcomes 
which will be investigated in chapter 7.  
 
The first and most obvious assessment to provide evidence of the construct validity of a 
candidate BoA is that it should to some degree show a correlation with chronological 
age since it is well acknowledge that this is associated with age-related decline and an 
increased risk of mortality. It should also be shown that the direction of correlation with 
age should be the same direction in a cross sectional analysis of different age groups 
(Ingram et al., 2001).  However, although physiological decline is an inevitable and 
inescapable consequence of advancing age, this decline is not uniform and there are 
often considerable differences between and within individuals reflecting biological age 
(Ekonomov et al., 1989; Fozard et al., 1990; Ueno et al., 2003). Therefore the rate of 
change of a BoA should not be dependant on chronological age, after all the value of a 
BoA is that it can measure biological ageing better than chronological age.  
 
A further assessment of the construct validity of a candidate BoA should be to evaluate 
their correlation with other known biomarkers that reflect biological ageing. In terms of 
the potential oxidative stress-related BoA investigated in this study these could be 1) 
parallel biomarkers, for example those that claim to measure oxidative stress; 2) 
biomarkers of known biological mechanisms of ageing, for example biomarkers of 
cellular senescence; 3) biomarkers of age-related functional decline, for example 
immunosenescence phenotypes; and 4) validated classical BoA.  
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Providing evidence of the correlation between other potential oxidative stress-related  
BoA with an association in the same direction would not only confirm that the 
biomarkers are likely to be measuring oxidative stress but also provide a further wealth 
of information. Although correlations may be seen, these may not be perfect suggesting 
that one marker may be more experimentally reliable than the other. If the oxidative 
stress-related biomarkers are from different tissues/sample mediums then it could be 
confirmed whether oxidative stress is dependant on tissue type or not. For example, a 
correlation between mitochondrial ROS production and dysfunction in PBMCs and 
plasma F2-isoprostanes would provide evidence that oxidative stress is tissue 
independent. This information is also valuable when searching for the most suitable 
biomarkers in large population studies where time, cost and the practicality of 
biomarker measurement and sample type are important.  
 
Investigating the association between other biomarkers of known cellular and molecular 
mechanisms of ageing would also add strength to the construct validation of candidate 
BoA. One of the most important models for investigating the mechanism of biological 
ageing is cellular senescence. There are other various markers that are claimed to be 
involved in oxidative stress-induced cellular senescence including telomere length 
shortening, increased DNA damage, decrease DNA repair and increased inflammatory 
cytokines (von Zglinicki et al., 1995; von Zglinicki, 2002; Passos et al., 2007; Wang et 
al., 2009; Passos et al., 2010; Nelson et al., 2012). Robust associations between these 
markers and increased mitochondrial ROS production and dysfunction are therefore 
expected. Since much evidence for the involvement of these markers in cellular 
senescence comes from cell culture studies this information would confirm that these 
associations also occur in vivo. Since this study will be investigating the very old 
population it is therefore more likely that these associations will be found than if the 
study was in a younger population, since it is expected that the elderly have a higher 
proportion of cellular senescent cells. This information would also aid in the validation 
of these cellular and molecular mechanisms, identify potential targets for and evaluate 
possible interventions.   
 
A functional aspect that could be utilized to investigate the construct validation of 
potential oxidative stress-related BoA in blood is the correlation with 
immunosenescence phenotypes. Immunosenescence refers to the age-related decline of 
immune function increasing the susceptibility to infectious diseases (Gavazzi and 
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Krause, 2002; Goronzy and Weyand, 2013). There are various phenotypical changes 
that have been shown to occur in the immune system with age that reflect 
immunosenescence (Figure 5.1.). These major changes include the decline in the ratio 
of various cell subpopulations including the lymphocyte to monocyte ratio, the CD4 to 
CD8 T lymphocyte ratio and the naïve to memory B and T lymphocyte ratio (Lerner et 
al., 1989; Lehtonen et al., 1990; Callahan et al., 1993; Herndler-Brandstetter et al., 
2013). These are thought to occur because of the decreased generative capacity of 
hematopoietic stem cells and the decreased maturation of hematopoietic progenitor cells 
within the thymus with chronological age (Rossi et al., 2007; Aw et al., 2008). Another 
important change occurring in the immune system with age is an increased fraction of 
CD27- memory cells (Nijhuis et al., 1994).  
 
The final set of biomarker that could be used to validate potential oxidative stress-
related BoA are those that are described in Chapter 1. Section 1.2.3 as classical BoA 
including various anthropometric, physical, physiological, haematological (particularly 
in relation to immunology and biochemical measurements. Since Chapter 3 revealed 
that the predictive validity of these classical BoA can change with age it is important to 
investigate only those that are valid predictors of age-related outcomes in the very old 
population. These have been identified as hand grip strength, TUG, systolic blood 
pressure, FEV1, red blood cell count, haematocrit, haemoglobin, free T3, vitamin D and 
NT-pro BNP (Martin-Ruiz et al., 2011). Physical activity is also a suggested classical 
BoA in the elderly population (>70 years) however this was not previously investigated 
in the very old population of the Newcastle 85+ study. Physical activity could also be a 
potential confounding variable since it may not only measure the physical fitness of 
individual, but also the voluntary amount of physical activity an individual has carried 
out pre blood sample withdrawal. It will therefore be investigated in the final part of this 
chapter as a confounder, as discussed below. 
 
Another important aspect of the construct validation of candidate BoA is the 
identification of potential confounding variables. These are extraneous factors that may 
be associated with both the candidate BoA and the outcome which may or may not be 
association with biological ageing. There are two main types of confounding 
assessments. The first was addressed in chapter 4, assessing the reliability of candidate 
BoA, which involves the identification of experimental handling variables that alter the  
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Figure 5.1. Phenotypic changes occurring in immunosenescence. (Lerner et al., 
1989; Lehtonen et al., 1990; Callahan et al., 1993; Herndler-Brandstetter et al., 2013). 
(Nijhuis et al., 1994). 
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candidate BoA and therefore should be controlled before the experimental 
measurement. The second assessment is the identification of individual variables that 
may confound future analysis but may be associated with biological mechanisms of 
ageing. The analysis of individual confounders can therefore get complex since this 
could form part of the reliability assessment but also provide construct validation of 
candidate BoA. This is because individual variables that alter candidate BoA could be 
controlled for before experimental analysis, for example participants are asked to refrain 
from a certain behaviour. However that behaviour, which may be associated with 
biological ageing, may be a regular occurrence of the individual and controlling it for all 
individual may reduce the power of the study, i.e. you would only want to control it if 
the behaviour is not a regular occurrence of the individual. It is difficult to know which 
variables are associated with both the candidate BoA and biological ageing and 
therefore various models of controlling for confounders should be investigated. 
 
5.3. Results 
 
5.3.1. Descriptive statistics 
 
Descriptives of potential oxidative stress-related BoA, potential confounders and age-
related construct variables of the very old from the Newcastle 85+ study are shown in 
Appendix C. Supplementary Table. 11., 12., and 13. respectively, stratified by all 
participants and also by participants with superoxide level, mitochondrial mass, 
mitochondria membrane potential and/or 8-iso Prostaglandin measurements to 
determine the representativeness of the whole population compared to those participants 
with oxidative-stress related measures. Possible selection bias occurred for: 1) 
differences in alcohol status, where a higher proportion of current drinkers  and a lower 
proportion of previous drinkers were present in those with oxidative-stress related 
measures (significant for mitochondrial mass, mitochondrial membrane potential and 8-
iso Prostaglandin) compared to the whole population; 2) differences in taking non-
prescribed medicines, supplements and/or herbal remedies, where a higher proportion of 
those who take non-prescribed medicines, supplements and/or herbal remedies were 
present in those with oxidative-stress related measures (significant for 8-iso 
Prostaglandin) compared to the whole population; 3) differences in the use of 
aid(s)/appliance(s), where a lower proportion of those who use aid(s)/appliance(s) were 
present in those with oxidative-stress related measures (significant for 8-iso 
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Prostaglandin) compared to the whole population; and 4) differences in FEV1, which 
was higher in those with oxidative-stress related measures (significant for mitochondrial 
membrane potential and 8-iso Prostaglandin) compared to the whole population. An 
explanation for these differences is that they most likely reflect age-related the changes 
in these variables since they were measured in phase 1 of the study. A summary of the 
younger control participants is shown in Appendix C. Supplementary Table. 19. 
 
5.3.2. Association with chronological age 
 
To investigate the association between potential oxidative stress-related BoA and 
chronological age cross-sectionally, the younger controls (with an age range of 22 to 55 
years) were compared with the very old population of the Newcastle 85+ study. 
Surprisingly, superoxide levels were significantly lower in the very old population 
compared to the younger controls (p<0.01), however mitochondrial mass was 
significantly higher (p=0.04) and mitochondrial membrane potential was significantly  
lower (p<0.01) (Figure 5.2. A.). This direction of association was supported by the 
direction of correlation with chronological age: superoxide levels decreased, although 
this was of low correlation and did not reach statistical significance (r=-0.33, p=0.26); 
mitochondrial mass increased, which was of moderate correlation but again not quite 
reaching statistical significance (r=0.51, p=0.08); and mitochondrial membrane 
potential significantly decreased, which was of high correlation and statistically 
significant (r=-0.72, p<0.01) (Figure 5.2. B.). There was however no significant 
difference in 8-iso Prostaglandin F2α concentration between the young controls and the 
very old population (p=0.69) (Figure 5.2. A.). There was also no significant correlation 
between in 8-iso Prostaglandin F2α and chronological age (r=-0.22, p=0.47) (Figure 5.2. 
B.). 
 
Longitudinal data was available for 8-iso Prostaglandin F2α in the very old population of 
the Newcastle 85+ study, which was measured at phase 1 (≈85 years), phase 2 (≈86.5 
years) and phase 3 (≈88 years). Despite extremely high intra-individual stability 
between all phases (See Chapter 4. Section 4.3.3.), 8-iso Prostaglandin F2α concentration 
did not follow a linear association with age in this population, where its concentration 
significantly decreased between phase 1 and 2 (p<0.01), however increased between 
phase 2 and 3 (p>0.01) (Figure 5.3.). 
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5.3.3. Association between potential oxidative stress-related BoA in the very old 
population 
 
The next construct validation assessment was to determine the agreement between the 
potential oxidative stress-related BoA. Superoxide levels were significantly associated 
with mitochondrial mass (positive in PBMCs: p=0.04; lymphocytes: p=0.01; and 
monocytes: p<0.01) and mitochondrial membrane potential (negative in PBMCs: 
p=0.01; but positive in lymphocytes: p=0.04 and monocytes: p<0.01), however the 
magnitude of correlations for all parameters was very low (r ≥ -0.18 and ≤ 0.22) (Table 
5.1.).  
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Figure 5.2. The association between potential oxidative stress-related BoA and 
chronological age. A. Median comparison between younger controls and the very old 
population and B. correlation with chronological age. Mann-Whitney U Test was used 
to test differences between the medians of two groups and Spearman’s correlation 
coefficient was used to test the strength of associations (For numbers see Appendix C. 
Supplementary Table. 11 and Table 18). (Age 88 years in the correlation analysis was 
the mean of the very old population, the rest were single repeats) (Numbers are 
different for 8-iso Prostaglandin in A. and B, since date of birth was known  for 12 
control,  however 19 in total were used for median comparison). 
p=0.69 
r=-0.33 
p=0.26 
r=0.51 
p=0.08 
r=-0.72 
p<0.01 
r=-0.22 
p=0.47 
 p<0.01 
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128 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Longitudinal changes of 8-iso Prostaglandin F2α in the very old 
population. Wilcoxon Signed-Rank Test was used to test differences between the 
medians of two groups and Friedman’sTest was used to test differences between the 
medians of three groups (n=287). (Longitudinal intra-individual stability was addressed 
in chapter 4. Section 4.3.4). 
 
 
 
 
 
 
 
 
 
p<0.01 
p<0.01 
p<0.01 
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Potential oxidative stress-related BoA 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 
PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes 
Superoxide levels 
PBMCs 
r _ _ _ _ _ _ _ _ _ 
p _ _ _ _ _ _ _ _ _ 
n _ _ _ _ _ _ _ _ _ 
Superoxide levels 
Lymphocytes 
r 0.88 _ _ _ _ _ _ _ _ 
p 0.00 _ _ _ _ _ _ _ _ 
n 248 _ _ _ _ _ _ _ _ 
Superoxide levels 
Monocytes 
r 0.84 0.78 _ _ _ _ _ _ _ 
p 0.00 0.00 _ _ _ _ _ _ _ 
n 248 248 _ _ _ _ _ _ _ 
 Mitochondrial mass 
PBMCs 
r 0.13 0.16 0.12 _ _ _ _ _ _ 
p 0.04 0.01 0.07 _ _ _ _ _ _ 
n 243 243 243 _ _ _ _ _ _ 
Mitochondrial mass 
Lymphocytes 
r 0.13 0.17 0.15 0.84 _ _ _ _ _ 
p 0.04 0.01 0.02 0.00 _ _ _ _ _ 
n 243 243 243 341 _ _ _ _ _ 
Mitochondrial mass 
Monocytes 
r 0.15 0.19 0.22 0.80 0.84 _ _ _ _ 
p 0.02 0.00 0.00 0.00 0.00 _ _ _ _ 
n 243 243 243 341 341 _ _ _ _ 
 
Mitochondrial membrane 
 Potential PBMCs 
r -0.18 -0.03 0.03 0.00 0.04 0.11 _ _ _ 
p 0.01 0.62 0.60 0.96 0.52 0.05 _ _ _ 
n 239 239 239 332 332 332 _ _ _ 
Mitochondrial membrane 
 Potential Lymphocytes 
r 0.09 0.14 0.18 -0.04 0.03 0.08 0.55 _ _ 
p 0.18 0.04 0.01 0.44 0.58 0.15 0.00 _ _ 
n 239 239 239 332 332 332 347 _ _ 
Mitochondrial membrane 
 Potential Monocytes 
r 0.06 0.18 0.22 -0.08 -0.06 0.06 0.66 0.40 _ 
p 0.37 0.00 0.00 0.15 0.26 0.29 0.00 0.00 _ 
n 239 239 239 332 332 332 347 347 _ 
8-iso Prostaglandin F2α 
r -0.05 -0.03 -0.04 0.06 0.03 0.01 0.03 0.02 0.00 
p 0.45 0.65 0.58 0.34 0.64 0.93 0.62 0.77 0.95 
n 216 216 216 302 302 302 304 304 304 
  
Table 5.1. Agreements between potential oxidative stress-related BoA (All data). (r: Spearman’s correlation coefficient, p: probability, n: number 
of participants, significant positive association, significant negative association). 
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Sensitivity analysis removed the significance of the association between superoxide 
levels and mitochondrial mass in the PBMC population (p=0.13), however the 
significance still remained in the lymphocyte (p=0.01) and monocyte (p<0.01) 
subpopulations (Table 5.2.). The sensitivity analysis slightly removed the significance 
of the association between superoxide levels and mitochondrial membrane potential in 
the lymphocyte population (p=0.05), however the significance still remained in the 
PBMC (p=0.01) and monocyte (p<0.01) subpopulations (Table 5.2.). Superoxide levels, 
mitochondrial mass and mitochondrial membrane potential were not associated with 8-
iso Prostaglandin F2α (p≥0.34), even when extreme outliers were removed in the 
sensitivity analysis (p≥0.42). The very low magnitude of correlations for significant 
associations still remained after  sensitivity analysis for all parameters (r ≥-0.18 and ≤ 
0.21) giving little evidence that they are suggestive of biological significance.  
 
5.3.4. Association with  biomarkers of oxidative stress-induced cellular senescence in 
the very old population 
 
The association between the potential oxidative stress-related BoA and other biomarkers 
of oxidative stress-induced cellular senescence was next investigated. There were 
consistent significant associations (i.e. for more than one cell population) between 
superoxide levels and DNA repair activity (negative, p≤0.02) and levels of the pro-
inflammatory cytokines IL-6 and TNF-α (negative, p<0.01) and also  between 
mitochondrial mass and telomere length (positive, p≤0.04) (Table 5.3.). The magnitude 
of these correlations was however very low (r≥-0.32 and ≤0.30). Sensitivity analysis by 
removing extreme outliers did not affect the significance or the direction of these 
association and also revealed a consistent association between mitochondrial membrane 
potential and C-reactive protein (CRP) (negative, p<0.01) (Table 5.4.). There was no 
association between 8-iso Prostaglandin F2α or any other biomarker of oxidative stress-
induced cellular senescence in the raw data analysis (p≥0.11) (Table 5.3.), however 
sensitivity analysis, after removal of extreme outliers, revealed an association between 
8-iso Prostaglandin F2α and inflammatory cytokines, IL-6 and TNF-α (positive, p≤0.04). 
The very low magnitude of correlations for significant associations still remained after 
sensitivity analysis for all parameters (r ≥-0.30 and ≤0.13) giving little evidence that 
they are suggestive of biological significance.  
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Potential oxidative stress-related BoA 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 
PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes 
Superoxide levels 
PBMCs 
r _ _ _ _ _ _ _ _ _ 
p _ _ _ _ _ _ _ _ _ 
n _ _ _ _ _ _ _ _ _ 
Superoxide levels 
Lymphocytes 
r 0.87 _ _ _ _ _ _ _ _ 
p 0.00 _ _ _ _ _ _ _ _ 
n 245 _ _ _ _ _ _ _ _ 
Superoxide levels 
Monocytes 
r 0.83 0.78 _ _ _ _ _ _ _ 
p 0.00 0.00 _ _ _ _ _ _ _ 
n 245 246 _ _ _ _ _ _ _ 
 Mitochondrial mass 
PBMCs 
r 0.10 0.14 0.09 _ _ _ _ _ _ 
p 0.13 0.03 0.15 _ _ _ _ _ _ 
n 240 241 241 _ _ _ _ _ _ 
Mitochondrial mass 
Lymphocytes 
r 0.13 0.17 0.16 0.83 _ _ _ _ _ 
p 0.05 0.01 0.01 0.00 _ _ _ _ _ 
n 236 237 237 337 _ _ _ _ _ 
Mitochondrial mass 
Monocytes 
r 0.12 0.17 0.21 0.80 0.83 _ _ _ _ 
p 0.07 0.01 0.00 0.00 0.00 _ _ _ _ 
n 239 240 240 339 336 _ _ _ _ 
 
Mitochondrial membrane 
 Potential PBMCs 
r -0.18 -0.04 0.04 0.01 0.06 0.11 _ _ _ 
p 0.01 0.53 0.58 0.88 0.27 0.04 _ _ _ 
n 234 235 235 328 324 327 _ _ _ 
Mitochondrial membrane 
 Potential Lymphocytes 
r 0.08 0.13 0.18 -0.04 0.06 0.09 0.54 _ _ 
p 0.21 0.05 0.01 0.52 0.29 0.09 0.00 _ _ 
n 237 238 238 331 327 330 343 _ _ 
Mitochondrial membrane 
 Potential Monocytes 
r 0.06 0.17 0.21 -0.09 -0.04 0.06 0.66 0.39 _ 
p 0.39 0.01 0.00 0.13 0.45 0.31 0.00 0.00 _ 
n 232 233 233 325 321 324 338 339 _ 
8-iso Prostaglandin F2α 
r -0.01 -0.01 0.01 0.05 0.03 0.01 0.02 0.05 0.00 
p 0.87 0.88 0.89 0.42 0.56 0.85 0.71 0.43 0.95 
n 201 202 202 286 282 284 284 287 281 
 
Table 5.2. Agreements between potential oxidative stress-related BoA (Sensitivity analysis – extreme outliers removed). (r: Spearman’s 
correlation coefficient, p: probability, n: number of participants, significant positive association, significant negative association). 
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Other biomarkers of  oxidative  
stress -induced cellular senescence 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 8-iso Prostaglandin F2α 
PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes Plasma 
Telomere length 
r 0.11 0.08 0.17 0.11 0.13 0.07 0.13 0.04 0.00 -0.01 
p 0.08 0.23 0.01 0.04 0.02 0.17 0.01 0.41 0.97 0.86 
n 248 248 248 340 340 340 345 345 345 376 
DNA damage 
r -0.06 -0.09 -0.07 0.05 -0.03 0.01 0.03 0.03 0.07 0.08 
p 0.33 0.16 0.25 0.38 0.53 0.82 0.63 0.64 0.23 0.12 
n 248 248 248 341 341 341 347 347 347 379 
DNA repair 
r -0.16 -0.15 -0.07 -0.06 -0.07 -0.01 0.06 -0.03 0.02 0.01 
p 0.01 0.02 0.29 0.26 0.21 0.79 0.24 0.59 0.69 0.92 
n 248 248 248 341 341 341 347 347 347 379 
IL-6 
r -0.31 -0.32 -0.30 -0.02 -0.05 -0.05 -0.07 -0.15 -0.10 0.08 
p 0.00 0.00 0.00 0.72 0.31 0.35 0.23 0.00 0.06 0.11 
n 247 247 247 340 340 340 345 345 345 377 
TNF-α 
r -0.23 -0.23 -0.24 -0.03 -0.05 -0.05 -0.03 -0.11 -0.09 0.05 
p 0.00 0.00 0.00 0.60 0.33 0.33 0.58 0.04 0.08 0.30 
n 247 247 247 340 340 340 345 345 345 377 
HbA1c 
r 0.04 0.06 0.04 0.02 0.02 0.01 0.05 0.02 0.06 -0.02 
p 0.49 0.32 0.53 0.71 0.77 0.84 0.34 0.72 0.25 0.64 
n 247 247 247 339 339 339 344 344 344 375 
CRP 
r 0.08 0.11 0.04 0.03 0.00 -0.03 -0.10 -0.01 -0.13 0.03 
p 0.19 0.08 0.55 0.56 0.94 0.64 0.05 0.81 0.02 0.58 
n 248 248 248 341 341 341 347 347 347 379 
Albumin 
r 0.05 0.06 -0.01 -0.03 -0.03 0.01 -0.04 -0.07 0.03 -0.08 
p 0.41 0.33 0.86 0.54 0.59 0.86 0.41 0.17 0.62 0.11 
n 248 248 248 341 341 341 347 347 347 379 
RhFP1 
r 0.11 0.10 0.03 0.13 0.08 0.07 -0.04 0.03 -0.03 0.02 
p 0.08 0.12 0.61 0.02 0.14 0.18 0.50 0.53 0.54 0.65 
n 239 239 239 328 328 328 335 335 335 367 
 
Table 5.3. Potential oxidative stress-related BoA in relation to other biomarkers of oxidative stress-induced cellular senescence (All data). (r: 
Spearman’s correlation coefficient, p: probability, n: number of participants, P1: Phase 1 data, significant positive association, significant negative 
association). 
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Other biomarkers of  oxidative  
stress -induced cellular senescence 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 8-iso Prostaglandin F2α 
PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes Plasma 
Telomere length 
r 0.08 0.06 0.15 0.11 0.12 0.07 0.12 0.04 0.00 0.02 
p 0.19 0.36 0.02 0.04 0.03 0.18 0.03 0.41 0.95 0.67 
n 245 246 246 340 336 338 342 345 338 356 
DNA damage 
r -0.05 -0.09 -0.07 0.05 -0.04 0.01 0.03 0.03 0.06 0.07 
p 0.39 0.17 0.27 0.38 0.51 0.88 0.63 0.62 0.27 0.21 
n 245 246 246 341 337 339 343 346 340 359 
DNA repair 
r -0.17 -0.15 -0.07 -0.06 -0.05 -0.01 0.07 -0.02 0.02 0.03 
p 0.01 0.02 0.29 0.26 0.33 0.90 0.19 0.65 0.71 0.60 
n 245 246 246 341 337 339 343 346 340 359 
IL-6 
r -0.30 -0.30 -0.26 0.02 -0.06 -0.04 -0.07 -0.18 -0.05 0.12 
p 0.00 0.00 0.00 0.73 0.29 0.53 0.25 0.00 0.42 0.04 
n 207 208 208 296 292 294 299 302 295 308 
TNF-α 
r -0.20 -0.20 -0.17 -0.04 -0.10 -0.08 -0.04 -0.12 -0.04 0.13 
p 0.00 0.00 0.01 0.54 0.07 0.15 0.53 0.03 0.47 0.02 
n 215 216 216 310 306 308 312 315 308 325 
HbA1c 
r 0.02 0.04 0.01 0.02 0.03 0.02 0.05 0.02 0.07 0.01 
p 0.78 0.50 0.87 0.67 0.63 0.68 0.34 0.75 0.19 0.85 
n 242 243 243 336 332 334 338 341 334 352 
CRP 
r 0.03 0.06 -0.02 0.07 0.03 -0.04 -0.15 -0.09 -0.15 0.06 
p 0.65 0.38 0.77 0.27 0.63 0.49 0.01 0.15 0.02 0.28 
n 201 202 202 274 270 273 277 280 274 289 
Albumin 
r 0.06 0.08 0.01 -0.04 -0.06 0.00 -0.03 -0.06 0.02 -0.06 
p 0.39 0.22 0.93 0.49 0.30 0.95 0.53 0.27 0.73 0.22 
n 244 245 245 340 336 338 342 345 339 358 
RhFP1 
r 0.09 0.08 0.01 0.13 0.09 0.06 -0.03 0.04 -0.04 0.05 
p 0.15 0.22 0.88 0.02 0.10 0.26 0.59 0.51 0.48 0.38 
n 236 237 237 328 324 326 331 334 328 348 
 
Table 5.4. Potential oxidative stress-related BoA in relation to other biomarkers of oxidative stress-induced cellular senescence (Sensitivity 
analysis – extreme outliers removed). (r: Spearman’s correlation coefficient, p: probability, n: number of participants, P1: Phase 1 data, significant 
positive association, significant negative association).  
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5.3.5. Association with markers of immunosenescence in the very old population and 
in separated immunosenescent cells 
 
To provide further construct validity with a more functional aspect of ageing, the 
association between potential oxidative stress-related BoA and immunosenescenc 
phenotypes in the very old population was investigated. There were consistent 
associations (i.e. for more than one cell population) between: superoxide levels and 
lymphocyte/monocyte ratio (negative, p≤0.01) and memory/naïve B lymphocyte ratio 
(positive, p≤0.03); mitochondrial mass and memory/naïve CD4 T lymphocyte ratio 
(positive, p≤0.01); and mitochondrial membrane potential and lymphocyte/monocyte 
ratio (positive, p≤0.03) (Table 5.5.). The magnitude of these correlations was however 
very low (r≥-0.30 and ≤0.21). Sensitivity analysis removed the significance of the 
association between superoxide levels and memory/naïve B lymphocyte ratio, however 
all other significant association remained (Table 5.6.). There was no association 
between 8-iso Prostaglandin F2α concentration and immunosenescence phenotypes, 
before or after removal of extreme outliers in sensitivity analysis (p≥0.12) (Table 5.5. 
and Table 5.6. respectively) The very low magnitude of correlations for significant 
associations remained for all parameters (r ≥-0.29 and ≤0.21) giving little evidence that 
they are suggestive of biological significance. 
 
Next, an experiment was conducted to investigate the association between ROS 
production and phenotypically separated PBMC subpopulations. It was shown that 
superoxide levels were increased in Senescent Memory Cytotoxic T lymphocytes  
(CD8+CD56-CD27-) compared to non-senescent cells including; Helper T lymphocytes 
(CD8-), Cytotoxic T lymphocytes (CD3+/CD8+), Natural Killer T lymphocytes 
(CD8+CD56+) and Naïve and Non-Senescent Memory Cytotoxic T lymphocytes  
(CD8+CD56-CD27+) (Figure 5.4.). This experiment was only carried out once, 
however a similar experiment was conducted by Thomas von Zglincki, who also 
investigated mitochondrial function. This experiment also found that superoxide levels 
were significantly increased in Senescent Memory Cytotoxic T lymphocytes  
(CD8+CD56-CD27-) compared to Natural Killer T lymphocytes (CD8+CD56+) 
(p<0.01) and Naïve and Non-Senescent Memory Cytotoxic  T lymphocytes  
(CD8+CD56-CD27+) (p<0.01) (Figure 5.5.). There was no significant difference in 
superoxide levels in Natural Killer T lymphocytes (CD8+CD56+) and Naïve and Non-  
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Immunosenescence phenotypes 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 8-iso Prostaglandin F2α 
PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes Plasma 
Lymphocyte / Monocyte ratio  
r -0.30 -0.19 -0.17 0.05 0.03 0.00 0.21 0.08 0.12 0.06 
p 0.00 0.00 0.01 0.36 0.56 0.98 0.00 0.14 0.03 0.22 
n 246 246 246 338 338 338 343 343 343 374 
CD4 / CD8  
T lymphocyte ratio 
r 0.00 -0.09 0.05 0.11 0.11 -0.03 0.02 0.01 0.01 0.06 
p 0.96 0.16 0.48 0.05 0.04 0.58 0.75 0.85 0.82 0.29 
n 239 239 239 319 319 319 325 325 325 355 
Memory / Naive  
B lymphocyte ratio 
r 0.14 0.14 0.15 0.05 0.11 0.11 0.11 0.02 0.09 0.00 
p 0.03 0.03 0.02 0.35 0.04 0.05 0.04 0.71 0.10 0.97 
n 246 246 246 339 339 339 344 344 344 376 
Memory / Naive CD4 
T lymphocyte ratio 
r -0.01 0.04 -0.05 0.15 0.16 0.09 -0.06 -0.01 -0.07 -0.06 
p 0.90 0.56 0.45 0.01 0.00 0.09 0.29 0.89 0.21 0.27 
n 245 245 245 338 338 338 343 343 343 375 
Memory / Naive CD8  
T lymphocyte ratio 
r -0.11 -0.01 -0.12 0.10 0.09 0.08 -0.02 0.00 -0.02 -0.04 
p 0.10 0.85 0.07 0.08 0.11 0.17 0.74 0.95 0.74 0.43 
n 236 236 236 316 316 316 322 322 322 352 
Senescent (CD27-/RO-) 
 CD4 T lymphocytes (%) 
r -0.11 -0.07 -0.10 0.08 0.08 0.07 0.04 -0.01 -0.04 -0.05 
p 0.09 0.31 0.13 0.15 0.13 0.21 0.42 0.91 0.51 0.29 
n 246 246 246 339 339 339 344 344 344 376 
Senescent (CD27-/RO-)   
CD8 T lymphocytes (%) 
r -0.09 -0.04 -0.05 0.09 0.08 0.00 0.03 -0.02 -0.02 0.08 
p 0.17 0.57 0.47 0.12 0.14 0.97 0.62 0.75 0.78 0.15 
n 237 237 237 317 317 317 323 323 323 353 
 
Table 5.5. Potential oxidative stress-related BoA in relation to immunosenescent phenotypes (All data). (r: Spearman’s correlation coefficient, p: 
probability, n: number of participants, significant positive association, significant negative association). 
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Immunosenescence phenotypes 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 8-iso Prostaglandin F2α 
PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes Plasma 
Lymphocyte / Monocyte ratio  
r -0.29 -0.19 -0.15 0.05 0.04 0.01 0.21 0.09 0.12 0.08 
p 0.00 0.00 0.02 0.35 0.48 0.85 0.00 0.10 0.03 0.12 
n 242 243 243 336 332 334 338 341 334 352 
CD4 / CD8  
T lymphocyte ratio 
r 0.01 -0.08 0.07 -0.11 -0.09 -0.01 0.05 0.05 0.05 0.06 
p 0.83 0.23 0.31 0.05 0.13 0.83 0.40 0.42 0.41 0.24 
n 231 232 232 309 305 307 314 316 309 326 
Memory / Naive  
B lymphocyte ratio 
r 0.12 0.11 0.15 0.03 0.08 0.08 0.12 0.02 0.09 0.01 
p 0.07 0.08 0.02 0.65 0.16 0.15 0.03 0.67 0.10 0.82 
n 235 235 235 324 320 322 326 327 321 336 
Memory / Naive CD4 
T lymphocyte ratio 
r 0.02 0.05 -0.01 0.15 0.15 0.11 -0.07 0.02 -0.09 -0.08 
p 0.72 0.49 0.83 0.01 0.01 0.05 0.22 0.73 0.13 0.13 
n 228 229 229 313 309 311 315 317 311 333 
Memory / Naive CD8  
T lymphocyte ratio 
r -0.11 -0.03 -0.12 0.10 0.09 0.08 -0.03 0.02 -0.04 0.00 
p 0.11 0.64 0.07 0.08 0.14 0.16 0.65 0.70 0.53 0.97 
n 225 226 226 302 298 300 306 308 302 322 
Senescent (CD27-/RO-) 
 CD4 T lymphocytes (%) 
r -0.09 -0.04 -0.08 0.06 0.08 0.06 0.06 0.01 -0.02 -0.07 
p 0.19 0.53 0.23 0.29 0.16 0.31 0.32 0.90 0.71 0.21 
n 228 229 229 314 311 312 316 319 313 332 
Senescent (CD27-/RO-)   
CD8 T lymphocytes (%) 
r -0.07 -0.03 -0.02 0.09 0.10 0.01 0.03 -0.02 -0.01 0.04 
p 0.27 0.70 0.71 0.12 0.09 0.85 0.58 0.75 0.90 0.52 
n 234 235 235 317 313 315 321 323 316 336 
 
Table 5.6. Potential oxidative stress-related BoA in relation to immunosenescent phenotypes (Sensitivity analysis – extreme outliers removed). 
(r: Spearman’s correlation coefficient, p: probability, n: number of participants, significant positive association, significant negative association).  
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Figure 5.4. Comparison of superoxide levels in separated lymphocytes. A. flow 
cytometry graphs for quantification and  B. comparison of superoxide levels in non-
senescent and senescent lymphocyte populations (n=1). (CD8- (Helper T lymphocytes 
(CD8-)); CD8+ (Cytotoxic T lymphocytes (CD3+/CD8+)); CD56+ (Natural Killer T 
lymphocytes (CD8+CD56+)); CD27+: (Naïve and Non-Senescent Memory Cytotoxic  
T lymphocytes  (CD8+CD56-CD27+)); CD27- (Senescent Memory Cytotoxic T 
lymphocytes  (CD8+CD56-CD27-)).  
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Figure 5.5. Comparison of superoxide levels, mitochondrial mass and 
mitochondrial membrane potential in separated lymphocytes. (This data was 
obtained and supplied by Thomas von Zglinicki) Superoxide levels (n=4), 
mitochondrial mass (n=3), Mitochondrial membrane potential (n=2). Student T-test was 
used to compare the means of two groups. Values are normalised to 100%. (CD56+ 
(Natural Killer T lymphocytes (CD8+CD56+)); CD27+: (Naïve and Non-Senescent 
Memory Cytotoxic  T lymphocytes  (CD8+CD56-CD27+)); CD27- (Senescent Memory 
Cytotoxic T lymphocytes  (CD8+CD56-CD27-))). 
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Senescent Memory Cytotoxic  T lymphocytes  (CD8+CD56-CD27+) (p=0.69) (Figure 
5.5.). There was a trend for mitochondrial function to be decreased in Senescent 
Memory Cytotoxic T lymphocytes  (CD8+CD56-CD27-) compared to Natural Killer T 
lymphocytes (CD8+CD56+) and Naïve and Non-Senescent Memory Cytotoxic  T 
lymphocytes  (CD8+CD56-CD27+), indicated by an increase in mitochondrial mass and 
decrease in mitochondrial membrane potential, however these did not reach statistical 
significance (p≥0.06) (Figure 5.5.). 
 
5.3.6. Association with informative BoA of the very old population 
 
Previously, 10 out of a list of 72 candidate markers were confirmed as informative BoA 
in the Newcastle 85+ study because they were associated with two or more of the 
following age-related outcomes: cognitive impairment, disability score, disease count 
and survival as discussed in Chapter 3 (Martin-Ruiz et al., 2011). The association 
between potential oxidative stress-related BoA of this study and the 10 informative BoA  
was investigated. Consistent associations (i.e. for more than one cell population) were 
found between superoxide levels and mitochondrial membrane potential with baseline 
vitamin D levels (negative for both, p≤0.04) (Table 5.7.). The magnitude of these 
correlations was however very low (r≥-0.18). Sensitivity analysis by removing extreme 
outliers however reduced the significance of the association between superoxide levels 
and vitamin D in the lymphocyte subpopulation (p=0.08); the other significant 
associations remained (Table 5.8.). There was an association between 8-iso 
Prostaglandin F2α and free T3, both before (positive, p=0.01); and after sensitivity 
analysis (positive, p=0.01) (Table 5.7. and Table 5.8. respectively).  Sensitivity analysis 
also revealed an association between 8-iso Prostaglandin F2α and FEV1 at baseline 
(negative, p=0.04) (Table 5.8.).  The very low magnitude of correlations for significant 
associations remained for all parameters (r ≥-0.18  and ≤0.14) giving little evidence that 
they are suggestive of biological significance. 
 
5.3.7. Confounding factors in the very old population 
 
The final construct validation assessment was to identify potential confounders of the 
potential oxidative stress-related BoA in the very old population. It was not relevant to 
test the association between ethnicity and place of birth since there was too little 
variance within the population (See Appendix C. Supplementary Table 12.).  There 
were consistent significant associations (i.e. for more than one cell population) between: 
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superoxide levels and taking non-prescribed medicines, supplements and/or herbal 
remedies (p=0.01) and season of blood withdraw (p<0.01) (Table 5.9. A.); and 
mitochondrial membrane potential and the number of years in main job/role (p≤0.02)  
and season of blood withdrawal (p<0.01) (Table 5.9. C.) Sensitivity analysis removed 
the consistent association between mitochondrial membrane potential and the number of 
years in main job/role: all other significant association however remained (data not 
shown). There was an association between 8-iso Prostaglandin F2  and gender (p=0.02) 
and also season of blood withdrawal (p=0.01) (Table 5.9. D.). These association 
remained after removal of extreme outliers by sensitivity analysis (data not shown). 
 
5.4. Discussion 
 
The first assessment of this chapter was to provide evidence that potential oxidative 
stress-related BoA to some degree show a correlation with chronological age. This is a 
required criteria for a valid BoA (Baker and Sprott, 1988), since chronological age is a 
major risk factor associated with age-related decline and an increased risk of mortality. 
It was therefore expected that the potential oxidative stress-related BoA investigated in 
this study would increase with chronological age, since oxidative stress is hypothesised 
to be the cause of the progressive loss of homeostatic regulation of biological function 
over time due to the damage caused by them at the cellular and molecular level, 
increasing vulnerability to detrimental health outcomes and thus mortality (Harman, 
1956). This was true for mitochondrial dysfunction, indicated by a significant increase 
in mitochondrial mass and decrease in membrane potential with chronological age, 
supporting their role as valid BoA; however, what was surprising was that superoxide 
levels actually decreased with chronological age when comparing the young controls to 
the very old population. These findings therefore do not support the theory that 
oxidative stress is the cause of the decline in mitochondrial and thus biological function 
with age, in leukocytes at least. There could be various explanations for this including 
the fact that ROS released during the oxidative burst of leukocytes play an important 
role in the immune system to kill invading microorganisms. Therefore this could be the 
reason for the reduced superoxide levels with age in leukocytes, which could reflect the 
decline in immune function and thus increased susceptibility to infection with age 
(Haddy, 1988). Some studies agree with this and find a decline in ROS production with 
chronologic age in leukocytes (Braga et al., 1998a; Braga et al., 1998b). This however
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Informative BoA 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 8-iso Prostaglandin F2α 
PBMCs Lymphocytes Monocytes Plasma Lymphocytes Monocytes PBMCs Lymphocytes Monocytes Plasma 
Hand grip strength  
r 0.01 0.00 0.01 -0.02 -0.05 -0.02 -0.06 -0.01 -0.08 -0.05 
p 0.85 0.95 0.93 0.71 0.35 0.76 0.29 0.87 0.13 0.34 
n 242 242 242 336 336 336 342 342 342 374 
TUG 
r -0.01 -0.01 0.01 0.03 0.05 0.06 0.06 0.07 0.05 0.03 
p 0.94 0.91 0.93 0.64 0.37 0.32 0.30 0.23 0.38 0.62 
n 218 218 218 304 304 304 312 312 312 340 
FEV1P1 
r 0.07 0.06 0.08 0.02 -0.04 0.01 0.01 -0.01 0.05 -0.10 
p 0.29 0.32 0.23 0.77 0.49 0.84 0.85 0.83 0.39 0.07 
n 244 244 244 335 335 335 341 341 341 372 
Systolic blood pressure 
r 0.02 -0.02 0.07 0.07 0.09 0.08 0.01 0.01 0.02 0.00 
p 0.77 0.79 0.27 0.22 0.09 0.16 0.92 0.87 0.65 1.00 
n 245 245 245 338 338 338 343 343 343 376 
Haematocrit 
r 0.06 0.07 0.03 0.05 -0.03 0.03 -0.04 -0.05 -0.09 0.10 
p 0.37 0.26 0.61 0.35 0.53 0.56 0.49 0.36 0.10 0.06 
n 246 246 246 338 338 338 343 343 343 374 
Haemoglobin 
r 0.05 0.07 0.02 0.08 -0.01 0.04 0.01 -0.06 -0.05 0.05 
p 0.44 0.25 0.78 0.16 0.81 0.44 0.82 0.29 0.36 0.33 
n 246 246 246 338 338 338 343 343 343 374 
Red blood cells 
r 0.08 0.12 0.05 0.10 0.05 0.09 -0.03 -0.08 -0.08 0.08 
p 0.20 0.07 0.41 0.08 0.36 0.11 0.60 0.13 0.16 0.14 
n 246 246 246 338 338 338 343 343 343 374 
Free T3 
r -0.09 -0.11 -0.08 0.03 -0.04 -0.03 -0.07 -0.12 -0.04 0.13 
p 0.16 0.08 0.22 0.61 0.51 0.60 0.19 0.03 0.45 0.01 
n 246 246 246 338 338 338 343 343 343 374 
Vitamin D P1 
r -0.12 -0.13 -0.16 -0.01 -0.05 -0.07 -0.10 -0.18 -0.15 0.01 
p 0.06 0.04 0.01 0.89 0.35 0.19 0.06 0.00 0.01 0.83 
n 240 240 240 331 331 331 338 338 338 371 
NT-pro BNP 
r -0.10 -0.19 -0.25 -0.09 -0.17 -0.12 -0.10 0.11 -0.09 0.02 
p 0.50 0.19 0.09 0.39 0.12 0.26 0.33 0.30 0.38 0.82 
n 46 46 46 85 85 85 95 95 95 108 
 
Table 5.7. Potential oxidative stress-related BoA in relation to informative BoA (All data). (r: Spearman’s correlation coefficient, p: probability, 
n: number of participants, 
P1: 
Phase 1 data, significant positive association, significant negative association). 
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Informative BoA 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 8-iso Prostaglandin F2α 
PBMCs Lymphocytes Monocytes Plasma Lymphocytes Monocytes PBMCs Lymphocytes Monocytes Plasma 
Hand grip strength  
r 0.01 0.00 0.01 -0.02 -0.05 -0.02 -0.04 0.00 -0.06 -0.07 
p 0.91 0.99 0.89 0.71 0.34 0.78 0.42 0.98 0.24 0.19 
n 240 241 241 336 332 335 338 341 335 354 
TUG 
r 0.00 -0.02 0.00 0.04 0.04 0.05 0.06 0.08 0.03 0.00 
p 0.95 0.80 0.98 0.49 0.44 0.36 0.32 0.17 0.64 0.94 
n 213 214 214 299 295 298 304 306 301 316 
FEV1P1 
r 0.05 0.06 0.07 0.02 -0.04 0.01 0.02 0.00 0.05 0.11 
p 0.41 0.35 0.25 0.77 0.45 0.90 0.72 0.95 0.40 0.04 
n 241 242 242 335 331 333 337 340 334 352 
Systolic blood pressure 
r 0.01 -0.02 0.07 0.07 0.08 0.07 0.01 0.01 0.03 -0.03 
p 0.90 0.78 0.27 0.22 0.14 0.19 0.82 0.78 0.56 0.51 
n 242 243 243 338 334 336 339 342 336 356 
Haematocrit 
r 0.06 0.07 0.04 0.05 -0.04 0.03 -0.04 -0.05 -0.06 0.09 
p 0.36 0.24 0.58 0.35 0.42 0.53 0.50 0.36 0.27 0.08 
n 243 244 244 338 334 336 340 343 336 354 
Haemoglobin 
r 0.06 0.08 0.02 0.08 -0.02 0.05 0.01 -0.06 -0.03 0.05 
p 0.39 0.20 0.70 0.16 0.66 0.40 0.89 0.29 0.61 0.33 
n 243 244 244 338 334 336 340 343 336 354 
Red blood cells 
r 0.09 0.12 0.06 0.10 0.04 0.09 -0.03 -0.08 -0.04 0.06 
p 0.17 0.06 0.39 0.08 0.48 0.10 0.62 0.13 0.47 0.29 
n 243 244 244 338 334 336 340 343 336 354 
Free T3 
r -0.08 -0.10 -0.07 0.03 -0.03 -0.02 -0.07 -0.12 -0.05 0.14 
p 0.20 0.11 0.30 0.61 0.62 0.72 0.19 0.03 0.40 0.01 
n 243 244 244 338 334 336 340 343 336 354 
Vitamin D P1 
r -0.11 -0.11 -0.14 -0.01 -0.07 -0.07 -0.10 -0.18 -0.13 0.00 
p 0.08 0.08 0.03 0.89 0.18 0.18 0.06 0.00 0.02 0.97 
n 237 238 238 331 327 329 334 337 331 352 
NT-pro BNP 
r -0.16 -0.18 -0.28 -0.09 -0.13 -0.12 -0.09 0.12 -0.09 -0.11 
p 0.31 0.25 0.07 0.44 0.24 0.30 0.40 0.26 0.39 0.30 
n 44 44 44 81 80 81 90 91 91 95 
Table 5.8. Potential oxidative stress-related BoA in relation to informative BoA (Sensitivity analysis – extreme outliers removed). (r: 
Spearman’s correlation coefficient, p: probability, n: number of participants, P1: Phase 1 data, significant positive association, significant negative 
association). 
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A.   
Potential confounders 
Superoxide levels (AU) 
PBMCs Lymphocytes Monocytes 
Gender 
P1 Median IQR n p Median IQR n p Median IQR n p 
Male 35.09 20.47 91 
0.43 
26.89 18.72 91 
0.20 
61.32 46.90 91 
0.94 
Female 32.44 20.00 157 23.74 21.27 157 61.66 46.04 157 
Mitochondrial haplogroup 
P1 Median IQR n p Median IQR n p Median IQR n p 
H 30.69 21.69 89 
0.13 
23.22 21.24 89 
0.21 
58.13 41.79 89 
0.64 
T 34.33 19.05 25 24.66 19.41 25 65.89 57.06 25 
J 33.78 18.92 22 24.22 17.32 22 60.91 42.91 22 
U 39.79 19.40 36 34.39 18.88 36 84.80 49.23 36 
K 25.55 13.19 15 19.77 9.42 15 53.99 37.28 15 
X 36.10 14.46 4 30.65 17.45 4 86.57 55.53 4 
W 35.20 15.34 8 30.24 20.26 8 72.84 51.79 8 
I 26.00 _ 3 17.11 _ 3 55.14 _ 3 
V 31.86 31.78 7 19.23 16.92 7 74.62 63.17 7 
Age of natural parents death (years) 
P1 r n p r n p r n p 
Mother 0.05 239 0.43 0.08 239 0.20 0.10 239 0.13 
Father 0.03 232 0.64 0.00 232 0.97 0.01 232 0.82 
Has/had a sibling(s) 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 33.07 19.89 221 
0.64 
25.60 20.76 221 
0.69 
60.73 45.69 221 
0.37 
No 34.68 30.97 26 24.20 27.44 26 73.14 57.37 26 
Had full-time higher education P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 30.69 29.50 33 
0.66 
21.31 21.41 33 
0.36 
57.18 45.51 33 
0.72 
No 34.33 19.81 215 26.05 20.82 215 61.99 46.20 215 
Number of years in main job/role 
P1
 
r n p r n p r n p 
0.06 197 0.37 -0.02 197 0.77 0.00 197 0.98 
Has offspring 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 33.94 20.10 206 
0.91 
24.95 19.81 206 
0.66 
61.04 45.12 206 
0.86 
No 32.77 20.82 41 27.37 23.78 41 61.99 59.84 41 
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Marital status 
P3 Median IQR n p Median IQR n p Median IQR n p 
Single 31.95 15.37 19 
0.57 
18.98 11.82 19 
0.57 
59.37 26.97 19 
0.19 
Married 37.16 25.15 54 29.79 23.76 54 62.52 59.75 54 
Re-married 41.68 _ 3 35.44 _ 3 91.72 _ 3 
Separated _ _ 0 _ _ 0 _ _ 0 
Divorced 36.90 33.71 7 34.55 28.37 7 92.87 56.11 7 
Widowed 32.64 19.90 164 23.31 17.01 164 60.55 42.58 164 
Lives alone 
P3 Median IQR n p Median IQR n p Median IQR n p 
Yes 31.75 20.54 141 
0.04 
23.22 18.48 141 
0.21 
59.69 42.21 141 
0.17 
No 37.02 26.85 79 28.77 22.37 79 70.56 58.66 79 
Housing type P3 Median IQR n p Median IQR n p Median IQR n p 
Standard housing 32.78 19.34 186 
0.77 
24.95 20.77 186 
0.62 
61.49 44.75 186 
0.51 Sheltered housing with warden 33.07 28.99 33 26.05 24.92 33 62.57 71.89 33 
Institution 35.17 15.62 27 24.98 14.91 27 59.53 37.04 27 
Alcohol status P1 Median IQR n p Median IQR n p Median IQR n p 
Current drinker 35.11 21.08 164 
0.12 
26.75 20.30 164 
0.34 
66.15 46.70 164 
0.12 
Occasional drinker 29.91 17.53 41 20.12 16.84 41 49.90 43.36 41 
Previous drinker 31.26 18.38 11 22.82 17.21 11 56.56 26.03 11 
Never drinker 31.44 29.00 32 20.15 27.85 32 61.20 54.43 32 
Smoking status 
P1 Median IQR n p Median IQR n p Median IQR n p 
Current smoker 32.59 18.65 10 
0.86 
24.74 14.75 10 
0.50 
60.90 30.31 10 
0.47 Past smoker 32.78 20.53 154 25.87 20.79 154 59.56 46.42 154 
Never smoker 34.48 21.85 84 22.79 22.07 84 64.69 47.54 84 
Takes non-prescribed medicines, supplements and/or herbal remedies
 P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 30.96 15.40 118 
0.01 
22.02 14.71 118 
0.01 
57.06 35.68 118 
0.01 
No 36.70 25.94 130 28.53 24.51 130 77.39 55.92 130 
Takes prescribed medication 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 34.24 20.18 238 
0.97 
25.87 20.83 238 
0.46 
61.49 46.27 238 
0.95 
No 33.10 29.17 8 17.78 33.54 8 69.04 60.87 8 
Self-reported physical activity score 
P3
 
r n p r n p r n p 
0.09 248 0.14 0.13 248 0.05 0.13 
248.00 
248 0.05 
Uses aid(s)/appliance(s) 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 33.07 20.31 211 
0.73 
24.66 20.95 211 
0.76 
62.07 44.43 211 
0.32 
No 34.55 19.86 37 26.89 15.90 37 53.19 51.57 37 
Social isolation score 
P3 r n p r n p r n p 
-0.01 
 
246 0.82 0.00 
 
246 0.96 0.05 
 
246 0.43 
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Key event impact 
P3 Median IQR n p Median IQR n p Median IQR n p 
Positive key event(s) 30.70 19.36 49 
0.58 
19.93 15.80 49 
0.44 
53.99 36.64 49 
0.32 
Negative key event(s) 34.29 16.74 65 26.07 20.18 65 72.93 48.36 65 
Positive and negative key event(s) 32.23 21.89 35 24.59 21.22 35 61.32 38.98 35 
Key event(s) but impact unknown 31.86 32.31 27 26.85 26.24 27 57.59 68.01 27 
No key event 36.62 23.94 72 28.44 22.76 72 66.11 47.05 72 
Has problems sleeping 
P3 Median IQR n p Median IQR n p Median IQR n p 
Yes 31.90 23.08 67 
0.33 
20.18 21.97 67 
0.22 
56.79 43.76 67 
0.43 
No 34.37 19.65 181 26.66 20.54 181 62.96 45.35 181 
Body mass index 
P3
 
r n p r n p r n p 
-0.08 
 
222 0.22 -0.04 
 
222 0.54 -0.11 
 
222 0.11 
Fasted blood sample 
P3 Median IQR n p Median IQR n p Median IQR n p 
Yes 33.94 19.99 242 
0.73 
25.65 20.74 242 
0.52 
61.49 45.90 242 
0.55 
No 38.36 33.50 6 17.94 32.50 6 73.48 68.19 6 
Season of blood sample 
P3 Median IQR n p Median IQR n p Median IQR n p 
Spring 40.52 17.59 87 
0.00 
33.66 15.77 87 
0.00 
84.58 46.41 87 
0.00 
Summer 28.27 11.07 75 18.62 7.48 75 48.86 14.41 75 
Autumn 23.41 10.04 34 15.06 5.09 34 42.89 27.64 34 
Winter 44.49 33.96 52 34.07 26.80 52 80.92 67.74 52 
B.  
Potential confounders 
Mitochondrial mass (AU) 
PBMCs Lymphocytes Monocytes 
Gender 
P1 Median IQR n p Median IQR n p Median IQR n p 
Male 41.51 17.69 124 
0.90 
43.06 32.59 124 
0.56 
59.37 30.00 124 
0.48 
Female 41.90 22.05 217 44.96 32.20 217 62.34 46.30 217 
Mitochondrial haplogroup P1 Median IQR n p Median IQR n p Median IQR n p 
H 42.16 21.40 127 
0.46 
42.85 30.68 127 
0.13 
60.82 41.48 127 
0.33 
T 42.33 16.37 34 44.65 33.37 34 51.47 35.57 34 
J 41.07 18.76 34 46.50 27.99 34 51.47 36.86 34 
U 42.76 17.40 50 49.44 29.26 50 63.96 47.70 50 
K 42.53 29.42 22 47.35 36.18 22 67.88 45.56 22 
X 31.45 22.78 5 32.43 26.96 5 65.38 28.00 5 
W 47.68 38.19 10 46.13 66.08 10 67.89 79.15 10 
I 46.46 19.90 4 57.60 26.23 4 92.05 43.05 4 
V 34.16 15.85 10 30.84 12.37 10 49.81 19.05 10 
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Age of natural parents death (years) 
P1 r n p r n p r n p 
Mother 0.95 332 0.95 0.03 332 0.55 0.05 332 0.34 
Father 0.08 318 0.14 0.02 318 0.76 0.08 318 0.18 
Has/had a sibling(s) 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 42.33 20.19 310 
0.04 
44.93 33.06 310 
0.14 
62.27 42.08 310 
0.12 
No 38.56 20.73 30 40.79 27.78 30 55.76 33.07 30 
Had full-time higher education 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 40.86 14.46 51 
0.53 
44.48 28.25 51 
0.78 
60.71 32.63 51 
0.85 
No 41.86 20.61 290 44.85 34.89 290 61.05 41.06 290 
Number of years in main job/role 
P1
 
r n p r n p r n p 
0.01 264 0.94 -0.05 264 0.42 -0.04 264 0.54 
Has offspring 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 41.51 19.99 284 
1.00 
44.98 32.45 284 
0.94 
60.93 39.01 284 
0.56 
No 42.10 18.06 56 44.21 28.18 56 61.30 47.07 56 
Marital status 
P3 Median IQR n p Median IQR n p Median IQR n p 
Single 43.71 22.91 28 
0.52 
43.38 27.74 28 
0.94 
63.73 49.54 28 
0.71 
Married 41.84 17.88 77 46.07 30.73 77 58.95 37.50 77 
Re-married 40.86 19.91 6 34.99 45.44 6 67.35 36.88 6 
Separated _ _ 1 _ _ 1 _ _ 1 
Divorced 42.73 31.78 7 40.83 55.86 7 69.20 61.62 7 
Widowed 40.79 21.75 220 44.93 34.32 220 62.36 40.23 220 
Lives alone 
P3 Median IQR n p Median IQR n p Median IQR n p 
Yes 42.37 20.96 188 
0.68 
46.01 30.49 188 
0.76 
63.77 42.45 188 
0.89 
No 41.89 17.43 116 44.90 30.79 116 60.26 38.81 116 
Housing type 
P3 Median IQR n p Median IQR n p Median IQR n p 
Standard housing 42.10 19.66 262 
0.10 
44.93 30.39 262 
0.11 
60.98 41.33 262 
0.01 Sheltered housing with warden 41.90 17.56 41 50.13 34.95 41 67.37 36.37 41 
Institution 33.81 24.11 36 35.96 37.90 36 45.68 34.19 36 
Alcohol status 
P1 Median IQR n p Median IQR n p Median IQR n p 
Current drinker 41.43 19.65 222 
0.91 
44.39 32.07 222 
0.96 
60.72 41.69 222 
0.88 
Occasional drinker 43.54 18.27 62 44.93 27.18 62 61.77 28.37 62 
Previous drinker 44.37 26.53 14 51.11 48.22 14 67.40 69.17 14 
Never drinker 38.89 27.27 43 45.70 43.64 43 56.67 64.88 43 
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Smoking status 
P1 Median IQR n p Median IQR n p Median IQR n p 
Current smoker 41.32 29.98 15 
0.57 
53.82 45.51 15 
0.75 
58.67 66.45 15 
0.53 Past smoker 41.88 20.20 213 44.89 32.41 213 62.78 38.28 213 
Never smoker 40.83 18.56 113 42.85 30.48 113 60.15 39.41 113 
Takes non-prescribed medicines, supplements and/or herbal remedies 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 41.45 19.33 155 
0.32 
44.80 31.17 155 
0.50 
62.51 45.28 155 
0.38 
No 41.77 21.93 186 44.57 33.02 186 60.50 38.09 186 
Takes prescribed medication 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 41.69 19.48 325 
0.58 
44.80 32.68 325 
0.51 
61.03 39.50 325 
0.98 
No 39.89 28.06 14 40.48 21.75 14 56.26 60.58 14 
Self-reported physical activity score 
P3
 
r n p r n p r n p 
0.03 341 0.57 0.05 341 0.35 0.04 341 0.47 
Uses aid(s)/appliance(s) 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 41.45 19.43 281 
0.20 
44.30 33.27 281 
0.62 
60.71 39.89 281 
0.30 
No 42.10 23.01 60 46.77 24.14 60 62.70 38.84 60 
Social isolation score 
P3 
r n p r n p r n p 
-0.06 339 0.25 0.00 339 1.00 -0.02 339 0.69 
Key event impact 
P3 Median IQR n p Median IQR n p Median IQR n p 
Positive key event(s) 42.36 20.11 63 
1.00 
47.65 41.61 63 
0.80 
62.62 50.57 63 
0.78 
Negative key event(s) 41.69 18.52 95 43.41 28.81 95 62.20 36.40 95 
Positive and negative key event(s) 41.90 24.20 63 39.79 28.72 63 58.95 29.73 63 
Key event(s) but impact unknown 42.30 18.99 36 45.81 46.77 36 67.91 50.54 36 
No key event 41.00 20.67 84 44.58 33.15 84 60.47 44.11 84 
Has problems sleeping 
P3 Median IQR n p Median IQR n p Median IQR n p 
Yes 41.13 18.73 89 0.98 44.55 33.48 89 0.85 62.62 41.42 89 0.47 
No 41.77 20.19 252  44.64 31.58 252  60.67 39.32 252  
Body mass index 
P3
 
r n p r n p r n p 
0.01 304 0.80 0.00 304 0.97 -0.01 
 
304 0.85 
Fasted blood sample 
P3 Median IQR n p Median IQR n p Median IQR n p 
Yes 41.90 19.85 331 
0.09 
44.60 32.33 331 
0.52 
61.24 40.73 331 
0.17 
No 34.89 16.07 10 43.92 36.50 10 53.77 32.62 10 
Season of blood sample 
P3 Median IQR n p Median IQR n p Median IQR n p 
Spring 40.73 16.95 88 
0.33 
49.29 37.59 88 
0.03 
64.40 52.19 88 
0.08 
Summer 42.69 19.71 105 44.59 33.68 105 59.82 33.27 105 
Autumn 38.77 26.47 76 39.00 28.03 76 54.88 42.71 76 
Winter 42.64 23.70 72 47.85 29.72 72 65.85 39.80 72 
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C.   
Potential confounders 
Mitochondrial membrane potential (AU)  
PBMCs Lymphocytes Monocytes 
Gender 
P1 Median IQR n p Median IQR n p Median IQR n p 
Male 2.80 0.97 131 
0.10 
3.87 2.07 131 
0.56 
2.46 1.06 131 
0.14 
Female 2.93 1.05 216 3.82 1.99 216 2.57 1.20 216 
Mitochondrial haplogroup P1 Median IQR n p Median IQR n p Median IQR n p 
H 2.82 1.00 132 
0.33 
3.91 1.98 132 
0.48 
2.41 1.00 132 
0.70 
T 2.96 1.29 34 3.74 1.84 34 2.59 1.09 34 
J 3.01 0.93 35 3.99 2.53 35 2.44 1.25 35 
U 2.77 0.85 51 3.71 1.89 51 2.63 1.26 51 
K 3.25 1.54 24 3.59 3.02 24 2.86 1.43 24 
X 3.07 3.01 4 4.16 3.12 4 2.74 2.81 4 
W 2.59 0.87 10 2.82 2.09 10 2.48 0.74 10 
I 3.30 2.58 4 3.78 1.68 4 2.97 2.39 4 
V 2.61 1.31 8 4.44 2.48 8 2.72 2.45 8 
Age of natural parents death (years) 
P1 r n p r n p r n p 
Mother 0.00 336 0.95 0.01 336 0.90 -0.03 336 0.54 
Father -0.03 322 0.59 -0.08 322 0.18 0.02 322 0.77 
Has/had a sibling(s) 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 2.88 0.99 314 
0.92 
3.85 1.99 314 
0.54 
2.52 1.13 314 
0.66 
No 2.76 0.96 32 3.89 2.91 32 2.38 1.64 32 
Had full-time higher education P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 2.79 1.04 53 
0.54 
3.46 1.78 53 
0.11 
2.60 0.92 53 
0.56 
No 2.89 1.04 294 3.88 2.02 294 2.51 1.22 294 
Number of years in main job/role P1 
r n p r n p r n p 
-0.12 271 0.05 -0.17 271 0.01 -0.14 271 0.02 
Has offspring 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 2.85 0.99 289 0.10 3.88 2.00 289 0.61 2.49 1.21 289 0.17 
No 3.05 0.98 57  3.73 2.00 57  2.70 1.00 57  
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Marital status P3 Median IQR n p Median IQR n p Median IQR n p 
Single 2.89 0.94 30 
0.18 
3.49 1.03 30 
0.07 
2.41 1.19 30 
0.05 
Married 2.87 1.13 78 4.00 1.89 78 2.50 1.16 78 
Re-married 3.17 1.72 7 4.96 1.86 7 3.63 2.00 7 
Separated _ _ 1 _ _ 1 _ _ 1 
Divorced 3.26 2.05 8 3.57 1.12 8 2.93 3.00 8 
Widowed 2.84 1.00 221 3.86 2.20 221 2.47 1.03 221 
Lives alone 
P3 Median IQR n p Median IQR n p Median IQR n p 
Yes 2.91 0.93 194 
0.68 
3.77 2.22 194 
0.53 
2.52 1.12 194 
0.38 
No 2.83 0.96 117 3.92 1.88 117 2.46 1.18 117 
Housing type 
P3 Median IQR n p Median IQR n p Median IQR n p 
Standard housing 2.86 0.90 263 
0.38 
3.79 2.04 263 
0.75 
2.51 1.10 263 
0.78 Sheltered housing with warden 2.95 1.19 47 4.00 2.13 47 2.58 1.29 47 
Institution 2.58 1.27 35 3.87 1.81 35 2.71 1.35 35 
Alcohol status P1 Median IQR n p Median IQR n p Median IQR n p 
Current drinker 2.84 0.98 228 
0.51 
3.78 2.02 228 
0.76 
2.50 1.11 228 
0.69 
Occasional drinker 3.05 1.09 62 4.00 2.01 62 2.62 1.18 62 
Previous drinker 2.77 1.02 14 3.72 1.71 14 2.47 1.51 14 
Never drinker 2.81 0.97 43 3.95 2.07 43 2.49 1.22 43 
Smoking status 
P1 Median IQR n p Median IQR n p Median IQR n p 
Current smoker 2.72 0.99 15 
0.38 
3.23 1.30 15 
0.41 
2.16 0.68 15 
0.09 Past smoker 2.84 0.97 216 3.84 2.20 216 2.47 1.12 216 
Never smoker 2.95 1.21 116 3.93 2.01 116 2.62 1.17 116 
Takes non-prescribed medicines, supplements and/or herbal remedies 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 2.87 0.94 158 
0.56 
3.70 2.03 158 
0.46 
2.52 1.20 158 
0.76 
No 2.86 1.08 189 3.95 1.98 189 2.51 1.12 189 
Takes prescribed medication 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 2.87 0.98 330 
0.93 
3.85 2.02 330 
0.85 
2.51 1.13 330 
0.46 
No 2.83 1.73 15 3.68 2.83 15 2.65 1.92 15 
Self-reported physical activity score 
P3
 
r n p r n p r n p 
0.03 347 0.52 0.10 347 0.08 0.06 347 0.26 
Uses aid(s)/appliance(s) 
P1 Median IQR n p Median IQR n p Median IQR n p 
Yes 2.85 1.00 286 
0.78 
3.83 1.98 286 
0.84 
2.48 1.14 286 
0.11 
No 2.94 0.94 61 3.88 1.88 61 2.70 1.09 61 
Social isolation score P3 
r n p r n p r n p 
0.04 345 0.44 0.09 345 0.11 0.08 345 0.15 
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Key event impact 
P3 Median IQR n p Median IQR n p Median IQR n p 
Positive key event(s) 2.90 1.21 63 
0.87 
3.59 1.79 63 
0.27 
2.50 1.23 63 
0.47 
Negative key event(s) 2.80 0.86 101 3.73 1.96 101 2.46 0.89 101 
Positive and negative key event(s) 2.83 0.88 63 3.71 1.84 63 2.60 1.20 63 
Key event(s) but impact unknown 3.02 1.45 35 4.11 2.45 35 2.81 1.84 35 
No key event 2.99 1.22 85 4.18 1.99 85 2.59 1.28 85 
Has problems sleeping 
P3 Median IQR n p Median IQR n p Median IQR n p 
Yes 2.86 1.04 91 
0.94 
4.00 2.05 91 
0.63 
2.55 1.24 91 
0.96 
No 2.87 0.99 256 3.83 2.02 256 2.51 1.16 256 
Body mass index P3 
r n p r n p r n p 
0.02 
 
310 0.68 0.05 
 
310 0.39 0.02 
 
310 0.70 
Fasted blood sample P3 Median IQR n p Median IQR n p Median IQR n p 
Yes 2.88 1.06 336 
0.25 
3.84 1.99 336 
0.48 
2.52 1.19 336 
0.05 
No 2.66 0.42 11 4.38 2.45 11 2.09 0.64 11 
Season of blood sample 
P3 Median IQR n p Median IQR n p Median IQR n p 
Spring 3.15 1.32 86 
0.00 
4.48 2.21 86 
0.00 
2.58 1.20 86 
0.00 
Summer 2.71 0.86 109 3.25 1.43 109 2.32 0.95 109 
Autumn 3.01 0.89 80 3.87 1.50 80 2.43 0.89 80 
Winter 2.90 1.56 72 4.54 3.41 72 3.15 2.93 72 
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D.  
Potential confounders 8-Iso Prostaglandin F2α (ng/ml) P3 
Gender P1 Median IQR n p 
Male 1.38 1.68 145 
0.02 
Female 1.57 2.64 234 
Mitochondrial haplogroup 
P1 Median IQR n p 
H 1.55 1.91 156 
0.45 
T 1.52 4.04 34 
J 1.45 1.95 35 
U 1.52 1.63 52 
K 1.97 5.58 27 
X 0.92 1.08 5 
W 1.50 1.85 9 
I 3.04 12.42 4 
V 1.27 1.86 11 
Age of natural parents death (years) 
P1 r n p 
Mother 0.03 366 0.54 
Father 0.05 351 0.33 
Has/had a sibling(s) 
P1 Median IQR n p 
Yes 1.50 2.11 340 
0.38 
No 1.44 1.68 38 
Had full-time higher education P1 Median IQR n p 
Yes 1.33 2.22 58 
0.27 
No 1.52 1.99 321 
Number of years in main job/role 
P1
 
r n p 
-0.08 297 0.18 
Has offspring 
P1 Median IQR n p 
Yes 1.48 1.86 318 
0.59 
No 1.59 2.38 60 
Marital status 
P3 Median IQR n p 
Single 1.44 6.23 28 
0.58 
Married 1.52 2.44 91 
Re-married 2.65 5.94 7 
Separated _ _ 1 
Divorced 1.26 4.61 6 
Widowed 1.50 1.71 244 
Lives alone 
P3 Median IQR n p 
Yes 1.64 2.10 215 
0.31 
No 1.46 1.87 127 
Housing type 
P3 Median IQR n p 
Standard housing 1.51 2.09 296 
0.13 Sheltered housing with warden 1.79 3.06 45 
Institution 1.12 1.05 36 
Alcohol status P1 Median IQR n p 
Current drinker 1.47 1.88 258 
0.49 
Occasional drinker 1.49 1.86 68 
Previous drinker 1.58 2.28 15 
Never drinker 1.94 4.04 38 
Smoking status 
P1 Median IQR n p 
Current smoker 1.13 0.99 15 
0.48 Past smoker 1.54 2.24 251 
Never smoker 1.45 1.90 113 
Takes non-prescribed medicines, supplements and/or herbal remedies
 P1 Median IQR n p 
Yes 1.47 1.96 179 
0.70 
No 1.53 2.07 200 
Takes prescribed medication 
P1 Median IQR n p 
Yes 1.50 1.98 360 
0.76 
No 1.45 3.93 16 
Self-reported physical activity score 
P3
 
r n p 
-0.04 379 0.45 
Uses aid(s)/appliance(s) 
P1 Median IQR n p 
Yes 1.49 2.11 306 
0.71 
No 1.50 1.81 73 
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Social isolation score 
P3 r n p 
-0.02 
 
376 0.73 
Key event impact 
P3 Median IQR n p 
Positive key event(s) 1.41 1.60 64 
0.77 
Negative key event(s) 1.53 2.57 118 
Positive and negative key event(s) 1.54 1.87 72 
Key event(s) but impact unknown 1.23 1.40 38 
No key event 1.58 3.12 87 
Has problems sleeping 
P3 Median IQR n p 
Yes 1.58 2.93 97 
0.28 
No 1.47 1.87 282 
Body mass index 
P3
 
r n p 
0.02 
 
343 0.70 
Fasted blood sample P3 Median IQR n p 
Yes 1.48 2.09 369 
0.69 
No 1.60 2.47 10 
Season of blood sample 
P3 Median IQR n p 
Spring 1.35 1.49 91 
0.01 
Summer 1.54 3.06 121 
Autumn 1.82 3.26 93 
Winter 1.27 1.66 74 
 
Table 5.9. Potential confounders of potential oxidative stress-related BoA.  
A. superoxide levels, B. mitochondrial mass, C. mitochondrial membrane potential and 
D. 8-Iso Prostaglandin F2α. All had a non-normal distribution in the study population, 
assessed using the Kolomogorov-Smirnov test for normality (p<0.05).  Spearman’s 
correlation was used to the relationship between two continuous variables, Mann-
Whitney U was used to test the difference between two groups and Kruskal-Wallis was 
used to test for the difference between three or more groups. (
P1
: Phase 1 data, 
P3
: Phase 
3 data).  
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does not support the findings of the next results of this study which shows an 
association with increased superoxide production with mitochondrial dysfunction. It 
could be that the younger population have much more defences against the high levels 
of ROS produced in leukocytes that are needed to kill microorganisms during infection, 
such as higher levels of antioxidants and oxidative repair mechanisms, and this could be 
why the younger population have a better mitochondrial function than the very old 
population. Another explanation for the decreased superoxide levels between the young 
and the old of this study could be that fact that the very old represent successful 
survivors and thus have better resistance to oxidative stress (Ungvari et al., 2011). 
However this does not explain why they have an increased mitochondrial dysfunction, 
therefore the former explanation is more likely. A limitation to this study is that the 
DHE stain is only specific to superoxide where as many other ROS could be involved in 
the decline of mitochondrial function with age. There are other studies that have shown 
an increased ROS generation with chronological age in various tissues, including 
leukocytes (Martins Chaves et al., 2000; Chen et al., 2001; Sasaki et al., 2008). A 
difference between the latter study and this study is that they used a chemiluminescence 
assay, and thus method and type of ROS detection could be a reason for their 
disagreement with this study.  ROS are short lived and thus chemiluminescence could 
be a better detection method than flow cytometry due to the handling and preparation 
needed. Also, a weakness to this study is that it is of low sample size and of limited age 
range. Also, chronological age is not the best validation assessment of a BoA due to 
variations in biological age between individuals.  
 
There was a tendency for  8-Iso Prostaglandin F2α  to decrease with chronological age 
when comparing the younger to the very old population, however this did not reach 
statistical significance. Some studies agree with these findings in humans and show no 
significant changes in plasma F2-isoprostanes with chronological age  (Chang et al., 
2012), however other studies in mice have reported an increase with chronological age 
(Ward et al., 2005). There are however differences between the methods used in these 
two studies and this study where the former study used LCMS and the latter study used 
GCMS, which could be a reason for the disagreements between studies, including 
differences in the specificity of the methods to specific F2-isoprostanes isomers as 
discussed in Chapter 4. Section 4.4. Interestingly however, in another study in mice, an 
association between increased mitochondrial dysfunction and decreased plasma F2-
isoprostanes was shown (Lapointe and Hekimi, 2008). They explain that this could be 
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because the majority of the oxidative metabolites of lipids that find their way into the 
plasma do not originate in the mitochondria but in cellular membranes, and thus the 
reduction in F2-isoprostanes are likely because of a decrease in cytoplasmic ROS 
generating processes (Lapointe and Hekimi, 2008). Another surprising results was that 
the longitudinal changes in 8-Iso Prostaglandin F2α in the very old was not linear and 
declined between phase 1 and 2 (85 to 86.5 years) however increased between phase 2 
and phase 3 (86.5 to 88 years). An explanation for the decreased in 8-iso Prostaglandin 
F2α between phase 1 and phase 2 could reflect less anxiety about participating in the 
study for the second time.   
 
The next step of the study was to find evidence for association between ROS 
production, mitochondrial function and oxidative stress.  Mitochondria are not only 
sources of ROS, a by-product of aerobic respiration, but, if antioxidant defences are 
compromised or unable to cope with excess ROS, they are also a target for their 
damage. It is accepted that ROS production is associated with mitochondrial function, 
observed by changes in mitochondrial mass and membrane potential (Forman and Kim, 
1989; Pieri et al., 1993). This study supports this by showing a positive association 
between superoxide levels vs. mitochondrial mass (PBMCs and Lymphocytes) and an 
association between superoxide levels vs. mitochondrial membrane potential (negative 
in PBMCs, positive in Lymphocytes and monocytes). The opposite associations 
between superoxide levels vs. mitochondrial membrane potential in PBMCs and PBMC 
subpopulations is likely to be because of the differences in superoxide levels and 
mitochondrial membrane potential between PBMC subpopulations, as shown in Chapter 
4. Section 4.3.2. and therefore the positive association between superoxide levels vs. 
mitochondrial membrane potential in separate PBMC subpopulations rather than the 
combined PBMC population is more reliable. Mitochondrial produced ROS is generated 
at the electron transport chain due to electron leakage, and thus a higher membrane 
potential is expected to generate more ROS, as shown in this study. However, it has 
been shown that in senescent and therefore dysfunctional cells, superoxide levels are 
associated with a decrease in membrane potential (Ksiazek et al., 2008). In normal 
functioning cells, ROS can be converted to non-radical derivatives such as hydrogen 
peroxide which is subsequently removed by antioxidant systems, maintaining cellular 
homeostasis. However, when this system is compromised, as suggested in cellular 
senescent cells, ROS are inefficiently removed, causing oxidative damage to the 
mitochondrial membrane and thus its depolarisation. Therefore this study suggests that 
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in the majority of PBMC subpopulations in the very old population samples, there are 
more cells where mitochondrial function is not compromised than cells with 
mitochondrial dysfunction, i.e. more non-senescent cells than senescent cells, which 
have efficient systems in place to prevent damage to the mitochondrial membrane and 
thus the relationship between ROS production and mitochondrial parameters reflect the 
non-senescent cells. It would be ideal that non-senescent cells could be separated from 
senescent cells to determine these relationships between ROS production and 
mitochondrial function. This was carried out at an individual sample level later in this 
study to compare ROS production and mitochondrial function in separated non-
senescent (CD27+) and senescent (CD27-) lymphocytes, and found that senescent 
lymphocytes do have increased superoxide production compared to non-senescent 
lymphocytes.  There was also a tendency for mitochondrial mass to be increased and 
mitochondrial membrane potential to be decreased in senescent  lymphocytes,  although 
this did not reach significance. A low sample size may have reduced the power of these 
findings. The relationship between ROS production and mitochondrial dysfunction 
would be difficult to investigate in a large population study since a large volume of 
blood sample is needed to gain the required number of cells for measuring ROS 
production and mitochondrial function by flow cytometry, especially since cell loss may 
occur during the cell separation step, and also due to time issues during this process. 
Alternately, future studies could be to compare the relationship between ROS 
production and mitochondrial parameters in normal and frail participants to determine 
these relationships. It is therefore hypothesized that in frail subjects or specifically 
defined senescent cells, superoxide levels would be associated with a decline in 
mitochondrial membrane potential. The positive association between superoxide levels 
vs. mitochondrial membrane potential, and thus the explanation the majority of cells 
within the very old samples do not have dysfunctional mitochondria however does not 
explain the positive association between superoxide levels vs. mitochondrial mass, 
which alternately suggests that mitochondria are dysfunctional since increased 
mitochondrial mass is commonly found in cellular senescence (Hagen et al., 1997; 
Hagen et al., 1999; Kokoszka et al., 2001; Moiseeva et al., 2009). However it seems 
that changes in mitochondrial mass and mitochondrial membrane potential are 
independent of each other, since no significant relationship was shown between these 
two parameters within the very old population.  Alternately this could potentially be due 
to a non-linear relationship that is worth further investigation. There was no association 
found between 8-Iso Prostaglandin F2α and ROS production or mitochondrial 
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parameters, which as discussed above, could be the fact that F2-isoprostanes are likely 
to reflect cytoplasmic ROS generating processes rather than mitochondrial processes 
(Lapointe and Hekimi, 2008). 8-iso prostaglandin F2α in plasma represents whole body 
exposures to oxidative stress whereas ROS production and mitochondrial function is 
specific to PBCMs, thus a lack of association could reflect different levels of oxidative 
stress and thus senescence in other tissues, suggesting different ageing rates in different 
tissues. Therefore although the measurement of ROS production and mitochondrial 
function may be valid BoA in PBMCs, it may not be an appropriate surrogate for 
predicting age-related outcomes concerning other tissues.  
 
The next step of the study was to find evidence for the validity of potential oxidative 
stress-related BoA in terms of their implication in the oxidative stress-driven pathway to 
cellular senescence in the very old population. The agreement between potential 
oxidative stress-related BoA vs. other markers implicated in the oxidative stress-driven 
pathway to cellular senescence in the very old was then investigated. It was 
hypothesized that the potential oxidative stress-related BoA would correlate with a 
decreased telomere length, an increased DNA damage, a decreased DNA repair, and an 
increase in inflammatory mediators since these parameters are cellular senescence 
phenotypes as discussed in Chapter 1. Section 1.3.8.  There were some significant 
agreements between potential oxidative stress-related BoA vs. other markers implicated 
in the oxidative stress-driven pathway to cellular senescence. However, although some 
support the hypothesized associations above including increased superoxide levels vs. 
decreased DNA repair, and increased inflammatory cytokines (il-6 and TNF-α) vs. 
increased 8-iso Prostaglandin F2α, some were in the opposite association as 
hypothesized. These included an increase in superoxide levels vs. decreased 
inflammatory cytokines, an increase in mitochondrial mass vs. an increase in telomere 
length, and an increase in mitochondrial membrane potential vs. decreased CRP. 
Reasons for this and also disagreements with other senescent markers could be 
heterogeneity in within and between cells, independent initiators of cellular senescence, 
method reliability, instability of these parameters in the very old and also the possibility 
that the correlations arose by chance since they were of very low magnitude.  
 
The next step of the study was to investigate the relationship between potential 
oxidative stress-related BoA and immunosenescence in the very old population.  It was 
hypothesised that those participants with an increased percentage of immunosenescent 
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cells, and thus a decreased immune function, should have higher oxidative stress levels. 
Therefore it was expected that there would be an increase in oxidative stress-related 
BoA with increasing percentages of various immunosenescent phenotypes, which are 
described in Figure 5.1., and thus provide further evidence of construct validity in terms 
of their association with age-related functional decline. An increased superoxide levels 
and decreased mitochondrial membrane potential were associated with a decline in the 
lymphocyte/monocyte ratio and mitochondrial mass was associated with an increase in 
the memory/naïve CD4 T lymphocyte ratio providing some evidence that mitochondria 
ROS production and dysfunction play a role in immunosenescence and thus immune 
dysfunction. There is however the possibility that these correlations arose by chance 
since they were of very low magnitude.  
 
 
This study also attempted to validate potential oxidative stress-related BoA by 
determining their agreement with informative BoA in the oldest old. These are markers 
that were validated in previous study of the Newcastle 85+ cohort, where a large panel 
of candidate BoA were investigated and defined as valid if they were associated with 
two or more age-related outcomes: cognitive impairment, disability score, disease count 
and survival (Martin-Ruiz et al., 2011). Increased superoxide levels and mitochondrial 
membrane potential in Phase 3 significantly correlated with decreased serum Vitamin D 
levels in Phase 1. Although a moderate intra-individual variation in vitamin D over 
approximately five years has been shown, a high correlation was observed, supporting 
the use of a one-time measurement of vitamin D within 5 years (Meng et al., 2012). It is 
therefore expected that vitamin D levels at phase 3 should show the same association to 
superoxide levels and mitochondrial membrane potential as phase 1 levels. However 
vitamin D supplementation and season of blood draw would affect the reliability of 
repeat measures of vitamin D. The association between superoxide levels and 
mitochondrial membrane potential and vitamin D levels could therefore be stronger if 
there were measurements at the same time point, however this was not available within 
the study. This could be worth further investigation. Mitochondrial membrane potential 
and 8-iso Prostaglandin F2α also significantly correlated with free T3. Since vitamin D 
levels and thyroid hormones vary with the season in the older population (Houston et 
al., 2013), this suggests that potential oxidative-stress related BoA could also be 
affected by seasonality. 8-iso Prostaglandin F2α at phase 3 was also associated with 
FEV1, for which measurement was only available at phase 1, however since 8-iso 
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Prostaglandin F2α was also available at phase 1, this was also investigated but no 
association was revealed (data not shown). There were however no other associations 
found between the potential oxidative-stress related BoA  and the other seven remaining 
informative BoA. Therefore the very few associations, which were of low magnitude of 
correlation, suggests there is the possibility that they arose by chance.  Since the 
validation of the ten informative BoA in the very old population, in terms of association 
with cognitive function, disability and multi-morbidity was cross-sectional, longitudinal 
studies should follow to determine their ability to predict age-related outcomes and thus 
further validate then as informative BoA.  
 
Lastly this chapter investigated potential confounding factors that may affect the intra-
individual variability of potential oxidative stress-related BoA in vivo (e.g. fasting 
status), and also grouped variability (i.e. fixed characteristics such as gender), by 
looking at their association between various participant characteristics. Since the effect 
of various participant characteristics on potential oxidative stress-related BoA was 
unknown and therefore were not controlled for before the study commenced (i.e. 
participants refrain from various activities before blood withdrawal) it was thought that 
an indirect investigation, by comparing the whole population, would provide some 
indication of factors that may need to be controlled in future predictive validation 
analyses. An interesting association with seasonality was found for all the potential 
oxidative stress-related BoA and thus this factor should be controlled for in future 
analyses. There were no other consistencies between potential oxidative stress-related 
BoA and other characteristics. A further interesting association was that superoxide 
levels at phase 3 were reduced in those participants who reported taking non-prescribed 
medicines, supplements and/or herbal remedies at phase 1. This not only adds to the 
construct validity of superoxide levels as a candidate BoA, but since there is an 
association seen approximately three years between these parameters then it is likely 
that taking non-prescribed medicines, supplements and/or herbal remedies is a regular 
occurrence of the individuals. Controlling for this factor is therefore not advised since 
this could reduce the power of future predictive validation analyses. 
 
5.5. Conclusion 
 
These results provide some evidence for the construct validity of potential oxidative 
stress-related BoA in the very old population in terms of associations with 
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chronological age, associations with some markers of oxidative stress-induced cellular 
senescence and a role in immunosenescence. The reliability and validity of the age-
related construct variables investigated against the oxidative stress-related BoA within 
this study could be a limitation. This could be further explored in future work. Seasonal 
variation is a potential confounder and should be controlled for in future predictive 
validation analyses. 
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Chapter 6. The role of ROS production and 
mitochondrial dysfunction in a mouse model of ageing 
 
6.1. Abstract 
 
Background Dietary restriction has been shown reduce the rate of mitochondrial 
superoxide production and the susceptibility of many types of tissue to oxidative stress. 
It is therefore a suitable model to investigate the construct validity of potential oxidative 
stress-related BoA. Aims This study aimed to provide evidence of construct validity of 
ROS production and mitochondrial function as candidate BoA in leukocytes by 
investigating the effects of dietary restriction in peripheral blood and bone marrow of 
mice. Methods Superoxide levels, mitochondrial mass and mitochondrial membrane 
potential were measured in PBMCs of 25 month old C57Bl/6 mice that were AL (n=5) 
or DR (n=6) and also in bone marrow of 2 month old AL (n=6), 25 month old AL 
(n=12) and DR (n=11), and 32 month old AL (n=10) and DR (n=10) C57Bl/6 mice.  
Results There was a tendency for superoxide levels and mitochondrial mass to be 
decreased and mitochondrial membrane potential to be increased in 25 month old DR 
mice compared to AL controls in all subpopulations of peripheral blood; however, none 
reached statistical significance (p≥0.07). There was a significant increase in superoxide 
levels with age in all bone marrow (p=0.04) and lymphoid cells (p=0.03) but not in 
myeloid cells (p=0.07), which was significantly reduced in both 25 and 32 month old 
DR mice in all cell subpopulations (p≤0.04), with the exception of lymphoid cells in 32 
month old mice (p=0.13). Mitochondrial mass had a non-linear association with age in 
bone marrow where in 2 month and 32 month old mice it was higher than in 25 month 
old mice in all subpopulations (p≤0.02). The high mitochondrial mass at 32 months of 
age was significantly reduced by DR in all bone marrow subpopulations (p≤0.01). There 
was no significant association between mitochondrial membrane potential and age in 
bone marrow; however, mitochondrial membrane potential was increased by DR in 32 
month old mice compared to AL controls in all subpopulations (p<0.01). Superoxide 
levels, mitochondrial mass and mitochondrial membrane potential were associated with 
lymphoid/myeloid cell ratio. Lymphoid/myeloid cell ratio was reduced with age and 
increased by DR. Conclusion This study provides evidence for the construct validity of 
ROS production and mitochondrial function in leukocytes as potential oxidative stress-
related BoA. 
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6.2. Introduction 
 
The use of interventions that are designed to delay age-related outcomes in animal 
models has been an important step in the validation of candidate BoA in humans 
(Turturro et al., 1999). Not only does this provide construct validation of the candidate 
BoA investigated, in terms of its reflection in the biological mechanisms of ageing, but 
also the assumption that it is valid across different species and that the intervention 
could also be extrapolated to humans. There are many advantages of validating 
candidate BoA using an animal model of ageing for use in large human population 
studies including the reduction of time, costs and ease of access to materials (Rifai et 
al., 2006). Also, extrinsic factors in human studies are difficult to control, or may even 
be uncontrollable, since some information is far too intense to capture including the 
effects of diet, medications and physiological parameters such as metabolism and 
genetic heterogeneity which may lead to measurement rather than genuine inter-
individual variability (Lee et al., 2005).  The use of animal models reduces the 
difficulties associated with the effects of these confounding extrinsic variables due to 
tightly controlled environmental surroundings and genetic homogeneity.   
 
Dietary restriction is one of the most frequently employed interventions in animal 
models studies that aim to understand the biological mechanisms of ageing. This is 
because of its robustness in extending life expectancy and delaying a wide range age-
related outcomes including physiologic alterations in behaviours, learning, immune 
responses, gene expression, enzyme activities, hormonal actions, glucose intolerance, 
DNA repair capacities and protein synthesis in a variety of different species (Weindruch  
and Walford, 1988). Early suggestions for the potential mechanisms of dietary 
restriction on biological ageing include: 1) the delay of growth and development 
(McCay et al., 1989), which is now contested since dietary restriction started in middle 
age increases life-span and reduces age-related outcomes (Weindruch and Walford, 
1982; Wang et al., 2010); 2) the reduction in body fat, where it is suggested that dietary 
restriction decreases the chronic effects of peptides, cytokines, complementary factors 
and substrates which play an important role in the regulation of metabolism and are 
secreted by fat cells which could have a beneficial effect on other tissues (Barzilai and 
Gupta, 1999; Tchkonia et al., 2010); and 3) the reduction in body temperature, which is 
thought to relate to metabolic process, although the exact mechanism is not understood 
(Lane et al., 1996). The reduction of metabolic rate seems to play an important role in 
162 
 
all the proposed mechanism of dietary restriction. In 1977, George A. Sacher suggested 
that lowering metabolic rate would enhance longevity (Sacher, 1977). It was then 
discovered that energy metabolism generates ROS (Turrens and Boveris, 1980) and thus 
the link between the reduction of metabolic rate by dietary restriction and delayed 
ageing could be made. It is therefore hypothesised that the mechanism behind dietary 
restriction is through the amelioration of oxidative stress by reducing the rate of 
mitochondrial superoxide production, which has been supported by studies in rodents 
(Sohal et al., 1994a). This mechanism however is not fully understood. Increasing the 
activity of antioxidant enzymes has been ruled out since studies have not shown a 
consistent pattern in response to dietary restriction (Sohal et al., 1994a); however, 
studies have shown that there is a decreased susceptibility of tissues to oxidative stress 
including reduced damage to lipids (Matsuo et al., 1993; Dandona et al., 2001),  
proteins (Dubey et al., 1996; Forster et al., 2000) and DNA (Sohal et al., 1994b; Wang 
et al., 2010). This suggests that repair of oxidative damage could be improved by 
dietary restriction. It has also been suggested that dietary restriction promotes 
mitochondrial turnover to prevent the accumulation of damaged mitochondria, which 
could explain the reduced superoxide production by dietary restriction and thus reduced 
oxidative damage to tissues (Miwa et al., 2008). It is also becoming increasingly 
recognised that dietary restriction may also reduce cellular senescence (Wang et al., 
2010). Dietary restriction is therefore a suitable model to investigate the validity of 
potential oxidative stress-related BoA.  
 
Since this study is interested in using peripheral blood as a surrogate tissue for 
measuring mitochondrial ROS production and dysfunction as potential oxidative stress-
related BoA in humans, evidence that these are reduced by dietary restriction in 
leukocytes is required for their validation. However, a structured literature review 
revealed that this information is sparse (Table 6.1). According to this review only a 
couple of studies have investigated this in terms of ROS production and mitochondrial 
membrane potential for which studies were inconsistent (Avula and Fernandes, 2002; 
Ueno et al., 2005).  No study investigating the effects of dietary restriction on leukocyte 
mitochondrial mass was identified. In the study by Avula and Fernandes in 2002, it was 
shown that basal ROS production increases and mitochondrial membrane potential 
stimulated with H202 was decreased with age in splenic lymphocytes from AL mice and 
40% dietary restriction prevented these changes (Avula and Fernandes, 2002). The 
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Oxidative 
stress and 
cellular 
senescence-
related BoA  
Reference Diet group Species Gender 
Age at 
start of 
diet 
Age at 
end of 
diet 
Duration n Cell/tissue  Marker Levels Units p Conclusion 
ROS 
production 
(Avula and 
Fernandes, 
2002) 
AL 
C57BL/6J 
mice 
Female 6 w 
6 m 
2 w 
5 m 
5 Splenocytes Dichlorofluorescein 
E
 55 
Mean % 
stained 
 ± SEM  
ns 
▼ 
CR (40%) E 50 
AL 19 m  
2 w 
18 m 
E
 75 
* 
CR (40%) E 53 
(Ueno et 
al., 2005) 
AL Institute of 
Cancer 
Research 
mice 
Male 7-8 w 8-9 w 1 w 
24 Circulating 
myeloid cells 
(PMNs and 
monocytes) 
Dihydrorhodamine 123 
E
 5 
Mean 
fluorescence 
intensity  
ns X CR (30%) 24 E 5.25 
CR (60%) 25 E 5 
Mitochondrial 
mass 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Mitochondrial 
membrane 
potential 
(Avula and 
Fernandes, 
2002) 
AL 
C57BL/6J 
mice 
Female 6 w 
6 m 
2 w 
5 m 
5 Splenocytes Rhodamine 123 
E
 65 
Mean 
fluorescence 
± SEM 
ns 
▲ 
CR (40%) E 70 
AL 19 m  
2 w 
18 m 
E
 55 
* 
CR (40%) E 62 
Telomere 
length 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DNA Damage 
(de la Maza 
et al., 2004) 
Weight 
maintainers 
(Weight 
change of 
3kg or less) 
Humans Male u/k u/k 10 y 
5 
Lymphocytes 8-hydroxydeoxyguanosine u/k u/k ns X 
Weight 
gainers 
(Weight 
increment of 
6kg or more) 
8 
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(Gedik et 
al., 2005) 
AL 
Hooded-
Lister rats 
(Rowett 
strain) 
Male 1 m 
1,3,5,7,9,1
1,13,15,17 
m 
0,2,4,6,8,1
0,12,14,16 
m 
6-8 Lymphocytes DNA strand breaks u/k u/k ns X 
CR (30%) 
PR (50%) 
CPR (30%) 
(Hofer et 
al., 2008) 
Baseline 
Humans Mixed 50-60 y 51-61 y 1 y 9 
White blood 
cells 
Oxidised DNA  
(8-oxoGua/106 dGuo) 
4.24  
± 0.39 
Mean  
± SE 
* ▼ 
CR (20%) 
2.19  
± 0.34 
(Ribeiro et 
al., 2004) 
AL 
Balb/c 
mice 
Male 12 w 
12 w  
19 d 
19 d 5 
White blood 
cells 
Tail moment 
2.2 
 ± 0.2 
Mean  
± SE 
* ▲ 
CR (25%) 
3.6  
± 0.2 
DNA repair 
(Gedik et 
al., 2005) 
AL 
Hooded-
Lister rats 
(Rowett 
strain) 
Male 1 m 
1,3,5,7,9,1
1,13,15,17 
m 
0,2,4,6,8,1
0,12,14,16 
m 
6-8 Lymphocytes 
Percentage repair of  
H2O2-induced DNA strand 
breaks 
u/k u/k ns X 
CR (30%) 
PR (50%) 
CPR (30%) 
(Raji et al., 
1998) 
NBMI (≥20) 
Humans Mixed 
8 -14 y  
u/k u/k 20 Lymphocytes 
Unscheduled DNA 
synthesis 
10.3  
± 5.3 
Mean 
femtomoles 
of [3H] 
thymidine 
incorporated 
per mg DNA 
± SD 
ns 
▲ 
LBMI (<18) 
9.2  
± 3.4 
NBMI (≥20) 
20-35 y 
15.7  
± 8.8 
* 
LBMI (<18) 
22.0  
± 15.4 
NBMI (≥20) ≥55 y 
12.1  
± 9.2 
* 
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LBMI (<18) 
26.7  
± 12.6 
NBMI (≥20) 
8-14 y 
DNA-polymerase β 
activity 
546 
 ± 227 
Mean 
picomoles 
[3H] TMP 
incorporated 
per 
milligram of 
protein per 
hour  
± SD 
ns 
LBMI (<18) 
659 
 ± 259 
NBMI (≥20) 
20-35 y 
244  
± 91 
* 
LBMI (<18) 
292  
± 53 
NBMI (≥20) 
≥55 y 
202  
± 96 
ns 
LBMI (<18) 
232  
± 61 
NBMI (≥20) 
8-14 y 
Activities of UV DNase 
249 
 ± 53 
Mean mg of 
DNA-P 
liberated per 
milligram 
DNA  
 ± SD 
* 
LBMI (<18) 
312 
 ± 61 
NBMI (≥20) 
20-35 y 
190  
± 67 
* 
LBMI (<18) 
292 
 ± 136 
NBMI (≥20) 
≥55 y 
148 
 ± 67 
* 
LBMI (<18) 
222  
± 68 
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NBMI (≥20) 
8-14 y 
Activities AP DNase 
390  
± 97 
Mean mg of 
DNA-P 
liberated per 
milligram 
DNA  
± SD 
ns 
LBMI (<18) 
406 
 ± 81 
NBMI (≥20) 
20-35 y 
268 
 ± 97 
ns 
LBMI (<18) 
304  
± 129 
NBMI (≥20) 
≥55 y 
156  
± 70 
* 
LBMI (<18) 
269 
 ± 73 
Interleukin-6 
(Apte et al., 
2002) 
AL Spague-
Dawley 
rats 
Male u/k u/k 21 d 4 Plasma - 
≈10 Mean pg/ml  
± SE 
* ▲ 
DR (35%) ≈40 
(Bosutti et 
al., 2008) 
AL 
Humans Male 24 y 
24 y 
14 d 
14 d 4-5 Plasma - 
11.4 
 ± 3.4 
Mean pg/ml  
± SE 
* ▼ 
DR (E 20%) 
1.7 
 ± 0.3 
(Komatsu et 
al., 2011)  
AL 
Wister rats Male 
1 m  
2 w  
6 m 4.5 m 4-8 Serum - ≈u/k 
Mean ng/ml  
± SE 
ns X 
DR (30%) 
(Lane et al., 
1995) 
AL 
Rhesus 
monkeys 
Male 
1.5-2 y 6.5-7 y 
4.5-7 y 
5 
Plasma - 
E
 4.75 
Mean pmol/l  
± SE 
* 
▼ 
DR (30%) 6 E 3.24 
AL 
3-5 y 8.5-10 y 
5 E 4.75 
* 
DR (30%) 6 E 2 
(Messier et 
al., 2012) 
E 
Humans u/k 65.6 y 
65.6 y  
18 m 
18 m u/k Serum - 
E
 u/k 
Mean pg/ml  
± SE 
* ▼ 
D E u/k 
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(Piccio et 
al., 2008) 
AL C57BL/6 
mice 
Female 5 w 10 w 5 w 
9 
Plasma - 
E
 10 Mean pg/ml  
± SE 
* ▼ 
DR (40%) 5 E 5 
(Redman et 
al., 2010) 
AL 
Humans u/k 25-50 y 
24 y  
24 w 
-50 y  
24 w 
24 w u/k Serum - u/k u/k ns X 
DR (25%) 
(Sherman et 
al., 2011)  
AL 
Mice u/k u/k u/k 4 m u/k Serum - u/k u/k * ▼ 
DR (u/k %) 
(Spaulding 
et al., 
1997),  
AL Mice 
(C3B1 
0RF1) 
Mixed 28 d 28-36 m 27-35 m 30-19 Serum - 
E
 400 Mean pg/ml  
± SE 
* ▼ 
DR (50%) E 100 
(Tam et al., 
2012) 
AL 
Humans Mixed 25-50 y 
25 y  
24 w 
 -50 y  
24 w 
24 w 
11 
Serum - 
145.9 
± 59.5 
Mean pg/ml  
± SE 
ns X 
DR (25%) 12 
66.5 ± 
20.2 
(Volk et al., 
1994) 
AL 
B6 Mice Male 12 m 
18 m 6 m 
30 
Serum - 
E 350 
Mean pg/ml u/k u/k 
DR (25%) 35 E 250 
AL 
25 m 13 m 
15 E 500 
DR (25%) 13 E 400 
(Wang et 
al., 2007) 
AL 
Mice Male 5 m 7 m u/k u Plasma - 
168.34 
±17.76 
Mean pg/ml  
± SE 
* ▼ 
DR (30%) 
139.71 
± 8.12 
Tumour 
necrosis  
factor-alpha 
(Avula and 
Fernandes, 
2002) 
AL 
C57BL/6J 
mice 
Female 6 w 
6 m 
2 w 
5 m 
5 
CD4 
Lymphocytes 
- 
E 18 
Mean % 
stained 
 ± SEM 
* 
▼ 
CR (40%) E 9 
AL 19 m 
2 w 
18 m 
E
 22 
* 
CR (40%) E 10 
AL 6 m  
2 w 
5 m 
CD8 
Lymphocytes 
E
 10 
* 
CR (40%) E 3 
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AL 19 m 
 2 w 
18m 
E
 16 
* 
CR (40%) E 11 
(Chiba and 
Ezaki, 
2010) 
AL SHRSP 
/lzm rats 
Male 10 w 12 w 2 w u/k Plasma - 
E
 0.9 Mean pg/ml  
± SE 
ns X 
CR (50%) E 0.3 
(Pali and 
Paszthy, 
2008) 
Control 
Humans Mixed u/k u/k u/k 
10 
Macrophages - u/k u/k ns X 
Anorexia 
nervosa 
11 
Obese 12 
(Paszthy et 
al., 2007) 
Control 
Humans Mixed u/k u/k u/k 
19 
Monocytes - U/K U/K ns X 
Anorexia 
nervosa 
21 
(Phillips 
and 
Leeuwenbu
rgh, 2005) 
AL 
Fischer 
344 rats 
u/k 3.5 m 26 m 22.5 m 8 Plasma - 
E
 20 
Mean pg/ml  
± SE 
* ▼ 
CR (40%) E 7.5 
(Redman et 
al., 2010) 
AL 
Humans u/k 25-50 y 
24 y 
 24 w 
-50 y  
24 w 
24 w u/k Serum - u/k u/k ns X 
DR (25%) 
(Sherman et 
al., 2011)  
AL 
Mice u/k u/k u/k 4 m u/k Serum - u/k u/k * ▼ 
DR (U/K %) 
(Spaulding 
et al., 1997)  
AL Mice 
(C3B1 
0RF1) 
Mixed 28 d 28-36 m 27-35 m 30-19 Serum - 
E
 350 Mean pg/ml  
± SE 
* ▼ 
DR (50%) E 30 
(Tam et al., 
2012) 
AL Humans Mixed 25-50 y 
25 y  
24 w 
 -50 y  
24 w 11 Serum - 
8.0 ± 
1.4 
Mean pg/ml  
± SE 
ns X 
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DR (25%) 
24 w 
12 
8.5 ± 
2.0 
   
Lymphoid / 
Myeloid ratio 
(Weindruch 
and Suffin, 
1980) 
AL 
B10C3F1 
mice 
Female 21-24 d 6 m 7m 8-9 
Thymus cortex 
- 
2.2 ± 
0.15 
Mean ratio  
± SE 
* 
▲ 
DR (
E
 30%) 
5.6 ± 
0.73 
DR (
E
 40%) 
3.9 ± 
0.15 
AL 
Thymus 
medulla 
0.8 ± 
0.04 
* DR (E 30%) 
1.0 ± 
0.04 
DR (
E 
40%) 
1.2 ± 
0.05 
  
Table 6.1. Structured literature search results identifying studies that have investigated the effects of dietary restriction on potential oxidative 
stress and cellular senescence-related BoA in leukocytes. Full details of the search terms are shown in Appendix B. (AL: Ad libitum, CR: Calorie 
restricted,  PR: Protein restricted, CPR: Calorie and protein restricted, NBMI: Normal body mass index, LBMI: Low body mass index, DR: Dietary 
restricted, E: Exercise only control, D: Intensive dietary restriction, d: days, w: weeks, m: months, y: years, n: number of participants, PMNs: 
Polymorphonuclear cells, u/k: Unknown, n/a: No study identified, SEM: Standard error of the mean, SD: Standard deviation of the mean, E: Estimate 
provided within literature or if data displayed on chart, *: Statistical significant difference (p<0.05), ns: No significant difference, ▲: Increases, X: No 
effect, ▼: Decreases)  
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remaining study by Ueno et al in 2005 investigated ROS production only in circulating 
myeloid cells; however, found no difference in basal ROS production in AL mice 
compared to mice with 40% and 60% calorie restriction (Ueno et al., 2005). They did 
however find that ROS production was significantly enhanced in AL mice compared to 
dietary restricted mice after 60 minutes of gut ischemic reperfusion, with or without 
phorbal myristate acetate stimulation. The evidence of an effect of dietary restriction on 
ROS production and mitochondrial dysfunction therefore only comes from splenic 
lymphocytes. The effects in peripheral blood cells should be shown since this tissue will 
be used in human studies. 
 
There is also only a handful of studies investigating the effects of dietary restriction on 
other potential oxidative stress and cellular senescence-related markers in leukocytes 
that were described in Chapter 1. Section 1.3.8. and Figure 1.10., for which 
inconsistencies are also shown (Table 6.1). Some studies have shown that dietary 
restriction decreases leukocyte DNA damage (Hofer et al., 2008), increases leukocyte 
DNA repair (Raji et al., 1998) and reduces inflammatory cytokines (Lane et al., 1995; 
Spaulding et al., 1997; Avula and Fernandes, 2002; Phillips and Leeuwenburgh, 2005; 
Wang et al., 2007; Bosutti et al., 2008; Piccio et al., 2008; Sherman et al., 2011; 
Messier et al., 2012); however, other studies contest this and even show opposing 
effects including increased leukocyte DNA damage (Ribeiro et al., 2004) and increased 
inflammatory cytokines (Apte et al., 2002). Interestingly, the latter studies were of short 
term dietary restriction. One hypothesis of the anti-ageing action of dietary restriction is 
its hormesis effect, first described by Masoro in 1998, defined as the beneficial actions 
resulting from the response of an organism to a low intensity stressor, in this case 
dietary restriction (Masoro, 1998). It is though that dietary restriction initially puts the 
organism under a low intensity stress and this some how prepares the organism to cope 
with further/more intense stressors (Masoro, 2000). This mechanism is not fully 
understood but could be through the up-regulation of stress response genes.  
 
One other interesting aspect of dietary restriction is whether it plays a role in improving 
immune function and if this is associated with a decline in ROS production and 
improved mitochondrial function in leukocytes. It is know that the number of 
circulating lymphocytes decreases with age and thus blood becomes increasingly biased 
towards myeloid cells, which is thought to reflect immune dysfunction (Rothstein, 
1993). This has been attributed to a shift in the clonal composition of hematopoietic 
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stem cells (Cho et al., 2008). Haematopoiesis and thus immune function can therefore 
be determined by calculating the ratio of lymphoid or lymphoid-derived cells to 
myeloid or myeloid-derived cells. The structured literature review revealed an early and 
only study to show that the ratio of volume fractions of thymus cortical and medullary 
lymphoid cells/cortical and medullary non-lymphoid cells increases in dietary restricted 
mice (Weindruch and Suffin, 1980). This effect of dietary restriction however has not 
been shown in peripheral or bone marrow cells. It would be interesting to determine if 
ROS production and mitochondrial dysfunction in leukocytes are associated with an 
increase in myeloid bias and thus immune dysfunction with age and that this can be 
ameliorated by dietary restriction. 
 
This study aimed to investigate the effects of dietary restriction on ROS production and 
mitochondrial function in peripheral blood and bone marrow of mice to provide further 
evidence for their validity as candidate BoA and also determine if these markers are 
associated with the age-associated functional decline in haematopoiesis and thus 
immune function by investigating peripheral blood and bone marrow cell subpopulation 
compositions.   
 
6.3. Results 
 
6.3.1. Comparison of superoxide levels, mitochondrial mass, mitochondrial membrane 
potential and lymphoid/myeloid derived cell ratio in peripheral blood and bone 
marrow cells of mice 
 
This study first set out to measure ROS production and mitochondrial function in 
peripheral blood from AL and DR mice since this was the tissue that would be used in 
human studies. However, it was very difficult to get enough PBMCs from the peripheral 
blood of one mouse sample since these were often of low volume where less than 400µl 
proved difficult to obtain the number of cells required (1x10
5
) (Table 6.2.). It was then 
decided that individual blood samples of low volume would be combined in order to 
continue the study in this tissue. Combined blood sample were always of the same diet 
group, age, gender and where possible similar visible pathology (Table 6.2). The latter 
however was not always possible since the mice displayed varying pathology which 
may confound future analysis. Another issue was that this then reduced the number of 
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Mouse 
sample 
Mouse 
group 
Gender 
Number 
of mice 
Age at analysis 
(Months) 
Mouse no 
Individual Blood 
volumes (µl) 
Tumour Visible pathology noted 
1 AL Male 4 24.42 
1 200 Yes Tumour on left lung 
2 200 No Polyp on small intestine 
3 200 No Polyp on small intestine and abnormally formed testes 
4 200 No Polyp on small intestine 
2 AL Male 1 24.42 1 400 No Enlarged seminal tubules and necrosis on liver 
3 AL Male 3 24.92 
1 250 No None 
2 250 No Two polyps on small intestine 
3 500 Yes Lymphoma  including thymus 
4 AL Male 1 24.92 1 500 Yes Tumours on pancreas, kidney, lung and thymus 
5 AL Male 1 24.92 1 500 No None 
6 DR Female 3 24.16 
1 200 No Two polyps and white nodules on spleen 
2 100 No Two polyps on small intestine 
3 100 No Polyp on small intestine 
7 DR Female 2 24.16 
1 100 No None 
2 300 No Four polyps on small intestine 
8 DR Female 2 24.16 
1 250 Yes Polyp on small intestine and ovarian tumour 
2 100 No Two polyps and white nodules on spleen 
9* DR Male 2 24.88 
1 250 Yes Pancreatic tumour and enlarged spleen 
2 350 No Thin, prolapse and enlarge spleen 
10 DR Male 1 24.88 1 600 No None 
11 DR Male 1 24.88 1 500 No None 
 
Table 6.2. Details of mice samples for which peripheral blood was derived (*:An error occurred for sample 9 in MitoTracker Green staining hence 
why there is one less mouse for the peripheral blood 25 month DR group for mitochondrial mass analysis) 
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samples available for analysis and thus would reduced the power of obtaining statistical 
significance if this was the case. It was therefore decided that the study should continue 
using bone marrow samples since plenty of cells could be obtained for the analysis from 
one mouse sample, avoiding the issues of combining samples. Details of the peripheral 
blood and bone marrow samples obtained are shown in Table 6.2. and Table 6.3. 
respectively, with a summary of all samples in Table 6.4. 
 
The comparison between the flow cytometry graphs in peripheral blood and bone 
marrow of mice, and thus quantification superoxide levels, mitochondrial mass and 
mitochondrial membrane potential is shown in Figure 6.1. Bone marrow cells were 
slightly larger and more granular than peripheral blood cells; however the myeloid 
derived cells could clearly be distinguished from the lymphoid derived cells in 
peripheral blood and bone marrow based on their larger size and granularity, as in the 
human peripheral blood samples (See Chapter 2. Figure  2.2.). The same standardised 
quantification of superoxide levels, mitochondrial mass and mitochondrial membrane 
potential in cell subpopulations could therefore be used for both human and mice 
samples.  
 
Normality tests and histograms revealed that superoxide levels, mitochondrial mass and 
mitochondrial membrane potential in both peripheral blood and bone marrow of mice 
followed a non-normal distribution (Table 6.5.). Non-parametric statistical tests were 
therefore used in future analysis.  
 
Using 25 month old AL mice samples only, so they were comparable, superoxide levels 
were significantly lower in peripheral blood compared to bone marrow cells in all cell 
subpopulations (p<0.01) whereas mitochondrial mass was higher (significant in 
lymphoid and myeloid derived cell subpopulations only (p≤0.02)) (Figure 6.2.).  
Mitochondrial membrane potential in peripheral blood was not significantly different 
compared to bone marrow cells in the combined and lymphoid-derived cell 
subpopulations (p≥0.34), however was higher compared to bone marrow cells in the 
myeloid-derived subpopulation (p=0.01) (Figure 6.2.).  There was a tendency for bone 
marrow to be more lymphoid derived cell biased compared to peripheral blood, 
however this did not quite reach statistical significance (p=0.05) (Figure 6.2.).  
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Mouse 
sample 
Mouse 
group 
Gender 
Number 
of mice 
Age at analysis 
(Months) 
Mouse no 
Individual Blood 
volumes (µl) 
Tumour Visible pathology noted 
12* AL Female 1 2.30 _ _ No None 
13 AL Female 1 2.86 
_ _ 
No None 
14 AL Female 1 2.86 
_ _ 
No None 
15 AL Male 1 2.14 
_ _ 
No None 
16 AL Male 1 2.14 
_ _ 
No None 
17* AL Male 1 2.30 _ _ No None 
18 AL Female 1 24.95 
_ _ 
Yes Lymphoma 
19 AL Female 1 24.95 
_ _ 
Yes Tumour on liver, spleen, pancreas and enlarged thymus 
20 AL Female 1 24.95 
_ _ 
No None 
21 AL Female 1 25.12 
_ _ 
No None 
22 AL Female 1 25.12 
_ _ 
Yes Tumour on pancreas and small intestine 
23 AL Female 1 25.12 
_ _ 
Yes Tumour on ovary, adrenal gland and blood clot on brain 
24 AL Male 1 25.35 
_ _ 
No None 
25 AL Male 1 25.35 
_ _ 
No Blood in lungs 
26 AL Male 1 25.35 
_ _ 
Yes Tumour on thymus and spleen 
27 AL Male 1 25.38 
_ _ 
No Enlarged seminal vesicles 
28 AL Male 1 25.38 
_ _ 
Yes 
Tumour on pancreas, cysts on liver, enlarged spleen and 
large seminal vesicles 
29 AL Male 1 25.38 
_ _ 
No Large seminal vesicles 
30 DR Female 1 24.95 
_ _ 
No None 
31 DR Female 1 24.95 
_ _ 
Yes Lymphoma 
32 DR Female 1 24.95 
_ _ 
No None 
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33 DR Female 1 25.12 
_ _ 
No Enlarged right ovary 
34 DR Female 1 25.12 
_ _ 
No Enlarged right ovary 
35 DR Female 1 25.12 
_ _ 
Yes Tumour on ovary 
36 DR Male 1 25.35 
_ _ 
No None 
37 DR Male 1 25.35 
_ _ 
No None 
38 DR Male 1 25.35 
_ _ 
No None 
39 DR Male 1 25.38 
_ _ 
No None 
40 DR Male 1 25.38 
_ _ 
No Prolapse 
41 AL Female 1 31.82 
_ _ 
Yes Tumour on kidney 
42 AL Female 1 31.82 
_ _ 
No Cyst on ovary 
43 AL Female 1 31.82 
_ _ 
Yes Tumour on liver and lung 
44 AL Female 1 31.82 
_ _ 
No Cyst on ovary and enlarged spleen 
45 AL Female 1 31.82 
_ _ 
Yes Tumour on liver and lung 
46 AL Male 1 32.05 
_ _ 
Yes Tumour on lung and enlarged seminal vesicles 
47 AL Male 1 32.05 
_ _ 
No Enlarged seminal vesicles 
48 AL Male 1 32.05 
_ _ 
Yes Tumour on spleen and lung 
49 AL Male 1 32.05 
_ _ 
Yes Tumour on spleen 
50 AL Male 1 32.05 
_ _ 
Yes Tumour on liver and lung 
51 DR Female 1 32.08 
_ _ 
Yes Tumour on spleen and cysts on ovary 
52 DR Female 1 32.08 
_ _ 
No Cysts on ovary 
53 DR Female 1 32.08 
_ _ 
Yes Tumour on lung 
54 DR Female 1 32.08 
_ _ 
Yes Tumour on lung and fibrotic liver 
55 DR Female 1 32.08 
_ _ 
No None 
56 DR Male 1 32.22 
_ _ 
Yes Tumour on spleen, kidney and lung 
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57 DR Male 1 32.22 
_ _ 
Yes Tumour on pancreas 
58 DR Male 1 32.22 
_ _ 
No None 
59 DR Male 1 32.22 
_ _ 
No None 
60 DR Male 1 32.22 
_ _ 
No None 
 
Table 6.3. Details of mice samples for which bone marrow was derived. (*:An error occurred for samples 12 and 17 in MitoTracker Green staining 
hence why there are two less mice for the bone marrow 2 month AL group for mitochondrial mass analysis)  
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
Table 6.4. Summary of mice samples (*: An error occurred for samples  9, 12 and 17 in MitoTracker Green staining hence why there is one less 
mouse for the 25 month DR peripheral blood group and two less mice for the 2 month AL bone marrow group for mitochondrial mass analysis) 
 
 Peripheral blood Bone marrow 
Age group 25 Months 2 Months 25 Months 32 Months 
Diet AL DR AL AL DR AL DR 
Total, n 5 6* 6* 12 11 10 10 
Male, n (%) 5 (100) 3 (50) 3 (50) 6 (50) 5 (45) 5 (50) 5 (50) 
Tumour present, n (%) 3 (60) 2 (33) 0 (0) 6 (50) 2 (18.18) 7 (70) 5 (50) 
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Figure 6.1. Comparison of mouse peripheral blood and bone marrow flow 
cytometry graphs for quantifying A. superoxide levels,  B. mitochondrial mass and 
C. mitochondrial membrane potential. Representative samples of AL mice aged 25 
months are shown. 
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A. Peripheral blood 
Normality test 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
 Statistic n p Statistic n p 
Superoxide levels (AU)       
PBMCs  0.19 11 0.20* 
# 
 0.91 11 0.27 
Lymphocytes 
 
 0.27 11 0.03  0.80 11 0.01 
Monocytes 
 
 0.20 11 0.20* 
#
 0.91 11 0.22 
Mitochondrial mass (AU)       
PBMCs 0.20 10 0.20* 
#
 0.83 10 0.03 
Lymphocytes 0.20 10 0.20* 
#
 0.94 10 0.58 
Monocytes 0.22 10 0.20* 
#
 0.82 10 0.03 
Mitochondrial membrane potential (AU)       
PBMCs 0.24 11 0.09 
#
 0.94 11 0.47 
Lymphocytes 0.17 11 0.20* 
#
 0.94 11 0.49 
Monocytes 0.17 11 0.20* 
#
 0.91 11 0.26 
Lymphocyte/monocyte ratio 0.19 11 0.20* 
#
 0.94 11 0.56 
 
 
B. Bone marrow 
Normality test 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
 Statistic n p Statistic n p 
Superoxide levels (AU)       
All bone marrow 0.14 49 0.02 0.93 49 0.01 
Lymphoid cells 0.12 49   0.10 
#
 0.96 49 0.07 
Myeloid cells 0.16 49 0.00 0.92 49 0.00 
Mitochondrial mass (AU)       
All bone marrow 0.17 47 0.00 0.89 47 0.00 
Lymphoid cells 0.18 47 0.00 0.88 47 0.00 
Myeloid cells 0.14 47 0.03 0.91 47 0.00 
Mitochondrial membrane potential (AU)       
All bone marrow 0.12 49 0.08 
#
 0.88 49 0.00 
Lymphoid cells 0.11 49 0.15 
#
 0.94 49 0.01 
Myeloid cells 0.07 49 0.20* 0.99 49 0.90 
Lymphoid/myeloid ratio 0.90 49  0.20* 
#
 0.97 49 0.24 
 
Table 6.5. Normality tests of superoxide levels, mitochondrial mass, mitochondrial 
membrane potential and lymphoid/myeloid derived cell ratio in A. peripheral 
blood and B. bone marrow of mice. All mice sample were included in this analysis.  
(
a
: Lilliefors Significance Correction, *: Lower bound of the true significance,                  
#
: Histograms were positively skewed and therefore analysed as having a non-normal 
distribution using non-parametric statistical tests) 
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Figure 6.2. Comparison of superoxide levels, mitochondrial mass, mitochondrial 
membrane potential and lymphoid/myeloid derived cell ratio in peripheral blood 
and bone marrow of mice. AL mice aged 25 months were included in this analysis: 
peripheral blood (n=5) and bone marrow (n=12). Mann-Whitney U Test was used to test 
differences between medians. 
 
p<0.01 
p<0.01 
p<0.01 
p=0.83 p=0.02 p=0.01 
p=0.92 
p=0.01 
p=0.34 
p=0.05 
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6.3.2. Agreements between superoxide levels, mitochondrial mass, mitochondrial 
membrane potential in lymphoid and myeloid derived cell subpopulations of 
mice 
 
Superoxide levels and mitochondrial mass were significantly higher in myeloid derived 
cells compared to lymphoid derived cells in both peripheral blood and bone marrow of 
mice (p≤0.01) (Figure 6.3. A. and B. respectively). There was no significant difference 
in mitochondrial membrane potential in myeloid derived cells compared to lymphoid 
derived cells of peripheral blood (p=0.66), however mitochondrial membrane potential 
was significantly lower in myeloid derived cells compared to lymphoid derived cells of 
bone marrow (p<0.01) (Figure 6.3. A. and B. respectively). There was a significant 
positive correlation between lymphoid and myeloid derived cells for superoxide levels 
in both peripheral blood and bone marrow cells, and mitochondrial mass and membrane 
potential in bone marrow cells only (r≥0.63, p≤0.01) (Figure 6.3. A. and B. 
respectively). There was a trend for a positive correlation between lymphoid and 
myeloid derived cells for mitochondrial mass and mitochondrial membrane potential in 
peripheral blood but this did not reach statistical significance (r≥0.27, p≥0.20) (Figure 
6.3. A.) 
 
6.3.3. Associations between ROS production, mitochondrial function and 
lymphoid/myeloid derived cell ratio in peripheral blood and bone marrow cells  
of mice 
 
There was no significant association between superoxide levels and mitochondrial mass 
in lymphocytes and monocytes of peripheral blood in 25 month old mice (r≥0.19, 
p≥0.28), however there was a negative association between superoxide levels and 
mitochondrial membrane potential which did not quite reach significance in 
lymphocytes (r=-0.57, p=0.07) however was significant in monocytes (r=-0.62, p=0.04) 
(Figure 6.4. A.). There was no significant association between mitochondrial mass and 
mitochondrial membrane potential in lymphocytes or monocytes of peripheral blood in 
25 month old mice (r=-0.21, p=0.56) (Figure 6.4. A.).  
 
There was no significant association between superoxide levels and mitochondrial mass 
or mitochondrial membrane potential in lymphoid or myeloid cells of bone marrow in  
25 month old mice (p≥0.06) (Figure 6.4. B.).   
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  A.   
          
            
r=0.42 
p=0.20 
p<0.01 
r=0.91 
p<0.01 
p=0.01 
r=0.27 
p=0.45 
p=0.66 
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Figure 6.3. Comparing superoxide levels, mitochondrial mass and mitochondrial membrane potential in A. peripheral blood and B. bone 
marrow lymphoid and myeloid derived cell subpopulations of mice. All mice sample were included in this analysis (see table 6.3.).Wilcoxon 
Signed-Rank Test was used to test differences between medians and Spearman’s correlation coefficient was used to test the strength of associations 
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Figure 6.4. The association between superoxide levels,  mitochondrial mass and mitochondrial membrane potential in A. peripheral blood and 
B. bone marrow of mice. i. Lymphoid-derived cells and ii. myeloid derived cells. All mice sample were included in this analysis (see table 6.3.). 
Spearman’s correlation coefficient was used to test the strength of associations. (Black dots: AL, White dots: DR) 
                      i.                                                                                           ii. 
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However, in bone marrow of 32 month old mice, there was a significant positive 
association between superoxide levels and mitochondrial mass in both lymphoid and 
myeloid cells (r≥0.54, p≤0.02), no significant association between superoxide levels and 
mitochondrial membrane potential in both lymphoid or myeloid cells (r≤-0.34, p≥0.14), 
no significant association between  mitochondrial  mass and membrane potential in 
lymphoid cells (r=-0.05, p=0.83) however this was negatively significant in myeloid 
cells at 32 years of age (r=-0.50, p=0.03) (Figure 6.4. B.).                                                                                                              
  
There was a significant negative association between superoxide levels and 
lymphoid/myeloid derived cell ratio in both peripheral blood and bone marrow at 25 
and 32 months of age (r≥-0.53, p≤0.02) (Figure 6.5. A. and B. respectively). There was 
also a trend for a negative association between mitochondrial mass and 
lymphoid/myeloid derived cell ratio which was significant in peripheral blood (r=-0.72, 
p=0.01) however was not significant in bone marrow at 25 or 32 months of age (r=≤-
0.34, p≥0.14) (Figure 6.5. A. and B. respectively). There was no association between 
mitochondrial membrane potential and lymphoid/myeloid derived cell ratio in 
peripheral blood and bone marrow at 25 months of age (r≤0.49, p≥0.12) however there 
was a significant positive association at 32 months of age in bone marrow cells (r=0.50, 
p=0.03) (Figure 6.5. A. and B. respectively).   
 
6.3.4. Association between superoxide levels, mitochondrial mass, mitochondrial 
membrane potential and lymphoid/myeloid derived cell ratio and potential 
confounders of mice 
 
There was no consistent associations between superoxide levels and gender by diet and 
age group however mitochondrial mass and mitochondrial membrane potential in bone 
marrow were significantly higher in female AL mice at 32 months of age compared to 
males in all subpopulations (p≤0.02), except mitochondrial membrane potential in 
lymphoid cells (p=0.05) (Table 6.6 A. B. and C. respectively). There was no significant 
association between lymphoid/myeloid ratio and gender (Table 6.6. D.). There was no 
significant association between superoxide levels, mitochondrial mass, mitochondrial 
membrane potential or lymphoid/myeloid ratio and tumour incidence (Table 6.7.). 
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Figure 6.5. The association between superoxide levels, mitochondrial mass, and mitochondrial membrane potential and lymphoid/myeloid 
ratio in A. peripheral blood and B. bone marrow of mice. Data for combined supopulations is shown. All mice sample were included in this 
analysis (see table 6.3.). Spearman’s correlation coefficient was used to test the strength of associations. (Black dots: AL, White dots: DR) 
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A. Superoxide levels (AU) 
Age Diet Gender 
All bone marrow Lymphoid cells Myeloid cells 
n Median IQR p n Median IQR p n Median IQR p 
2 Months AL 
Female
 
3 90.61 
_
 
0.51 
3 55.85 
_
 
0.51 
3 115.09 
_
 
0.51 
Male 3 103.94 
_
 3 61.42 
_
 3 146.37 
_
 
25 Months 
AL 
Female
 
6 147.70 81.75 
0.52 
6 92.89 27.33 
0.34 
6 201.24 105.44 
0.34 
Male 6 125.69 57.90 6 84.95 19.98 6 163.72 84.04 
DR 
Female
 
6 96.57 23.26 
0.10 
6 63.66 6.48 
0.01 
6 138.84 27.86 
0.36 
Male 5 132.77 43.75 5 100.74 34.81 5 155.47 56.40 
32 Months 
AL 
Female
 
5 143.30 61.48 
0.08 
5 84.52 51.64 
0.12 
5 178.22 59.85 
0.08 
Male 5 121.96 20.19 5 74.96 22.60 5 145.96 17.67 
DR 
Female
 
5 178.22 59.85 
0.25 
5 71.60 27.83 
0.35 
5 126.22 60.64 
0.75 
Male 5 145.96 17.67 5 74.64 18.20 5 144.31 24.73 
B. Mitochondrial mass (AU) 
Age Diet Gender 
All bone marrow Lymphoid cells Myeloid cells 
n Median IQR p n Median IQR p n Median IQR p 
2 Months AL 
Female
 
2 32.84 
_
 
1.00 
2 25.28 
_
 
1.00 
2 37.96 
_
 
1.00 
Male 2 32.83 
_
 2 27.08 
_
 2 37.12 
_
 
25 Months 
AL 
Female
 
6 21.56 7.11 
0.11 
6 14.78 5.55 
0.05 
6 26.20 8.38 
0.05 
Male 6 25.71 7.49 6 17.87 4.04 6 30.27 9.56 
DR 
Female
 
6 21.45 6.88 
0.07 
6 15.67 6.08 
0.10 
6 26.41 5.80 
0.07 
Male 5 25.21 2.70 5 17.59 2.87 5 30.51 4.34 
32 Months 
AL 
Female
 
5 43.60 11.43 
0.01 
5 32.69 10.90 
0.01 
5 51.01 12.63 
0.01 
Male 5 28.96 7.49 5 20.48 7.74 5 32.62 8.13 
DR 
Female
 
5 20.22 4.37 
0.35 
5 14.69 4.24 
0.17 
5 23.46 6.51 
0.46 
Male 5 23.13 7.84 5 18.40 10.02 5 21.75 7.02 
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C. Mitochondrial membrane potential (AU) 
Age Diet Gender 
All bone marrow Lymphoid cells Myeloid cells 
n Median IQR p n Median IQR p n Median IQR p 
2 Months AL 
Female
 
3 2.63 
_
 
0.05 
3 3.47 
_
 
0.28 
3 2.42 
_
 
0.05 
Male 3 2.94 
_
 3 3.20 
_
 3 2.86 
_
 
25 Months 
AL 
Female
 
6 2.62 0.97 
0.63 
6 3.38 1.59 
0.42 
6 2.25 1.25 
0.52 
Male 6 2.75 0.79 6 3.16 1.05 6 2.65 0.73 
DR 
Female
 
6 2.36 0.88 
0.14 
6 3.23 1.37 
0.58 
6 2.18 0.81 
0.10 
Male 5 2.89 0.15 5 3.72 0.56 5 2.71 0.13 
32 Months 
AL 
Female
 
5 2.95 0.56 
0.02 
5 4.29 0.92 
0.05 
5 2.83 0.49 
0.01 
Male 5 2.47 0.30 5 3.62 0.74 5 2.40 0.29 
DR 
Female
 
5 2.83 0.49 
0.47 
5 5.03 1.12 
0.92 
5 3.03 0.37 
0.92 
Male 5 2.40 0.29 5 4.94 1.74 5 3.31 0.65 
D. Lymphoid/myeloid cell ratio Table 6.6. Association between  
A. superoxide levels , B. mitochondrial 
mass, C. mitochondrial membrane  
potential, D. lymphoid/myeloid cell ratio  
and gender by age and diet in all bone  
marrow and cell subpopulations of mice.   
Mann-Whitney U Test was used to test 
differences between medians. 
Age Diet Gender 
All bone marrow 
n Median IQR p 
2 Months 
AL Female
 
3 0.80 
_
 
0.28 
 Male 3 1.23 
_
 
25 Months 
AL Female
 
6 0.97 0.60 
0.57 
 Male 6 0.88 0.20 
DR Female
 
6 1.20 0.44 
0.36 
 Male 5 1.03 0.23 
32 Months 
AL Female
 
5 0.74 0.17 
0.21 
 Male 5 0.64 0.18 
DR Female
 
5 1.27 0.48 
0.05 
 Male 5 1.03 0.36 
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A. Superoxide levels (AU) 
Age Diet Tumour 
All bone marrow Lymphoid cells Myeloid cells 
n Median IQR p n Median IQR p n Median IQR p 
2 Months AL 
No
 
6 103.4 
_
 
_
 
6 59.76 
_
 
_
 
6 135.94 
_
 
_
 
Yes 0 
_
 
_
 0 
_
 
_
 0 
_
 
_
 
25 Months 
AL 
No
 
6 125.69 42.87 
0.42 
6 84.95 10.50 
0.34 
6 163.72 83.42 
0.52 
Yes 6 159.27 84.24 6 100.10 31.46 6 200.59 106.39 
DR 
No
 
9 100.07 36.72 
0.64 
9 65.84 29.90 
0.48 
9 140.32 40.41 
0.48 
Yes 2 115.98 
_
 2 83.90 
_
 2 147.56 
_
 
32 Months 
AL 
No
 
3 134.84 
_
 
0.91 
3 83.14 
_
 
0.91 
3 156.94 . 
0.91 
Yes 7 124.48 58.29 7 82.85 53.40 7 146.23 59.29 
DR 
No
 
5 117.61 20.50 
0.46 
5 74.90 22.87 
0.35 
5 144.49 25.17 
0.35 
Yes 5 101.61 39.95 5 71.60 23.03 5 126.22 60.10 
B. Mitochondrial mass (AU) 
Age Diet Tumour 
All bone marrow Lymphoid cells Myeloid cells 
n Median IQR p n Median IQR p n Median IQR p 
2 Months AL 
No
 
4 32.84 8.52 
_
 
c 25.28 8.48 
_
 
4 37.12 7.69 
_
 
Yes 0 
_
 
_
 0 
_
 
_
 0 
_
 
_
 
25 Months 
AL 
No
 
6 21.66 9.06 
0.42 
6 16.18 4.79 
0.87 
6 26.70 11.33 
0.87 
Yes 6 23.51 5.49 6 16.98 5.71 6 26.71 7.27 
DR 
No
 
9 23.10 4.41 
0.48 
9 17.19 2.52 
1.00 
9 27.90 5.21 
0.35 
Yes 2 20.39 
_
 2 15.77 
_
 2 23.73 
_
 
32 Months 
AL 
No
 
3 28.96 
_
 
0.57 
3 20.48 
_
 
0.73 
c 20.48 
_
 
0.73 
Yes 7 38.49 9.80 7 26.63 8.45 7 26.63 8.45 
DR 
No
 
5 23.98 6.21 
0.08 
5 18.14 9.56 
0.12 
5 22.70 7.47 
0.46 
Yes 5 20.22 5.57 5 14.69 4.83 5 23.46 6.54 
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C. Mitochondrial membrane potential (AU) 
Age Diet Tumour 
All bone marrow Lymphoid cells Myeloid cells 
n Median IQR p n Median IQR p n Median IQR p 
2 Months AL 
No
 
6 2.89 0.42 _ 6 3.37 0.48 _ 6 2.67 0.61 _ 
Yes 0 
_
 
_
  0 
_
 
_
  0 
_
 
_
  
25 Months 
AL 
No
 
6 2.75 0.93 
0.75 
6 3.23 0.42 
0.52 
6 2.65 0.98 
0.75 
Yes 6 2.62 0.84 6 3.68 2.32 6 2.32 1.01 
DR 
No
 
9 2.85 0.76 
0.34 
9 3.72 1.11 
0.64 
9 2.58 0.73 
0.35 
Yes 2 2.97 
_
 2 3.40 
_
 2 2.89 
_
 
32 Months 
AL 
No
 
3 2.91 
_
 
0.73 
3 3.81 
_
 
0.73 
3 2.25 
_
 
0.14 
Yes 7 2.76 0.75 7 3.69 1.19 7 2.68 0.52 
DR 
No
 
5 3.49 1.47 
0.75 
5 5.32 1.01 
0.35 
5 3.00 0.32 
0.05 
Yes 5 3.42 0.51 5 4.64 1.55 5 3.31 0.43 
D. Lymphoid / Myeloid cell ratio Table 6.7. Association between A. 
superoxide levels, B. mitochondrial mass, 
C. mitochondrial membrane potential, D. 
lymphoid/myeloid cells ratio and tumour 
presence by age and diet in bone marrow 
of mice.   Mann-Whitney U Test was used to 
test differences between medians. 
Age Diet Tumour 
All bone marrow 
n Median IQR p 
2 Months 
AL No
 
6 0.94 0.54 _
 
 Yes 0 
_
 
_
 
25 Months 
AL No
 
6 0.88 0.24 
0.81 
 Yes 6 0.97 0.48 
DR 
No
 
9 1.04 0.30 
0.91 
Yes 2 1.16 
_
 
32 Months 
AL No
 
3 0.70 
_
 
0.82 
 Yes 7 0.72 0.22 
DR No
 
5 1.16 0.35 
0.75 
 Yes 5 1.05 0.67 
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6.3.5. Effect of dietary restriction on ROS production and mitochondrial function in 
peripheral blood and bone marrow cells 
 
There was a tendency for superoxide levels and mitochondrial mass to be decreased and 
mitochondrial membrane potential to be increased in 25 month old DR mice compared 
to AL controls in all subpopulations of peripheral blood; however, none reached 
statistical significance (p≥0.07) (Figure 6.6 A. i. B. i. and C. i. respectively).  
 
There was an increase in superoxide levels with age in bone marrow cells (significant in 
combined bone marrow and lymphoid cells (p≤0.04) however not in myeloid cells 
(p≥0.09)), which was reduced at both 25 and 32 months of dietary restriction 
(significant in all cell subpopulations of bone marrow compared to AL controls 
(p≤0.04) with the exception of lymphoid cells at 32 month of dietary restriction 
(p=0.13) (Figure 6.6. A. ii.). Although there was a trend for an increase in superoxide 
levels with age in bone marrow cells in both male and females, the significance was 
removed which could be due to a reduced sample size (Figure 6.6. A. ii.).  The 
reduction of superoxide levels by dietary restriction was only significant in females and 
not in males (Figure 6.6. A. ii.).  
 
Mitochondrial mass had a non-linear association with age where at 2 month and 32 
months of age it was higher than the 25 month old mice in all bone marrow 
subpopulations (p≤0.02) (Figure 6.6. B. ii.). There was no effect of dietary restriction on 
mitochondrial mass at 25 months of age in all bone marrow subpopulations (p≥0.67); 
however, the high mitochondrial mass at 32 months of age was significantly reduced by 
dietary restriction in all bone marrow subpopulations (p≤0.01) (Figure 6.6. B. ii.). This 
again was more pronounced in females than in males (Figure 6.6. B. ii.).  
 
There was no significant association between mitochondrial membrane potential and 
age in all bone marrow subpopulations (p≥0.07) (Figure 6.6. C. ii.). There was no effect 
of dietary restriction on mitochondrial membrane potential at 25 months of age in all 
bone marrow subpopulation (p≥0.74);  however, at 32 months of age, mitochondrial 
membrane potential was significantly increased by dietary restriction in all bone 
marrow subpopulations (p<0.01) (Figure 6.6. C. ii.). Interestingly, mitochondrial 
membrane potential significantly decreased with age  and was increased by dietary 
restriction at 32 months of age in male mice only (Figure 6.6. C. ii.).
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Figure 6.6. The effects of chronological age and dietary restriction on  
A. superoxide levels, B. mitochondrial mass and C. mitochondrial membrane 
potential in i. peripheral blood and ii. bone marrow of mice. All mice sample were 
included in this analysis (see table 6.3.).  Mann-Whitney U Test was used to test 
differences between the medians of two groups.  
 
 
6.3.6. Effect of dietary restriction on lymphoid/myeloid derived cell ratio 
 
Lymphocyte/monocyte ratio in peripheral blood was significantly increased by dietary 
restriction in 25 month old mice (p=0.02) (Figure 6.7. A.). 
 
There was a decline in lymphoid/myeloid ratio in bone marrow of mice between 25 and 
32 months of age (p=0.01) which was significantly increased by dietary restriction at 
both 25 and 32 month of age (p=0.03) (Figure 6.7. B.). The decline in 
lymphoid/myeloid ratio with age was only significant in males; however, there was the 
same trend for an increase in lymphoid/myeloid ratio by dietary restriction for both 
males and females, however  this only reach significance at 32 month of age (Figure 
6.7. B.). 
 
6.4. Discussion 
 
The first analysis of this study was to compare basal levels of superoxide levels, 
mitochondrial mass and mitochondrial membrane potential between peripheral blood 
and bone marrow cells of mice. This was because the future analysis of the mice model 
study, due to difficulties in obtaining enough peripheral blood, would be in bone 
marrow cells however this study should be comparable to the same tissue used in the 
human work, which used peripheral blood. Comparisons between these two tissues in 
terms of ROS production and mitochondrial function, to knowledge, has never been 
investigated. It was shown that superoxide levels were higher in bone marrow cells than 
in peripheral blood cells however mitochondrial mass was lower, consistent between 
lymphoid and myeloid derived cells. There were inconsistencies between mitochondrial 
membrane potential in cell subpopulations, where there was no difference between 
peripheral blood and bone marrow in lymphoid derived cells however this was higher in 
peripheral blood cells compared to bone marrow cells in myeloid derived cells. This 
therefore goes against the theory that an increase in mitochondrial mass and decreased 
membrane potential is associated with higher ROS production. However, this
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Figure 6.7. The effects of chronological age and dietary restriction on the 
lymphoid/myeloid derived cell ratio in A. peripheral blood and B. bone marrow of 
mice.  i. Representative flow cytometry graphs for quantification of lymphoid and 
myeloid derived cell counts, ii. Percentages of lymphoid and myeloid derived cells in 
individual samples and iii. median comparisons.  All mice sample were included in this 
analysis (see table 6.3.).  Mann-Whitney U Test was used to test differences between 
the medians of two groups. 
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association may only be seen when cells are dysfunctional (i.e. as seen in senescent 
cells) and thus a decrease in mitochondrial mass at least could indicate that the 
mitochondria are less likely to be dysfunctional within these mice cells at 25 months of 
age. This could be due to effective antioxidant and/or repair mechanisms to remove to 
prevent mitochondrial damage by ROS. This conclusion will be important in the future 
findings of this study as discussed below. However, a weakness of this experiment, 
although mice were matched by age and diet group, is that peripheral blood and bone 
marrow cells were only compared in separate mice groups of peripheral blood and bone 
marrow. A better experiment would be to investigate differences within the same mice. 
This would then tell us that superoxide levels, mitochondrial mass and mitochondrial 
membrane potential are correlated between different tissues within the same mice, and 
thus could be tissue independent. This has important relevance of using peripheral blood 
as a surrogate tissue for other inaccessible tissues.  A future experiment could also be to 
investigate further tissues to determine their agreements in ROS production and 
mitochondrial function. Despite the differences between peripheral blood and bone 
marrow cells, it was shown that within the same mice there are agreements between 
superoxide levels, mitochondrial mass and mitochondrial membrane potential in 
lymphoid derived and myeloid derived cells, as seen in the human samples (See Chapter 
4. Figure.  4.11.) and therefore provides evidence that they are not cell type dependent; 
whether they are tissue dependent however is in need of further investigation.  
 
The next part of this study was to determine the relationship between ROS production 
and mitochondrial function.  There was no association between superoxide levels and 
mitochondrial mass in peripheral blood of 25 month old mice. Again in bone marrow of 
the 25 month old mice there was no association between superoxide and mitochondrial 
mass or mitochondrial membrane potential; however, at 32 month of age, a positive 
association between superoxide levels and mitochondrial mass, and a tendency for a 
negative association between superoxide levels and mitochondrial membrane potential 
is revealed. It is therefore hypothesised that the cells of the 32 month old mice are more 
likely to be dysfunctional than at 25 month of age, which could reflect the presence of 
more senescent cells. It was also revealed that increased ROS production, a trend for 
increased mitochondrial mass and a decline in mitochondrial membrane potential (at 32 
months only in bone marrow) was associated with a decline in lymphoid/myeloid 
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derived cell ratio suggesting a role for mitochondrial ROS production and dysfunction 
in the decline of hematopoiesis and thus immune function.  
 
This study then aimed to determine the effect of age and dietary restriction on ROS 
production and mitochondrial dysfunction, with the expectation that superoxide levels 
and mitochondrial mass should be reduced and mitochondrial membrane potential 
should be increased by dietary restriction.  It was shown that superoxide levels increase 
with age however mitochondrial mass displayed a non-linear association with age. The 
reason mitochondrial mass is not increased at 25 months could support the above 
hypothesis that the majority of leukocytes at this age do not have dysfunctional 
mitochondria, and have efficient mechanisms such as antioxidant defenses and/or repair 
mechanisms to prevent damage to the mitochondria by the increased superoxide levels. 
At 32 months however, cells become more susceptible to damage by increasing 
superoxide production with age and thus mitochondria become more dysfunctional, 
indicated by an increase in mass. Interestingly, this was only the case in females; 
mitochondrial mass did not significantly change up to 32 month of age in males. It is 
therefore further hypothesized that the cells of males have less dysfunctional 
mitochondria/less senescent cells than females at 32 months of age and thus ageing 
occurs at a faster rate in females than in males. To support this, studies have reported 
that male mice actually have a longer life expectancy than females in the C57BL/6 
strain and this has been attributed to a decrease in  oxidative stress (Kunstyr and 
Leuenberger, 1975; Ali et al., 2006). However, the study by Ali et al. in 2006 suggested 
that non-mitochondrial ROS are responsible for lifespan differences between males and 
females. This study however, although did not find differences in superoxide levels 
between males and females, mitochondrial mass and membrane potential were higher in 
females than males at 32 months of age suggesting a role of the mitochondria in the 
gender differences in lifespan in mice. To further validate ROS production and 
mitochondrial function as a BoA, it was confirmed that superoxide levels were 
decreased by dietary restriction at 25 and 32 months of age, and interestingly, 
mitochondrial function was only improved at 32 months of age, when it is hypothesised 
that cells are more dysfunctional and thus senescent. The effect of dietary restriction, in 
terms of reduction in superoxide levels and mitochondrial mass, was more prominent in 
females than in males. To support this, studies have shown that life extension by dietary 
restriction is more prominent in C57BL/6 females than in males (Cameron et al., 2012). 
However, in terms of increased mitochondrial membrane potential, dietary restriction 
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was more effective in males than in females at 32 month of age in this study. There are 
therefore obvious gender differences in the effects of dietary restriction on 
mitochondrial function.  
 
A further criteria of a BoA that is required to provide evidence of its construct validity 
is to  demonstrate that it can differentiate between groups with established differences in 
the rate of ageing and/or lifespan (Ingram et al., 2001). However although this is well 
documented in dietary restriction, this information was not known in this study and 
therefore it can not be concluded that the dietary restriction regime was affective in 
terms of life or health expansion. However, it was shown that the decline in the 
lymphocyte/myeloid ratio with age was improvement by dietary restriction reflecting an 
improved immune function. It could be interesting that monocytes have a higher ROS 
production than lymphocytes and become the majority of cells with age, since this could 
be associated with an increase in oxidative stress within leukocytes and therefore be 
associated with immune decline with ageing. 
 
6.5. Conclusion 
 
The overall aim of this chapter was to provide further evidence of the construct validity 
of leukocyte ROS production and mitochondrial function as a candidate BoA. Not only 
did this study provide evidence of their construct validity, by investigating a well 
known intervention known to increase life- and health-span, it also permitted their 
validity in leukocyte cells derived from different tissues, their association with 
chorological age and their validity in a functional aspect of ageing; the association with 
a biomarker of haematopoiesis and thus immune function. This is the first study, to 
knowledge, to report effect of dietary restriction on ROS production and mitochondrial 
function and also its effect on lymphoid/myeloid ratio in peripheral blood and bone 
marrow cells.  
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Chapter 7.  The predictive validity of potential 
oxidative stress-related BoA in the very old population 
 
 
7.1.  Abstract 
 
Background A major requirement of a candidate BoA is to show some evidence of 
predictive validity in terms of its association with various age-related outcomes and 
survival.   
 
Aims The final chapter of this study therefore aimed to determine whether PBMC ROS 
production and mitochondrial function and plasma F2-isoprostanes are associated with 
various age-related outcomes in the very old population.  
 
Methods The associations between PBMC superoxide levels, mitochondrial mass and 
mitochondrial membrane potential and plasma 8-iso Prostaglandin F2α with four age-
related outcomes: disability, cognitive impairment, disease only morbidity count and 
survival was investigated in the very old population.  
 
Results No significant associations between any of the four age-related outcomes were 
shown, even when adjustments were made for potential confounders.  
 
Conclusion This study does not provide evidence for the predictive validity of various 
oxidative stress-related BoA in the very old population.   
 
 
 
 
 
 
 
 
 
 
 
203 
 
7.2. Introduction 
 
A major requirement of a candidate BoA is that they are able to predict the years of 
remaining good health and the trajectory towards age-related outcomes and mortality 
better than chronological age (Sprott, 2010; Martin-Ruiz, 2013). Evidence should 
therefore at least show that the candidate BoA can distinguish between individuals with 
different levels of age-related decline.  
 
The final validation assessment of the potential oxidative-stress related BoA therefore 
aimed to provide evidence to support their predictive validity in terms of their 
association with various age-related outcomes and survival in the very old population.  
 
7.3. Results 
 
7.3.1. Descriptives 
 
Descriptives of the potential oxidative stress-related BoA, potential confounders and 
age-related outcomes of the very old from the Newcastle 85+ study are shown in 
Appendix C. Supplementary Table. 11., 12. and 14. respectively, stratified by all 
participants and also by participants with superoxide level, mitochondrial mass, 
mitochondria membrane potential and/or 8-iso Prostaglandin F2α measurements to 
determine the representativeness of the whole population compared to those participants 
with oxidative-stress related measures. A description of possible selection bias for 
potential confounders are discussed in Section 7.3.1.  Possible selection bias occurred 
for: 1) differences in disease only morbidity count which was lower in those with 
mitochondria mass and 8-iso Prostaglandin measures compared to the whole 
population; and 2) differences in those who have passed away, where a lower proportion 
of those who had passed away  were present in those with oxidative-stress related 
measures. An explanation for these differences is that they most likely reflect age-
related the changes in these variables. Cut-off values for grouped continuous potential 
oxidative stress-related BoA and age-related outcomes are shown in Appendix C. 
Supplementary Table 15 and Table 18 respectively. 
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7.3.2. Association with age-related outcomes in the very old population 
 
The first assessment was to determine the agreement between potential oxidative stress-
related BoA with continuous scores of disability, cognitive impairment and disease only 
morbidity. Three models of correlation analysis were investigated where data was either 
1) unadjusted (Table 7.1), 2) unadjusted with extreme outliers removed as a form of 
sensitivity analysis (Table 7.2),  or 3) adjusted for gender and season with extreme 
outliers removed (Table 7.3).  However, none of theses models provided evidence for 
the association between any of the four age-related outcomes in the very old population.  
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A. 
Model 1 
Age-related outcome 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 8-iso Prostaglandin F2α 
PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes Plasma 
Disability score 
r 0.00 0.01 0.04 -0.03 0.01 0.00 0.02 0.07 0.03 -0.05 
p 0.95 0.90 0.55 0.60 0.83 1.00 0.75 0.21 0.61 0.37 
n 247 247 247 339 339 339 345 345 345 377 
SMMSE score 
r 0.07 0.08 0.03 0.08 0.04 0.08 0.05 -0.08 -0.02 0.02 
p 0.25 0.19 0.67 0.13 0.42 0.16 0.37 0.12 0.77 0.68 
n 247 247 247 340 340 340 346 346 346 378 
Disease count 
r 0.08 0.08 0.06 0.04 0.07 -0.01 -0.03 -0.01 -0.03 -0.08 
p 0.20 0.25 0.32 0.46 0.22 0.90 0.55 0.90 0.63 0.15 
n 239 239 239 328 328 328 334 334 334 367 
 
 
B. 
Model 2 
Age-related outcome 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 8-iso Prostaglandin F2α 
PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes Plasma 
Disability score 
r 0.01 0.01 0.05 -0.03 0.01 -0.01 0.01 0.06 0.00 -0.05 
p 0.82 0.90 0.43 0.60 0.85 0.80 0.89 0.27 0.98 0.38 
n 244 245 245 339 335 337 341 344 338 357 
SMMSE score 
r 0.06 0.07 0.01 0.08 0.03 0.06 0.04 -0.09 -0.02 0.00 
p 0.33 0.28 0.90 0.13 0.61 0.30 0.45 0.08 0.70 0.95 
n 241 242 242 335 331 333 337 340 334 352 
Disease count 
r 0.10 0.08 0.07 0.04 0.06 -0.01 -0.04 -0.02 -0.04 -0.06 
p 0.11 0.19 0.29 0.46 0.24 0.91 0.48 0.77 0.51 0.24 
n 236 237 237 328 324 326 330 333 328 349 
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C. 
Model 3 
Age-related outcome 
Superoxide levels Mitochondrial mass Mitochondrial membrane potential 8-iso Prostaglandin F2α 
PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes PBMCs Lymphocytes Monocytes Plasma 
Disability score 
r 0.02 0.04 0.04 -0.07 0.00 -0.10 0.01 0.07 0.00 -0.07 
p 0.77 0.56 0.52 0.19 0.98 0.06 0.82 0.17 0.94 0.20 
n 240 241 241 335 331 333 337 340 334 353 
SMMSE score 
r 0.01 0.00 0.01 0.10 0.04 0.09 0.00 -0.07 -0.05 0.07 
p 0.85 1.00 0.89 0.07 0.43 0.12 0.97 0.23 0.32 0.19 
n 237 238 238 331 327 329 333 336 330 348 
Disease count 
r 0.11 0.08 0.07 0.03 0.10 0.00 -0.08 -0.02 -0.07 -0.06 
p 0.10 0.20 0.26 0.65 0.07 0.98 0.18 0.69 0.22 0.27 
n 232 233 233 324 320 322 326 329 324 345 
 
Table 7.1: Agreements between continuous potential oxidative-stress related BoA and age-related outcomes. A. Model 1: unadjusted data*,
 
B. 
Model 2: unadjusted data with extreme outliers removed*, and C. adjusted for gender and season with extreme outliers removed** (r: correlation 
coefficient (*Spearmans, **Partial), p: probability, n: number of participants). 
 
 
207 
 
 
Next the association between the potential oxidative stress-related BoA and grouped 
scores of disability, cognitive impairment and disease only morbidity was investigated 
by comparing median values. However again, there was no significant association 
shown for any of the age-related outcome (Figure 7.1.). Interestingly however, 8-iso 
Prostaglandin F2α seemed to show a U shaped relationship with disease only morbidity 
count however this did not quite reach significance (p=0.09). 
 
7.3.3. Association with survival in the very old population 
 
The final assessment was to determine whether the potential oxidative-stress related 
BoA were associated with survival. Cox regression analysis was employed using two 
models: 1) unadjusted data and 2) adjusted for gender and season.  No significant 
association were shown (Figure 7.2.). There was a tendency for those with a high or low 
mitochondrial membrane potential to have a reduced survival than those with medium 
mitochondrial membrane potential, however this did not quite reach significance before 
and after adjusting for confounders (p=0.06 and p=0.05 respectively). There was also a 
tendency for those with  high or medium 8-iso Prostaglandin F2α concentration to have 
an increased survival than those with low 8-iso Prostaglandin F2α concentration, 
however this was not significant before and after adjusting for confounders (p=0.13 and 
p=0.16 respectively). 
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p = 0.97  p = 0.10  p = 0.60  
p = 0.57  p = 0.27 p = 0.85  
A. 
B. 
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Figure 7.1.  Association between continuous potential oxidative-stress related BoA and grouped age-related outcome scores. A. superoxide 
levels, B. mitochondrial mass, C. mitochondrial membrane potential and D. 8-iso Prostaglandin F2α. Kruskal wallis was used to compare medians. 
Extreme outliers were removed from continuous data.  (Results for PBMCs are shown,  there was also no significant association in lymphocyte and 
monocyte separately, data not shown)
p = 0.98  p = 0.82  p = 0.69  
p = 0.09  p = 0.27  p = 0.58  
C. 
D. 
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Figure 7.2. Association between potential oxidative stress-related BoA and survival 
of the very old population. A. superoxide levels, B. mitochondrial mass, C. 
mitochondrial membrane potential and D 8-iso Prostaglandin F2α. Cox regression 
analysis (Model 1: unadjusted data,
 
Model 2: adjusted for gender and season). (Results 
for PBMCs are shown,  there was also no significant association in lymphocyte and 
monocyte separately, data not shown) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p = 0.16 
 Model 2 
p = 0.13 
 Model 1 
D. 8-iso Prostaglandin F2α 
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7.4. Discussion 
 
Attempts were made to further validate various oxidative stress-related BoA in terms of 
their association with various age-related outcomes in the very old population. 
However, no significant associations were found with cognitive impairment, disability 
score, disease count or survival, even after adjustment of potential confounders. 
However, since multi morbidity is common in the very old (Collerton et al., 2009), this 
study could be confounded by the presence of other age-related outcomes. A more 
general approach could be to investigate the association between potential BoA and a 
frailty score. A previous analysis in the Newcastle 85+ study identified the importance 
of inflammatory markers in frailty in the very old population (Collerton et al., 2012). 
However, limited evidence was found for the role of immunosenescence and no 
evidence for the role of telomere length, markers of oxidative damage or DNA damage 
and repair in frailty was found. Furthermore, a recent analysis in the same cohort found 
no association between frailty and mitochondrial DNA haplogroups (Collerton et al., 
2013). These are maternally inherited variations in mtDNA sequences for which the 
population can be divided into several groups based on specific nucleotide 
polymorphisms variants. It is thought that some variants of mitochondrial DNA 
haplogroups have functional differences including lower rates of ROS production and 
better capacity to cope with oxidative stress (Chen et al., 2012; Mueller et al., 2012) and 
several studies have shown associations with various age-related outcomes (van der 
Walt et al., 2004; Ghezzi et al., 2005; Kofler et al., 2009; Wolf et al., 2010). However 
there are inconsistencies regarding which variant is more susceptible to age-related 
outcomes. This study however found no association between mitochondria haplogroup 
and potential oxidative-stress related BoA in the very old, supporting the study by 
Collerton et al., 2013.  
 
Validating BoA within human studies can be extremely difficult due to variability in 
unknown intrinsic and extrinsic factors that influence candidate BoA, even in those of 
the same chronological age, as explained in Chapter 6. Section 6.2. It could be 
differences in genetic factors that could, for example, influence different rates in the 
metabolism of various nutrients or medications that influence candidate BoA. 
Therefore, although information on diet and medication could be captured by 
questionnaire and then controlled for in future analysis, this variability would mean 
controlling for these factors would be ineffective. Another genetic factor could be 
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differences in susceptibilities of tissues to oxidative damage between individuals. 
Therefore although, for example, superoxide levels could be identical between 
individuals, this could have different impacts in terms of tissue damage.  Environmental 
exposures could also vary between individuals that are not captured and thus controlled 
for by the study. An interesting environmental variable discovered to affect all potential 
oxidative-stress related BoA in this study was seasonal variation. This could be due to 
changes in sunlight exposure, temperature or other indirect effects of seasonal changes 
e.g. physical activity.  However, even after controlling for this variable, no associations 
with age-related outcomes were shown. The use of an animal model in chapter 6 was 
most probably more informative of PBMC ROS production and mitochondrial function 
as candidate BoA since the mice are in a tightly controlled environment and are 
genetically similar. Mice used in this study were all of the same genetic background (the 
C57BL/6 strain), were housed in identical cages, provided with the same bedding 
materials and housed at the same temperature under the same a 12 hour light/dark 
photoperiod. Of course genetic mutations and polymorphisms could still occur between 
these mice, which could be reflected in the different pathologies shown between mice of 
the same gender and age (See Chapter 6. Table 6.3), however the results of the animal 
model study provide evidence that intrinsic and extrinsic factors are likely to be 
eliminated since evidence for the construct validity of ROS production and 
mitochondrial function is shown. Unknown intrinsic and extrinsic factors are therefore 
possible reasons for the inconsistencies in the validation of BoA in human studies and 
where possible efforts should be made to identify theses factors. 
 
Another issue is that it is often thought it is unlikely that a single BoA that can be 
measured in a surrogate tissue exists because different biological systems age at 
different rates within the same individual, having varying susceptibility to cellular and 
molecular damage. This would explain why there is a great variability in the timing, 
type and number of age-related diseases or disorders amongst individuals. An individual 
is therefore likely to have a number of different functional ages for specific cells and/or 
tissues and therefore a number of BoA would be needed. A powerful approach could be 
to combine scores from a battery of biomarkers, reflecting each biological system, into a 
single biomarker of ageing (Hochschild, 1990). This however would still require an 
extensive collection of biomarker measurements from each system, many being 
impractical to measure, increasing cost and time. The ideal BoA would therefore be one 
that could be measured in different biological systems at the one time and not be 
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invasive or difficult to measure. If it was physically possible to track and measure 
initiators of cellular senescence, such as mitochondrial ROS production, or senescent 
cells them selves (i.e. p16 positive cells ((Baker et al., 2011)) as a BoA in each system, 
this would not only have the potential to understand mechanisms, predict timing and 
test interventions but would also allow the targeting of therapeutic interventions to 
specific cells/tissues. 
 
A limitation to this study in terms of cognitive impairment, disability score, disease 
count, is that analysis was cross-sectional and longitudinal analysis would be more 
informative. Further analysis of this cohort could therefore be to longitudinally 
investigate the role of ROS production and mitochondrial function in the development 
of frailty within the very old. 
 
7.5. Conclusion 
 
Further attempts to validate various potential oxidative stress-related BoA in terms of 
their association with disability, cognitive impairment, disease only morbidity count and 
survival in the very old population were unsuccessful. Since some evidence for their 
construct validity has been shown within this study it is suggested that further efforts 
could be made including; determining whether they are tissue independent, the 
identification of potential intrinsic and extrinsic confounding variables, the investigation 
of a more generalised frailty model and also longitudinal analysis.   
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Appendix  A: 
 
Literature search of candidate BoA and their ability to predictor age-related 
outcomes; specifically mortality, co-morbidity, disability and/or cognitive 
impairment. 
 
 
The electronic database MEDLINE via the database provider OvidSP was searched up 
to 2012 where a typical search for each candidate BoA would consist of: 
 
 
1. (“Candidate BoA” adj10 predict$ adj10 survival).mp.  
2. (“Candidate BoA” adj10 predict$ adj10 death).mp.  
3. (“Candidate BoA” adj10 predict$ adj10 mortality).mp.  
4. (“Candidate BoA” adj10 predict$ adj10 $morbid$).mp.  
5. (“Candidate BoA” adj10 predict$ adj10 disabil$).mp.  
6. (“Candidate BoA” adj10 predict$ adj10 cognit$).mp.  
7. 1 or 2 or 3 or 4 or 5 or 6  
8. limit 26 to (abstracts and humans) 
 
 
The following “Candidate BoA” with the appropriate words/truncations were searched: 
(n=number of articles returned)  
 
 
No Candidate BoA Search words/truncations n 
1 
Body mass index ((body adj mass) and index) 457 
2 
Waist to hip ratio waist adj to adj hip adj ratio 20 
3 
Fat percentage 
fat adj % 
78 
 fat adj percent$ 
4 
Fat free mass fat adj free adj mass 3 
5 
Total body water total adj body adj water 1 
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6 
Physical activity physical adj activity 107 
7 
Hand grip strength hand adj grip adj strength 10 
8 
Timed up and go timed up and go 5 
9 
Diastolic blood pressure 
diastolic adj blood adj pressure 
62 
 diastolic adj bp 
10 
Systolic blood pressure 
systolic adj blood adj pressure 
221 
 systolic adj bp 
11 
Forced expiratory volume 
forced adj expiratory adj volume 
130 
 fev 
12 
Forced vital capacity 
forced adj vital adj capacity 
78 
 fvc 
13 
Peak expiratory flow 
peak adj expiratory adj flow 
14 
 pef 
14 
Oxygen saturation oxygen adj saturation 31 
15 
Red blood cell 
red adj blood adj cell 
42 
 rbc 
16 
White blood cell 
white adj blood adj cell 
119 
 wbc 
17 
Lymphocyte lymphocyte 148 
18 
Monocyte monocyte 23 
19 
Neutrophil neutrophil 64 
20 
Basophil basophil 0 
21 
Eosinophil eosinophil 3 
22 
Haematocrit haematocrit 5 
23 
Haemoglobin haemoglobin 55 
24 
Mean cell haemoglobin mean adj cell adj haemoglobin 0 
25 
Mean corpuscular volume 
mean adj corpuscular adj volume 
3 
 mcv 
26 
Platelet platelet 160 
27 
Sodium sodium 96 
28 
Potassium potassium 18 
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29 
Urea urea 87 
30 
Urate urate 7 
31 
Creatinine creatinine 431 
32 
Total protein total adj protein 5 
33 
Bilirubin bilirubin 140 
34 
Alanin transaminase 
alanine adj transaminase 
23 
 alt 
35 
Albumin albumin 459 
36 
Calcium calcium 67 
37 
Adjusted calcium adjusted adj calcium 0 
38 
Phosphate phosphate 15 
39 
Alkaline phosphatase alkaline adj phosphatase 44 
40 
Glucose glucose 278 
41 
Glycosylated harmoglobin 
glycosylated adj haemoglobin 
29 
 HbA1c 
42 
Tryglcerides triglycerid$ 5 
43 
Cholesterol cholesterol 246 
44 
High density lipoprotein 
high adj density adj lipoprotein 
96 
 hdl 
45 
Low density lipoprotien 
low adj density adj lipoprotein 
51 
 ldl 
46 
Apolipoprotein A1 apolipoprotein adj A1 0 
47 
Apolipoprotein B apolipoprotein adj B 3 
48 
Cortisol cortisol 55 
49 
Free thyroxine 
free adj thyroxine 
1 
 free adj t4 
50 
Free triiodothyronine 
free adj triiodothyronine 
3 
 free adj t3 
51 
Thyroid stimulating hormone 
thyroid adj stimulating adj hormone 
7 
 tsh 
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52 
Thyroid peroxidase thyroid adj peroxidase 1 
53 
C reactive protein 
c adj reactive adj protein 
515 
 crp 
54 
Rheumatoid factor rheumatoid adj factor 12 
55 
Vitamin B2 vitamin adj b2 0 
56 
Vitamin B6 vitamin adj b6 0 
57 
Vitamin B12 vitamin adj b12 5 
58 
Vitamin D vitamin adj d 34 
59 
Ferittin ferritin 15 
60 
Red cell folate red adj cell adj folate 0 
61 
Homocysteine homocysteine 49 
62 
Brain natriuretic peptide 
brain adj natriuretic adj peptide 
335 
 bnp 
63 
Telomere length telomere adj length 22 
64 
DNA damage dna adj damage 9 
65 
DNA repair dna adj repair 18 
66 
Immunosenescence immunosenescence 4 
67 
Interleukin 6 
interleukin adj "6" 
194 
 il adj "6" 
68 
Tumour necrosis factor 
tumour adj necrosis adj factor 
45 
 tnf 
69 
Mitochondrial Function mitochondrial adj function 1 
70 
Reactive oxygen species reactive adj oxygen adj species 0 
71 
Oxidative stress oxidative adj stress 21 
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Appendix  B: 
 
Literature search of the effects of dietary restriction on potential oxidative 
stress and cellular senescence-related BoA in leukocytes. 
 
 
The electronic databases MEDLINE via the database provider OvidSP and also 
PubMeD was searched during July 2012 using the following search terms where a 
typical search for each potential oxidative stress and cellular senescence-related BoA 
would consist of: 
 
 
1. Calorie restriction 
2. Dietary restriction 
3. 1 or 2 
4. Peripheral blood 
5. White blood cells 
6. Lymphocytes 
7. Monocytes 
8. Bone marrow 
9. Lymphoid 
10. Myeloid 
11. Plasma* 
12. Serum* 
13. 4 or 5 or 6 or 7 or 8 or 9 or 10 
14. “Potential oxidative stress and cellular senescence-related BoA”  
15. 3 and 13 and 14 
16. limit 13 to abstract 
*Interleukin-6 and tumour necrosis factor-alpha only 
 
 
The following ‘Potential oxidative stress and cellular senescence-related BoA” with the 
appropriate words/truncations were searched, including the stages of identifying the 
included articles 
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ROS production and mitochondrial function 
Search words/truncations: Reactive oxygen species or ROS or Superoxide or 
Mitochondria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Telomere length 
Search words/truncations: Telomere length 
 
 
 
 
 
DNA damage  
Search words/truncations: DNA damage 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 studies were retrieved for more detailed evaluation 
 
15 potentially relevant studies were identified and screened for retrieval 
 
5 studies did not meet the inclusion criteria and excluded based whole paper   
 
8 studies were duplicates and excluded 
 
2 studies were included 
 
0 studies were identified 
 
9 studies were retrieved for more detailed evaluation 
 
21 potentially relevant studies were identified and screened for retrieval 
 
5 studies did not meet the inclusion criteria and excluded based whole paper   
 
12 studies were duplicates and 
excluded 
4 studies were included 
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DNA repair 
Search words/truncations: DNA repair 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interleukin-6  
Search words/truncations: IL 6 or IL-6 or Interleukin 6 or Interleukin-6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 studies were retrieved for more detailed evaluation 
 
13 potentially relevant studies were identified and screened for retrieval 
 
2 studies did not meet the inclusion criteria and excluded based whole paper   
 
9 studies were duplicates and excluded 
 
2 studies were included 
 
37 studies were retrieved for more detailed evaluation 
 
78 potentially relevant studies were identified and screened for retrieval 
 
23 studies did not meet the inclusion criteria and excluded based whole paper   
 
4 studies were duplicates and excluded 
 
14 studies were included 
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Tumour necrosis factor-alpha 
Search words/truncations: TNF or TNF-a or TNF alpha or TNF-alpha or Tumour 
necrosis factor a or Tumour necrosis factor-a or Tumour necrosis factor alpha or 
Tumour necrosis factor-alpha 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lymphoid / Myeloid ratio 
Search words/truncations: Ratio or Bias or Percentage or Proportion or Fraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 7 studies reported a change in lymphoid or lymphocytes but no measurements of myeloid or monocytes 
changes in DR 
 
 
 
22 studies were retrieved for more detailed evaluation 
 
59 potentially relevant studies were identified and screened for retrieval 
 
11 studies did not meet the inclusion criteria and excluded based whole paper   
 
37 studies were duplicates and 
excluded 
11 studies were included 
 
22 studies were retrieved for more detailed evaluation 
 
58 potentially relevant studies were identified and screened for retrieval 
 
24* studies did not meet the inclusion criteria and excluded based whole paper   
 
33 studies were duplicates and excluded 
 
1 study was included 
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Appendix C: 
 
 Supplementary data 
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Cell type Superoxide levels (AU) Mitochondrial mass (AU) Mitochondrial membrane potential (AU) 
PBMCs        
Control sample 1 2 3 1 2 3 1 2 3 
Repeat 1 40.15 48.51 68.32 45.34 51.13 76.66 3.37 3.19 3.76 
Repeat 2 43.22 51.08 68.47 50.52 58.37 80.02 3.46 3.28 4.07 
Repeat 3 50.32 51.1 61.69 48.46 51.64 82.70 2.73 3.22 3.66 
Mean 44.56 50.23 66.16 48.11 53.71 79.79 3.19 3.23 3.83 
SD 5.22 1.49 3.87 2.61 4.04 3.03 0.40 0.04 0.21 
% CV 11.71 2.97 5.85 5.42 7.52 3.79 12.40 1.38 5.50 
Average % CV 6.84 5.58 6.43 
Lymphocytes          
Control sample 1 2 3 1 2 3 1 2 3 
Repeat 1 34.07 36.23 58.9 56.94 89.71 107.29 9.27 8.03 9.61 
Repeat 2 36.76 39.6 62.48 56.19 81.48 106.93 7.72 8.78 10.08 
Repeat 3 35.76 44.47 57.78 52.95 84.84 105.38 6.61 8.59 9.23 
Mean 35.53 40.1 59.72 55.36 85.34 106.53 7.87 8.47 9.64 
SD 1.36 4.14 2.45 2.12 4.14 1.01 1.34 0.39 0.42 
% CV 3.83 10.33 4.11 3.83 4.85 0.95 16.99 4.57 4.38 
Average % CV 6.09 3.21 8.64 
Monocytes          
Control sample 1 2 3 1 2 3 1 2 3 
Repeat 1 109.36 115.77 139.61 94.51 148.89 181.64 1.87 1.67 2.53 
Repeat 2 128.43 125.02 142.22 102.56 134.07 228.07 2.02 2.41 2.85 
Repeat 3 124.41 126.32 138.75 85.05 159.70 212.50 2.19 2.03 2.30 
Mean 120.73 122.37 140.19 94.04 147.55 207.40 2.02 2.04 2.56 
SD 10.05 5.75 1.81 8.76 12.87 23.63 0.16 0.37 0.28 
% CV 8.33 4.70 1.29 9.32 8.72 11.39 7.77 18.16 10.75 
Average % CV 4.77 9.81 12.23 
 
Supplementary Table 1. (Raw data to complement Figure 4.1.) Intra-assay precision of superoxide levels, mitochondrial mass and 
mitochondrial membrane potential in PBMCs and cell subpopulations, lymphocytes and monocytes, by flow cytometry analysis.  
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Supplementary Table 2. (Raw data to complement Figure 4.2.) Inter-assay precision of superoxide levels, mitochondrial mass and 
mitochondrial membrane potential in PBMCs and cell subpopulations, lymphocytes and monocytes, by flow cytometry analysis.  
Cell type Superoxide levels (AU) Mitochondrial mass (AU) Mitochondrial membrane potential (AU) 
PBMCs        
Control sample 1 2 3 1 2 3 1 2 3 
Repeat 1 14.65 22.83 40.01 44.42 41.40 56.39 73.43 131.07 169.40 
Repeat 2 13.51 24.42 41.77 38.13 48.57 51.27 81.74 88.29 186.51 
Repeat 3 15.57 20.80 39.41 31.21 53.17 49.59 84.04 126.26 217.42 
Mean 14.58 22.68 40.40 37.92 47.71 52.42 79.74 115.21 191.11 
SD 1.03 1.81 1.23 6.61 5.93 3.54 5.58 23.43 24.34 
% CV 7.08 8.00 3.04 17.42 12.43 6.76 7.00 20.34 12.74 
Average % CV                6.04                 12.20                             22.45 
Lymphocytes          
Control sample 1 2 3 1 2 3 1 2 3 
Repeat 1 11.15 19.62 30.89 52.24 83.36 81.10 6.83 8.57 9.79 
Repeat 2 11.49 18.32 27.28 46.65 74.48 82.55 8.01 7.21 9.59 
Repeat 3 12.04 17.88 27.69 36.43 75.90 94.40 8.08 9.48 8.15 
Mean 11.56 18.61 28.62 45.11 77.91 86.02 7.64 8.42 9.18 
SD 0.45 0.90 1.98 8.02 4.77 7.30 0.70 1.14 0.89 
% CV 3.89 4.86 6.91 17.77 6.12 8.48 9.21 13.55 9.72 
Average % CV                5.22                10.79                             10.83 
Monocytes          
Control sample 1 2 3 1 2 3 1 2 3 
Repeat 1 35.45 65.56 94.21 73.43 131.07 169.40 1.58 1.21 2.35 
Repeat 2 29.46 70.34 94.18 81.74 88.29 186.51 2.12 2.35 2.34 
Repeat 3 33.84 72.07 104.59 84.04 126.26 217.42 1.72 2.40 2.40 
Mean 32.92 69.32 97.66 79.74 115.21 191.11 1.81 1.99 2.36 
SD 3.10 3.37 6.00 5.58 23.43 24.34 0.28 0.67 0.04 
% CV 9.42 4.86 6.15 7.00 20.34 12.74 15.69 33.82 1.57 
Average % CV                6.81                13.36                             17.02 
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Supplementary Table 3. (Raw data to complement Figure 4.3.) Intra-assay 
precision of 8-iso-prostaglandin F2α by AutoDELFIA analysis. 
 
 
  8-iso-prostaglandin F2α (ng/ml) 
Control sample 1 2 3 
Repeat 1 1.27 5.63 9.44 
Repeat 2 0.40 6.33 9.41 
Repeat 3 0.42 5.51 9.02 
Repeat 4 0.36 6.04 9.17 
Repeat 5 0.49 5.80 9.31 
Repeat 6 0.69 6.52 9.88 
Repeat 7 0.20 5.55 9.63 
Repeat 8 0.85 6.75 9.46 
Repeat 9 0.49 6.17 8.65 
Repeat 10 0.31 5.40 8.47 
Repeat 11 0.58 5.96 9.45 
Repeat 12 0.57 6.30 9.12 
Repeat 13 0.79 5.61 8.28 
Repeat 14 1.41 5.57 8.71 
Repeat 15 0.09 5.81 9.36 
Repeat 16 0.51 5.92 9.50 
Repeat 17 0.61 4.86 8.18 
Repeat 18 0.42 6.24 9.05 
Repeat 19 1.30 6.86 9.25 
Repeat 20 0.54 6.22 9.31 
Mean 0.62 5.95 9.13 
SD 0.36 0.49 0.46 
% CV 57.73 8.20 4.99 
Average % CV 23.64 
 
Supplementary Table 4. (Raw data to complement Figure 4.4.) Inter-assay 
precision of 8-iso-prostaglandin F2α by AutoDELFIA analysis.
 8-iso-prostaglandin F2α (ng/ml) 
Control sample 1 2 3 
Repeat 1 0.69 5.67 8.32 
Repeat 2 0.64 5.73 8.72 
Repeat 3 0.25 5.71 9.21 
Repeat 4 1.68 6.09 9.73 
Repeat 5 1.17 5.82 9.70 
Repeat 6 0.43 5.74 9.43 
Repeat 7 0.47 5.74 8.67 
Repeat 8 0.72 5.80 8.22 
Repeat 9 0.25 5.86 9.22 
Repeat 10 0.36 5.53 8.74 
Mean 0.67 5.77 9.00 
SD 0.45 0.14 0.54 
% CV 67.34 2.51 6.00 
Average % CV                        25.28 
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Cell type Superoxide levels (AU) Mitochondrial mass (AU) Mitochondrial membrane potential (AU) 
PBMCs                   
Contol subject 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 
Day 1 (Baseline) 33.43 52.82 49.76 63.00 56.70 49.75 37.01 40.45 40.33 32.24 32.09 45.59 5.34 3.53 3.09 2.64 3.20 3.70 
Day 7 49.32 58.24 53.98 58.98 59.31 48.21 32.90 41.42 42.69 36.42 32.20 44.22 9.43 6.63 7.98 5.50 4.56 4.57 
Mean 41.37 55.53 51.87 60.99 58.01 48.98 34.95 40.93 41.51 34.33 32.15 44.91 7.38 5.08 5.54 4.07 3.88 4.14 
SD 11.24 3.83 2.99 2.84 1.85 1.09 2.91 0.68 1.67 2.95 0.08 0.97 2.89 2.19 3.46 2.02 0.96 0.61 
% CV 27.17 6.90 5.76 4.66 3.18 2.22 8.32 1.67 4.02 8.60 0.24 2.16 39.20 43.20 62.47 49.68 24.73 14.87 
Average % CV 8.31 4.17 39.02 
Lymphocytes         
Contol subject 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 
Day 1 (Baseline) 31.01 44.35 40.52 48.41 51.56 43.89 35.31 37.53 35.84 30.60 30.06 44.43 6.57 4.49 5.33 4.62 3.99 4.70 
Day 7 39.64 51.42 46.62 45.47 50.42 40.96 28.14 39.57 36.95 33.57 30.10 42.26 10.31 6.88 8.62 6.90 5.09 4.96 
Mean 35.32 47.88 43.57 46.94 50.99 42.43 31.72 38.55 36.40 32.08 30.08 43.34 8.44 5.68 6.98 5.76 4.54 4.83 
SD 6.10 5.00 4.32 2.08 0.81 2.07 5.07 1.44 0.78 2.10 0.03 1.54 2.64 1.69 2.33 1.61 0.78 0.19 
% CV 17.27 10.45 9.91 4.42 1.59 4.88 15.97 3.74 2.16 6.56 0.09 3.55 31.32 29.74 33.35 28.03 17.21 3.88 
Average % CV 8.09 5.34 23.92 
Monocytes                   
Contol subject 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 
Day 1 (Baseline) 85.41 104.61 90.34 96.78 134.59 128.06 65.19 57.44 51.91 36.95 47.16 53.24 3.62 2.10 1.34 1.78 2.42 2.73 
Day 7 96.99 130.57 106.29 105.80 120.47 90.42 49.63 57.78 65.92 50.13 43.52 66.51 8.57 5.91 7.18 4.69 3.67 4.05 
Mean 91.20 117.59 98.31 101.29 127.53 109.24 57.41 57.61 58.91 43.54 45.34 59.87 6.09 4.01 4.26 3.23 3.04 3.39 
SD 8.18 18.36 11.28 6.38 9.98 26.62 11.00 0.24 9.91 9.32 2.57 9.39 3.50 2.70 4.13 2.06 0.88 0.93 
% CV 8.97 15.61 11.47 6.30 7.83 24.37 19.17 0.41 16.82 21.41 5.68 15.68 57.46 67.29 97.00 63.70 28.95 27.43 
Average % CV 12.42 13.19 56.97 
 
Supplementary Table 5. (Raw data to complement Figure 4.5.) Short-term day-day precision of superoxide levels, mitochondrial mass and 
mitochondrial membrane potential in PBMCs and cell subpopulations, lymphocytes and  monocytes, by flow cytometry analysis. (Day 1 and 
day 7 measured independently) 
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8-iso-prostaglandin F2α (ng/ml) 
Control subject 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Day 1 (Baseline) 0.58 1.99 0.25 3.74 31.73 1.99 2.18 7.03 2.33 18.89 2.48 0.25 8.00 1.19 2.10 0.25 
Day 7 0.25 2.82 8.07 3.99 38.72 0.25 0.25 4.92 0.25 13.43 0.26 0.25 6.72 1.11 1.40 0.25 
Mean 0.42 2.40 4.16 3.87 35.22 1.12 1.21 5.98 1.29 16.16 1.37 0.25 7.36 1.15 1.75 0.25 
SD 0.24 0.58 5.53 0.18 4.94 1.23 1.36 1.49 1.47 3.87 1.57 0.00 0.91 0.05 0.50 0.00 
% CV 56.48 24.35 132.92 4.58 14.03 109.80 112.30 24.96 113.98 23.93 115.02 0.00 12.35 4.59 28.55 0.00 
Average % CV 48.62 
 
Supplementary Table 6. (Raw data to complement Figure 4.7.) Short-term day-day precision of 8-iso-prostaglandin F2α by AutoDELFIA 
analysis. (Day 1 and day 7 measured on the same occasion) 
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Potential oxidative stress-related BoA 
Normality test 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
 Statistic n p Statistic n p 
Superoxide levels (AU) 
P3
       
PBMCs 0.12 248 0.00 0.85 248 0.00 
Lymphocytes 0.14 248 0.00 0.80 248 0.00 
Monocytes 0.14 248 0.00 0.86 248 0.00 
Mitochondrial mass (AU) 
P3
       
PBMCs 0.07 341 0.00 0.96 341 0.00 
Lymphocytes 0.13 341 0.00 0.76 341 0.00 
Monocytes 0.14 341 0.00 0.91 341 0.00 
Mitochondrial membrane potential (AU) 
P3
       
PBMCs 0.17 347 0.00 0.68 347 0.00 
Lymphocytes 0.12 347 0.00 0.89 347 0.00 
Monocytes 0.16 347 0.00 0.83 347 0.00 
8-Iso Prostaglandin F2α (ng/ml) 
P3
 0.24 379 0.00 0.70 379 0.00 
 
Supplementary Table 7. Normality tests of continuous potential oxidative stress-
related BoA of the very old population from the Newcastle 85+ Study. (
P3
: Phase 3 
data, a: Lilliefors Significance Correction) 
 
 
 
 
 
 
 
Potential confounders 
Normality test 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
 Statistic n p Statistic n p 
Age of parents death 
P1
       
Mother 0.11 810 0.00 0.93 810 0.00 
Father 0.10 776 0.00 0.95 776 0.00 
Number of years in main job/role 
P1
 0.07 666 0.00 0.97 666 0.00 
Self-reported physical activity score 
P3
 0.16 484 0.00 0.90 484 0.00 
Social isolation score 
P3
 0.06 480 0.00 0.99 480 0.01 
Body mass index 
P3
 0.04 401 0.10 0.99 401 0.00 
 
Supplementary Table 8. Normality tests of continuous potential confounders BoA 
of the very old population from the Newcastle 85+ Study. (
P1
: Phase 1 data, 
P3
: Phase 
3 data, a: Lilliefors Significance Correction) 
 
 
 
 
 
 
230 
 
 
 
 
Age-related construct variables 
Normality test 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
 Statistic n p Statistic n p 
PBMC telomere length (bp) 
P3
  0.07 430 0.00 0.98 430 0.00 
PBMC DNA damage (%) 
P3
 0.04 431 0.06 0.98 431 0.00 
PBMC DNA repair (%) 
P3
 0.07 431 0.00 0.96 431 0.00 
Interleukin-6 (pg/ml) 
P3
 0.45 430 0.00 0.19 430 0.00 
Tumour necrosis factor-alpha (pg/ml) 
P3
 0.45 430 0.00 0.17 430 0.00 
Glycosylated haemoglobin (%) 
P3
 0.13 428 0.00 0.89 428 0.00 
High sensitivity C-reactive protein (mg/l) 
P3
 0.34 434 0.00 0.36 434 0.00 
Albumin (g/l) 
P3
 0.09 434 0.00 0.96 434 0.00 
Rheumatoid factor (IU/ml) 
P1
 0.44 774 0.00 0.12 774 0.00 
Lymphocyte/Monocyte ratio 
P3
 0.16 427 0.00 0.49 427 0.00 
CD4 / Upper CD8 T lymphocyte ratio 
P3
 0.45 405 0.00 0.05 405 0.00 
Memory / Naive B lymphocyte ratio 
P3
 0.39 429 0.00 0.19 429 0.00 
Memory / Naive CD4 T lymphocyte ratio 
P3
 0.37 428 0.00 0.29 428 0.00 
Memory / Naive CD8 T lymphocyte ratio 
P3
 0.29 402 0.00 0.55 402 0.00 
Senescent (CD27-/RO-) CD4 T lymphocytes (%)
 P3
 0.29 429 0.00 0.53 429 0.00 
Senescent (CD27-/RO-) CD8 T lymphocytes (%)
 P3
 0.08 403 0.00 0.95 403 0.00 
Hand grip strength (kg) 
P3
 0.07 453 0.00 0.97 453 0.00 
Timed up and go test (seconds) 
P3
 0.22 402 0.00 0.54 402 0.00 
Forced expiratory volume in 1 second (l) 
P1
 0.07 776 0.00 0.98 776 0.00 
Systolic blood pressure (mmHg) 
P3
 0.03 462 0.20 1.00 462 0.26 
Haematocrit (%) 
P3
 0.04 427 0.20 1.00 427 0.24 
Haemoglobin (g/dl) 
P3
 0.05 427 0.01 0.99 427 0.06 
Red blood cells (x 10^12/l) 
P3
 0.04 427 0.09 1.00 427 0.19 
Free  triiodothyronine (pmol/l) 
P3
 0.08 426 0.00 0.99 426 0.00 
Vitamin D (nmol/l) 
P1
 0.11 778 0.00 0.93 778 0.00 
Prohormone brain-type natriuretic peptide (pg/ml) 
P3
 0.21 124 0.00 0.68 124 0.00 
 
Supplementary Table 9. Normality tests of continuous age-related construct 
variables of the very old population from the Newcastle 85+ Study. (
P1
: Phase 1 
data, 
P3
: Phase 3 data, a: Lilliefors Significance Correction) 
  
 
Age-related outcomes 
Normality test 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
Disability score 
P3
 0.11 482 0.00 0.94 482 0.00 
SMMSE score 
P3
 0.20 471 0.00 0.75 471 0.00 
Disease Only Morbidity Count 
P3
 0.16 751 0.00 0.94 751 0.00 
 
Supplementary Table 10. Normality tests of continuous age-related outcomes of 
the very old population from the Newcastle 85+ Study. (
P3
: Phase 3 data, a: Lilliefors 
Significance Correction) 
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Supplementary Figure 1. Q-Q plots of continuous potential oxidative stress-related BoA of the very old population from the Newcastle 85+ 
Study.  
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Supplementary Figure 2. Q-Q plots of continuous potential confounders BoA of the very old population from the Newcastle 85+ Study. 
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Supplementary Figure 3. Q-Q plots of continuous age-related construct variables of the very old population from the Newcastle 85+ Study. 
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Supplementary Figure 4. Q-Q plots of continuous age-related construct variables of the very old population from the Newcastle 85+ Study. 
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Supplementary Table 11. Descriptive statistics of potential oxidative stress-related BoA of the very old population from the Newcastle 85+ 
Study. A. Superoxide levels population only, B. Mitochondrial mass population only, C. Mitochondrial membrane potential population only and D. 8-
Iso Prostaglandin F2α population only. Continuous data are displayed as median and, inter-quartile ranges since all measures had a non-normal 
distribution. (
P3
: Phase 3 data) 
 
Potential oxidative stress-related BoA All A. B. C. D. 
 Statistic n Statistic n p Statistic n p Statistic n p Statistic n p 
Superoxide levels (AU) P3               
PBMCs 33.94 20.17 (248) 33.94 20.17 (248) - 34.29 20.01 (243) 0.76 34.29 20.07 (239) 0.91 34.31 19.72 (216) 0.70 
Lymphocytes 25.39 20.81 (248) 25.39 20.81 (248) - 26.05 20.83 (243) 0.79 25.69 20.82 (239) 0.86 26.06 20.75 (216) 0.79 
Monocyte 61.49 46.09 (248) 61.49 46.09 (248) - 62.07 46.24 (243) 0.83 61.66 46.22 (239) 0.87 63.17 46.60 (216) 0.79 
Mitochondrial mass (AU) P3                    
PBMCs 41.69 19.99 (341) 40.09 18.62 (243) 0.36 41.69 19.99 (341) - 41.86 19.76 (332) 0.99 41.89 20.64 (302) 0.75 
Lymphocytes 44.60 32.06 (341) 44.89 37.43 (243) 0.55 44.60 32.06 (341) - 44.60 31.49 (332) 0.88 44.57 31.29 (302) 0.96 
Monocytes 61.03 40.24 (341) 61.03 45.38 (243) 0.93 61.03 40.24 (341) - 61.05 38.75 (332) 0.99 61.29 40.47 (302) 0.89 
Mitochondrial membrane potential (AU) 
P3                    
PBMCs 2.86 0.98 (347) 2.90 1.07 (239) 0.83 2.88 1.07 (332) 0.79 2.86 0.98 (347) - 2.87 1.02 (304) 0.83 
Lymphocytes 3.85 2.00 (347) 4.02 2.32 (239) 0.07 3.87 2.08 (332) 0.68 3.85 2.00 (347) - 3.87 2.14 (304) 0.77 
Monocytes 2.51 1.16 (347) 2.50 1.18 (239) 0.98 2.52 1.19 (332) 0.97 2.51 1.16 (347) - 2.52 1.19 (304) 0.79 
8-Iso Prostaglandin F2α (ng/ml) 
P3 1.49 2.08 (379) 1.47 2.09 (216) 0.94 1.49 1.99 (302) 0.82 1.47 2.05 (304) 0.96 1.49 2.08 (379) - 
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Potential confounders All A. B. C. D. 
 Statistic n Statistic n p Statistic n p Statistic n p Statistic n p 
Gender P1                    
Male 36.12 % (375) 36.69 % (91) 
0.87 
36.36 % (124) 
0.94 
37.75 % (131) 
0.59 
38.26 % (145) 
0.46 
Female 63.87 % (663) 63.31 % (157) 63.64 % (217) 62.25 % (216) 61.74 % (234) 
Ethnicity P1                    
White 99.65 % (845) 99.19 % (246) 
0.57 
99.41 % (339) 
0.73 
99.42 % (345) 
0.74 
99.21 % (376) 
0.80 
Black - Caribbean 0.12 % (1) 0.40 % (1) 0.29 % (1) 0.29 % (1) 0.26 % (1) 
Black - African 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 
Black - Other black groups 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 
Indian 0.12 % (1) 0.40 % (1) 0.29 % (1) 0.29 % (1) 0.26 % (1) 
Pakistani 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 
Bangladeshi 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 
Chinese 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 
None of these 0.12 % (1) 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.26 % (1) 
Mitochondrial haplogroup P1                    
H 46.18 % (326) 42.58 % (89) 
0.98 
42.91 % (127) 
0.99 
43.71 % (132) 
0.97 
46.85 % (156) 
1.00 
T 10.20 % (72) 11.96 % (25) 11.49 % (34) 11.26 % (34) 10.21 % (34) 
J 10.91 % (77) 10.53 % (22) 11.49 % (34) 11.59 % (35) 10.51 % (35) 
U 15.44 % (109) 17.22 % (36) 16.89 % (50) 16.89 % (51) 15.62 % (52) 
K 7.22 % (51) 7.18 % (15) 7.43 % (22) 7.95 % (24) 8.11 % (27) 
X 1.84 % (13) 1.91 % (4) 1.69 % (5) 1.32 % (4) 1.50 % (5) 
W 2.83 % (20) 3.83 % (8) 3.38 % (10) 3.31 % (10) 2.70 % (9) 
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I 1.84 % (13) 1.44 % (3)  1.35 % (4)  1.32 % (4)  1.20 % (4)  
V 3.54 % (25) 3.35 % (7)  3.38 % (10)  2.65 % (8)  3.30 % (11)  
Age of natural parents death (years) P1                    
Mother 78.00 19.00 (810) 80.00 18.00 (239) 0.37 79.00 18.75 (332) 0.68 79.00 18.00 (336) 0.65 78.00 18.00 (366) 0.70 
Father 72.00 19.00 (776) 72.00 19.75 (232) 0.99 74.00 19.00 (318) 0.19 74.00 19.00 (322) 0.27 73.00 17.00 (351) 0.42 
Place of birth P1                    
Country                    
England 91.03 % (771) 90.32 % (224) 
0.70 
90.62 % (309) 
0.83 
90.49 % (314) 
0.87 
91.03 % (345) 
0.86 
Wales 0.71 % (6) 0.40 % (1) 0.88 % (3) 0.86 % (3) 0.53 % (2) 
Scotland 4.49 % (38) 6.05 % (15) 5.28 % (18) 5.19 % (18) 4.75 % (18) 
Northern Ireland 0.47 % (4) 0.40 % (1) 0.29 % (1) 0.29 % (1) 0.26 % (1) 
UK (unknown constituent country) 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 
Republic of Ireland 0.47 % (4) 0.00 % (0) 0.00 % (0) 0.00 % (0) 0.00 % (0) 
Other Europe 1.53 % (13) 0.81 % (2) 1.17 % (4) 1.44 % (5) 1.85 % (7) 
Non-Europe 1.30 % (11) 2.02 % (5) 1.76 % (6) 1.73 % (6) 1.58 % (6) 
Region of England                    
North East England 84.55 % (651) 82.14 % (184) 
0.47 
83.82 % (259) 
0.53 
83.44 % (262) 
0.47 
82.90 % (286) 
0.60 Cumbria 0.91 % (7) 0.45 % (1) 0.32 % (1) 0.32 % (1) 0.58 % (2) 
Other 14.55 % (112) 17.41 % (39) 15.86 % (49) 16.24 % (51) 16.52 % (57) 
Has/had a sibling(s) P1                    
Yes 90.40 % (763) 89.47 % (221) 
0.67 
91.18 % (310) 
0.68 
90.75 % (314) 
0.85 
89.95 % (340) 
0.80 
No 9.60 % (81) 10.53 % (26) 8.82 % (30) 9.25 % (32) 10.05 % (38) 
Had full-time higher education P1                    
Yes 11.86 % (100) 13.31 % (33) 
0.54 
14.96 % (51) 
0.15 
15.27 % (53) 
0.11 
15.30 % (58) 
0.10 
No 88.14 % (743) 86.69 % (215) 85.04 % (290) 84.73 % (294) 84.70 % (321) 
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Number of years in main job/role P1 33.00 23.00 (666) 33.00 21.00 (197) 0.94 34.00 21.75 (264) 0.44 34.00 22.00 (271) 0.39 34.00 22.00 (297) 0.46 
Has offspring P1                    
Yes 82.78 % (702) 83.40 % (206) 
0.82 
83.53 % (284) 
0.76 
83.53 % (289) 
0.76 
84.13 % (318) 
0.56 
No 17.22 % (146) 16.60 % (41) 16.47 % (56) 16.47 % (57) 15.87 % (60) 
Martial status P3                    
Single 8.92 % (43) 7.69 % (19) 
0.88 
8.26 % (28) 
1.00 
8.70 % (30) 
1.00 
7.43 % (28) 
0.96 
Married 22.41 % (108) 21.86 % (54) 22.71 % (77) 22.61 % (78) 24.14 % (91) 
Re-married 1.66 % (8) 1.21 % (3) 1.77 % (6) 2.03 % (7) 1.86 % (7) 
Separated 0.21 % (1) 0.00 % (0) 0.29 % (1) 0.29 % (1) 0.27 % (1) 
Divorced 1.87 % (9) 2.83 % (7) 2.06 % (7) 2.32 % (8) 1.59 % (6) 
Widowed 64.94 % (313) 66.40 % (164) 64.90 % (220) 64.06 % (221) 64.72 % (244) 
Lives alone P3                    
Yes 64.47 % (274) 64.09 % (141) 
0.93 
61.84 % (188) 
0.47 
62.38 % (194) 
0.56 
62.87 % (215) 
0.65 
No 35.53 % (151) 35.91 % (79) 38.16 % (116) 37.62 % (117) 37.13 % (127) 
Housing type P3                    
Standard housing 74.90 % (361) 75.61 % (186) 
0.83 
77.29 % (262) 
0.68 
76.23 % (263) 
0.57 
78.51 % (296) 
0.36 Sheltered housing with warden 12.66 % (61) 13.41 % (33) 12.09 % (41) 13.62 % (47) 11.94 % (45) 
Institution 12.45 % (60) 10.98 % (27) 10.62 % (36) 10.14 % (35) 9.55 % (36) 
Alcohol status P1                    
Current drinker 59.93 % (492) 66.13 % (164) 
0.05 
65.10 % (222) 
0.03 
65.71 % (228) 
0.02 
68.07 % (258) 
0.01 
Occasional drinker 20.22 % (166) 16.53 % (41) 18.18 % (62) 17.87 % (62) 17.94 % (68) 
Previous drinker 8.77 % (72) 4.44 % (11) 4.11 % (14) 4.03 % (14) 3.96 % (15) 
Never drinker 11.08 % (91) 12.90 % (32) 12.61 % (43) 12.39 % (43) 10.03 % (38) 
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Smoking status P1                    
Current smoker 5.79 % (49) 4.03 % (10) 
0.41 
4.40 % (15) 
0.50 
4.32 % (15) 
0.44 
3.96 % (15) 
0.36 Past smoker 63.52 % (538) 62.10 % (154) 62.46 % (213) 62.25 % (216) 66.23 % (251) 
Never smoker 30.70 % (260) 33.87 % (84) 33.14 % (113) 33.43 % (116) 29.82 % (113) 
Takes non-prescribed medicines, 
supplements and/or herbal remedies P1 
                   
Yes 41.08 % (350) 47.58 % (118) 
0.07 
45.45 % (155) 
0.17 
45.53 % (158) 
0.16 
47.23 % (179) 
0.04 
No 58.92 % (502) 52.42 % (130) 54.55 % (186) 54.47 % (189) 52.77 % (200) 
Takes prescribed medication P1                    
Yes 95.07 % (983) 96.75 % (238) 
0.26 
95.87 % (325) 
0.55 
95.65 % (330) 
0.66 
95.74 % (360) 
0.60 
No 4.93 % (51) 3.25 % (8) 4.13 % (14) 4.35 % (15) 4.26 % (16) 
Self-reported physical activity score P3 9.00 4.00 (484) 9.00 3.00 (248) 0.35 9.00 4.00 (341) 0.22 9.00 4.00 (347) 0.18 9.00 4.00 (379) 0.40 
Uses aid(s)/appliance(s) P1                    
Yes 85.53 % (727) 85.08 % (211) 
0.86 
82.40 % (281) 
0.18 
82.42 % (286) 
0.18 
80.74 % (306) 
0.03 
No 14.47 % (123) 14.92 % (37) 17.60 % (60) 17.58 % (61) 19.26 % (73) 
Social isolation score P3 59.00 9.00 (480) 59.00 10.00 (246) 0.44 58.00 10.00 (339) 0.16 58.00 10.00 (345) 0.17 58.00 10.00 (376) 0.19 
Key event impact P3                    
Positive key event(s) 16.74 % (81) 19.76 % (49) 
0.40 
18.48 % (63) 
0.89 
18.16 % (63) 
0.97 
16.89 % (64) 
0.94 
Negative key event(s) 30.79 % (149) 26.21 % (65) 27.86 % (95) 29.11 % (101) 31.13 % (118) 
Positive and negative key event(s) 17.15 % (83) 14.11 % (35) 18.48 % (63) 18.16 % (63) 19.00 % (72) 
Key event(s) but impact unknown 10.33 % (50) 10.89 % (27) 10.56 % (36) 10.09 % (35) 10.03 % (38) 
No key event 25.00 % (121) 29.03 % (72) 24.63 % (84) 24.50 % (85) 22.96 % (87) 
Has problems sleeping P3                    
Yes 26.29 % (127) 27.02 % (67) 
0.83 
26.10 % (89) 
0.95 
26.22 % (91) 
1.00 
25.59 % (97) 
0.82 
No 73.71 % (356) 72.98 % (181) 73.90 % (252) 73.78 % (256) 74.41 % (282) 
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Body mass index P3 23.47 6.10 (401) 23.83 6.31 (222) 0.48 23.56 6.14 (304) 0.77 23.51 6.13 (310) 0.76 23.29 6.17 (343) 0.77 
Fasted blood sample P3                    
Yes - - - 0.98 % (242) 
- 
0.97 % (331) 
- 
0.97 % (336) 
- 
0.97 % (369) 
- 
No - - - 0.02 % (6) 0.03 % (10) 0.03 % (11) 0.03 % (10) 
Season of blood sample P3                    
Spring - - - 35.08 % (87) 
- 
25.81 % (88) 
- 
24.78 % (86) 
- 
24.01 % (91) 
- 
Summer - - - 30.24 % (75) 30.79 % (105) 31.41 % (109) 31.93 % (121) 
Autumn - - - 13.71 % (34) 22.29 % (76) 23.05 % (80) 24.54 % (93) 
Winter - - - 20.97 % (52) 21.11 % (72) 20.75 % (72) 19.53 % (74) 
 
Supplementary Table 12. Descriptive statistics of potential confounders of the very old population from the Newcastle 85+ Study. A. 
Superoxide levels population only, B. Mitochondrial mass population only, C. Mitochondrial membrane potential population only and D. 8-Iso 
Prostaglandin F2α population only. Continuous and discrete data are displayed as median and, inter-quartile ranges since all measures had a non-normal 
distribution and grouped data are displayed as percentage of population. (
P1
: Phase 1 data, 
P3
: Phase 3 data) 
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Age-related construct variables All A. B. C. D. 
 Statistic n Statistic n p Statistic n p Statistic n p Statistic n p 
Telomere shortening                     
PBMC telomere length (bp) P3 ~ 2715.77 1057.17 (430) 2786.50 1068.93 (248) 0.62 2722.65 1042.64 (340) 0.88 2709.72 1051.81 (345) 0.98 2738.62 1027.77 (376) 0.73 
DNA damage and repair                     
PBMC DNA damage (%) P3 ~ 47.26 29.65 (431) 44.25 27.56 (248) 0.10 45.37 30.41 (341) 0.56 46.00 29.99 (347) 0.75 47.20 28.84 (379) 0.90 
PBMC DNA repair (%) P3 ~ 46.24 47.27 (431) 43.29 43.94 (248) 0.56 44.79 46.29 (341) 0.76 45.75 46.94 (347) 0.97 46.54 48.37 (379) 0.85 
Inflammation                     
Interleukin-6 (pg/ml) P3 ~ 10.25 31.43 (430) 6.79 33.89 (247) 0.07 9.77 31.19 (340) 0.68 10.21 32.06 (345) 0.84 9.90 31.56 (377) 0.94 
Tumour necrosis factor-alpha (pg/ml) P3 ~ 2.55 4.42 (430) 2.10 4.18 (247) 0.07 2.45 4.26 (340) 0.50 2.48 4.45 (345) 0.61 2.64 4.49 (377) 0.78 
Glycosylated haemoglobin (%) P3 ~ 5.90 0.60 (428) 5.90 0.50 (247) 0.41 5.90 0.60 (339) 0.67 5.90 0.60 (344) 0.74 5.90 0.60 (375) 0.97 
High sensitivity C-reactive protein (mg/l)  P3 ~ 2.40 3.70 (434) 2.35 3.28 (248) 0.81 2.40 3.70 (341) 0.73 2.40 3.70 (347) 0.67 2.40 3.60 (379) 0.85 
Albumin (g/l) P3 ~ 40.00 4.00 (434) 40.00 4.00 (248) 0.88 40.00 4.00 (341) 0.70 40.00 4.00 (347) 0.81 40.00 4.00 (379) 0.70 
Rheumatoid factor (IU/ml) P1 ~ 10.00 0.00 (774) 10.00 0.00 (239) 0.04 10.00 0.00 (328) 0.75 10.00 0.00 (335) 0.56 10.00 0.00 (367) 1.00 
Immunosenescence                    
Lymphocyte/Monocyte ratio P3 ~ 3.25 1.64 (427) 3.17 1.80 (246) 0.26 3.29 1.76 (338) 0.60 3.28 1.74 (343) 0.75 3.28 1.69 (374) 0.95 
CD4 / Upper CD8 T lymphocye ratio P3 ~ 2.37 2.78 (405) 2.42 2.56 (239) 0.99 2.43 2.75 (319) 0.89 2.37 2.77 (325) 0.83 2.43 2.66 (355) 0.69 
Memory / Naive B lymphocyte ratio P3 ~ 0.23 0.36 (429) 0.23 0.33 (246) 0.94 0.23 0.33 (339) 0.77 0.23 0.34 (344) 0.77 0.23 0.33 (376) 0.76 
Memory / Naive CD4 T lymphocyte ratio P3 ~ 0.25 0.51 (428) 0.25 0.51 (245) 0.77 0.25 0.55 (338) 0.86 0.25 0.55 (343) 0.63 0.24 0.48 (375) 0.76 
Memory / Naive CD8 T lymphocyte ratio P3 ~ 1.19 3.51 (402) 1.02 2.69 (236) 0.49 1.22 3.34 (316) 0.82 1.19 3.56 (322) 0.83 1.15 3.48 (352) 0.93 
Senescent (CD27-/RO-) CD4 T lymphocytes (%) P3 ~ 1.46 3.32 (429) 1.45 3.37 (246) 0.70 1.58 3.54 (339) 0.83 1.58 3.48 (344) 0.77 1.44 3.15 (376) 0.67 
Senescent (CD27-/RO-)  CD8 T lymphocytes (%) P3 ~ 21.81 25.69 (403) 21.52 24.43 (237) 0.98 21.40 25.27 (317) 0.91 21.89 25.70 (323) 0.85 21.81 26.34 (353) 0.92 
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Informative classical BoA                    
Hand grip strength (kg) P3 ~ 16.10 9.03 (453) 16.45 8.40 (242) 0.61 16.43 8.68 (336) 0.59 16.60 8.80 (342) 0.27 16.40 9.43 (374) 0.57 
Timed up and go test (seconds) P3 ~ 17.09 12.19 (402) 17.02 12.79 (218) 0.81 16.62 12.39 (304) 0.85 16.60 12.38 (312) 0.81 16.91 11.98 (340) 0.73 
Forced expiratory volume in 1 second (l) P1 ~ 137.00 71.75 (776) 142.50 64.50 (244) 0.10 142.00 66.00 (335) 0.06 142.00 67.50 (341) 0.03 142.00 71.75 (372) 0.05 
Systolic blood pressure (mmHg) P3 ^  143.04 0.96 (462) 144.18 1.31 (245) 0.50 144.16 1.10 (338) 0.44 143.80 1.08 (343) 0.62 143.69 1.05 (376) 0.63 
Haematocrit (%) P3 ^ 0.39 0.00 (427) 0.39 0.00 (246) 0.98 0.39 0.00 (338) 0.98 0.39 0.00 (343) 1.00 0.39 0.00 (374) 0.89 
Haemoglobin (g/dl) P3 ~ 13.00 1.70 (427) 13.00 1.70 (246) 1.00 13.00 1.70 (338) 0.93 13.00 1.70 (343) 0.92 13.00 1.63 (374) 0.83 
Red blood cells (x 1012/l) P3 ^ 4.25 0.02 (427) 4.24 0.03 (246) 0.85 4.24 0.03 (338) 0.84 4.25 0.03 (343) 0.98 4.25 0.02 (374) 0.83 
Free  triiodothyronine (pmol/l) P3 ~ 4.40 0.80 (426) 4.35 0.83 (246) 0.12 4.40 0.80 (338) 0.84 4.40 0.80 (343) 0.84 4.40 0.70 (374) 1.00 
Vitamin D (nmol/l) P1 ~ 39.00 37.00 (778) 40.50 38.00 (240) 0.78 39.00 35.00 (331) 1.00 39.00 35.00 (338) 0.80 39.00 34.00 (371) 0.82 
Prohormone brain-type natriuretic peptide (pg/ml) P3 ~ 514.00 791.75 (124) 479.50 787.75 (46) 0.55 503.00 693.00 (85) 0.74 516.00 806.00 (95) 0.88 505.00 798.75 (108) 0.84 
 
Supplementary Table 13. Descriptive statistics of age-related construct variables of the very old population from the Newcastle 85+ Study. A. 
Superoxide levels population only, B. Mitochondrial mass population only, C. Mitochondrial membrane potential population only and D. 8-Iso 
Prostaglandin F2α population only. Continuous data with non-normal distributions are displayed as medians and inter-quartile ranges and continuous 
data with normal distribution are displayed a means and standard error. (
P1
: Phase 1 data, 
P3
: Phase 3 data,
 
 
~
: non-normal distribution,  ^: normal 
distribution) 
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Age-related outcomes All A. B. C. D. 
 Statistic n Statistic n p Statistic n p Statistic n p Statistic n p 
Disability score P3 6.00 7.25 (482) 6.00 7.00 (247) 0.42 6.00 7.00 (339) 0.28 6.00 7.00 (345) 0.22 6.00 7.00 (377) 0.17 
SMMSE score P3 27.00 5.00 (471) 27.00 5.00 (247) 0.80 27.00 5.00 (339) 0.70 27.00 5.00 (345) 0.95 27.00 5.00 (378) 0.40 
Disease Only Morbidity Count P3 3.00 2.00 (751) 3.00 2.00 (239) 0.27 2.00 2.00 (328) 0.05 3.00 2.00 (334) 0.09 2.00 2.00 (367) 0.02 
Passed Away? (censored at 30/04/2012)                    
Yes 49.06 % (417) 25.81 % (64) 
0.00 
25.22 % (86) 
0.00 
25.94 % (90) 
0.00 
26.65 % (101) 
0.00 
No 50.94 % (433) 74.19 % (184) 74.78 % (255) 74.06 % (257) 73.35 % (278) 
 
Supplementary Table 14. Descriptive statistics of age-related outcomes of the very old population from the Newcastle 85+ Study. A. Superoxide 
levels population only, B. Mitochondrial mass population only, C. Mitochondrial membrane potential population only and D. 8-Iso Prostaglandin F2α 
population only. Discrete data are displayed as medians and inter-quartile ranges since all measures had a non-normal distribution and grouped data are 
displayed as percentage of population. (
P3
: Phase 3 data) 
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Supplementary Figure 5. Identifying extreme outliers of continuous potential 
oxidative stress-related BoA of the very old population from the Newcastle 85+ 
Study for sensitivity analysis. Extreme outliers were values more than 3 times the 
interquartile range (IQR) below the 25
th
 or above the 75
th 
percentiles, which were 
identified by default in SPSS boxplots. (All are phase 3 measures) 
 
 
 
 
* Extreme outliers 
    ≥ 108.43AU  
   (n=3) 
 * Extreme outliers  
≥ 115.88AU  
(n=2) 
* Extreme outliers  
≥ 241.69AU  
(n=2) 
* Extreme outliers  
≥ 158.91AU  
(n=4) 
* Extreme outliers  
≥ 224.59AU  
(n=2) 
* Extreme outliers  
≥ 6.45AU  
(n=4) 
* Extreme outliers  
≥ 15.84AU  
(n=1) 
* Extreme outliers  
≥ 6.65AU  
(n=7) 
* Extreme outliers  
≥ 9.09ng/ml  
(n=20) 
No  extreme outliers 
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Supplementary Figure 6. Identifying extreme outliers of continuous potential 
confounders of the very old population from the Newcastle 85+ Study for 
sensitivity analysis. Extreme outliers were values more than 3 times the interquartile 
range (IQR) below the 25
th
 or above the 75
th 
percentiles, which were identified by 
default in SPSS boxplots. (All are phase 3 measures except unchangeable characteristics 
(age of parents death and number of years in main job/role) which were assessed at 
phase 1) 
 
 
 
 
 
 
 
 
 
 
No extreme outliers No extreme outliers No extreme outliers 
No extreme outliers No extreme outliers No extreme outliers 
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Cont... 
 
  
No extreme outliers No extreme outliers No extreme outliers 
* Extreme outliers  
≥ 134.38pg/ml  
(n=56) 
* Extreme outliers  
≥ 22.08pg/ml 
 (n=38) 
* Extreme outliers 
 ≥ 8.10% 
 (n=4) 
* Extreme outliers  
≥ 16.5mg/l 
(n=28) 
* Extreme outliers 
 ≤ 24.00g/l  
(n=1) 
* Extreme outliers 
 All 
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Cont... 
 
 
* Extreme outliers  
≥ 9.26  
(n=2) 
* Extreme outliers  
≥ 12.88  
(n=14) 
* Extreme outliers  
≥ 1.54  
(n=24) 
* Extreme outliers  
≥ 2.16  
(n=30) 
* Extreme outliers  
≥ 14.5  
(n=16) 
* Extreme outliers  
≥ 14.5%  
(n=32) 
No extreme outliers 
253 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 7. Identifying extreme outliers of continuous age-related 
construct variables of the very old population from the Newcastle 85+Study for 
sensitivity analysis. Extreme outliers were values more than 3 times the interquartile 
range (IQR) below the 25
th
 or above the 75
th 
percentiles, which were identified by 
default in SPSS boxplots. (All are phase 3 measures except rheumatoid factor, forced 
expiratory volume and vitamin D which were measured at phase 1) 
 
 
 
 
No extreme outliers * Extreme outliers 
 ≥ 66.6 seconds  
(n=8) 
No extreme outliers 
No extreme outliers No extreme outliers No extreme outliers 
No extreme outliers No extreme outliers No extreme outliers 
* Extreme outliers  
≥ 3,652.00pg/ml  
(n=4) 
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Supplementary Figure 8. Identifying extreme outliers of continuous age-related 
outcomes of the very old population from the Newcastle 85+Study for sensitivity 
analysis. Extreme outliers were values more than 3 times the interquartile range (IQR) 
below the 25
th
 or above the 75
th 
percentiles, which were identified by default in SPSS 
boxplots. (All are phase 3 measures) 
  
No extreme outliers * Extreme outliers  
≤ 8 
 (n=11) 
No extreme outliers 
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Supplementary Table 15. Cut-off values for grouped continuous potential oxidative stress-related BoA. Quartile cut-offs were first identified and 
values were assigned to Q1, Q2, Q3 or Q4 groups by default in SPSS. Q2 and Q3 were then grouped manually. (Q: Quartile, 
P3
: Phase 3 data) 
 
 
 
 
 
 
 
 
 
Potential oxidative stress-related BoA Low (Q1) Medium (Q2+Q3) High (Q4) Total 
 Cut-off n Minimum Maximum Cut-off n Minimum Maximum Cut-off n Minimum Maximum n 
Superoxide levels (AU) P3              
PBMCs ≤ 25.5600 63 13.7700 25.5600 25.5601 - 45.7250 123 25.6600 45.7200 ≥ 45.7251 62 45.7300 133.4900 248 
Lymphocytes ≤ 17.0450 62 10.1100 17.0400 17.0451 - 37.8200 124 17.0500 37.7500 ≥ 37.8201 62 37.8900 147.6300 248 
Monocyte ≤ 46.0400 62 24.2300 45.9700 46.0401 - 92.0250 124 46.1100 91.8800 ≥ 92.0251 62 92.1700 297.2400 248 
Mitochondrial mass (AU) P3              
PBMCs ≤ 32.0700 86 10.8000 32.0700 32.0701 -51.9300 170 32.1100 51.9300 ≥ 51.9301 85 51.9400 107.4700 341 
Lymphocytes ≤ 31.1600 86 9.8300 31.1600 31.1600 - 63.0200 170 31.4800 63.0200 ≥ 63.0200 85 63.1600 351.1700 341 
Monocyte ≤ 43.9900 86 9.4300 43.9900 43.9901 - 83.7000 170 44.8000 83.7000 ≥ 83.7001 85 84.6900 239.1000 341 
Mitochondrial membrane potential (AU) P3              
PBMCs ≤ 2.4670 87 0.4684 2.4670 2.4671 - 3.4503 174 2.4684 3.4503 ≥ 3.4504 86 3.4569 18.1070 347 
Lymphocytes ≤ 2.9901 87 0.0608 2.9901 2.9902 - 4.9902 174 2.9970 4.9902 ≥ 4.9903 86 5.0032 15.8400 347 
Monocyte ≤ 2.0155 87 0.3501 2.0155 2.0155 - 3.1763 174 2.0173 3.1763 ≥ 3.1763 86 3.2009 9.5704 347 
8-Iso Prostaglandin F2α (ng/ml) 
P3 ≤ 0.85 95 0.25 0.85 0.86 - 2.93 191 0.87 2.93 ≥ 2.94+ 93 2.94 18.81 379 
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Supplementary Table 16. Cut-off values for grouped continuous potential confounders . Quartile cut-offs were first identified and values were 
assigned to Q1, Q2, Q3 or Q4 groups by default in SPSS. Q2 and Q3 were then grouped manually. (Q: Quartile, 
P1
: Phase 1
 
data,
 P3
: Phase 3 data) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potential confounders Low (Q1) Medium (Q2+Q3) High (Q4) Total 
 Cut-off n Minimum Maximum Cut-off n Minimum Maximum Cut-off n Minimum Maximum n 
Age of parents death P1              
Mother ≤ 67 204 25 67 68 - 86 439 68 86 ≥ 87 167 87 103 810 
Father ≤ 61 198 23 61 62 - 80 403 62 80 ≥ 81 175 81 101 776 
Number of years in main job/role P1 ≤ 22 177 0 22 23 - 45 327 23 45 ≥ 46 162 46 68 666 
Self-reported physical activity score P3 ≥ 9 353 9 12 8 32 8 8 ≤ 7 99 3 7 484 
Social isolation score P3 ≤ 54 127 40 54 55 - 63 242 55 63 ≥ 64 111 64 74 480 
Body mass index P3 ≤ 21 102 14.50 20.52 22 - 27 226 20.55 27.46 ≥ 28 73 27.66 38.05 401 
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Age-reated construct variables Low (Q1) Medium (Q2+Q3) High (Q4) Total 
 Cut-off n Minimum Maximum Cut-off n Minimum Maximum Cut-off n Minimum Maximum n 
PBMC telomere length (bp) P3 
≤2290.3 
542103 
108 
1335.5 
452961 
2290.3 
542103 
2290.3542104 - 
3345.6611576 
215 
2294.92 
40552 
3345.6 
611576 
≥3345.6 
611577 
107 
3352.5 
440824 
5534.0 
784103 
430 
PBMC DNA damage (%) P3 
≤ 31.25 
20980 
108 
3.510 
5316 
31.25 
20980 
31.2520981 - 
60.2634508 
216 
31.31 
22172 
60.90 
13181 
≥ 60.9 
013182 
107 
61.00 
00000 
85.49 
54035 
431 
PBMC DNA repair (%) P3 
≤ 23.98 
19005 
108 
0.800 
1581 
23.98 
19005 
23.9819006 - 
71.2566201 
216 
24.06 
29685 
71.25 
66201 
≥ 71.2 
566202 
107 
71.28 
28880 
100.38 
24092 
431 
Interluekin-6 (pg/ml) P3 
≤3.137 
65058 
108 
0.000 
0000 
3.137 
6506 
3.13765059 -
34.54857549 
215 
3.14 
40295 
34.54 
85755 
≥ 34.54 
857550 
107 
34.59 
98125 
27372.4 
342218 
430 
Tumour necrosis factor-alpha (pg/ml) P3 
≤1.006 
68331 
108 
0.000 
0000 
1.006 
6833 
1.00668332 - 
5.39988836 
215 
1.022 
3697 
5.399 
8884 
≥ 5.39 
988837 
107 
5.519 
6799 
2397.3 
236148 
430 
Glycosylated haemoglobin (%) P3 ≤ 5.60 113 4.50 5.60 5.61 - 5.90 235 5.70 6.20 ≥ 6.21 80 6.30 8.40 428 
High sensitivity C-reactive protein (mg/l) P3 ≤ 1.10 115 0.20 1.10 1.11 - 4.80 213 1.20 4.80 ≥ 4.81 106 4.90 133.00 434 
Albumin (g/l) P3 ≤ 38.00 123 24.00 38.00 39.00 - 42.00 226 39.00 42.00 ≥ 43.00 85 43.00 51.00 434 
Rheumatoid factor (IU/ml) P1 ≤ 17.7 701 10.00 17.70 17.80 - 870 48 17.90 87.00 ≥ 87 25 88.80 1620.00 774 
Lymphocyte/Monocyte ratio P3 ≤ 2.52 107 0.90 2.52 2.53 - 4.16 214 2.52 4.16 ≥ 4.17 106 4.18 40.80 427 
CD4 / Upper CD8 T lymphocyte ratio P3 ≤ 1.31 102 0.23 1.31 1.32 - 4.08 202 1.33 4.08 ≥ 4.09 101 4.09 813.17 405 
Memory / Naive B lymphocyte ratio P3 ≤ 0.11 115 0.00 0.11 0.12 - 0.46 207 0.12 0.46 ≥ 0.47 107 0.47 32.79 429 
Memory / Naive CD4 T lymphocyte ratio P3 ≤ 0.11 111 0.01 0.11 0.12 - 0.62 210 0.12 0.61 ≥ .63 107 0.62 26.98 428 
Memory / Naive CD8 T lymphocyte ratio P3 ≤ 0.35 101 0.01 0.35 0.36 - 3.85 201 0.36 3.85 ≥ 3.86 100 3.88 53.81 402 
Senescent (CD27-/RO-) CD4 T lymphocytes (%P) P3 ≤ 0.74 109 0.04 0.74 0.75 - 4.03 213 0.75 4.03 ≥ 4.04 107 4.09 58.50 429 
Senescent (CD27-/RO-) CD8 T lymphocytes (%) P3 ≤10.41 101 0.27 10.41 10.42 - 36.10 202 10.52 36.10 ≥ 36.11 100 36.29 82.52 403 
Hand grip strength (kg) P3 ≤12.00 115 0.00 12.00 12.01 - 20.95 225 12.05 20.95 ≥ 20.96 113 21.05 41.85 453 
Timed up and go test (seconds) P3 ≤ 12.32 101 5.34 12.32 12.33 - 24.50 203 12.37 24.50 ≥ 24.51 98 24.57 177.16 402 
Forced expiratory volume in 1 second (l) P1 ≤ 106.50 194 34.00 106.00 106.51 - 178.00 391 107.00 178.00 ≥ 179.00 191 179.00 359.00 776 
Systolic blood pressure (mmHg) P3 ≤ 129.00 119 77.00 129.00 129.01 - 157.00 233 129.50 157.00 ≥ 157.01 110 157.50 212.00 462 
Haematocrit (%) P3 ≤ 0.368 107 0.267 0.368 0.369 - .418 216 0.369 0.418 ≥ 0.419 104 0.419 0.533 427 
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Haemoglobin (g/dl) P3 ≤ 12.10 114 7.90 12.10 12.11 - 13.80 213 12.20 13.80 ≥ 13.81 100 13.90 17.10 427 
Red blood cells (x 1012/l) P3 ≤ 3.94 109 2.66 3.94 3.95 - 4.56 213 3.95 4.56 ≥ 4.57 105 4.57 5.96 427 
Free  triiodothyronine (pmol/l) P3 ≤ 4.00 108 2.70 4.00 4.01 - 4.80 237 4.10 4.80 ≥ 4.81 81 4.90 6.10 426 
Vitamin D (nmol/l) P1 ≤ 25.00 210 5.00 25.00 26.00 - 62.00 381 26.00 62.00 ≥ 63.00 187 63.00 148.00 778 
Prohormone brain-type natriuretic peptide (pg/ml) P3 ≤ 277.00 31 42.00 276.00 278.00 - 1063.50 62 278.00 1054.00 ≥ 1063.51 31 1073.00 6232.00 124 
 
Supplementary Table 17. Cut-off values for grouped continuous age-related construct variables. Quartile cut-offs were first identified and values 
were assigned to Q1, Q2, Q3 or Q4 groups by default in SPSS. Q2 and Q3 were then grouped manually. (Q: Quartile, 
P1
: Phase 1
 
data,
 P3
: Phase 3 data) 
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Age-related outcomes Group Total 
 Cut-off n Cut-off n Cut-off n Cut-off n n 
Disability score P3 
Fully independent 
(0) 
31 1 - 6 223 7 - 12 138 ≥13 90 482 
SMMSE score P3 
Severe cognitive impairment 
(0-17) 
39 
Moderate cognitive impairment 
(18 - 21) 
35 
Mild cognitive impairment 
(22 - 25) 
86 
No cognitive impairment 
(26-30) 
311 471 
Disease Only Morbidity Count P3 None 36 1 - 2 299 3 - 6 388 ≥7 28 751 
 
Supplementary Table 18. Cut-off values for grouped continuous age-related outcomes for sensitivity analysis. (
P1
: Phase 1
 
data,
 P3
: Phase 3 data) 
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Control 
no 
Date of blood 
collection 1 
Date of blood 
collection 2 
Date of 
birth 
Age at analysis 
(years) 
Gender 
1 20/10/2010* No sample _ _ _ 
2 20/10/2010* 27/10/2010* _ _ _ 
3 20/10/2010* 27/10/2010* _ _ _ 
4 20/10/2010* 27/10/2010* _ _ _ 
5 20/10/2010* 27/10/2010* _ _ _ 
6 20/10/2010* 27/10/2010* _ _ _ 
7 20/10/2010* No sample _ _ _ 
8 22/11/2011 29/11/2011 05/02/1991 22 Male 
9 22/11/2011 29/11/2011 08/02/1987 26 Male 
10 22/11/2011 29/11/2011 22/02/1990 23 Male 
11 22/11/2011 29/11/2011 22/02/1990 23 Male 
12 22/11/2011 29/11/2011* 29/11/1986 26 Female 
13 22/11/2011 29/11/2011 09/04/1979 34 Male 
14 23/11/2011 30/11/2011 22/05/1958 55 Female 
15 23/11/2011 01/12/2011* 07/05/1980 33 Male 
16 23/11/2011 30/11/2011* 21/10/1961 51 Female 
17 23/11/2011 No sample 24/07/1968 44 Female 
18 23/11/2011 30/11/2011* 09/12/1986 26 Male 
19 23/11/2011 30/11/2011 10/03/1983 30 Male 
 
Supplementary Table 19. Summary of younger control PBMC samples (*: 
Unsuitable for flow cytometry analysis due to delay of more than 24 hours or error 
occurring during flow cytometry preparation/analysis/staining,
–
:not recorded). 
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